<SEC-DOCUMENT>0001193125-21-300184.txt : 20211015
<SEC-HEADER>0001193125-21-300184.hdr.sgml : 20211015
<ACCEPTANCE-DATETIME>20211015172536
ACCESSION NUMBER:		0001193125-21-300184
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20211015
DATE AS OF CHANGE:		20211015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MiNK Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259503
		FILM NUMBER:		211326818

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		212-994-8250

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgenTus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210112
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d111280d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4)<BR>Registration No. 333-259503 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>3,333,334 shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g89a09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MiNK Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">This is an initial public
offering of shares of common stock of MiNK Therapeutics, Inc. We are selling 3,333,334&nbsp;shares of our common stock. The initial public offering price is $12.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Our common stock has been approved for listing on the Nasdaq Global Market under the symbol &#147;INKT.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; and &#147;smaller reporting company&#148; under applicable federal securities laws and will be subject to reduced
public company reporting requirements. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company and Smaller Reporting Company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Agenus Inc. (Agenus) is currently our majority stockholder. Agenus has agreed to purchase 1,400,000 shares of our common stock in this offering at the initial
public offering price. Following the completion of this offering, and after giving effect to the conversion of our convertible affiliated note held by Agenus into 5,451,958 shares of common stock, Agenus will own approximately 79.8% of the total
number of our outstanding shares of common stock based on our shares outstanding as of September&nbsp;28, 2021, and we will remain a subsidiary of Agenus. As a result, we will be a &#147;controlled company&#148; under the corporate governance rules
for Nasdaq-listed companies. See &#147;Prospectus Summary &#151; Implication of Being a Controlled Company&#148; and &#147;Risk Factors &#151; Risks Related to Our Relationship with Agenus&#148; for more information. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,800,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds to MiNK Therapeutics, Inc., before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,200,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">See &#147;Underwriting&#148; for additional disclosure regarding underwriting compensation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up to 500,000 additional shares of common stock from us
at the initial public offering price, less underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See
&#147;<A HREF="#cov111280_100">Risk Factors</A>&#148; beginning on page&nbsp;11 of this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The underwriters expect to deliver the shares to purchasers on or about October 19, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><I>Book-Running Managers </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Evercore ISI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>William Blair</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><I>Co-Managers </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><B>B. Riley Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Baird</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>October 14, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_3">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_11">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_14">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_18">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_19">Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Our Common
 Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_20">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_23">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111280_24">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide any information other than that contained in this prospectus
or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the
underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of
this prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or distribution
of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any
restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trademarks
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use MiNK<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, which we have an application pending for with the United States Patent and
Trademark Office, CARDIS<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> and other marks as trademarks in the United States and/or in other countries. This prospectus contains references to our trademarks and service marks and to those
belonging to other entities. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. Solely for convenience, the
trademarks, service marks and trade names referred to in this prospectus may be listed without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, <SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> and <SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market and Industry Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general
expectations, market position and market opportunity, is based on our management&#146;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. We believe that the
information from these third-party publications, research, surveys and studies included in this prospectus is reliable. Management&#146;s estimates are derived from publicly available information, their knowledge of our industry and their
assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors,
including those described in &#147;Risk Factors.&#148; These and other factors could cause our future performance to differ materially from our assumptions and estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information included elsewhere in this prospectus. This summary does not contain all the information you should consider before
investing in our common stock. You should read and consider this entire prospectus carefully, including the sections titled &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements,&#148; &#147;Management&#146;s Discussion
and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making any investment decision. Unless the context otherwise requires,
the terms &#147;MiNK,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; relate to MiNK Therapeutics, Inc., together with its consolidated subsidiaries. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical
company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that
combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of
tumors and infected cells and suppress graft-versus-host-disease (GvHD). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly
versatile application for therapeutic development in cancer and immune diseases. We are leveraging our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells, and
anticipate having multiple clinical and preclinical readouts in 2021 and 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our current product development pipeline:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g19z56.jpg" ALT="LOGO">
 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">In process of submitting an investigational new drug (IND) application. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced product candidate, <FONT STYLE="white-space:nowrap">AGENT-797,</FONT> is an off-the-shelf, allogeneic, native iNKT cell therapy that is
currently in multiple Phase 1 clinical trials. We have commenced a Phase&nbsp;1 clinical trial of <FONT STYLE="white-space:nowrap">AGENT-797</FONT> for the treatment of multiple myeloma and expect to report top-line data from this trial in the
fourth quarter of 2021. In addition, in August 2021, we received FDA clearance to initiate a clinical study for the treatment of solid tumors, which we intend to advance as our lead indication for AGENT-797 as a monotherapy and in combination
</P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with checkpoint inhibitors. We currently expect to have preliminary readouts from this clinical trial in the first half of 2022 in indications that may lead to an accelerated path to marketing
approval. We also intend to initiate a Phase 1 study of AGENT-797 in GvHD in the fourth quarter of 2021, and we currently expect to report top-line data from this trial in the second half of 2022. Finally, with the unique circumstances of the
COVID-19 pandemic, we were able to commence first-in-human studies of AGENT-797 in acute respiratory distress (ARDS) secondary to COVID-19 and are preparing a protocol to expand into ARDS secondary to other life-threatening infectious diseases such
as influenza. We currently expect to report top-line data from this Phase&nbsp;1 trial in the fourth quarter of 2021 and a Phase&nbsp;2 trial in the second half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are advancing a pipeline of next-generation allogeneic, engineered iNKT programs. Our two most advanced engineered programs are (1) a chimeric
antigen receptor (CAR)-iNKT program targeting B-cell maturation antigen (BCMA), which we refer to as BCMA-CAR-iNKT, and (2) a tumor stromal targeting CAR-iNKT program, which we refer to as stromal target-CAR-iNKT. These programs are both in
preclinical development and we expect to file IND applications for each in 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Current Approaches to Cell Therapy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The field of immuno-oncology has revolutionized cancer treatment by harnessing and redirecting immune cell tumor targeting, with the most profound impact being
made within cell therapy. T cells engineered with CARs have changed the paradigm of treatment for patients with B-cell malignancies with high response rates in previously intractable cancers. Despite this progress, there are limitations to CAR-T
cell therapy in both the autologous and evolving allogeneic settings, including practical, logistical and toxicity issues. As a result of these limitations, there is rapidly growing interest in other immune effector cells for CAR engineering,
including NK cells, <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells and macrophages. We believe our approach, harnessing iNKT cells, offers significant advantages over existing cell therapies.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution: Allogeneic iNKT Cell Therapy Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our platform builds on the unique features of native iNKT cells and our advanced manufacturing and engineering capabilities. We believe this enables us to
develop a portfolio of robust, highly pure, off-the-shelf, allogeneic products that can be delivered to patients worldwide for treatment of a wide array of indications in cancer and other immune-mediated diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allogeneic iNKT cell therapy is an adoptive cell therapy that involves the infusion of cells derived from healthy donors. We believe that iNKT cell therapies
have the potential to address many of the key limitations of current cell therapy approaches, particularly through the ability to (1) rapidly treat patients real-time after diagnosis, (2) improve response rates and the durability of responses, (3)
address more indications and a broader patient population, (4) improve tolerability, (5) be administered without lympho-depletion and (6) scale at a favorable cost profile. Below are the key elements that constitute our platform. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g13a26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building on
our foundational leadership team from Agenus, we have assembled a diverse group of experienced company builders, scientists, manufacturing scientists, engineers and operators to execute our business plan. Our leadership team, including our chief
executive officer, chief technology officer and head of manufacturing, has a track record of building a pipeline of high value assets and advancing from discovery to Biologics License Application (BLA) filing. In the past six years, members of our
team have been integral to Agenus delivering 17&nbsp;discoveries into the clinic and executing on partnership transactions that have resulted in proceeds to Agenus of nearly $800&nbsp;million. Members of our team have built industry experience
through their time at companies such as Agenus, Bristol-Myers Squibb Company, Merck &amp; Co., Inc., Pfizer Inc., Eli Lilly and Company, Genmab A/S and Cell Medica Ltd. (now known as Kuur Therapeutics Inc., which was recently acquired by Athenex,
Inc.). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our experienced manufacturing team, led by Sandra Craig, has been operating together for more than 20 years in a manufacturing facility that we
believe pioneered the industrialization and international distribution of autologous cancer vaccines and later the customization of synthetic, off-the-shelf cancer vaccines, immune stimulating adjuvants and antibodies. The facility and team are now
dedicated to delivering allogeneic iNKT cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to discover, develop and commercialize novel allogeneic, off-the-shelf, iNKT cell therapies to treat cancer and other immune-mediated diseases with
high unmet need. We believe that allogeneic iNKT cells exhibit highly adaptable properties for broad therapeutic development, and we plan to achieve our goal by executing a strategy with the following key elements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance AGENT-797 native iNKT cells to treat cancer, including solid tumors, as monotherapy and in combination
with checkpoint antibodies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Validate broad applicability of iNKT cells through our opportunistic development of AGENT-797 in GvHD, a
potentially fast-to-market indication, as well as in ARDS secondary to infectious disease. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Apply our proprietary technologies to build a broad pipeline of engineered iNKT cells, starting with
BCMA-CAR-iNKT and stromal target-CAR-iNKT with current expectations of filing IND applications for both candidates in 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to develop our in-house manufacturing processes and build our capability to cost-efficiently optimize
speed, control, flexibility and scalability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selectively explore additional strategic partnerships that can enhance the potential of our iNKT cell product
candidates and combination therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the
&#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred losses since inception associated with our research and development costs. We expect to incur
losses for the foreseeable future and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need additional funding to advance our programs. If we are unable to raise capital when needed, we would
be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our short operating history as an independent company, and the fact that we have not operated as a standalone
public company, may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business is highly dependent on our iNKT cell platform. Utilizing allogeneic iNKT cells represents a novel
approach to immunotherapy, and we must overcome significant challenges to develop, commercialize and manufacture our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are very early in our development efforts and only have one product candidate in early stage clinical
development. It will be many years before we commercialize a product candidate, if ever. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If any of the product candidates we may develop, or the delivery modes we rely on to administer them, cause
serious adverse events, undesirable side effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of, or limit the commercial potential of, the product candidates, or result in
significant negative consequences following any potential marketing approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The resources Agenus provides us may not be sufficient for us to operate as a standalone company, and we may
experience difficulty in separating our resources from Agenus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Agenus will continue to own a majority of our common stock after this offering and will be able to exert control
over specific matters subject to stockholder approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Certain of our directors and officers may have actual or potential conflicts of interest because of their
positions with Agenus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We contract with third parties for the manufacture of materials for our research programs, preclinical studies
and clinical trials and expect to do so for commercialization of any product candidates that we may develop. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any
medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The intellectual property landscape around cell-based immunotherapies is highly dynamic, and third parties may
initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery,
development and commercialization efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is only a summary of some of our risks. For a more detailed discussion of
these and other risks you should consider before making an investment in our common stock, see &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an
Emerging Growth Company and Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business
Startups Act of 2012 (the JOBS Act).&nbsp;As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our
executive compensation arrangements, exemption from the requirements to hold <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation and golden parachute payments, and exemption from the auditor attestation
requirement in the assessment of our internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until the last day of the
fiscal year following the fifth anniversary of this offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company earlier if we have more than $1.07&nbsp;billion in annual revenue, we
have more than $700.0&nbsp;million in market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> (and we have been a public company for at least 12 months and have filed one Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K)</FONT> or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities over a three-year period. For so long as we remain an emerging growth company, we are
permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We may choose to take advantage of some, but not all, of the available
exemptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new
or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such
extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or
revised standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company. Therefore, the reported results of
operations contained in our consolidated financial statements may not be directly comparable to those of other public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a
&#147;smaller reporting company,&#148; meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than
$700.0&nbsp;million and our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year. We will continue to be a smaller reporting company after this offering until the last day of the fiscal year in which
(i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equaled or exceeded $250.0&nbsp;million as of the prior June 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and (ii)&nbsp;our annual
revenue equaled or exceeded $100.0&nbsp;million during the such completed fiscal year the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equaled or exceeded $700.0&nbsp;million as of the prior June 30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller
reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar
to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Controlled Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are presently a &#147;controlled company&#148; under the Nasdaq Marketplace Rules because Agenus controls a majority of the voting power of our outstanding
common stock. As a controlled company, we are entitled to rely on certain exemptions to Nasdaq&#146;s corporate governance requirements, including the requirement (i)&nbsp;that a majority of the board of directors consist of independent directors,
(ii)&nbsp;to have a governance committee that is composed entirely of independent directors with a written charter addressing the committee&#146;s purpose and responsibilities, (iii)&nbsp;to have a compensation committee that is composed entirely of
independent directors with a written charter addressing the committee&#146;s purpose and responsibilities, (iv)&nbsp;that the compensation committee consider certain independence factors when engaging legal counsel and other committee advisors and
(v)&nbsp;for an annual performance evaluation of the governance and compensation committees. Immediately following this offering, Agenus will own approximately 79.8% of the outstanding shares of our common stock based on 33,004,349 shares of our
common stock outstanding as of September&nbsp;28, 2021, after giving effect to our issuance of 3,333,334 shares of our common stock in this offering and the conversion of our convertible affiliate note, as amended in accordance with the terms of the
note using the initial public offering price set forth on the cover page of this prospectus. We expect to remain a controlled company following this offering and for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated as
AgenTus Biosciences Inc. in Delaware in July 2017. We changed our name to AgenTus Therapeutics, Inc. in October 2017 and to MiNK Therapeutics, Inc. in June 2021. Our principal executive offices are located at 149 Fifth Avenue Suite 500, New York, NY
10010, and our telephone number is 212-994-8250. Our website is minktherapeutics.com. Information contained on, or that can be accessed through, our website is not part of this prospectus. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock offered by us</B> </P></TD>
<TD><B></B>3,333,334 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock to be outstanding after this offering</B> </P></TD>
<TD>32,587,301 shares (33,087,301 shares if the underwriters exercise their option to purchase additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Underwriters&#146; option to purchase additional shares of common stock from us </B> </P></TD>
<TD>We have granted the underwriters an option to purchase up to an aggregate of 500,000 additional shares of common stock from us at the initial public offering price, less underwriting discounts and commissions, for a period of 30 days after the
date of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds </B> </P></TD>
<TD>Our net proceeds from the sale of our common stock in this offering will be approximately $34.3&nbsp;million, or $39.9&nbsp;million if the underwriters exercise in full their option to purchase additional shares, and after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We currently expect to use the net proceeds from this offering, together with our existing cash, as follows: </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">(1) approximately $7.8&nbsp;million to fund our planned early development of our monotherapy and combination study of AGENT-797 with
PD-1/CTLA-4 checkpoint inhibitors for the treatment of patients with solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma and hepatocellular carcinoma; (2)&nbsp;approximately $1.3&nbsp;million to fund the
development of AGENT-797 through completion of our Phase 1 clinical trial for the treatment of patients with multiple myeloma; (3) approximately $3.3 million to fund the development of AGENT-797 through completion of our planned Phase 1/2 clinical
trial for the treatment of patients with GvHD; (4) approximately $1.8&nbsp;million to fund the development of AGENT-797 through completion of our Phase&nbsp;1 clinical trial for the treatment of patients with ARDS secondary to COVID-19 and,
potentially, expanding into other life-threatening infectious diseases; (5) approximately $2.0&nbsp;million to fund IND-enabling studies, process development and manufacturing of our CAR-iNKT-programs; (6)&nbsp;approximately $4.1&nbsp;million to
fund our process validation and manufacturing batches for AGENT-797; and (7)&nbsp;the remainder for working capital and other general corporate purposes, which includes funding for additional research, hiring additional personnel, capital
expenditures and the costs of operating as a public company. See &#147;Use of Proceeds.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B> </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; section of this prospectus and the other information included in this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market symbol </B></P></TD>
<TD>&#147;INKT&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agenus has agreed to purchase 1,400,000 shares of common stock in this offering at the initial public
offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding following this offering is based on 24,177,313 shares of common stock outstanding
as of June 30, 2021. This amount excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,845,203 shares of common stock issuable upon the exercise of stock options outstanding as of June 30, 2021
having a weighted average exercise price of $1.35 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,373,485 shares of common stock available for future issuance under our 2018 Equity Incentive Plan (the 2018
Plan), as of June 30, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">695,750 restricted stock units granted to our president and chief executive officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,000,000 shares of common stock reserved for issuance under our 2021 Equity Incentive Plan (the 2021 Plan),
which will become effective in connection with this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">375,000 shares of common stock reserved for issuance under our 2021 Employee Stock Purchase Plan (the 2021 ESPP),
which will become effective in connection with this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise noted, the information in this prospectus assumes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a 2.783-for-1 forward stock split of common stock effected on September 29, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of the outstanding convertible affiliated note, as amended, into an aggregate of
5,076,654&nbsp;shares of common stock immediately prior to the closing of this offering, based upon the initial public offering price of $12.00 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding stock options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no issuance of warrants on or after June 30, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase 500,000 additional shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our
amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> upon the closing of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the tables below, we provide you with our summary financial data for the periods indicated. You should read the following summary financial data together
with our consolidated financial statements and the related notes appearing elsewhere in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. We
have derived the following summary of our condensed consolidated statements of operations data for the six months ended June 30, 2021 and 2020 and our condensed consolidated balance sheet data as of June 30, 2021 from our unaudited condensed
consolidated financial statements appearing at the end of this prospectus. We have derived the statement of operations data for the years ended December&nbsp;31, 2020 and 2019 from our audited financial statements appearing elsewhere in this
prospectus. Our historical results are not necessarily indicative of the results that may be expected in any future period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Summary of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">689,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,682,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,217,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,509,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,654,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,462,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,828,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,840,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,620,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,188,598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,637,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,284,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,560,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,472,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,601,712</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,517,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,181,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,660,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,238,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,802,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,177,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,077,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,108,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,059,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average common shares outstanding, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,394,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,921,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,951,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,548,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pro forma weighted average common shares outstanding, basic and diluted (unaudited), is calculated as if the
convertible affiliated note, as amended, converted in accordance with the terms of the note (See Note 10 to the consolidated financial statements found elsewhere in this prospectus) at the beginning of each period presented, based on the initial
public offering price of $12.00 per share. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;forma&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;forma&nbsp;as</B><br><B>adjusted&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,658,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,658,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,928,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,753,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,753,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,023,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,526,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,021,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,021,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,021,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,177,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,651,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,618,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma balance sheet data give effect to the conversion of our convertible affiliated note, as amended,
into 5,076,654 shares of our common stock, in accordance with its terms (See Note 10 to the audited consolidated financial statements found elsewhere in this prospectus), based upon the initial public offering price of $12.00 per share.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted consolidated balance sheet data give further effect to our issuance and sale of
3,333,334 shares of our common stock in this offering at the initial public offering price of $12.00&nbsp;per share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_4"></A><A NAME="cov111280_100"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of
the other information contained in this prospectus, including our consolidated financial statements and related notes appearing at the end of this prospectus, before deciding to invest in our common stock. If any of the events or developments
described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and
uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, we have incurred operating losses associated with our research, clinical development and manufacturing efforts. We have devoted
substantially all of our efforts and financial resources in building our invariant natural killer T (iNKT) cell platform, identifying our current product candidates, conducting preclinical development and initiating clinical trials of <FONT
STYLE="white-space:nowrap">AGENT-797.</FONT> Our net loss was $10.2 million for the six months ended June 30, 2021, and $16.2&nbsp;million and $23.8&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively. As of June
30,&nbsp;2021, we had an accumulated deficit of $62.9&nbsp;million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to
quarter. We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our clinical and preclinical development of product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to develop our iNKT cell platform further and identify additional research programs and additional product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate preclinical testing and clinical trials for any product candidates we identify and develop from our
current research programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of
third-party expenses related to our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek marketing approvals for any of our product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any biologics for
which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional research and development personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire clinical and commercial personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our
product development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates, intellectual property and
technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operate as a standalone public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have only recently initiated two Phase 1 clinical trials for our lead product candidate, <FONT STYLE="white-space:nowrap">AGENT-797,</FONT> and all of our
other product candidates remain in preclinical development. We do not have any products approved for sale and have not generated any revenue from product supplies or royalties. Based on our current plans, we do not expect to generate product or
royalty revenues unless and until we obtain marketing approval for a product candidate. We expect that it will be many years, if ever, before we have a product candidate that receives such approval. To become and remain profitable, we must develop
and, either directly or through collaborators, eventually commercialize a medicine or medicines with significant market potential. This will require us to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successful in a range of challenging activities, including identifying product candidates, completing preclinical testing and clinical trials of product candidates, obtaining marketing approval
for these product candidates, manufacturing, marketing and selling those medicines for which we may obtain marketing approval, and satisfying any post-marketing requirements. Even if one or more of the product candidates we may develop are approved
for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration (FDA) or other
regulatory authorities to perform clinical and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved product candidates, we may not become profitable and may need to
obtain additional funding to continue operations and, even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value
of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and
product development programs or future commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase in connection with the maturation of our
programs and ongoing activities, particularly as we identify, continue the research and development of, initiate and continue clinical trials of, and seek marketing approval for, our product candidates, including
<FONT STYLE="white-space:nowrap">AGENT-797.</FONT> In addition, if we obtain marketing approval for any product candidates we may develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing
and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a collaborator. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as
a standalone public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our primary
source of funding to date has been through Agenus. As of June 30, 2021, our cash balance was $1.7&nbsp;million. The net proceeds of this offering will be approximately $34.3&nbsp;million, based on the initial public offering price of $12.00 per
share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We expect that the net proceeds from this offering, together with our existing cash, will enable us to fund our operating expenses and
capital expenditure requirements through the end of 2023. However, our operating plan may change as a result of factors currently unknown to us, and we may need to seek funding sooner than planned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and, if we
are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development
initiatives. Our license agreements and any future collaboration agreements may also be terminated if we are unable to meet payment or other obligations under such agreements. We could be required to seek collaborators for product candidates we may
develop at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, or relinquish or license on unfavorable terms our rights to product candidates we may develop in markets where we
otherwise would seek to pursue development or commercialization ourselves. In addition, any fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
activities, which may adversely affect our ability to develop and commercialize our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause
dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt
financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt
financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends and possibly other restrictions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies, future revenue streams, research programs or product candidates we may develop, or we may have to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt
financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and
market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our short operating history as an independent company, and the fact that we have not operated as a standalone public company, may
make it difficult for you to evaluate the success of our business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were formed in 2017 as a
subsidiary of Agenus and have operated as a majority-owned subsidiary of Agenus since that time. Our operations to date have been limited to organizing and staffing our company, business planning, identifying potential product candidates and
undertaking clinical trials and preclinical studies, and some of these activities have been performed by Agenus pursuant to our services agreement. We have only recently initiated two Phase 1 clinical trials for
<FONT STYLE="white-space:nowrap">AGENT-797</FONT> and our other programs are still in the preclinical or research stage of development, where the risk of failure is high. We have not yet demonstrated an ability to successfully complete any clinical
trials, including large-scale, pivotal clinical trials; obtain marketing approvals; manufacture a commercial-scale medicine, or arrange for a third party to do so on our behalf; or conduct sales and marketing activities necessary for successful
commercialization. It takes many&nbsp;years to develop a new medicine from the time it is discovered to when it is available for treating patients. Consequently, any predictions you make about our future success or viability may not be as accurate
as they could be if we had a longer independent operating history. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our limited independent operating history, particularly in light of rapidly evolving
cell therapies, may make it difficult to evaluate our technology and industry and predict our future performance. Our very short history as an operating company makes any assessment of our future success or viability subject to significant
uncertainty. We will encounter risks and difficulties frequently experienced by very early stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a new business, we may encounter other unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will
need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is substantial doubt about our ability to continue as a going concern. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A history of operating losses and negative cash flows from operations combined with our anticipated use of cash to fund operations raises substantial doubt
about our ability to continue as a going concern absent the capital raised in connection with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future viability as an ongoing business
is dependent on our ability to generate cash from our operating activities or to raise additional capital to finance our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no
assurance that we will succeed in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all. The perception that we might be unable to continue as a going concern may also make it more difficult to obtain
financing for the continuation of our operations on terms that are favorable to us, or at all, and could result in the loss of confidence by investors and employees. Our financial statements do not include any adjustments that might result from the
outcome of this uncertainty. If we are unable to continue as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that our investors will lose
all or a part of their investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be
limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred substantial net operating losses (NOLs) during our history. U.S. federal and certain state NOLs generated in taxable
years beginning after December&nbsp;31, 2017 are not subject to expiration. Federal NOLs generally may not be carried back to prior taxable years except that, under the Coronavirus Aid, Relief, and Economic Securities Act (the CARES Act), federal
NOLs generated in 2018, 2019 and 2020 may be carried back to each of the five taxable years preceding the taxable year in which the loss arises. Additionally, for taxable years beginning after December&nbsp;31, 2020, the deductibility of federal
NOLs generated in taxable years beginning after December&nbsp;31, 2017 is limited to 80% of our taxable income in such taxable year. NOLs generated in tax years beginning before January&nbsp;1, 2018 may still be used to offset future taxable income
without regard to the 80% limitation, although they have the potential to expire without being utilized if we do not achieve profitability in the future. In addition, in general, under Sections&nbsp;382 and 383 of the U.S. Internal Revenue Code of
1986, as amended (the Code), a corporation that undergoes an &#147;ownership change&#148; is subject to limitations on its ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs to offset future taxable income. For these
purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#146;s stock increases its ownership by more than 50 percentage points
over its lowest ownership percentage within a specified testing period. We may experience ownership changes in the future as a result of future transactions in our stock, some of which may be outside our control. If we undergo an ownership change in
connection with or after this offering, our ability to use our NOLs could be further limited. For these reasons, we may not be able to use a material portion of our NOLs, even if we attain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Discovery, Development and Commercialization of Our Allogeneic iNKT Cells </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is highly dependent on the success of our lead product candidate, <FONT STYLE="white-space:nowrap">AGENT-797,</FONT> which is our only
product candidate in clinical development. We have a limited history of conducting clinical trials and may fail to develop <FONT STYLE="white-space:nowrap">AGENT-797</FONT> successfully or be unable to obtain regulatory approval for it. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot guarantee that AGENT-797 will be safe and effective, or will be approved for commercialization on a timely basis or at all. Although certain of our
employees and consultants have prior experience with clinical trials, regulatory approvals and current Good Manufacturing Processes (cGMP) manufacturing, we have not previously completed any clinical trials or submitted a Biologics License
Application (BLA) to the FDA, or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that AGENT-797 will be successful in clinical trials or receive regulatory approval. The FDA
and other comparable global regulatory authorities can delay, limit or deny approval of a product candidate for many reasons. Any delay in obtaining, or inability to obtain, applicable regulatory approval will delay or harm our ability to
successfully commercialize AGENT-797 and materially adversely affect our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because AGENT-797 is our most advanced product candidate and our only product candidate in a clinical trial, and because our other product
candidates are based on similar technology, if our clinical trials of AGENT-797 encounter safety, efficacy or manufacturing problems, development delays, regulatory issues or other problems, our development plans for AGENT-797 and our other product
candidates in our pipeline could be significantly impaired, which could materially adversely affect our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to develop our product candidates both as monotherapy and potentially as combination therapy, a common form of cancer treatment, with one or more
currently approved cancer therapies. Even if any product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or
similar regulatory authorities outside of the United States could revoke approval of the combination therapy used with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This
could result in our own products being removed from the market or being less successful commercially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also evaluate our product candidates in
combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. If the FDA or similar regulatory authorities outside of the United States do
not approve these other drugs or revoke their approval, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with any product candidate we develop for our combination therapy, we may be
unable to obtain approval of or market our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Utilizing allogeneic iNKT cells represents a novel approach to immunotherapy, and we
must overcome significant challenges to develop, commercialize and manufacture our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have concentrated our research and
development efforts on utilizing allogeneic iNKT cells as an immunotherapy. To date, the FDA has approved only a few adoptive cell therapies for commercialization and no allogeneic iNKT cell therapy has been approved for commercial use by any
regulatory authority. The processes and requirements imposed by the FDA or other applicable regulatory authorities may cause delays and additional costs in obtaining approvals for marketing authorization for our product candidates. Because our
allogeneic iNKT cell platform products are novel, and adoptive cell therapies are relatively new, regulatory agencies may lack experience in evaluating product candidates like our iNKT cell product candidates, including our lead product candidate,
AGENT-797. This novelty may heighten regulatory scrutiny of our therapies or lengthen the regulatory review process, including the time it takes for the FDA to review our investigational new drug (IND) applications if and when submitted, increase
our development costs and delay or prevent commercialization of our allogeneic iNKT cell platform products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, advancing novel cell therapies
involve significant challenges for us, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">educating medical personnel regarding the potential side-effect profile of our product candidates and, as the
clinical program progresses, on observed side effects with the therapy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">training a sufficient number of medical personnel on how to properly administer our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enrolling sufficient numbers of patients in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a reliable, safe and effective means of genetically modifying certain of our cells;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing a cost-effective and large-scale manufacturing capacity suitable for the manufacture of our product
candidates in line with expanding enrollment in our clinical trials and our projected commercial requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sourcing starting material suitable for clinical and commercial manufacturing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales and marketing capabilities to successfully launch and commercialize our product candidates if
and when we obtain any required regulatory approvals, and risks associated with gaining market acceptance of a novel therapy if we receive approval, as well as developing a manufacturing process and distribution network to support the
commercialization of any approved products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We must be able to overcome these challenges in order for us to develop, commercialize and
manufacture our product candidates utilizing allogeneic iNKT cells. Failure to do so could materially adversely affect our business, financial condition, results of operations and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are very early in our development efforts and only have one product candidate in early stage
clinical development. It will be many years before we commercialize a product candidate, if ever. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are very early in our development efforts.
Our future success depends heavily on the successful development of our product candidates. Currently, with the exception of <FONT STYLE="white-space:nowrap">AGENT-797,</FONT> which is in two Phase 1 clinical trials, all of our other product
candidates are in preclinical development or in discovery. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of
the product candidates. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never
occur. We currently generate no revenue from sales of any product and we may never be able to develop or commercialize a marketable product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commercialization of our product candidates will require additional preclinical and/or clinical development; regulatory and marketing approval in multiple
jurisdictions, including by the FDA and the European Medicines Agency (EMA); obtaining manufacturing supply, capacity and expertise; building of a commercial organization; and significant marketing efforts. The success of product candidates we may
identify and develop will depend on many factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficiency of our financial and other resources to complete the necessary preclinical studies, <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in, and completion of, clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of arrangements with third-party manufacturers for clinical supply and commercial manufacturing
and, where applicable, commercial manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful development of our internal manufacturing processes and transfer to larger-scale facilities operated
by either a contract manufacturing organization (CMO) or by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent, trade secret and other intellectual property protection and <FONT
STYLE="white-space:nowrap">non-patent</FONT> exclusivity for our medicines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching commercial sales of the medicines, if and when approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of the products, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other therapies and treatment options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a continued acceptable safety profile of the medicines following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enforcing and defending intellectual property and proprietary rights and claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supplying the products at a price that is acceptable to the pricing or reimbursement authorities in different
countries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not successfully achieve one or more of these activities in a timely manner or at all, we could experience
significant delays or an inability to successfully commercialize any product candidates we may develop, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue
our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is highly dependent on our iNKT cell platform, and our product candidates will require significant additional testing
before we can seek regulatory approval. We may not be successful in our efforts to identify and develop additional product candidates. Additional product candidates include, but are not limited to, iNKT cell products genetically engineered to
express chimeric antigen receptors (CARs) and other modifications that are </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>
designed to enhance safety and efficacy. They may also include combinations with other drug substances such as small molecules and immuno-oncology antibodies. If these efforts are unsuccessful,
we may never become a commercial stage company or generate any revenues. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to
identify, develop and commercialize product candidates based on our iNKT cell platform. All of our product development programs are still in clinical research or in the preclinical stage of development. The process for obtaining marketing approval
for any candidate is very long and risky and there will be significant challenges for us to address in order to obtain marketing approval, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no guarantee that the results obtained in current Phase 1 and anticipated clinical trials for <FONT STYLE="white-space:nowrap">AGENT-797</FONT> will
be sufficient for us to plan one or more pivotal clinical trials and obtain regulatory approval or marketing authorization, or that preclinical development of our other product candidates or <FONT STYLE="white-space:nowrap">AGENT-797</FONT> in other
indications will be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research programs may also fail to identify additional potential product candidates for clinical development for a
number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates, our potential product candidates may be shown to have harmful side effects in preclinical <I>in vitro</I> experiments or animal model
studies, they may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable or unlikely to receive marketing
approval. In addition, although we believe our iNKT cell platform will allow us to expand our portfolio of product candidates beyond our current product candidates, we have not yet successfully developed any product candidate and our ability to
expand our portfolio may never materialize. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced to abandon our research or development efforts for a program
or programs, which would have a material adverse effect on our business, financial condition, results of operations and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We
may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful, which would be costly and time-consuming. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of the product candidates we may develop, or the delivery modes we rely on to administer them, cause serious adverse events, undesirable side
effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential or result in significant negative consequences following any
potential marketing approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have not completed a clinical trial for any of our product candidates. Moreover, there have been only a
limited number of clinical trials involving the use of iNKT cells and none involving therapies similar to our therapies. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. In the adoptive cell
therapy field, there have been significant adverse events from allogeneic cell treatments in the past, including cytokine release syndrome (CRS), peripheral neuropathies and adverse events linked to lymphodepleting chemotherapy regimens used in the
field prior to administration of cell therapy products. We have also observed serious adverse events in our ongoing AGENT-797 trial in patients with COVID-19 requiring mechanical ventilation and with moderate-to-severe acute respiratory distress
(ARDS). These events include three deaths related to underlying disease (COVID-19). All such serious adverse events to date have been determined by the study investigator to be unrelated to AGENT-797. There have been no observations of neurotoxicity
or cytokine release syndrome. There can be no assurance that our product candidates will not cause undesirable side effects in the future, which may include serious adverse effects that are related to our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any product candidates we develop are associated with serious adverse events, undesirable side effects or unexpected characteristics, we may need to
abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit
perspective, any of which would have a material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse effect on our business, financial condition, results of operations and prospects. Many product candidates that initially showed promise in early stage testing for treating cancer or
life-threatening diseases have later been found to cause side effects that prevented further clinical development of the product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If in the
future we are unable to demonstrate that any of the above adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of,
any product candidates we are able to develop for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of
enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any product candidate we may develop, the commercial prospects of such product candidates may be harmed and our
ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result
of operations and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if we successfully develop a product candidate and it receives marketing approval, the FDA could
require us to adopt a Risk Evaluation and Mitigation Strategy (REMS), to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a medication guide
outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive and more costly than what
is typical for the industry. The FDA has required REMS programs for other cell therapies, including autologous CAR-T cell therapies. Furthermore, if we or others later identify undesirable side effects caused by any product candidate that we
develop, several potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may suspend or withdraw approvals of such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label or limit the approved use of such product
candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to conduct additional clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of any product candidates we may identify and develop and could have a
material adverse effect on our business, financial condition, results of operations and prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The data produced in our clinical trial of <FONT
STYLE="white-space:nowrap">AGENT-797</FONT> for ARDS secondary to COVID-19 and, potentially, other life-threatening infectious diseases is at an early stage and future data may not show responses in patients treated or support continued development.
In addition, the results ultimately obtained from our preclinical studies or other clinical trials for <FONT STYLE="white-space:nowrap">AGENT-797</FONT> or any of our other product candidates may not be predictive of future results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">AGENT-797</FONT> for ARDS secondary to COVID-19 commenced in October 2020, and we began
preparing a protocol to expand into ARDS secondary to other life-threatening infectious diseases, such as influenza, in July 2021. We also commenced a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">AGENT-797</FONT> for the treatment of
multiple myeloma in March 2021. We do not know at this stage whether patient response data from such trials will be favorable, and initial success in clinical trials may not be indicative of results obtained when such trials are completed. In
February 2021, we released interim data from our first four patients dosed in our clinical trial for ARDS secondary to COVID-19; such interim data, and any future interim data from clinical trials that we may conduct, including the clinical trials
for <FONT STYLE="white-space:nowrap">AGENT-797</FONT> for the treatment of multiple myeloma and in ARDS secondary to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and, potentially, other life-threatening infectious diseases, are subject to the
risk that one or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. We cannot provide any assurance that additional data will be provided
frequently or that data updates will be available at any particular time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary data also remain subject to audit and verification procedures that
may result in the final data being materially different from the preliminary data we previously announced. Negative differences between preliminary or interim data and final data could materially adversely affect the prospects of any product
candidate that is impacted by such data updates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the results of any preclinical studies of <FONT STYLE="white-space:nowrap">AGENT-797</FONT>
or for our other product candidates may not be predictive of the results of clinical trials. For example, preclinical models as applied to cell therapy in oncology do not adequately represent the clinical setting, and thus cannot predict clinical
activity nor all potential risks, and may not provide adequate guidance as to appropriate dose or administration regimen of a given therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may
not be able to submit INDs or the foreign equivalent outside of the United States to commence additional clinical trials for cell therapies on the timeframes we expect, which would adversely affect our ability to obtain regulatory approvals or
commercialize these programs on a timely basis or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be certain of the timely completion or outcome of our preclinical testing and
studies and cannot predict if the regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. As a result, we cannot be
sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory
authorities allowing clinical trials to begin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any product candidates we may develop receive marketing approval, they may fail to achieve
the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commercial success of any of the product candidates we may develop will depend upon its degree of market acceptance by physicians, patients, third-party
payors and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical
community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety of such product candidates as demonstrated in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential and perceived advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limitation to our targeted patient population and limitations or warnings contained in approved labeling by
the FDA or other regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to offer our medicines for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product candidate is approved by the FDA, the EMA or other regulatory
agencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try novel therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including
any limitations or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relative convenience and ease of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity concerning our products or competing products and treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficient third-party coverage or reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the product candidates we develop are approved, but do not achieve an adequate level of acceptance, we may not generate significant product revenues
and we may not become profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with
third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our company does not have a sales or marketing infrastructure and has no experience in the sale, marketing or distribution of pharmaceutical products. To
achieve commercial success for any approved medicine for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to
build a focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of the product candidates we may develop if and when they are approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services.
For example, recruiting and training a sales force or reimbursement specialists is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish
marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot
retain or reposition our commercialization personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize the product candidates we may develop on our
own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer
service, medical affairs and other support personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to
prescribe any future medicines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and
other acceptance by payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute the product candidates we may
develop to segments of the patient population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent commercialization organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product
revenues or the profitability of these product revenues to us may be lower than if we were to market and sell any medicines we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to
commercialize the product candidates we may develop or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and
market our medicines effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing the product candidates we may develop. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition in an environment of rapid technological change, and there is a
possibility that our competitors may achieve regulatory approval before us or develop adoptive cell therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or
commercialize any product candidates we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of new adoptive cell therapy products is highly
competitive. We face competition from existing and future competitors with respect to each of our product candidates currently in development, and will face competition with respect to other product candidates that we may seek to develop or
commercialize in the future. Our competitors include major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide, as well as academic institutions, government agencies and other public and private
research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, key competitors developing autologous <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies include, but are not limited to, Appia Bio,
Inc., Bristol-Myers Squibb Company (Celgene/Juno Therapeutics), Gilead Sciences, Inc. (Kite Pharma), GlaxoSmithKline plc, Janssen Pharmaceutica N.V., Novartis AG, Kuur Therapeutics Limited, which was acquired by Athenex, Inc. in May 2021, and Suda
Pharmaceuticals. Key competitors developing allogeneic T cell therapies include, but are not limited to, Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc., Cellectis S.A., Celularity, Inc., Celyad Oncology SA, CRISPR Therapeutics AG, Poseida
Therapeutics, Inc. and Precision BioSciences, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other key competitors in the natural killer (NK) cell therapy space include, but are not limited to,
Fate Therapeutics, Inc., Glycostem Therapeutics B.V., Nkarta, Inc., Sanofi and Takeda Pharmaceutical Company Limited; and in the <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cell therapy space
include, but are not limited to, Adicet Bio, Inc., GammaDelta Therapeutics Limited, In8bio, Inc. and TC BioPharm Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our competitors have
initiated clinical trials for graft-versus-host-disease (GvHD) and multiple myeloma, settings in which our iNKT cell therapy platform is currently being investigated. We are also aware of competitors pursuing cell therapy drug candidates, including
but not limited to stem cell-based approaches, for the treatment of ARDS secondary to COVID-19. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in
the future that are approved to treat the same diseases for which we may obtain approval for the product candidates we may develop. This may include other types of therapies, such as bispecific T&nbsp;cell engagers, oncolytic viruses and antibody
drug conjugates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical,
biotechnology and adoptive cell therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for
clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more
effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop or that would render any product candidates that we may develop obsolete or
<FONT STYLE="white-space:nowrap">non-competitive.</FONT> Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors
establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any
product candidates we may develop against competitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a result of the expiration or successful challenge of our patent rights, we could face more
litigation with respect to the validity and/or scope of patents relating to our competitors&#146; products. The availability of our competitors&#146; products could limit the demand, and the price we are able to charge, for any product candidates
that we may develop and commercialize. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to commercialize any product candidates, such products may become subject to unfavorable
pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulations that
govern marketing approvals, pricing and reimbursement for new medicines vary widely from country to country. Some countries require approval of the sale price of a medicine before the product can be marketed. In many countries, the pricing review
period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might
obtain marketing approval for a medicine in a particular country, but then be subject to price regulations that delay or might even prevent our commercial launch of the medicine, possibly for lengthy time periods, and negatively impact the revenues
we are able to generate from the sale of the medicine in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates we may develop, even if any product candidates we may develop obtain
marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any medicines successfully also will depend in part on the extent to which reimbursement for these
medicines and related treatments will be available from government authorities or healthcare programs, private health plans and other organizations. Government authorities and third-party payors, such as private health plans, decide which
medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage
and the amount of reimbursement for particular medications. Increasingly, third-party payors are challenging the prices charged for medical products and requiring that drug companies provide them with discounts from list prices. Novel medical
products, if covered at all, may be subject to enhanced utilization management controls designed to ensure that the products are used only when medically necessary. Such utilization management controls may discourage the prescription or use of a
medical product by increasing the administrative burden associated with its prescription or creating coverage uncertainties for prescribers and patients. We cannot be sure that reimbursement will be available for any medicine that we may
commercialize or, if reimbursement is available, that the level of reimbursement will be adequate. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not
available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining reimbursement for newly approved medicines, and coverage may be more limited than the purposes for which the
medicine is approved by the FDA, the EMA or other regulatory authorities outside the United States. Coverage by one payor does not mean that other payors will also provide coverage. Moreover, eligibility for reimbursement does not imply that any
medicine will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new medicines, if applicable, may also not be sufficient to cover our
costs and may not be made permanent. Reimbursement rates may vary according to the use of the medicine and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost medicines and may be incorporated
into existing payments for other services. Net prices for medicines may be reduced by mandatory discounts or rebates required to be provided to government healthcare programs or private payors and by any future relaxation of laws that presently
restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved
medicines we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize any medicines we may develop, and our overall financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to successfully identify patients who are likely to benefit from therapy with any
product candidates we develop, or experience significant delays in doing so, we may not realize the full commercial potential of any medicines we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success may depend, in part, on our ability to identify patients who are likely to benefit from therapy with any medicines we may develop. If we, or any
third parties that we engage to assist us, are unable to successfully identify such patients, or experience delays in doing so, then: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop any product candidates may be adversely affected if we are unable to appropriately select
patients for enrollment in our clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not realize the full commercial potential of any product candidates we develop that receive marketing
approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our medicines. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidates we develop may require use of a companion diagnostic to identify patients who are likely to benefit from therapy. If safe and effective
use of any of the product candidates we may develop depends on a companion diagnostic, we may not receive marketing approval, or marketing approval may be delayed, if we are unable to or are delayed in developing, identifying or obtaining regulatory
approval or clearance for the companion diagnostic product for use with our product candidate. Identifying a manufacturer of the companion diagnostic and entering into an agreement with the manufacturer could also delay the development of our
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of these factors, we may be unable to successfully develop and realize the commercial potential of any product candidates
we may identify and develop, and our business, financial condition, results of operations and prospects would be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may
develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing in clinical trials of any product candidates we may develop
and will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities.
Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates or medicines that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant time and costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any medicines that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Agenus maintains product liability insurance coverage for us, it may not be adequate to cover all liabilities that we may incur. In the future, we
may need to procure our own insurance coverage. Additionally, we anticipate that we will need to increase our insurance coverage when we begin additional clinical trials and if we successfully commercialize any medicine. Insurance coverage is
increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adoptive cell therapy treatments are novel, and any product candidates we develop may be complex and
difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development or commercialization programs, limit the supply of our product candidates we may develop or
otherwise harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidates we may develop will likely require processing steps that are more complex than those required
for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as the product candidates we intend to develop generally cannot be fully characterized. As a result, assays of the
finished product candidate may not be sufficient to ensure that the product candidate will perform in the intended manner. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or
manufacturing failures that result in lot failures, product recalls, product liability claims, insufficient inventory or potentially delay progression of our potential IND filings. If we successfully develop product candidates, we may encounter
problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA, the EMA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols
showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing
process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or
product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, or our CMOs,
also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining
compliance with applicable regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing.
Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the raw materials that we anticipate will be required in our manufacturing
process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the
manufacture of any product candidates we may develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive
collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or
facilities also could restrict our ability to ensure sufficient clinical material for any clinical trials we may be conducting or are planning to conduct and meet market demand for any product candidates we develop and commercialize. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we may be unable to find sufficient healthy donors for isolation of the iNKT cells that form the basis of our products to meet clinical or
market demands, or we may be unable to timely access our donor pool due to events outside of our control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Review and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our ongoing clinical trials of <FONT STYLE="white-space:nowrap">AGENT-797</FONT> or any of our future trials fail to demonstrate safety and efficacy
to our satisfaction and the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of such product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, can take many years to complete
and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim
results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed
satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product
candidates we develop may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit
commercial use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our collaborators, if any, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay
or prevent our ability to receive marketing approval or commercialize any product candidates we may identify and develop, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with regulators on trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, institutional review boards (IRBs), or independent ethics committees may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching or failing to reach agreement on acceptable clinical trial contracts or clinical trial
protocols with prospective contract research organizations (CROs) and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of any product candidates we may develop may produce negative or inconclusive results, and we may
decide, or regulators may require us, to conduct additional clinical trials or abandon product development or research programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in designing well-controlled clinical trials due to ethical considerations which may render it
inappropriate to conduct a trial with a control arm that can be effectively compared to a treatment arm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in designing clinical trials and selecting endpoints for diseases that have not been well-studied and
for which the natural history and course of the disease is poorly understood; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of any product candidates we may develop may be larger than
we anticipate, enrollment of suitable participants in these clinical trials may be delayed or slower than we anticipate or patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations
to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs or independent ethics committees may require that we or our investigators suspend or terminate
clinical research or clinical trials of any product candidates we may develop for various reasons, including noncompliance with regulatory requirements, a finding of undesirable side effects or other unexpected characteristics, or that the
participants are being exposed to unacceptable health risks or after an inspection of our clinical trial operations or trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of any product candidates we may develop may be greater than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of any product candidates we may develop or other materials necessary to conduct clinical
trials of any product candidates we may develop may be insufficient or inadequate, including as a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
result of delays in the testing, validation, manufacturing and delivery of any product candidates we may develop to the clinical sites by us or by third parties with whom we have contracted to
perform certain of those functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having patients complete participation in a trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events associated with any product candidates we may develop that are viewed to
outweigh their potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in
healthcare services or cultural customs, or additional administrative burdens associated with foreign regulatory schemes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of ourselves or any third-party manufacturers, contractors or suppliers to comply with regulatory
requirements, maintain adequate quality controls or be able to provide sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the likelihood that we encounter such
difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing preclinical studies and clinical trials, as applicable. For example, on March&nbsp;18, 2020, the FDA announced its intention to temporarily postpone
routine surveillance inspections of domestic manufacturing facilities in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting
their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions. If we experience delays in the initiation, enrollment or completion of
any preclinical study or clinical trial of our product candidates, or if any preclinical studies or clinical trials of our product candidates are canceled, the commercial prospects of our product candidates may be materially adversely affected, and
our ability to generate product revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our clinical trials may increase our costs and slow down our product candidate development
and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our collaborators are required to conduct additional clinical trials or other testing of any product candidates we may
develop beyond those that we currently contemplate, if we or our collaborators are unable to successfully complete clinical trials or other testing of any product candidates we may develop, or if the results of these trials or tests are not positive
or are only modestly positive or if there are safety concerns, we or our collaborators may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining marketing approval for any such product candidates we may develop or not obtain marketing
approval at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings,
including boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to changes in the way the product is administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing
testing requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its
distribution in the form of a REMS or through modification to an existing REMS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be sued; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product development costs will also increase if we or our collaborators experience delays in clinical trials or other testing or in obtaining marketing
approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the
exclusive right to commercialize any product candidates we may develop, could allow our competitors to bring products to market before we do, and could impair our ability to successfully commercialize any product candidates we may develop, any of
which may harm our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays or difficulties in the enrollment
of patients in our clinical trials for <FONT STYLE="white-space:nowrap">AGENT-797</FONT> or any future trials, our receipt of necessary regulatory approvals could be delayed or prevented. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or our collaborators may not be able to continue our current and anticipated clinical trials for <FONT STYLE="white-space:nowrap">AGENT-797</FONT> or
initiate trials for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the EMA or other analogous regulatory authorities
outside the United States, or as needed to provide appropriate statistical power for a given trial. In addition, if patients are unwilling to participate in our clinical trials because of negative publicity from adverse events related to the
biotechnology, adoptive cell therapy, competitive clinical trials for similar patient populations, clinical trials in competing products or for other reasons, the timeline for recruiting patients, conducting studies and obtaining regulatory approval
of any product candidates we may develop may be delayed. Moreover, some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as any product candidates we may develop, and patients who would
otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#146; product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patient enrollment is
also affected by other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">size of the patient population and process for identifying patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design of the trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and efficacy of approved medications for the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to obtain and maintain patient informed consent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that enrolled patients will drop out before completion of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility and exclusion criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the product candidate under trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of adoptive cell therapy as a therapeutic approach; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to monitor patients adequately during and after treatment; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients, especially for those conditions
which have small patient pools. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As COVID-19 vaccination rates have increased in the general population, we have observed a decline in the
number of patients that are hospitalized with ARDS secondary to COVID-19, which has slowed our ability to enroll patients in our clinical trial for ARDS secondary to COVID-19. In July 2021, we began preparing a protocol to expand this trial to
include ARDS secondary to other life-threatening infectious diseases, including influenza. We are in the process of opening additional sites at which to complete our clinical trial for ARDS secondary to COVID-19 and, potentially, other
life-threatening infectious diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to
numerous risks unique to conducting business in foreign countries, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in establishing or managing relationships with CROs and physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different standards for the conduct of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for
patients with a particular disease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in locating qualified local consultants, physicians and partners; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements,
including the regulation of pharmaceutical and biotechnology products and treatments and of cell-based immunotherapies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
our clinical trials may also compete to recruit patients with other clinical trials for product candidates that are in a similar adoptive cell therapy area as our product candidates, and this competition could reduce the number and types of patients
available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some
of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enrollment delays in our clinical trials may result in increased development costs for any product candidates we may develop, which would cause the value of
our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate
ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because adoptive cell therapy is novel and the regulatory landscape that will govern any product candidates we may develop is uncertain and may change,
we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
regulatory requirements that will govern any novel cell-based immunotherapies we develop are not entirely clear and may change. Within the broader adoptive cell therapy field, we are aware of a limited number of adoptive cell therapies and products
that have received marketing authorization from the FDA and the EMA. Even with respect to more established products that fit into the categories of adoptive cell therapy, the regulatory landscape is still developing. Regulatory requirements
governing adoptive cell therapy products have changed frequently and will likely continue to change in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adverse developments in post-marketing
experience or in clinical trials conducted by others of adoptive cell therapy may cause the FDA, the EMA and other regulatory bodies to revise the requirements for development or approval of any product candidates we may develop or limit the use of
products utilizing adoptive cell therapy, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the
safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as the product
candidates we may develop can be more expensive and take longer than for other, better known or more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products
utilizing adoptive cell therapy in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our research programs or the
commercialization of resulting products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory review committees and advisory groups described above and the new guidelines they promulgate may
lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these
treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply
with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary trials for <FONT STYLE="white-space:nowrap">AGENT-797</FONT> or any other product candidates we may develop, the
marketing approval process is expensive, time-consuming and uncertain. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing,
product candidates we may develop, and our ability to generate revenue will be materially impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidates we may develop and the
activities associated with their development and commercialization, including their design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale, import, export and distribution, are subject to comprehensive
regulation by the FDA, the EMA and other regulatory authorities in the United States and by comparable authorities in other countries or jurisdictions. Failure to obtain marketing approval for a product candidate will prevent us from commercializing
the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. Securing regulatory approval requires the submission of extensive preclinical and clinical
data and supporting information to the various regulatory authorities for each therapeutic indication to establish the biological product candidate&#146;s safety, purity and potency. Securing regulatory approval also requires the submission of
extensive information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if approval is obtained at all and can vary substantially based upon a variety of factors, including the type, complexity and novelty
of the product candidates involved. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends <FONT STYLE="white-space:nowrap">non-approval</FONT> or restrictions on approval. Changes in marketing approval
policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may
decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing
approval of a product candidate. Regulatory authorities may also approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. These
regulatory authorities may require labeling that includes precautions or contra-indications with respect to conditions of use, or they may grant approval subject to the performance of costly post-marketing clinical trials. Regulatory authorities may
not approve the labeling claims that are necessary or desirable for the successful commercialization of any product candidates we may develop. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval
commitments as described above, which could render the approved medicine not commercially viable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we
may develop, the commercial prospects for those product candidates may be harmed and our ability to generate revenues will be materially impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we may develop from being marketed in such
jurisdictions, which, in turn, would materially impair our ability to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To market and sell any product candidates we may develop
in the European Union and other foreign jurisdictions, we or our third-party collaborators must obtain separate marketing approvals (a single one for the European Union) and comply with numerous and varying regulatory requirements. The approval
procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally
includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product candidate be approved for reimbursement before the product candidate can be approved for sale
in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or
jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not
receive necessary approvals to commercialize our medicines in any jurisdiction, which would materially impair our ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
June&nbsp;23, 2016, the United Kingdom electorate voted in favor of leaving the European Union, commonly referred to as &#147;Brexit.&#148; The United Kingdom formally left the European Union on January&nbsp;31, 2020 and a transition period, during
which European Union pharmaceutical law remained applicable to the United Kingdom ended on December&nbsp;31, 2020. Since the regulatory framework for pharmaceutical products in the United Kingdom relating to quality, safety and efficacy of
pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European Union directives and regulations, Brexit will materially impact the future regulatory regime
which applies to products and the approval of product candidates in the United Kingdom. Over time the United Kingdom is likely to develop its own legislation that diverges from that in the European Union, but at this time the impact of Brexit
remains uncertain and could have an adverse impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we, or any collaborators we may have, obtain marketing approvals for
any product candidates we develop, the terms of approvals and ongoing regulation of our product candidates could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our product candidates, which
could materially impair our ability to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidate for which we obtain marketing approval, along with the
manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities. These requirements
include submissions of safety and other post-marketing information and reports, facility registration and drug listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and
documents, and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine
may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates we develop, we, and such
collaborators, and our and their contract manufacturers will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we and such collaborators are
not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#146;, ability to market any future
products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial
condition and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the
market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA, the EMA and other regulatory agencies closely regulate the post-approval marketing and promotion of medicines to ensure that they are marketed only
for the approved indications and in accordance with the provisions of the approved labeling. The FDA, the EMA and other regulatory agencies impose stringent restrictions on manufacturers&#146; communications regarding
<FONT STYLE="white-space:nowrap">off-label</FONT> use, and if we market our medicines for <FONT STYLE="white-space:nowrap">off-label</FONT> use, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing
by the FDA and other federal and state enforcement agencies, including the Department of Justice. Violation of the Federal Food, Drug, and Cosmetic Act (FDCA) and other statutes, including the False Claims Act, and equivalent legislation in other
countries relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state and other countries&#146; health care fraud and abuse laws and state consumer protection
laws. Even if it is later determined we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions and have to divert significant management resources from other matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown problems with our medicines, manufacturers, or manufacturing processes, or failure to comply with
regulatory requirements, may yield various negative consequences, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on such medicines, manufacturers or manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a medicine; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the distribution or use of a medicine; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of warning or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the medicines from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of medicines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on future procurements with governmental authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension of any ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our medicines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and
resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we may develop and adversely affect our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with healthcare providers, third-party payors and patients as well as our
activities generally will be subject to a broad range of healthcare laws and regulations and any failure to comply with such laws and regulations could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and
diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain federal and state healthcare laws and regulations pertaining to product promotion, fraud and
abuse, privacy and price reporting and payment constrain the activities of pharmaceutical companies and their interactions with healthcare providers, third-party payors and patients. Those laws and regulations, including certain laws and regulations
applicable only if we have marketed products, include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any
person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting,
receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs
such as Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which, in addition to privacy
protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing
such products for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the
government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;federal sunshine&#148; law under the Healthcare
Reform Act, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare&nbsp;&amp; Medicaid Services within the U.S. Department of
Health and Human Services for <FONT STYLE="white-space:nowrap">re-disclosure</FONT> to the public, as well as ownership and investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback, anti-bribery and false claims
laws, which may apply to healthcare items or services that are reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some state laws also require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical
companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial
costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices
may not comply with healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs,
such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of
medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union Member States, such as the U.K. Bribery Act 2010. Infringement of
these laws could result in substantial fines and imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain European Union Member States must be publicly
disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual
European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in
reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The change in presidential administration may dramatically
shift the approach to regulatory reform in the United States, making it difficult to predict the effect on the FDA&#146;s regulatory oversight and implementation priorities. Any change in regulatory approach has the potential to negatively impact
our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the Trump Administration numerous actions, including the issuance of a number of executive orders, were taken that affected
the FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking or issuances of guidance. On January&nbsp;30, 2017, President Trump issued an executive order, applicable to all
executive agencies, including the FDA, that required that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by
law. These requirements are referred to as the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;two-for-one&#148;</FONT></FONT> provisions. For fiscal years 2018 and beyond, the executive order required agencies to identify
regulations to offset any incremental cost of a new regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within the Office of Management and on February&nbsp;2, 2017, the administration indicated that the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;two-for-one&#148;</FONT></FONT> provisions may apply not only to agency regulations, but also to significant agency guidance documents. While the Biden Administration is likely to
retract such policies and promote more active regulatory and administrative action by agencies, including the FDA, it is unclear exactly how the Biden Administration will structure its priorities, particularly with regard to FDA&#146;s oversight,
approval, review and regulation of novel biological products. Any change in regulation or regulatory approach, whether it impose constraints on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course or
expand the FDA&#146;s regulatory discretion, has the potential to negatively impact our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare and other reform legislation may
increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize any product candidates we may develop and affect the prices we, or they, may obtain. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been and continue to be ongoing efforts to implement legislative and regulatory changes
regarding the healthcare system. Such changes could prevent or delay marketing approval of any product candidates that we may develop, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for
which we obtain marketing approval. Although we cannot predict what healthcare or other reform efforts will be successful, such efforts may result in more rigorous coverage criteria, in additional downward pressure on the price that we, or our
future collaborators, may receive for any approved products or in other consequences that may adversely affect our ability to achieve or maintain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within the United States, the federal government and individual states have aggressively pursued healthcare
reform, as evidenced by the passing of the Healthcare Reform Act and the ongoing efforts to modify or repeal that legislation, as well as to implement new reforms. The Healthcare Reform Act substantially changed the way healthcare is financed by
both governmental and private insurers and contains a number of provisions that affect coverage and reimbursement of drug products and/or that could potentially reduce the demand for pharmaceutical products such as increasing drug rebates under
state Medicaid programs for brand name prescription drugs and extending those rebates to Medicaid managed care and assessing a fee on manufacturers and importers of brand name prescription drugs reimbursed under certain government programs,
including Medicare and Medicaid. Other aspects of healthcare reform, such as expanded government enforcement authority and heightened standards that could increase compliance-related costs, could also affect our business. Modifications to the
Healthcare Reform Act have been implemented under the Trump Administration and additional modifications or repeal may occur. Health care reforms have also been implemented in the wake of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic,
such as the expansion in Medicare coverage of telehealth services. There may be additional reforms promulgated by the Biden Administration as, for example, President Biden advocated for action to address the high cost of drugs during his campaign.
There are, and may continue to be judicial challenges to the various reform efforts. We cannot predict the ultimate content, timing or effect of any changes to the Healthcare Reform Act or other federal and state reform efforts. There is no
assurance that federal or state health care reform will not adversely affect our future business and financial results, and we cannot predict how future federal or state legislative, judicial or administrative changes relating to healthcare reform
will affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Federal and state governments have shown significant interest in implementing cost-containment programs to limit the growth of
government-paid healthcare costs, including price controls, waivers from Medicaid drug rebate law requirements, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. The private sector
has also sought to control healthcare costs by limiting coverage or reimbursement or requiring discounts and rebates on products. We are unable to predict what additional legislation, regulations or policies, if any, relating to the healthcare
industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation, regulations or policies would have on our business. Any cost-containment measures could significantly decrease the available coverage
and the price we might establish for our potential products, which would have an adverse effect on our net revenues and operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may
seek fast track, breakthrough or regenerative medicine advanced therapy designation by the FDA for product candidates but may be unable to obtain such designations. Even if such a designation is granted, it may not actually lead to a faster
development or regulatory review or approval process, and does not assure FDA approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FDA&#146;s fast track, breakthrough and regenerative
medicine advanced therapy (RMAT) programs are intended to expedite the development of certain qualifying products intended for the treatment of serious diseases and conditions. If a product candidate is intended for the treatment of a serious or
life-threatening condition and preclinical or clinical data demonstrate the product&#146;s potential to address an unmet medical need for this condition, the sponsor may apply for FDA fast track designation. A product candidate may be designated as
a breakthrough therapy if it is intended to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more
clinically significant endpoints. A product candidate may receive RMAT designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening condition, and preliminary clinical evidence
indicates that the product candidate has the potential to address an unmet medical need for such condition. While we may seek fast track, breakthrough and/or RMAT designation, there is no guarantee that we will be successful in obtaining any such
designation. Even if we do obtain such designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A fast track, breakthrough or RMAT designation does not ensure that the product
candidate will receive marketing approval or that approval will be granted within any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
particular timeframe. In addition, the FDA may withdraw fast track, breakthrough or RMAT designation if it believes that the designation is no longer supported by data from our clinical
development program. Fast track, breakthrough and/or RMAT designation alone do not guarantee qualification for the FDA&#146;s priority review procedures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek priority review designation by the FDA, but we may not be able to obtain such designation and, even if obtained, priority review may not
lead to a faster regulatory review or approval process and, in any event, would not assure FDA approval of any product candidates we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA determines that a product candidate is intended to treat a serious disease or condition and, if approved, would provide a significant improvement in
the safety or effectiveness of the treatment, prevention or diagnosis of such disease or condition, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review a marketing
application is six months from filing of the application, rather than the standard review period of ten months. We may request priority review for certain of our product candidates. The FDA has broad discretion with respect to whether or not to
grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may disagree and decide not to grant it. Moreover, a priority review designation does not
necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the <FONT
STYLE="white-space:nowrap">six-month</FONT> review cycle or thereafter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain orphan drug exclusivity for one or more of our
product candidates which we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug or biologic intended to treat a rare disease or
condition. A similar regulatory scheme governs approval of orphan product candidates by the EMA in the European Union. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for
which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for another product candidate for the same orphan therapeutic indication for
that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug
designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#146;s standards for
granting orphan drug exclusivity in the cell-based immunotherapies context are unclear and evolving. In order for the FDA to grant orphan drug exclusivity to one of our product candidates, the agency must find that the product candidate is indicated
for the treatment of a condition or disease that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of
developing and making the product candidate available for the disease or condition will be recovered from sales of the product in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does
not meet this standard. Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different product candidates can be approved for the same
condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product candidate for the same condition if the FDA concludes that the later product candidate is clinically superior in that it is shown to be
safer, more effective or makes a major contribution to patient care compared with the product that has orphan exclusivity. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially
defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#146;s policies related to orphan drug exclusivity, including for adoptive cell therapies, are
subject to ongoing evaluation. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to
its orphan drug regulations and policies, our business could be adversely impacted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Relationship with Agenus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may experience difficulty in separating our resources from Agenus. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agenus currently performs or supports some important corporate functions for our company pursuant to a services agreement. Because our services agreement was
negotiated in the context of a parent-subsidiary relationship, the terms of the agreement, including the fees charged for the services, may be higher or lower than those that would be agreed to by parties bargaining at arm&#146;s length for similar
services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because our operations have not been fully separated from Agenus in the past, we may have difficulty doing so. We may need to acquire resources
in addition to, and eventually in lieu of, those provided by Agenus to our company, and may also face difficulty in separating our resources from Agenus&#146; resources and integrating newly acquired resources into our business. At present, we plan
to prioritize separating our research and development functions from Agenus while continuing to rely on Agenus to provide human resources, finance, information technology, legal and other general and administrative functions. We plan to internalize
such functions in the future as our business evolves. We continue to rely on, and plan to continue relying on, access to Agenus&#146; facilities for our research and development and the eventual manufacturing of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Agenus may prioritize its own needs ahead of the services Agenus has agreed to provide us. Agenus employees who conduct services for us may
prioritize Agenus&#146; interests over our interests, or Agenus employees we rely upon to provide certain services may leave Agenus. Our business, financial condition and results of operations could be harmed if we have difficulty operating as a
standalone company, fail to acquire resources that prove to be important to our operations or incur unexpected costs in separating our resources from Agenus&#146; resources or integrating newly acquired resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will need to replicate or replace certain functions, systems and infrastructure to which we will no longer have the same access after this offering. We may
also need to make investments or hire additional employees to operate without the same access to Agenus&#146;s existing operational and administrative infrastructure. These initiatives may be costly to implement. Due to the scope and complexity of
the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to replace these services or enter into appropriate third-party agreements on terms and conditions, including cost, comparable to those
that we will receive from Agenus under our services agreement. Additionally, after the agreement terminates, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits
from Agenus. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively
or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Agenus, which may not be addressed in the services agreement and may diminish or be eliminated following this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the historical financial information included in this prospectus does not reflect the results we would have achieved as a standalone public
company during the periods presented, and may not be a reliable indicator of our future results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agenus will continue to own a majority of our common stock and will be able to exert control over
specific matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agenus and its officers and directors currently own over 90% of our common stock and will
continue to own a majority of our common stock after this offering is completed. Upon the closing of this offering, Agenus will beneficially own approximately 79.8% of the voting power of our outstanding common stock, or approximately 78.6% if the
underwriters exercise their option to purchase additional common stock from us in full based on our shares outstanding as of September 28, 2021. Therefore, even after this offering, Agenus will have the ability to substantially influence us through
this ownership position. For example, Agenus may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. Agenus&#146; interests may not
always coincide with our corporate interests or the interests of other stockholders, and they may act in a manner with which you may not agree or that may not be in the best interests of us or our other stockholders. So long as Agenus continues to
own a significant amount of our equity, it will continue to be able to strongly influence or effectively control our decisions. Agenus could remain our controlling stockholder for an extended period of time or indefinitely. Even if Agenus were to
control less than a majority of the voting power of our outstanding common stock, it may be able to influence the outcome of our corporate actions so long as it owns a significant portion of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to be a &#147;controlled company&#148; within the meaning of the applicable rules of Nasdaq and, as a result, will qualify for exemptions from
certain corporate governance requirements. If we rely on these exemptions, you will not have the same protections afforded to stockholders of companies that are subject to such requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, Agenus will continue to control a majority of the voting power of our outstanding common stock. As a result, we expect to be
a &#147;controlled company&#148; within the meaning of the Nasdaq corporate governance requirements. Under these rules, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another
company is a &#147;controlled company&#148; and may elect not to comply with certain corporate governance requirements, including the requirements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that a majority of the board of directors consists of independent directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for an annual performance evaluation of the nominating and corporate governance and compensation committees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we have a nominating and corporate governance committee that is composed entirely of independent directors
with a written charter addressing the committee&#146;s purpose and responsibilities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we have a compensation committee that is composed entirely of independent directors with a written charter
addressing the committee&#146;s purpose and responsibility. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use these exemptions upon the closing of this offering and we
may continue to use all or some of these exemptions in the future. As a result, you may not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Agenus sells a controlling interest in our company to a third party in a private transaction, you may not realize a change of control premium on
shares of our common stock, and we may become subject to the control of a presently unknown third party. In addition, Agenus may distribute a portion of the shares of our common stock it currently holds to its stockholders, which could impact our
share price or volatility. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agenus owns a significant equity interest in our company. This means that Agenus could choose to sell some or all of
its shares of our common stock in a privately negotiated transaction, which, if sufficient in size, could result in a change of control of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agenus&#146; ability to sell its shares of our common stock privately, with no requirement for a concurrent
offer to be made to acquire your shares of our common stock, could prevent you from realizing any change of control premium on your shares of our common stock that may otherwise accrue to Agenus on its private sale of our common stock. Additionally,
if Agenus privately sells its significant equity interest in our company, we may become subject to the control of a presently unknown third party. Such third party may have conflicts of interest with those of other stockholders. In addition, if
Agenus sells a controlling interest in our company to a third party, such a sale could negatively impact or accelerate any future indebtedness we may incur, and negatively impact any other commercial agreements and relationships, all of which may
adversely affect our ability to run our business as described herein and may have a material adverse effect on our operating results and financial condition. Furthermore, Agenus may elect to distribute to its stockholders a portion of the shares of
our common stock that it holds. Such Agenus stockholders may then sell the shares of our common stock into the public market. Such sales may not be subject to the volume, manner of sale, holding period and other limitations of Rule&nbsp;144 and,
therefore, may adversely impact our stock price or volatility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our directors and officers may have actual or potential conflicts of
interest because of their positions with Agenus. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Garo H. Armen, Ph.D. (Chairman of the Board), Jennifer S. Buell, Ph.D. (President, Chief
Executive Officer and Director), Brian Corvese (Director) and Ulf Wiinberg (Director) are all officers and/or directors of Agenus. These individuals own Agenus equity and Agenus equity awards. Their relationship with Agenus and the ownership of any
Agenus equity or equity awards creates, or may create the appearance of, conflicts of interest when we ask these individuals to make decisions that could have different implications for Agenus than the decisions have for us. In addition, our
certificate of incorporation provides for the allocation of certain corporate opportunities between us and Agenus. Under these provisions, neither Agenus or its other affiliates, nor any of their officers, directors, agents or stockholders, will
have any obligation to present to us certain corporate opportunities. For example, a director of our company who also serves as a director, officer or employee of Agenus or any of its other affiliates may present to Agenus certain acquisitions, <FONT
STYLE="white-space:nowrap">in-licenses,</FONT> potential development programs or other opportunities that may be complementary to our business and, as a result, such opportunities may not be available to us. To the extent attractive corporate
opportunities are allocated to Agenus or its other affiliates instead of to us, we may not be able to benefit from these opportunities. Additionally, conflicts of interest and certain other disputes may arise between us and Agenus, and we may not be
able to resolve favorably such disputes with respect to our past and ongoing relationships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Relationships with Third Parties
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may
not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We depend upon
independent investigators, such as medical institutions, universities, CROs, clinical data management organizations and clinical investigators to conduct our ongoing clinical trials for <FONT STYLE="white-space:nowrap">AGENT-797</FONT> and expect to
rely on third parties for future clinical trials. We also currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical testing. Any of these third parties may terminate their engagements with
us at any time under certain criteria. If we need to enter into alternative arrangements, it may delay our product development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our reliance
on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials for <FONT
STYLE="white-space:nowrap">AGENT-797</FONT> is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA, EMA and other regulatory authorities require us to comply with standards, commonly referred
to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. In the United States, we also are required to
register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal
sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we have designed the ongoing clinical trials for <FONT STYLE="white-space:nowrap">AGENT-797,</FONT> and will design any future
clinical trials for our product candidates, independent investigators at New York-Presbyterian/Weill Cornell Medical Center and Dana Farber Cancer Institute are conducting our clinical trial for <FONT STYLE="white-space:nowrap">AGENT-797</FONT> in
ARDS secondary to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and multiple myeloma, respectively, and third parties may also conduct our future clinical trials. As a result, many important aspects of our development programs, including their
conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies
and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside
parties may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have staffing difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to comply with contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience regulatory compliance issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undergo changes in priorities or become financially distressed; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">form relationships with other entities, some of which may be our competitors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may
subject us to unexpected cost increases that are beyond our control. If third-party investigators do not perform preclinical studies and clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory
requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development programs may be
materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by third parties, we could be required to repeat, extend the duration of or increase the size of any preclinical studies or clinical trials we
conduct and this could significantly delay commercialization and require greater expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also rely on other third parties to store and
distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines,
producing additional losses and depriving us of potential product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of materials for our
research programs, preclinical studies and clinical trials and expect to do so for commercialization of any product candidates that we may develop. This reliance on third parties increases the risk that we will not have sufficient quantities of such
materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any manufacturing facilities at the present time. We currently rely on third-party manufacturers for the manufacture of our
materials for preclinical studies and clinical trials. We do not have a long-term supply agreement with any of the third-party manufacturers, and we purchase our required supply on a purchase order basis. Additionally, we are in the process of
transferring our manufacturing to an in-house facility pursuant to the Intercompany General &amp; Administrative Services Agreement with Agenus, and we may experience delays or other difficulties associated with such a transition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms.
Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third party for regulatory compliance, quality assurance, safety and pharmacovigilance and
related reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside
the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of
approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any medicines that we may develop may compete with other product candidates and products for
access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have
arrangements in place for redundant supply for bulk drug substances. If any one of our current contract manufacturer cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential
alternative manufacturers who could manufacture any product candidates we may develop, we may incur added costs and delays in identifying and qualifying any such replacement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we utilize third parties to manufacture any product candidates or medicines we may develop, it may adversely affect our future profit margins and our
ability to commercialize any medicines that receive marketing approval on a timely and competitive basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If conflicts arise between us and our
collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our academic collaborators and strategic
partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners, however, may develop, either alone or with others, products in related fields
that are competitive with the product candidates we may develop that are the subject of these collaborations with us. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners
have rights, may result in the withdrawal of partner support for the product candidates we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our collaborators or strategic partners
could also become our competitors in the future. Our collaborators or strategic partners could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate
their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could harm our product development efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to establish collaborations on commercially reasonable terms, we may have to alter
our development and commercialization plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product development and research programs and the potential commercialization of any product
candidates we may develop will require substantial additional cash to fund expenses. For some of the product candidates we may develop, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and
potential commercialization of those product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a
definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#146;s evaluation
of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, the EMA or similar regulatory authorities outside the United States, the potential market for the subject product
candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a
challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available
to collaborate on and whether such a collaboration could be more attractive than the one with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also be restricted under future collaboration
agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among
large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to negotiate collaborations
on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our
other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to
increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be
able to develop product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent and other intellectual property protection for any product candidates we develop and for our cell-based
immunotherapies, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and therapies similar or identical to ours, and our ability to
successfully commercialize any product candidates we may develop, and our cell-based immunotherapies may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial
success will depend in large part on our ability to obtain and maintain patent, trademark, trade secret and other intellectual property protection of our cell-based immunotherapies, product candidates and other therapies, methods used to manufacture
them and methods of treatment, as well as successfully defending our patent and other intellectual property rights against third-party challenges. It is difficult and costly to protect our cell-based immunotherapies and product candidates, and we
may not be able to ensure their protection. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing the product candidates is dependent upon the extent to which we have
rights under valid and enforceable patents or trade secrets that cover these activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We seek to protect our proprietary position by <FONT STYLE="white-space:nowrap">in-licensing</FONT>
intellectual property relating to our platform technology and filing patent applications in the United States and abroad related to our cell-based immunotherapies and product candidates that are important to our business. If we or our licensors are
unable to obtain or maintain patent protection with respect to our cell-based immunotherapies and product candidates we may develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and
commercialize products and technology similar or identical to ours and our ability to commercialize any product candidates we may develop may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary
or desirable patents or patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all desired markets or in a particular market. It is also possible that we will fail to identify
patentable aspects of our research and development output in time to obtain patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential
or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may
breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the
differences between our inventions and the prior art allow our inventions to be deemed patentable over the prior art. Furthermore, publications of discoveries in the scientific literature lag behind the discoveries per se and patent applications in
the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all before the grant of patent rights. Therefore, we cannot be certain that we or our licensors were the first to make the
inventions claimed in any licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the
subject of much litigation in recent years. As a result, whether patent rights will be granted and the scope, validity, enforceability and commercial value of our patent rights are highly uncertain, and we may become involved in complex and costly
litigation. Our pending and future patent applications intended to protect our cell-based immunotherapies and product candidates we may develop may not be granted, and if granted may not effectively prevent others from commercializing competitive
technologies and products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No consistent policy regarding patentability in the field of cell-based immunotherapies has emerged in the United States.
Patentability in this field outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain,
enforce and defend our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our licensed patent rights. With respect to our <FONT STYLE="white-space:nowrap">in-licensed</FONT>
intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will be deemed valid and
enforceable and provide sufficient protection from competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the scope of claims being pursued in a patent application can be significantly
reduced before a patent is issued, and the scope of claims can be reinterpreted after issuance. Even if patent applications we <FONT STYLE="white-space:nowrap">in-license</FONT> or own currently or in the future were to issue as patents, they may
not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents that we own or <FONT
STYLE="white-space:nowrap">in-license</FONT> may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether any of our platform advances and product candidates we may develop will be protectable or
remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT>
manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to ours. Moreover, some of our future <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may in the future be <FONT STYLE="white-space:nowrap">co-owned</FONT> by our licensors with third
parties. If we are unable to obtain an exclusive license to the rights of such third-party <FONT STYLE="white-space:nowrap">co-owners</FONT> in such patents or patent applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able
to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of
our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our rights to develop and commercialize our cell-based immunotherapies and product candidates are subject, in part, to
the terms and conditions of licenses granted to us by others, including Agenus. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We depend on intellectual property licensed from third parties,
and our licensors may not act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights
that are important to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> and are dependent on certain rights and proprietary
technology from third parties that are important or necessary to the development of some of our cell-based immunotherapies and product candidates. If we fail to comply with our obligations under any license, the licensor may have the right to
terminate the license, in which event we would not be able to develop or market our cell-based immunotherapies or any other therapies or product candidates covered by the licensed intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">in-licenses</FONT> may not provide exclusive rights to use such intellectual property and technology in all relevant
fields of use and in all territories in which we may wish to develop or commercialize our cell-based immunotherapies and product candidates in the future. Some licenses granted to us may be expressly subject to certain preexisting rights held by the
licensor or certain third parties. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in certain territories or fields. If we determine that rights to such excluded fields are necessary to
commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to continue developing, manufacturing or marketing our product candidates. We may not be able to obtain such a
license on an exclusive basis, on commercially reasonable terms or at all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to access technology that is important to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not have complete control in the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications intended to
protect the technology that we license from third parties in the future. It is possible that our licensors&#146; enforcement of patents against infringers or defense of such patents against challenges to validity or enforceability may be less
vigorous than if we had conducted the proceedings ourselves. We cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced or defended in a manner consistent with the best interests of our
business. If our future licensors fail to prosecute, maintain, enforce and defend such patents, or if they lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and
commercialize any of the product candidates we may develop that rely in any way on such licensed rights could be adversely affected, and we may not be able to prevent competitors from making, using, selling and importing competing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future licensors may rely on third-party consultants or collaborators or on funds from third parties and may not be the sole and exclusive owners of the
intellectual property we have <FONT STYLE="white-space:nowrap">in-licensed.</FONT> If other third parties have ownership rights to our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, the license granted to us in jurisdictions where the
consent of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">co-owner</FONT> is necessary to grant such a license may not be valid and such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license such
patents to our competitors, and our competitors could market competing products and technology. If one or more of such joint owners breaches any pertinent inter-institutional or operating agreements, our rights to
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may be adversely affected. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of
operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event any of our third-party licensors takes the position that, in spite of our efforts, we have materially breached a
license agreement or have failed to meet certain obligations thereunder, it may elect to terminate the applicable license agreement or, in some cases, one or more license(s) under the applicable license agreement and such termination would result in
our no longer having the ability to develop and commercialize product candidates and technology covered by that license agreement or license. In the event of such termination of a third-party <FONT STYLE="white-space:nowrap">in-license,</FONT> or if
the underlying patents under a third-party <FONT STYLE="white-space:nowrap">in-license</FONT> fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. Any
of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our patent, patent applications and any future patents may not provide sufficient protection of our cell-based immunotherapies, our product candidates
and our future product candidates or result in any competitive advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agenus has assigned to us a U.S. patent and a U.S. patent application
directed to T cell receptor discovery technologies, as well as a number of U.S. and foreign patent applications directed to T cell receptors. Agenus has also assigned to us know-how that supports our cell-based immunotherapies and uses with respect
to treatment of particular diseases and conditions and that may provide us with the opportunity to obtain additional patent protection. U.S. provisional patent applications do not themselves mature into granted patent rights, but a <FONT
STYLE="white-space:nowrap">non-provisional</FONT> U.S. and other applications that can result in granted patent rights may claim the benefit of a provisional application if filed within 12 months of the filing date of the provisional application. In
any particular case, the failure to file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application claiming the benefit of the provisional application within the <FONT STYLE="white-space:nowrap">12-month</FONT> period could cause
us to lose the ability to obtain patent protection for the inventions disclosed in the provisional application. We cannot be certain that any patent applications that we file will issue as patents, and if they do, that such patents will protect our
cell-based immunotherapies or our product candidates, or that such patents will not be challenged, narrowed, circumvented, invalidated or held unenforceable. Any failure to obtain or maintain patent protection with respect to our cell-based
immunotherapies and product candidates could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Claims to therapeutic methods in a patent do not prevent a competitor or other third party from developing or marketing an identical product for an indication
that is outside the scope of such claims. Moreover, even if competitors or other third parties do not actively promote their product to treat the indications recited in such patent claims, health care providers may recommend that patients use the
competitor products <FONT STYLE="white-space:nowrap">off-label,</FONT> or patients may do so themselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology and
pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future may fail to result in issued patents with claims that
cover our product candidates or uses thereof in the United States or other countries. For example, during the pendency of any of our patent applications, we may be subject to a third party <FONT STYLE="white-space:nowrap">pre-issuance</FONT>
submission of prior art to the United States Patent and Trademark Office (the USPTO), or we may become involved in interference or derivation proceedings, or various <FONT STYLE="white-space:nowrap">pre-grant</FONT> third-party challenges in foreign
jurisdictions. Even if patents are issued, third parties may challenge the inventorship, validity, enforceability or scope thereof, including through opposition, revocation, reexamination, post-grant review and <I>inter partes</I> review
proceedings, and litigation. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our technology or
product candidates and compete directly with us, without payment to us, or result in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings
declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our licensor&#146;s priority of invention or other features of patentability with
respect to our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and product candidates. Furthermore, even if they are unchallenged,
our current and future patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we own with
respect to our cell-based immunotherapies and product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in
development, testing and regulatory review of new product candidates, the period of time during which we could market our product candidates under patent protection would be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given that patent applications in the United States and other countries are confidential for a period of time after filing, at any moment in time, we cannot
be certain that we or our licensors were in the past or will be in the future the first to file any patent application related to our cell-based immunotherapies or product candidates. In addition, some patent applications in the United States may be
maintained in secrecy until the patents are issued. As a result, there may be prior art of which we or our licensors are not aware that may affect the validity or enforceability of a patent claim, and we or our licensors may be subject to priority
disputes. For our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolios, we will rely on our licensors to determine inventorship, and to obtain and file inventor assignments of any given priority application before the filing of a
subsequent PCT or other application claiming the benefit of the priority application. The failure to do so in a timely fashion may give rise to a challenge as to entitlement of priority for such subsequent applications in jurisdictions outside the
United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be required to disclaim part or all of the term of certain patents or patent applications. There may be prior art of which we are
not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we or our future licensors are aware, but which we or our future licensors do not believe affects the validity or enforceability of a
claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that, if challenged, our current or future patents would be declared by a court, patent office or other governmental
authority to be valid or enforceable or that even if found valid and enforceable, a competitor&#146;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we
believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, that block our efforts or
potentially result in our product candidates or our activities being found to infringe such claims. It is possible that our competitors may have filed, and may in the future file, patent applications with claims covering our products or technology
similar to ours. Those patent applications may have priority over our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. The
possibility also exists that others will develop on an independent basis products that have the same effect as our product candidates and that do not infringe our patent or other intellectual property rights, or will design around the claims of our
patent applications or our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent applications that cover our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Likewise, our patent applications directed to our proprietary cell-based immunotherapies and our product candidates, if issued, would result in patents
expected to expire from 2038 through 2042, without taking into account any possible patent term adjustments or extensions. Our potential future patents may expire before, or soon after, our first product candidate achieves marketing approval in the
United States or foreign jurisdictions. Additionally, no assurance can be given that the USPTO or relevant foreign patent offices will grant any of the pending patent applications we own currently or in the future. Upon the expiration any patents,
we would lose the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
right to exclude others from practicing the respective claimed inventions. The expiration of these patents could have a material adverse effect on our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited foreign intellectual property rights and may not be able to protect our intellectual property and
proprietary rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending
patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In
addition, the laws of foreign countries do not protect intellectual property rights to the same extent as federal and state laws of the United States. Further, our intellectual property license agreements may not always include worldwide rights.
Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but
where enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent such competition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of
certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property rights, particularly those relating to biotechnology and pharmaceutical products, which could make
it difficult for us to stop the infringement of our patents or marketing of competing products by third parties in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our patents and other intellectual
property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent
applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Moreover,
the initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Accordingly,
our efforts to enforce or defend our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries
limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is
forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may
need to obtain additional licenses from Agenus and others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on
reasonable terms, if at all. In either event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of
which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affected product candidates, which could harm our business, financial condition, results of operations and prospects significantly. We cannot provide any assurances that there are no third-party
patents that might be enforced against our current therapies, including our cell-based immunotherapies, manufacturing methods, product candidates, or future methods or products, resulting in either an injunction prohibiting our manufacture or future
sales, or an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In spite of our
efforts, our licensors might conclude that we have materially breached our obligations under our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products
and technology covered by these license agreements. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the
freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of or cell-based immunotherapies or product candidates. Any of the foregoing could have a
material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects. Disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights to third parties under our collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement with respect to the use of the licensed technology in
relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the agreement under which we currently license intellectual property or technology from Agenus is complex, and certain provisions in such
agreement may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or
broaden what we believe to be the scope of Agenus&#146; rights to our intellectual property and technology, or increase what we believe to be our financial or other obligations under the agreement, any of which could have a material adverse effect
on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable
terms, we may be unable to successfully develop and commercialize the affected product candidates. As a result, any termination of or disputes over our intellectual property licenses could result in the loss of our ability to develop and
commercialize our cell-based immunotherapies or other product candidates or we could lose other significant rights, any of which could have a material adverse effect on our business, financial conditions, results of operations and prospects. It is
also possible that a third party could be granted limited licenses to some of the same technology, in certain circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be
successful in acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> necessary rights to key technologies or any product candidates we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future growth of our business will depend in part on our ability to <FONT STYLE="white-space:nowrap">in-license</FONT> or otherwise acquire the rights to
additional product candidates and technologies. We cannot assure you that we will be able to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the rights to any product candidates or technologies from third parties on acceptable terms or
at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, there has been extensive patenting activity in the field of cell-based immunotherapies, and
pharmaceutical companies, biotechnology companies and academic institutions are competing with us or are expected to compete with us in the field of cell-based immunotherapies and are filing patent applications potentially relevant to our business,
and there may be certain third-party patent applications that, if issued, may allow the third party to limit our activities. To market our product candidates, we may find it necessary or prudent to obtain licenses from such third party intellectual
property holders. However, we may be unable to secure such licenses or otherwise acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> the rights to any compositions, methods of use, processes or other technology from third parties that we
identify as necessary for product candidates we may develop and cell-based immunotherapies. We may also require licenses from third parties for certain other cell-based immunotherapies including certain delivery methods that we are evaluating for
use with product candidates we may develop. Some institutions may receive funding that obligates the institution to require certain terms from collaborators or that creates rights in the funding body, such as a government, that cannot be waived. The
obligations and rights may limit the scope or exclusivity of a potential patent right arising from the collaboration. For example, if a patent right is created as part of a collaboration with an entity funded by the United States government, the
government may have rights under the Bayh-Dole Act, including <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights to allow use of the patent right by the government or third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we may collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these
institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate
a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our
program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the licensing or acquisition of third party intellectual property rights is a highly competitive area, and a number of more
established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size,
capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third
party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing
intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The intellectual property landscape around cell-based immunotherapies is highly dynamic, and third parties may initiate legal proceedings alleging that
we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The field of cell-based immunotherapies is still in its infancy. Due to the intense research and development being conducted in this field by several
companies, including us and our competitors, the intellectual property landscape is evolving and in flux, and it may remain uncertain for the coming years. There may be significant intellectual property-related litigation and proceedings relating to
our <FONT STYLE="white-space:nowrap">in-licensed,</FONT> and other third-party, intellectual property and proprietary rights in the future, or any such intellectual property we may own in the future. Our commercial success depends upon our ability
and the ability of our collaborators and licensors to develop, manufacture, market and sell any product candidates that we may develop and to use our proprietary technologies without infringing, misappropriating or otherwise violating the
intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights, as well as administrative proceedings
for challenging patents, including interference, derivation, <I>inter partes</I> review, post grant review and reexamination proceedings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be subject to and may in the future become party to, or threatened with, adversarial proceedings
or litigation regarding intellectual property rights with respect to our cell-based immunotherapies and any product candidates we may develop, including interference proceedings, post-grant review, <I>inter partes</I> review, and derivation
proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office (EPO). Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist
in the fields in which we are developing our product candidates and such third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of the merits thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the biotechnology and pharmaceutical industries expand and more patents are issued, this increases the risk that our cell-based immunotherapies and product
candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover which of various types of therapies, products or their methods of use or
manufacture. We are aware of certain third-party patent applications that, if issued, may be construed to cover our cell-based immunotherapies and product candidates. There may also be third-party patents of which we are currently unaware with
claims to technologies, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that
may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon those patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A large number of patents and patent applications exist in our field. Third parties may allege that they have patent rights encompassing our product
candidates, technologies or methods. Third parties may assert that we are employing their proprietary technology without authorization and may file patent infringement lawsuits against us, and if we are found to infringe such third-party patents, we
may be required to pay damages, cease commercialization of the infringing technology or obtain a license from such third parties, which may not be available on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any product candidates we may develop in the United States and abroad may be adversely affected if we cannot obtain a license on
commercially reasonable terms to relevant third-party patents that cover our cell-based immunotherapies and product candidates. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would
find in our favor on questions of infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our
ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third party patents. To successfully challenge the validity of any such U.S. patent in federal court, we would
need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would
invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#146;s intellectual property rights, and we are unsuccessful in demonstrating that such patents are invalid or unenforceable, we could be required to obtain a
license from such third party to continue developing, manufacturing and marketing any product candidates we may develop and our technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even
if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make
substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our cell-based immunotherapies or product candidates or such
commercialization efforts may be significantly delayed, which could in turn significantly harm our business. We also could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or
product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#146; fees, if we are found to have willfully infringed a patent or
other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Defense of third-party claims of infringement, misappropriation or other violation of intellectual property rights involves substantial
litigation expense and would be a substantial diversion of management and employee time and resources from our business. Some third parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could
otherwise have a material adverse effect on our business, financial condition, results of operations and prospects. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if
securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Any of the foregoing events could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our present or future patents or the
patents of our licensors, which could be expensive, time-consuming, and unsuccessful and could result in a finding that such patents are unenforceable or invalid. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe our present or future patents or the patents of our licensing partners, or we may be required to defend against claims of
infringement. In addition, our present or future patents or the patents of our licensing partners also are, and may in the future become, involved in inventorship, priority, validity or enforceability disputes. Countering or defending against such
claims can be expensive and time-consuming. In an infringement proceeding, a court may decide that a patent is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our present patent,
or potential future owned patents, do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our present, or potential future, owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents at risk of being invalidated or interpreted narrowly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or
abroad, even outside the context of litigation. These types of mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes</I> review, interference proceedings, derivation proceedings and equivalent
proceedings in foreign jurisdictions (e.g., opposition proceedings). These types of proceedings could result in revocation or amendment to our patents such that they no longer cover our product candidates. The outcome for any particular patent
following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our future licensors, our patent counsel
and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and
perhaps all, of the patent protection on our therapies and/or product candidates. Defense of these types of claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources
from our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conversely, we may choose to challenge the patentability of claims in a third party&#146;s U.S. patent by requesting that the USPTO
review the patent claims in <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes</I> review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition
proceedings). We are currently challenging, and in the future may choose to challenge, third party patents in patent opposition proceedings in the EPO or another foreign patent office. Even if successful, the costs of these opposition proceedings
could be substantial, and may consume our time or other resources. If we fail to obtain a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates, cell-based
immunotherapies or other proprietary therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property
claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is
a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments,
and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce
the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may
be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and
continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other
government fees on patents and applications must be paid to the USPTO and foreign patent agencies outside of the United States over the lifetime of our present, or potential future, owned or licensed patents and applications. In certain
circumstances, we rely on our licensing partners to pay these fees. The USPTO and foreign patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during and after the patent application
process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can be cured in some instances by payment of a late fee or
by other means in accordance with the applicable rules, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in a partial or complete loss of patent rights in the relevant jurisdiction. Were a
non-compliance event to occur, our competitors might be able to enter the market with similar or identical products or therapies, which could have a material adverse effect on our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law in the United States and in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions could diminish the value of
patents in general, thereby impairing our ability to protect our cell-based immunotherapies and product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other
biotech and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is
therefore costly, time-consuming and inherently uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws could increase the
uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents. For example, under the Leahy-Smith America Invents Act (the America Invents Act), the United States changed from a
&#147;first to invent&#148; to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-inventor-to-file&#148;</FONT></FONT> patent system. Under a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-inventor-to-file&#148;</FONT></FONT> system, assuming that other requirements for patentability are met, the first inventor to file a patent application generally will be
entitled to a patent on an invention regardless of whether another inventor made the invention earlier. For example, under the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-inventor-to-file</FONT></FONT> system, if we and a
third party independently make the same invention, and the third party files a patent application in the USPTO before we do, the third party could be awarded the patent and we could be denied the patent even if we were the first to make the
invention. U.S. patent law requires </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us to be cognizant going forward of the time from invention to the filing of a patent application seeking to protect the invention. Since patent applications in the United States and most other
countries are confidential for at least a period of time after filing and in some cases until issuance, we cannot be certain that we or our licensors were the first to file any patent application related to our therapies or product candidates or the
first to invent any of the inventions claimed in our or our licensor&#146;s patents or patent applications. The America Invents Act also included a number of other significant changes to U.S. patent law, including provisions affecting the way patent
applications are prosecuted, allowing third party submission of prior art and establishing post-grant review, <I>inter partes</I> review and derivation proceedings. The full effects of these changes are still unclear because the USPTO continues to
promulgate new regulations and procedures in connection with the America Invents Act, and many of the substantive changes to patent law, including the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-inventor-to-file&#148;</FONT></FONT> provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions, and the
applicability of the act and new regulations on the specific patents discussed in this filing have not been determined and would need to be reviewed. Generally, the America Invents Act and its implementation could increase the uncertainties and
costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, recent U.S. Supreme Court
rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future,
this combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing
patents could change further in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how recent and future decisions or actions by
the courts, the U.S. Congress or the USPTO may impact the value of our patents. Similarly, any adverse changes in the patent laws or practice of other jurisdictions could also have a material adverse effect on our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate
amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. The term of a patent in any particular jurisdiction depends on the law governing patent term in
the jurisdiction. In most countries, including the United States, the basic term of a utility patent expires 20 years from the earliest effective <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date, if all necessary maintenance fees
are paid on time. The nature and duration of protection afforded by a patent varies from country to country and depends upon many factors, including the type of patent, the scope of its claims, the availability of regulatory-related extensions, the
availability of legal remedies in a particular country and the validity and enforceability of the patent. Some countries, including the United States, provide for patent term adjustment (PTA), which increases the term of a patent beyond its basic
term to compensate for certain delays in prosecution of the underlying patent application. Patent term extension (PTE) may also be available when a patent claims certain kinds of inventions requiring regulatory approval in order to market, including
certain pharmaceutical-related inventions, and can also increase the term of a patent beyond its basic term. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from
competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our
partners commercialize those candidates. As a result, our present, or potential future, owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain PTE and data exclusivity for any product candidates we may develop, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may
be eligible for limited PTE under the Drug Price Competition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Patent Term Restoration Act of 1984 (the Hatch-Waxman Amendments). The Hatch-Waxman Amendments provide for a PTE term of up to five years as compensation for patent term that could not be
enjoyed during the FDA regulatory review process. PTE cannot extend the remaining term of a patent such that the patent would expire beyond 14 years from the date of product approval, only one patent per product may be extended and only those claims
covering the approved drug or a method for using it may be extended. Even if we were to seek PTE, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure
to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be
less than we request. If we are unable to obtain PTE at all or the term of any such obtained extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial
condition, results of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our proprietary
knowledge, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for our technology and product candidates, we
also rely on <FONT STYLE="white-space:nowrap">know-how,</FONT> as well as confidentiality agreements, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements and invention assignment agreements with our employees, consultants and third
parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It
is our policy to require our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties to execute confidentiality agreements upon the commencement of employment,
consulting or other relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed by or made known to the individual or entity during the course of the party&#146;s
relationship with us is to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and that are related to
our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In the case of consultants and other third parties, the
agreements provide that all inventions conceived in connection with the services provided are our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our
proprietary technology and processes. Additionally, the assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of these parties may breach the agreements and disclose our proprietary information and we may not be able to obtain adequate remedies for
such breaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate
precautions, such as physical and technological security measures. However, <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. These measures may not provide adequate protection for our proprietary information. Our
security measures may not prevent an employee or consultant from misappropriating our proprietary knowledge and providing it to a competitor, and any recourse we might have for this type of misconduct may not result in an adequate remedy. In
addition, our proprietary technology and processes may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information were to be disclosed or
misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties
may assert that our employees, consultants or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, we employ individuals that are currently or were previously employed at universities, research
institutions or other biotechnology or pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT
STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these individuals have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such individual&#146;s current or former employer. Also, we may in the future be subject to claims that these individuals are violating <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements with their former employers.
We may then have to pursue litigation to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in
defending against such claims, litigation could result in substantial costs and be a distraction to our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of
hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. This type of
litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities, and we may not have sufficient financial or other resources to adequately conduct this type of litigation or
proceedings. For example, some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources. In any case, uncertainties
resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our
business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or
declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest.
At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or
trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names,
copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not
adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product candidates we may develop will eventually become commercially available in generic or biosimilar
product forms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make adoptive cell therapy products that are similar to any product candidates we may
develop or utilize similar cell-based immunotherapies but that are not covered by the claims of the patents that we license or may own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our license partners or current or future collaborators, might not have been the first to make the
inventions covered by issued patents or pending patent applications that we license or own, currently or in the future; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our license partners or current or future collaborators, might not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our license partners or current or future collaborators, may fail to meet our obligations to the U.S.
government regarding any patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or licensed intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending or potential future owned or licensed patent applications or those that we may
own in the future will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are prior public disclosures that could invalidate our patent, or parts of our patent;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may
later be issued with claims covering our product candidates or therapies similar to ours; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our current and future patents or patent applications omit individual(s) that should be
listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid, unenforceable or narrowed in scope, including as a
result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the claims of our patent or patent applications, if and when issued, may not cover our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the laws of foreign countries may not protect our proprietary rights or the proprietary rights of license
partners or current or future collaborators to the same extent as the laws of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventors of our current and future patents or patent applications may become involved with competitors,
develop products or processes that design around our patents, or become hostile to us or uncooperative as to the patents or patent applications on which they are named as inventors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have engaged in scientific collaborations in the past and will continue to do so in the future and our
collaborators may develop adjacent or competing products that are outside the scope of our patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product candidates we develop may be covered by third parties&#146; patents or other exclusive rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent application in order to maintain certain subject matter as trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently develop and file a patent application disclosing the same subject matter. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of
fraud or other misconduct by our employees, consultants, commercial partners and our principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European
Union and other jurisdictions, provide accurate information to the FDA, the EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data
accurately, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could
involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, the EMA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have
adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or
unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in
defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health and safety laws and regulations, we could become
subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and any contract
manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use,
storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and
flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of
contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain
environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our
research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance to cover us for costs and
expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance
coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or
injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health
and safety laws, regulations and permitting requirements. These current or future laws, regulations and permitting requirements may impair our research, development, or production efforts. Failure to comply with these laws, regulations and
permitting requirements also may result in substantial fines, penalties or other sanctions or business disruption, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health and safety laws and regulations.
Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Laws and regulations governing any of our international operations or those we may have in the future may preclude us from developing,
manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and
maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Foreign Corrupt Practices Act (the FCPA), prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of
value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA
also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation,
including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The
Securities and Exchange Commission (the SEC) is involved with enforcement of the books and records provisions of the FCPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly, the U.K. Bribery
Act 2010 has extra-territorial effect for companies and individuals having a connection with the United Kingdom. The U.K. Bribery Act prohibits inducements both to public officials and private individuals and organizations. Compliance with the FCPA
and the U.K. Bribery Act is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals
are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government
officials and have led to FCPA enforcement actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various laws, regulations and executive orders also restrict the use and dissemination outside of the
United States, or the sharing with certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion
outside of the United States has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates
outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or
debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims
are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to
procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and
security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to data
privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission
of personal information, including comprehensive regulatory systems in the United States and the European Union. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has
been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of
company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. For example, HIPAA
and its implementing regulations establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical
and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. We have also assumed contractual obligations related to
protecting the privacy and security of personal information. While we have determined that we are neither a &#147;covered entity&#148; nor a &#147;business associate&#148; directly subject to HIPAA, many of the U.S. health care providers, including
U.S. clinical trial sites, with which we interact are subject to HIPAA, and we have assumed contractual obligations related to protecting the privacy of personal information. Determining whether protected health information has been handled in
compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are
unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts and we could face civil and criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable
information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. For example, the
processing of personal data in the European Economic Area (the EEA), is subject to the General Data Protection Regulation (the GDPR), which took effect in May 2018. The GDPR increases obligations with respect to clinical trials conducted in the EEA,
such as in relation to the provision of fair processing notices, responding to data subjects who exercise their rights and reporting certain data breaches to regulators and affected individuals. The GDPR also requires us to enter certain contractual
arrangements with third parties that process GDPR-covered personal data on our behalf. The GDPR also increases the scrutiny applied to transfers of personal data from the EEA (including from clinical trial sites in the EEA) to countries that are
considered by the European Commission to lack an adequate level of data protection, such as the United States. The July 2020 invalidation by the Court of Justice of the European Union of the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy
Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States, has led to increased scrutiny on data transfers from the EEA to the United States generally and may increase our costs of
compliance with data privacy legislation. If our or our partners&#146; or service providers&#146; privacy or data security measures fail to comply with the GDPR requirements, we may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to &#128;20.0&nbsp;million or up to 4% of the total
worldwide annual turnover of the preceding financial year, whichever is higher, as well as claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill. Additionally, following Brexit, we must
comply with the GDPR and the United Kingdom GDPR, each regime having the ability to fine up to the greater of &#128;20.0&nbsp;million or 4% of global turnover for violations. The relationship between the United Kingdom and the European Union in
relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. In addition, we may be the subject of litigation
and/or adverse publicity, which could adversely affect our business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data privacy remains an evolving
landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our ongoing efforts to comply with evolving laws and regulations may be costly and require ongoing modifications to
our policies, procedures and systems. Our efforts to comply may also be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. Failure to comply with laws regarding data
protection would expose us to risk of enforcement actions taken by data protection authorities in the European Union and elsewhere and carries with it the potential for significant penalties if we are found to be
<FONT STYLE="white-space:nowrap">non-compliant.</FONT> Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such
failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages by data subjects, regulatory investigations and enforcement action, litigation and
significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources
and generate negative publicity, which could harm our business, financial condition, results of operations or prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee
Matters, Managing Growth, Information Technology and Our Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have a limited number of employees, and our future success
depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent on the
principal members of our management and scientific teams, as well as our majority stockholder. Such principal members are employed &#147;at will,&#148; meaning we or they may terminate the employment at any time. We do not maintain &#147;key
person&#148; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be
able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel
from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and
advisors, including our scientific <FONT STYLE="white-space:nowrap">co-founders,</FONT> may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability
to us. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development, regulatory and future sales and marketing
capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the
growth and advancement of our pipeline and becoming a public company, we expect to increase the number of our employees and the scope of our operations, particularly in the areas of drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development, regulatory affairs, and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational, and financial systems,
expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able
to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business
development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a growing
biotechnology company, we are actively pursuing new platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and
manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we
may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal
or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from
other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our
revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our product candidates, if approved, will depend in part on our ability to
effectively manage the future development and expansion of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of our third-party vendors,
collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from
accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our internal computer systems
and those of our current and any future third-party vendors, collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, computer hackers, malicious code, employee theft or misuse, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war and telecommunication and
electrical failures. While we seek to protect our information technology systems from system failure, accident and security breach, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our
development programs and our business operations, whether due to a loss of our proprietary information or other disruptions. For example, the loss of clinical trial data from ongoing or future clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated with the investigation, remediation and
potential notification of the breach to counter-parties and data subjects could be material. In addition, our remediation efforts may not be successful. If we do not allocate and effectively manage the resources necessary to build and sustain the
proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to
intellectual property or other proprietary information. In July 2020, the United States government charged a pair of Chinese hackers working on behalf of China&#146;s intelligence service in relation to the hacking of U.S.-based biotechnology
companies researching <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any disruption or security breach were to result in a
loss of, or damage to, our or our third-party vendors&#146;, collaborators&#146; or other contractors&#146; or consultants&#146; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability
including litigation exposure, penalties and fines, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we could become the subject of regulatory action or investigation, our competitive position could be harmed and the further development and commercialization of our product candidates could be
delayed. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
continuing outbreak <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;in</FONT> the United States and other countries may adversely affect our business and that of our suppliers, CROs or other third parties relevant to our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic</FONT> is impacting worldwide economic activity, particularly economic activity in the
United States, and poses the risk that we or our employees, contractors, suppliers, or other partners may be prevented or delayed from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested
or mandated by governmental authorities. The continued prevalence <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;and</FONT> the measures taken by the governments of countries affected could disrupt our supply chain and manufacturing, cause
diversion of healthcare resources away from the conduct of preclinical and clinical trial matters to focus on pandemic concerns, limit travel in a manner that interrupts key trial activities, such as trial site initiations and monitoring, delay
regulatory filings with regulatory agencies in affected areas or adversely affect our ability to obtain regulatory approvals. These disruptions could also affect other facets of our business, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit employees from outside of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our employees to travel between our facilities in the United States and the United Kingdom;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our CROs to conduct preclinical studies in countries outside of the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to import materials from outside of the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to export materials to our CROs and other third-parties located outside of the United States.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">The&nbsp;COVID-19&nbsp;pandemic</FONT> and mitigation measures also may have an adverse impact on
global economic conditions, which could adversely impact our business, financial condition or results of operations. Additionally, <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> has resulted in significant financial market
volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the recent past as a result of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19</FONT> outbreak could have an adverse effect on our
ability to access capital and on the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2020, we put in place a number of protective measures in response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. These measures included cancelling all commercial business travel, requesting employees to limit <FONT STYLE="white-space:nowrap">non-essential</FONT> personal travel, asking some employees to
self-quarantine at home, adjusting our facilities janitorial and sanitary policies, encouraging employees to work from home to the extent their job function enables them to do so, staggering the working hours of employees that are unable to perform
their duties remotely and reconfiguring our facilities for physical distancing. We have revisited these measures on a regular basis throughout the pandemic and we will continue to do so. Although restrictions imposed by governmental authorities have
begun to ease, if conditions worsen, we may need to implement new restrictive measures that could adversely affect our business. These measures have resulted, and any future actions are likely to result, in a disruption to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not know whether a market will develop for our common stock or what the market price of our common stock will be, and, as a result, it may be
difficult for you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before this offering, there was no public trading market for our common stock. If a
market for our common stock does not develop or is not sustained, it may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible
that in one or more future periods our results of operations may be below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will incur immediate and substantial dilution as a result of this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you purchase common stock in this offering, you will incur immediate and substantial dilution of $11.28 per share, representing the difference between the
initial public offering price of $12.00 per share, and our pro forma net tangible book value per share after giving effect to this offering. Moreover, we issued options in the past that allow the holders to acquire common stock at prices
significantly below the assumed initial public offering price. As of June&nbsp;30, 2021, there were 4,845,203 shares subject to outstanding options with a weighted-average exercise price of $1.35&nbsp;per share. To the extent that these outstanding
options are ultimately exercised or the underwriters exercise their option to purchase additional shares, you will incur further dilution. For a further description of the dilution you will experience immediately after this offering, see
&#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our
common stock, the price of our common stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will rely in part on the research and reports
that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our common
stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our common stock, the price of our common stock could decline. If one or more of these analysts
cease to cover our common stock, we could lose visibility in the market for our common stock, which in turn could cause our common stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which
could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of
shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common
stock. After this offering, we will have 32,587,301 shares of common stock outstanding, or 33,087,301 shares if the underwriters exercise their option to purchase additional shares in full, in each case based on the 24,177,313 shares of our common
stock outstanding as of June&nbsp;30, 2021. Of these shares, the 3,333,334 shares (or 3,833,334 shares if the underwriters exercise their option to purchase additional shares in full) we are selling in this offering may be resold in the public
market immediately, unless purchased by our affiliates. The remaining 24,177,313 shares are currently restricted under securities laws or as a result of <FONT STYLE="white-space:nowrap">lock-up</FONT> or other agreements, but will be able to be sold
after this offering as described in the &#147;Shares Eligible for Future Sale&#148; section of this prospectus. We also plan to register all shares of common stock that we may issue under our equity compensation plans or that are issuable upon
exercise of outstanding options. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the &#147;Underwriting&#148; section of this prospectus. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the
market price of our common stock could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to establish and maintain proper and effective internal control over financial
reporting, our operating results and our ability to operate our business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring that we have adequate internal financial and
accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be <FONT STYLE="white-space:nowrap">re-evaluated</FONT> frequently. Our internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In
connection with this offering, we intend to begin the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (SOX Section&nbsp;404), which will
require annual management assessment of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectiveness of our internal control over financial reporting. While we continue to outsource our finance and accounting personnel, we have begun recruiting additional finance and accounting
personnel with certain skill sets that we will need as a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Implementing any appropriate changes to our internal controls may distract our
officers and employees, entail substantial costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain
that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#146; perceptions that our internal controls are inadequate or that
we are unable to produce accurate financial statements on a timely basis may harm our common stock price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth
company&#148; and a &#147;smaller reporting company,&#148; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we
remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required
to comply with the auditor attestation requirements of SOX Section&nbsp;404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a
supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to
other public companies. In this prospectus, we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock
less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our common stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our amended and restated certificate of incorporation, our amended and
<FONT STYLE="white-space:nowrap">restated&nbsp;by-laws&nbsp;and</FONT> Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent
attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, amended and <FONT
STYLE="white-space:nowrap">restated&nbsp;by-laws&nbsp;and</FONT> Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider
favorable, including transactions in which you might otherwise receive a premium for your shares. Our amended and restated certificate of incorporation <FONT STYLE="white-space:nowrap">and&nbsp;by-laws,&nbsp;which</FONT> will become effective upon
the closing of this offering, include provisions that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize &#147;blank check&#148; preferred stock, which could be issued by our board of directors without
stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specify that special meetings of our stockholders can be called only by our board of directors, the Chairman of
our board of directors or our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that vacancies on our board of directors may, unless and until filled by our stockholders, be filled only
by a majority of directors then in office, even though less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not permit any stockholder to cumulate votes at any election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expressly authorized our board of directors to make, alter, amend or repeal our amended and restated <FONT
STYLE="white-space:nowrap">by-laws;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and
restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, alone
or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby
depressing the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of
Section&nbsp;203 of the General Corporation Law of the State of Delaware (the DGCL), which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of
the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any provision of our amended and restated certificate of incorporation, amended and <FONT STYLE="white-space:nowrap">restated&nbsp;by-laws&nbsp;or</FONT>
Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing
to pay for our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of incorporation and amended and restated
<FONT STYLE="white-space:nowrap">by-laws</FONT> designate the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our
stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation provides that, subject to limited exceptions, the state or federal courts within the State of Delaware will be exclusive forums for (1)&nbsp;any derivative action or proceeding brought on our behalf,
(2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the DGCL,
our amended and restated certificate of incorporation or our amended and <FONT STYLE="white-space:nowrap">restated&nbsp;by-laws,</FONT> (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our amended and restated
certificate of incorporation or our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> or (5)&nbsp;any other action asserting a claim against us that is governed by the internal affairs doctrine. Under our amended and restated
certificate of incorporation, this exclusive forum provision will not apply to claims that are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of
the State of Delaware does not have subject matter jurisdiction and explicitly not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended
(the Securities Act), the Exchange Act of 1934, as amended (the Exchange Act), or the rules and regulations thereunder. Furthermore, our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> also provide that unless we consent in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action
arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of
incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> described above. These choice of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of
incorporation or amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with
resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in this offering.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial public offering price for our common stock was determined through negotiations with the underwriters. This initial public offering
price may vary from the market price of our common stock after the offering. As a result, you may not be able to sell your common stock at or above the initial public offering price. Some of the factors that may cause the market price of our common
stock to fluctuate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of existing or new competitive product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and results of preclinical studies or clinical trials for any product candidates that we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure or discontinuation of any of our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors,
or announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or changing views regarding the use of allogeneic cell therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement or termination of collaborations for our product development and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our research programs, clinical development programs or product
candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to develop additional product candidates or products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us, our insiders or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ongoing and future impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and actions taken
to slow its spread; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect
the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. Following periods of such volatility in the
market price of a company&#146;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities litigation could result in substantial costs and divert management&#146;s attention and resources from our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not expect to pay any dividends for the foreseeable future. Investors in this offering may never obtain a return on their investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our
common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the
only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will
incur increased costs as a result of operating as a standalone public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have historically operated our business as part of a public company. As a standalone public company, and particularly after we are no longer an emerging
growth company, we will incur significant legal, accounting and other expenses that we have not incurred historically. The Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing
requirements of Nasdaq, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices.
We expect that we will need to hire additional accounting, finance and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel will need to
devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we
expect that the rules and regulations applicable to us as a standalone public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and
retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often
subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing
uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad
discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot specify with certainty the particular
uses of the net proceeds we will receive from this offering. Our management will have broad discretion in the application of the net proceeds, including for any of the purposes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
described in &#147;Use of Proceeds.&#148; Accordingly, you will have to rely upon the judgment of our management with respect to the use of the proceeds, with only limited information concerning
management&#146;s specific intentions. Our management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply
these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus are forward-looking
statements. In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148;
&#147;target,&#148; &#147;project,&#148; &#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions, although not
all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our research and development programs, preclinical studies and
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate, and the timing of,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">preclinical&nbsp;proof-of-concept</FONT></FONT><I>&nbsp;in vivo</I>&nbsp;for multiple programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance any product candidates that we may develop and successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to quickly leverage our initial programs and to progress additional programs to create a clinical
portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our strategic plans for our business, programs, product candidates and technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our collaborative relationship with Agenus Inc. (Agenus), as well as our ability to
identify and enter into future license agreements and collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of proceeds from this offering, estimates of our expenses, capital requirements and needs for additional
financing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus are only predictions and are based largely on our current expectations and
projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of
known and unknown risks, uncertainties and assumptions, including those described under the sections in this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on
these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the
forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by
applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. The forward-looking statements contained in
this prospectus are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds to us from the sale of the shares of common stock in this offering will be approximately $34.3&nbsp;million, or approximately
$39.9&nbsp;million if the underwriters exercise their option to purchase additional shares in full, after deducting underwriting discounts and commissions and estimated offering expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2021, we had a cash balance of $1.7 million. The principal purposes of this offering are to increase our financial flexibility, create a public
market for our common stock and to facilitate our access to the public equity markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently expect to use the net proceeds from this offering,
together with our existing cash, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $7.8 million to fund our planned early development of our monotherapy and combination study of
AGENT-797 with PD-1/CTLA-4 checkpoint inhibitors for the treatment of patients with solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma and hepatocellular carcinoma; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $1.3&nbsp;million to fund the development of AGENT-797 through completion of our Phase&nbsp;1
clinical trial for the treatment of patients with multiple myeloma; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $3.3&nbsp;million to fund the development of AGENT-797 through completion of our planned
Phase&nbsp;1/2 clinical trial for the treatment of patients with GvHD; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $1.8&nbsp;million to fund the development of AGENT-797 through completion of our Phase&nbsp;1
clinical trial for the treatment of patients with ARDS secondary to COVID-19 and, potentially, expanding into other infectious diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $2.0 million to fund IND-enabling studies, process development and manufacturing of our
CAR-iNKT-programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $4.1&nbsp;million to fund our process validation and manufacturing batches for AGENT-797; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and other general corporate purposes, which includes funding for additional
research, hiring additional personnel, capital expenditures and the costs of operating as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may find it necessary or
advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds; however, no proceeds from the offering will be used to fund Agenus operations. Pending the uses described above, we plan
to invest the net proceeds from this offering in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and expansion of
our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition,
results of operations, capital requirements, business prospects and other factors our board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. Our ability to pay cash dividends on our capital
stock in the future may also be limited by the terms of any preferred securities we may issue or agreements governing any indebtedness we may incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash and capitalization as of June&nbsp;30, 2021: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis, to give effect to the conversion of our convertible affiliated note, as amended, into
5,076,654 shares of our common stock, in accordance with the terms of the note (see Note 10 to the consolidated financial statements found elsewhere in this prospectus), based on the initial public offering price of $12.00 per share; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis, to further reflect the sale and issuance by us of&nbsp;3,333,334 shares of
common stock in this offering at an initial public offering price of $12.00&nbsp;per share, after deducting underwriting discounts and commissions and estimated offering expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read the information in this table together with the consolidated financial statements and related notes to those statements, as well as the
information set forth under the heading &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;forma&nbsp;as<BR>adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,658,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,658,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,928,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,526,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,909,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock ($0.00001 par value; no shares authorized, issued and outstanding, actual and pro
forma; 5,000,000 shares authorized and no shares issued or outstanding, pro forma as adjusted)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock ($0.00001 par value; actual: 35,000,000 shares authorized, actual: 24,177,313 shares
issued and outstanding; pro forma: 35,000,000 shares authorized, 29,253,967 shares issued and outstanding; pro forma as adjusted: 150,000,000 shares authorized, 32,587,301 shares issued and outstanding)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,074,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,599,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,869,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,335,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,335,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,335,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,916,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,916,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,916,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,177,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,651,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,618,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,268,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 24,001,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outstanding share information in the table above excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,845,203 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2021
having a weighted average exercise price of $1.35 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,373,485 shares of common stock available for future issuance under the 2018 Plan as of June&nbsp;30, 2021;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">695,750 restricted stock units granted to our president and chief executive officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,000,000 shares of common stock reserved for issuance under the 2021 Plan, which will become effective in
connection with this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">375,000 shares of common stock reserved for issuance under the 2021 ESPP, which will become effective in
connection with this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_9"></A>DILUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, you will experience immediate and substantial dilution in the pro forma as adjusted net tangible book value
of your shares of common stock. Dilution in pro forma as adjusted net tangible book value represents the difference between the assumed initial price to the public per share of our common stock and the pro forma as adjusted net tangible book value
per share of our common stock immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) per share represents our total tangible
assets, less total liabilities divided by the number of shares of outstanding common stock as of June&nbsp;30, 2021, or 24,177,313&nbsp;shares. The historical net tangible deficit of our common stock as of June&nbsp;30, 2021 was $(63.2) million, or
$(2.61) per share. Our pro forma net tangible book value as of June&nbsp;30, 2021 was $(10.7) million, or $(0.36) per share. Pro forma net tangible book value represents the amount of our total tangible assets, less our total liabilities, divided by
the pro forma number of shares of our common stock outstanding after giving effect to the conversion of our convertible affiliated note into an aggregate of 5,076,654&nbsp;shares of common stock upon the closing of this offering, based upon the
initial public offering price of $12.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the conversion of our convertible affiliated note as described above and our
sale of 3,333,334 shares of common stock in this offering at the initial public offering price of $12.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted
net tangible book value as of June&nbsp;30, 2021 would have been approximately $23.6&nbsp;million, or $0.72 per share. This represents an immediate increase in pro forma as adjusted net tangible book value of $1.09 per share to existing stockholders
and an immediate dilution of $11.28 per share to investors participating in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share
basis to new investors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible deficit per share of common stock as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share of common stock attributable to pro forma
adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share of common stock as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share of common stock attributable to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share of common stock after this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share of common stock to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase additional shares of common stock from us in this offering, our
pro forma as adjusted net tangible book value per share after the offering would be $0.88, and the dilution per share to new investors would be $11.12, in each case based on the initial public offering price of $12.00 per share, after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes, on the pro forma as adjusted basis as of June&nbsp;30, 2021, the differences
between the number of shares of common stock purchased from us, the total consideration paid to us in cash and the average price per share paid by existing stockholders (including Agenus) and by investors participating in this offering. The table
below excludes 29,191,348 shares for which no cash consideration was received. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;price</B><br><B>per&nbsp;share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,462,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,800,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,933,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,200,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,395,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Including shares for which no cash consideration was received, the number of shares held by existing stockholders following
this offering will be 94.1% of the total number of shares of common stock to be outstanding upon completion of this offering, and the number of shares of common stock held by investors participating in this offering will be 5.9% of the total number
of shares of common stock to be outstanding upon completion of this offering. In addition, if the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares held by existing stockholders will be reduced to
92.6% of the total number of shares of common stock to be outstanding upon completion of this offering, and the number of shares of common stock held by investors participating in this offering will be further increased to 7.4% of the total number
of shares of common stock to be outstanding upon completion of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding following this
offering is based on 24,177,313 shares of common stock outstanding as of June 30, 2021. The outstanding share information in the tables above excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,845,203 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2021
having a weighted average exercise price of $1.35 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,373,485 shares of common stock available for future issuance under the 2018 Plan as of June&nbsp;30, 2021;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">695,750 restricted stock units granted to our president and chief executive officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,000,000 shares of common stock reserved for issuance under the 2021 Plan, which will become effective in
connection with this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">375,000 shares of common stock reserved for issuance under the 2021 ESPP, which will become effective in
connection with this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, we may choose to raise additional capital through the sale of equity or convertible debt
securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. New investors will experience further dilution if any of our outstanding options are exercised,
new options are issued and exercised under our equity incentive plans or we issue additional shares of common stock, other equity securities or convertible debt securities for lower consideration per share than in this offering in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of our financial condition and results of operations should be read in
conjunction with our audited consolidated financial statements, our unaudited interim condensed consolidated financial statements, and the related notes to those statements included elsewhere in this prospectus. In addition to historical financial
information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results
may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under &#147;Risk Factors&#148; and elsewhere in this prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical
company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that
combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of
tumors and infected cells and suppress graft-versus-host-disease (GvHD). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly
versatile application for therapeutic development in cancer and immune diseases. We have leveraged our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline for both native and engineered iNKT cells, and
have multiple preclinical and clinical readouts expected in 2021 and 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business activities include product research and development,
manufacturing, regulatory and clinical affairs, corporate finance and development, and support of our collaborations. Our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace.
Certain of our operations are fully integrated with Agenus, including our finance, human resources and legal functions. We are a party to an Intercompany General &amp; Administrative Services Agreement and an Intellectual Property Assignment and
License Agreement with Agenus. Under the Intercompany General &amp; Administrative Services Agreement, Agenus provides us with administrative support, including, without limitation, financial, legal, information technology and human resources
administrative support and non-administrative services as may be agreed to between the parties from time to time, and use of certain facilities. Under the Intellectual Property Assignment and License Agreement, Agenus assigned patent rights and
know-how related to our technology to us. We also have a field-limited exclusive license under certain Agenus patents and know-how. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced
product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. We have commenced a Phase&nbsp;1 clinical trial of <FONT STYLE="white-space:nowrap">AGENT-797</FONT> for the treatment of multiple myeloma and expect to report
top-line data from this trial in the fourth quarter of 2021. In addition, in August 2021, we received FDA clearance to initiate a clinical study for the treatment of solid tumors, which we intend to advance as our lead indication for <FONT
STYLE="white-space:nowrap">AGENT-797</FONT> as a monotherapy and in combination with checkpoint inhibitors. We currently expect to have preliminary readouts from this clinical trial in the first half of 2022 in indications that may lead to an
accelerated path to marketing approval. We also intend to initiate a Phase 1 study of AGENT-797 in GvHD in the fourth quarter of 2021, and we currently expect to report top-line data from this trial in the second half of 2022. Finally, with the
unique circumstances of the COVID-19 pandemic, we were able to commence first-in-human studies of AGENT-797 in ARDS secondary to COVID-19 and are preparing a protocol to expand into ARDS secondary to other life-threatening infectious diseases such
as influenza. We currently expect to report top-line data from this Phase&nbsp;1 trial in the fourth quarter of 2021 and a Phase&nbsp;2 trial in the second half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are advancing a pipeline of next-generation allogeneic, engineered iNKT programs. Our two most advanced engineered programs are (1) a CAR-iNKT
program targeting B-cell maturation antigen (BCMA), which we refer to as BCMA-CAR-iNKT, and (2) a tumor stromal targeting CAR-iNKT program, which we refer to as stromal target-CAR-iNKT. These programs are both in preclinical development and we
expect to file IND applications for each in 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development expenses for the six months ended June 30, 2021 and the years ended
December&nbsp;31, 2020 and 2019 were $6.7 million, $9.5 million and $19.7 million, respectively. We have incurred losses since our inception. As of June 30, 2021, we had an accumulated deficit of $62.9&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date we have been reliant on Agenus to finance our operations. We expect to continue to incur operating losses and negative cash flows for the foreseeable
future. Until we are successful in our efforts to raise capital, and because the completion of such is not entirely within our control, a substantial doubt exists about our ability to continue as a going concern for a period of one year after the
date of filing of these financial statements. Management continues to address our liquidity position and will adjust spending as needed in order to preserve liquidity. Our future liquidity needs will be determined primarily by the success of our
operations with respect to the progression of our product candidates and key development and regulatory events in the future. Potential sources of additional funding include: (1)&nbsp;pursuing collaboration,
<FONT STYLE="white-space:nowrap">out-licensing</FONT> and/or partnering opportunities for our portfolio programs and product candidates with one or more third parties, (2)&nbsp;selling assets, (3)&nbsp;securing additional debt financing and/or
(4)&nbsp;selling equity securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Historical Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Six Months Ended June 30, 2021 Compared to the Six Months Ended June 30, 2020</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development
(R&amp;D) expense includes compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions. R&amp;D expense increased 8% to $6.7 million for the six months ended June 30, 2021 from $6.2 million for the six
months ended June 30, 2020. This increase is primarily due to the increased costs associated with an increase in preclinical activities, the initiation of our clinical trials late in 2020 and increased costs associated with the allocation of Agenus
services, partially offset by reduced payroll costs and the reduced activity of our Belgium subsidiary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense (G&amp;A) consists primarily of personnel costs, facility expenses, and professional fees. G&amp;A expense increased 30% to
$1.5 million for the six months ended June 30, 2021 from $1.1 million for the six months ended June 30, 2020. This increase results primarily from increased stock-based compensation expense and increased costs associated with the allocation of
Agenus services, partially offset by the reduced activity of our Belgium subsidiary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in fair value of convertible affiliated note </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible affiliated note reflects the result of our fair value measurement using a scenario-based methodology evaluating the terms
of our note at the balance sheet date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense relates to our outstanding convertible affiliated note and has increased 39%, to $1.5 million for the six months ended June 30, 2021 from $1.1
million for the six months ended June 30, 2020, due to the increased principal amount outstanding period over period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Year Ended December&nbsp;31,
2020 Compared to the Year Ended December 31, 2019</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognized $690,000 of grant revenue during the year ended December&nbsp;31, 2019, related to our agreement with the Belgium Walloon Region Government.
During 2020, we discontinued research efforts related to this agreement and accordingly no revenue was recognized during the year ended December 31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R&amp;D expense decreased 52% to $9.5 million for the year ended December 31, 2020 from $19.7 million for the year ended December 31, 2019. This decrease
results primarily from the discontinuation of our research efforts in Belgium in addition to a reduction in our workforce during 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and
administrative expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">G&amp;A expense decreased 66% to $1.3 million for the year ended December 31, 2020 from $3.8 million for the year ended
December 31, 2019. This decrease results primarily from the discontinuation of our research efforts in Belgium in addition to a reduction in our workforce during 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in fair value of convertible affiliated note </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible affiliated note reflects the result of our fair value measurement using a scenario-based methodology evaluating the terms
of our note at the balance sheet date. <I></I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense relates to our outstanding convertible affiliated note and has increased $880,000 or 56%, to $2.4 million for the year ended December 31, 2020
from $1.6 million for the year ended December 31, 2019, due to the increased principal amount outstanding period over period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development
Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R&amp;D program costs include compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;six&nbsp;months</B><br><B>ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$1,480,172</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,007,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,823,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,197,943</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,025,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,051,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocated services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">697,786</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">430,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,306,421</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,349,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$6,682,322</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,509,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,654,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates are in various stages of development and significant additional expenditures will be required if we
start new clinical trials, encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations and/or bring our product candidates to market. The total cost of any particular clinical
trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, number of patients and trial sponsorship. The process of obtaining and maintaining regulatory approvals for new products is lengthy,
expensive and uncertain. Because of the current stage of our product candidates, among other factors, we are unable to reliably estimate the cost of completing our research and development programs or the timing for bringing such programs to various
markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows are likely to commence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred annual
operating losses since inception, and we had an accumulated deficit of $62.9&nbsp;million as of June 30, 2021. We expect to incur losses over the next several years as we continue development of our technologies and product candidates, manage our
regulatory processes, initiate and continue clinical trials, and prepare for potential commercialization of products. To date, we have been reliant on Agenus to finance our operations. From our inception through June 30, 2021, we received funding of
$42.8&nbsp;million from Agenus.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2021, we had a convertible affiliated note (the Note) outstanding of $42.8&nbsp;million in
principal plus accrued and unpaid interest of $6.0&nbsp;million payable in cash or equity shares at Agenus&#146; election upon certain triggering events described in Note 10 to our audited consolidated financial statements included within this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2018, we entered into an agreement with the Belgium Walloon Region Government (the Walloon Region) in which the Walloon Region
agreed to provide a grant of &#128;1.3 million and a repayable advance of &#128;8.3&nbsp;million for the development of one of our research programs. As of June 30, 2021, we received $881,000 of the grant portion and $5.5 million of the repayable
advance. During 2020, we discontinued research efforts related to this program and are evaluating our options in accordance with the terms of the agreement. We recognized the grant portion received as income during the years ended December 31, 2019
and 2020 and have included the repayable advance balance of $5.5 million in other current liabilities in our consolidated balance sheet at June&nbsp;30, 2021 while we finalize the termination of the agreement with the Walloon Region. We received a
notice from the Walloon Region in February 2021 informing us that, pursuant to the terms of the agreement, they have assumed we plan to exploit the results of our research under the program and as such expect us to reimburse the repayable advance,
and we have responded to the Walloon Region that we do not plan to exploit the results of such research. It is uncertain at this time if we will be obligated to repay any or all of this advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, we entered into a promissory note with Bank of America, NA for aggregate loan proceeds of $356,000 (the Loan) under the Small Business
Administration (the SBA) Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the CARES Act). We believe we used at least 60% of the Loan proceeds for covered payroll costs in accordance with the relevant
terms and conditions of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act. The Loan has a two-year term and bears interest at a rate of 1% per annum. The Loan may be forgiven partially or fully if the Loan proceeds are
used for covered costs provided that such amounts are incurred during the covered period commencing on receipt of the Loan proceeds and at least 60% of any forgiven amount has been used for covered payroll costs. The Loan was forgiven in August
2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cash balance at June 30, 2021 was $1.7 million. Until we are successful in our efforts to raise capital, which is not entirely within our
control, a substantial doubt exists about our ability to continue as a going concern for a period of one year after the date of filing of these financial statements. We believe that the net proceeds from this offering, together with our existing
cash, will enable us to fund our operating expenses and capital expenditure requirements through the end of 2023. There is no guaranty that Agenus will continue funding our operations at the current level, or at all. In addition, the ability of
Agenus to continue to provide financial support, if it chooses to do so, is dependent on its ability to secure additional funding. In May 2021, Agenus entered into a license agreement with Bristol-Myers Squibb Company pursuant to which Agenus
received a $200 million upfront cash payment in July 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to address our liquidity position and will adjust spending as needed in
order to preserve liquidity. Our future liquidity needs will be determined primarily by the success of our operations with respect to the progression of our product candidates and key development and regulatory events in the future. Potential
sources of additional funding include: (1)&nbsp;pursuing collaboration, out-licensing and/or partnering opportunities for our portfolio programs and product candidates with one or more third parties, (2)&nbsp;selling assets, (3)&nbsp;securing
additional debt financing and/or (4)&nbsp;selling equity securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the six months ended June 30, 2021 was
$7.6 million. Our future ability to generate cash from operations will depend on achieving regulatory approval and market acceptance of our product candidates, and our ability to enter into collaborations. Please see &#147;Special Note Regarding
Forward-Looking Statements&#148; and the risks highlighted under &#147;Risk Factors&#148; of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and
Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC defines &#147;critical accounting policies&#148; as those that require the application of management&#146;s most difficult,
subjective, or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting
principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. We base those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is not intended to represent all of our accounting policies. Our significant accounting policies are described in Note 2 of the notes to our
audited consolidated financial statements contained elsewhere in this prospectus. In many cases, the accounting treatment of a particular transaction is dictated by U.S. generally accepted accounting principles, with no need for our judgment in its
application. There are also areas in which our judgment in selecting an available alternative would not produce a materially different result. We have identified the following as our critical accounting policy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the
Fair Value Option subsection of Accounting Standards Codification (ASC) 825, <I>Financial Instruments - Overall</I>, we measure the Note at fair value. In accordance with ASC 820, <I>Fair Value</I> <I>Measurements and Disclosures</I>, we measure
fair value based on a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. We measured the Note using a
scenario based present value methodology which was derived by evaluating the nature and terms of each note and considering the prevailing economic and market conditions at the balance sheet date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to Note 2 to our
audited consolidated financial statements and Note 11 to our unaudited interim condensed consolidated financial statements included within this prospectus for a description of recent accounting pronouncements applicable to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth
company&#148; as defined in the JOBS Act.&nbsp;As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure
about our executive compensation arrangements, exemption from the requirements to hold <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation and golden parachute payments and exemption from the auditor
attestation requirement in the assessment of our internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until the last day
of the fiscal year following the fifth anniversary of this offering or such earlier time that we are no longer an emerging growth company.&nbsp;We would cease to be an emerging growth company earlier if we have more than $1.07&nbsp;billion in annual
revenue, we have more than $700.0&nbsp;million in market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> (and we have been a public company for at least 12&nbsp;months and have filed one annual report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K)</FONT> or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities over a three-year period.&nbsp;For so long as we remain an emerging growth company,
we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We may choose to take advantage of some, but not all, of the available
exemptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new
or revised accounting standards.&nbsp;This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such
extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or
revised standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company. Therefore, the reported results of
operations contained in our consolidated financial statements may not be directly comparable to those of other public companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf iNKT cell therapies
to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of NK cells. iNKT cells offer distinct therapeutic advantages as a platform for
allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress GvHD. Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As
such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We are leveraging our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed
pipeline of both native and engineered iNKT cells, and anticipate having multiple clinical and preclinical readouts in 2021 and 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our strategy</B>
is to advance an accessible, scalable and effective cell therapy platform, leveraging the innate and durable biologic benefits of iNKT cells and optimizing scalability and rapid clinical development. <B>Our plan</B> is to employ iNKT cells in their
native form in diseases where iNKT cells have demonstrated activity and accelerated approval pathways exist. These indications include, but are not limited to oncology, GvHD and ARDS secondary to life-threatening infectious diseases. <B>Our
discovery efforts</B> are focused on delivering novel engineered iNKT CAR&nbsp;T cell therapies and bispecific iNKT cell engagers providing potential first- or best-in-class approaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our current product development pipeline: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g19z56.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">In process of submitting an IND application. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced product candidate, <FONT STYLE="white-space:nowrap">AGENT-797,</FONT> is an off-the-shelf, allogeneic, native iNKT cell therapy. We have
commenced a Phase&nbsp;1 clinical trial of <FONT STYLE="white-space:nowrap">AGENT-797</FONT> for the treatment of multiple myeloma and expect to report top-line data from this trial in the fourth quarter of 2021. In addition, in August 2021, we
received FDA clearance to initiate a clinical study for the treatment of solid tumors, which we intend to advance as our lead indication for AGENT-797 as a monotherapy and in combination with checkpoint inhibitors. We currently expect to have
preliminary readouts from this clinical trial in the first half of 2022 in indications that may lead to an accelerated path to marketing approval. We also intend to initiate a Phase 1 study of AGENT-797 in GvHD in the fourth quarter of 2021, and we
currently expect to report top-line data from this trial in the second half of 2022. Finally, with the unique circumstances of the COVID-19 pandemic, we were able to commence first-in-human studies of AGENT-797 in ARDS secondary to COVID-19 and are
preparing a protocol to expand into ARDS secondary to other life-threatening infectious diseases such as influenza. We currently expect to report top-line data from this Phase&nbsp;1 trial in the fourth quarter of 2021 and top-line data from a
Phase&nbsp;2 trial in the second half of 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are advancing a pipeline of next-generation allogeneic, engineered iNKT programs. Our two
most advanced engineered programs are (1) a CAR-iNKT program targeting BCMA, which we refer to as BCMA-CAR-iNKT, and (2) a tumor stromal targeting CAR-iNKT program, which we refer to as stromal target-CAR-iNKT. These programs are both in preclinical
development and we expect to file IND applications for each in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MiNK Therapeutics, Inc. was born out of the veteran immuno-oncology company, Agenus
Inc. The foundational leadership team at MiNK, including the chief executive officer, chief technology officer and head of manufacturing, are individuals who were critical to the delivery of the numerous scientific and clinical milestones at Agenus
since 2015. In addition to building Agenus from 50 to approximately 300 employees, this team has advanced 17&nbsp;discoveries to the clinic and secured approximately $800 million in upfront and milestone payments and equity investments through
partnering transactions, with the most recent achievement being a significant collaboration with Bristol-Myers Squibb Company on a preclinical antibody targeting TIGIT, which included a $200 million upfront payment and up to $1.36 billion in
milestone payments in addition to royalties on net product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This foundational leadership team has recruited and assembled a management team who
bring extensive industry expertise to our company, including decades of experience in manufacturing autologous and off-the-shelf products. We believe the expertise of our management team, and the established current Good Manufacturing Processes
(cGMP) manufacturing facility, greatly de-risks the challenges often associated with capital-intensive cell therapy companies. The combined team has a strong track record in discovering and developing immuno-oncology and cell therapies as well as
executing on value-accretive business development opportunities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to discover, develop and commercialize novel allogeneic, off-the-shelf, iNKT cell therapies to treat cancer and other immune-mediated diseases with
high unmet need. We believe that allogeneic iNKT cells exhibit highly adaptable properties for broad therapeutic development, and we plan to achieve our goal by executing a strategy with the following key elements: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance AGENT-797 native iNKT cells in cancer, including solid tumors, as monotherapy and in combination with
checkpoint antibodies.</B> We commenced a Phase 1 clinical trial in multiple myeloma in March 2021, and we currently expect to report top-line data from this Phase 1 clinical trial in the fourth quarter of 2021. In addition, we received IND
clearance from the FDA in August 2021 for the treatment of solid tumors, which we intend to advance as our lead indication for AGENT-797 as a monotherapy and in combination with checkpoint inhibitors. We expect to have preliminary readouts from our
solid tumor trial in the first half of 2022. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Validate broad applicability of iNKT cells through our opportunistic development of AGENT-797 in GvHD, a
potentially fast-to-market indication, as well as in ARDS secondary to infectious disease.</B> We also intend to initiate a Phase 1 study of AGENT-797 in GvHD in the fourth quarter of 2021, and we currently expect to report top-line data from this
trial in the second half of 2022. Given the unique circumstances of the COVID-19 pandemic, we were able to commence first-in-human studies of AGENT-797 in ARDS secondary to COVID-19 and are preparing a protocol to expand into ARDS secondary to other
life-threatening infectious diseases, such as influenza. We currently expect to report top-line data from this Phase&nbsp;1 trial in the fourth quarter of 2021 and top-line data from a Phase&nbsp;2 trial in the second half of 2022.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Apply our proprietary technologies to build a broad pipeline of engineered iNKT cells, starting with
BCMA-CAR-iNKT and stromal target-CAR-iNKT with current expectations of filing IND applications for both candidates in 2022.</B> We believe our discovery efforts can deliver novel engineered iNKT CAR T cell therapies and bispecific iNKT cell engagers
providing potential first- or best-in-class approaches targeting stromal-rich cancers and off-the-shelf approach to validated targets such as BCMA. In addition, we are advancing a pipeline of next-generation engineered iNKT programs. Our two most
advanced engineered programs are (1) a CAR-iNKT program targeting </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
BCMA, which we refer to as BCMA-CAR-iNKT, and (2) a tumor stromal targeting CAR-iNKT program, which we refer to as stromal target-CAR-iNKT. These programs are both in preclinical development and
we expect to file IND applications for each in 2022. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to develop our in-house manufacturing processes and build our capability to cost-efficiently optimize
speed, control, flexibility and scalability</B>. We are in the process of completing the transfer of our manufacturing from a third-party to an in-house system. Our automated, closed-system allogeneic cell product batch production will provide
rapid, scalable production with rigorous quality control and consistent and reproducible product release with minimal risk of batch failure. Our manufacturing process uses healthy, donor derived peripheral blood mononuclear cells (PBMCs) collected
by apheresis, which eliminates a key supply bottleneck compared to autologous cell therapies. The donor cells are processed using a proprietary combination of iNKT cell enrichment, stimulant mediated cell activation, and selective expansion,
yielding highly pure iNKT cells essentially without potentially alloreactive T cells (contaminating conventional &#945;&szlig; T cells). After robust testing to ensure product purity and potency, iNKT cells are cryopreserved for distribution and
storage. Our automated process reduces hands-on time, with the potential to optimize personnel usage and facility qualification and validation processes. These steps increase reproducibility, minimize run failures and greatly increase scalability.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Selectively explore additional strategic partnerships that can enhance the potential of our iNKT cell product
candidates and combination therapies. </B>We appreciate that there may be significant potential over time to enhance the efficacy and addressable population of our products through combination of our iNKT cells with other classes of therapeutics. We
intend to enter into a collaboration with Agenus to have access to their pipeline of checkpoint modulating antibodies and adjuvants for our development activities. We continue to explore further potential collaborations with third parties, either to
bring in access to products or expertise to advance the development and further differentiate of our pipeline. Furthermore, if therapeutics areas of interest reveal themselves beyond our core areas of focus we may look to partner with appropriately
qualified partners. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Existing Cell Therapy Approaches </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The field of immuno-oncology has revolutionized cancer treatment by harnessing and redirecting immune cell tumor targeting, with the most profound impact being
made within cell therapy. T cells engineered with CARs have changed the paradigm of treatment for patients with B-cell malignancies with high response rates in previously intractable cancers. Despite this progress, there are limitations to CAR-T
cell therapy in both the autologous and evolving allogeneic settings, including practical, logistical and toxicity issues. As a result of these limitations, there is rapidly growing interest in other immune effector cells for CAR engineering,
including NK cells, <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells and macrophages. We believe our approach, harnessing iNKT cells, offers significant advantages over existing cell therapies.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach to Cell Therapy &#150; iNKT Cells </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are advancing a novel approach through the deployment of iNKT cells, a select subset of T cells with the capabilities to orchestrate both innate and adaptive immunity and the potential to deliver durable memory responses associated with T cell
therapies with the cytolytic power of NK cells. The immune system is a complex network of soluble factors and cellular components that defends the body against cancer and infection, with two main lines of defense: innate immunity (e.g. NK cells) and
adaptive immunity (T and B cells). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T&nbsp;cells are key to the adaptive immune response to cancer and infections, and through expression of
specific TCRs they recognize antigens displayed on the surface of target cells. The diversity of TCRs arising from gene rearrangements allows TCRs to be generated against a virtually unlimited number of antigens and is the hallmark of adaptive
immunity. Remarkably, this mechanism has also led to the evolution of specialized &#147;innate-like&#148; T&nbsp;cell populations which, akin to the cells of the innate immune system, detect molecular markers common among pathogens, infected cells,
and cancer, such as lipids or metabolites. Such specialized innate-like T cells demonstrate additional innate characteristics underscoring their hybrid phenotype, such as the expression of innate immuno-receptors and the ability to rapidly respond
to cell stress caused by cancer and infections. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g22b02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mechanistically, we and others have observed that iNKT cells: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Home to tumors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Are activated by CD1d, the key ligand for the invariant TCR, and by stress ligands for potent tumor killing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Can secrete a wide array of inflammatory cytokines to clear infections and tumors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recruit and activate NK and T cells to regulate the immune response; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dampen inflammatory donor T cell activity to naturally suppress GvHD. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">iNKT cells use an invariant TCR &#945;-chain and recognize the glycolipid &#945;-GalCer, as well as other exogenous and endogenous glycolipids presented by
monomorphic major histocompatibility complex (MHC)-I-like CD1d. iNKT cells contribute to natural anti-tumor responses through their <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>-production and the
subsequent activation of DCs, NK cells and cytotoxic T lymphocytes, and their presence within tumors correlates with favorable prognosis in multiple cancers. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in
that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress GvHD. Additionally, we have observed persistence of over 35 days in some of our preclinical models, making iNKT cells well-suited for therapeutic
application. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Key Features of iNKT Cells </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Combine Key Features of Innate and Adaptive Immunity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">iNKT cells offer significant advantages compared to other allogeneic cell types as they can directly attack tumor cells through both <FONT
STYLE="white-space:nowrap">TCR-mediated</FONT> as well as <FONT STYLE="white-space:nowrap">NK-receptor-mediated</FONT> mechanisms. In addition to their direct cancer targeting and killing properties, iNKT cells are also powerful orchestrators of the
immune </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
responses within the tumor microenvironment (TME). iNKT cells directly attack suppressive myeloid cells in the TME and recruit and activate NK cells and T cells, a distinguishing feature not
shared by other innate lymphocytes such as NK cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Potent Cancer Killing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">iNKT cells are largely tissue-resident, and a small percentage (less than 1% of circulating T cells) are present in the blood. We believe iNKT
cells&#146; tissue homing properties make them highly suitable for therapeutic application in solid tumor indications. Like NK cells, they respond with wide-ranging effector potential, and express a specific invariant TCR that recognizes CD1d, a key
monomorphic human leukocyte antigen (HLA)-related molecule expressed in a wide range of cancers. iNKT cells have the capacity to mount strong anti-tumor responses both directly and by activating other immune cells, potentiating endogenous NK cells
and T cells within the TME. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In preclinical and clinical studies, iNKT cells have been observed to home to tumor tissues and target CD1d-,
NKG2D-, and other <FONT STYLE="white-space:nowrap">NK-receptor</FONT> ligands expressed on solid and liquid tumors to mediate tumor killing and modification of the TME. The invariant TCR can recognize glycolipids presented by CD1d, arming the iNKT
cells with the ability to respond to lipid antigenic stimulation within minutes by secreting a wide variety of cytokines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Naturally
Suited for Allogeneic Approaches </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">GvHD is an important driver of toxicity with most cell therapy approaches. Unlike conventional &#945;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> T cells, iNKT cells do not require gene editing of the TCR to eliminate risk of GvHD due to the monomorphic nature of the CD1d ligand of the iNKT cell TCR. Although no allogeneic iNKT cell therapy has been
approved by the FDA or any comparable regulatory authority, in both clinical and preclinical studies, iNKT cells have been observed not to cause, but instead to actively suppress, GvHD, lowering the safety risks associated with other allogeneic
immune cells. Higher iNKT cell counts following HSCT for acute leukemia correlates with lower risk for GvHD, and vice versa. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Enhanced
Tolerability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Lymphodepletion is a requirement for most cell therapies and leads to significant side effects. Since iNKT cells are
largely resident in non-lymphoid tissue, we believe that allogeneic iNKT cells may engraft better than other allogeneic cell types and thus require less lymphodepletion. We believe reducing or eliminating lymphodepletion would significantly improve
patients&#146; quality of life, increase their ability and willingness to undergo treatment, and potentially increase long-term anti-tumor immunity. Reduced or no lymphodepletion leaves the patient&#146;s immune system in a better condition. A
healthy and intact immune system is a key requirement for long-term cancer control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Ability to Scale and Manufacture Effectively
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">iNKT cells can be induced to grow exponentially for an extended period of time in our manufacturing process, whilst retaining full
immunomodulatory and cytotoxic features and metabolic fitness. This is enabled by a combination of intrinsic proliferative properties of iNKT cells and the proprietary process conditions we use to expand and condition the cells. In our current
process we are able to expand iNKT cells over 10,000 fold without inducing exhaustion, and our internal research indicates that we can further increase these yields. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our iNKT Cell Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our platform builds on the unique
features of native iNKT cells and our advanced capabilities for manufacturing and engineering. We believe this enables us to develop a portfolio of robust, highly pure, off-the-shelf, allogeneic products that can be delivered to patients worldwide
for treatment of a wide array of indications in cancer and other immune-mediated diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allogeneic iNKT cell therapy is an adoptive cell therapy that involves the infusion of cells derived from
healthy donors. We believe that iNKT cell therapies have the potential to address many of the key limitations of current cell therapy approaches, particularly through the ability to (1) rapidly treat patients real-time after diagnosis, (2) improve
response rates and the durability of responses, (3) address more indications and a broader patient population, (4) improve tolerability, (5) be administered without lymphodepletion and (6) scale at a favorable cost profile. Below are the key
elements that constitute our platform. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g13a26.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>High yield production of a pure and potent iNKT cell product:</I> Using a proprietary in-house manufacturing
process and iNKT-selection antibody reagents, we have generated significant product yields of tens of billions of iNKT cells per donor, with purity exceeding 99%. The product purity and potency of our manufactured iNKT cells can be retained in fresh
and cryopreserved conditions to support mass distribution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Ex-vivo activation and expansion protocol</I>: We utilize a proprietary reagent composition and dosing for
optimal activation and expansion. This process is designed to optimize product performance and fitness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In-house cell manufacturing and capabilities</I>: Our manufacturing process takes place using an existing
expert cGMP grade manufacturing infrastructure, using our own in-house production team of cell manufacturing experts. Our manufacturing capabilities include a proprietary closed-system process, minimizing contamination risk. We are currently in the
process of transferring our manufacturing to this facility. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>CARDIS - CAR Display</I>: This is a novel CAR discovery and engineering platform developed fully in house over
the last five years. It is a hybrid of phage and mammalian display technologies, enabling direct functional selection from cellular immune libraries. This yields a higher frequency of candidate hits with improved pharmaceutical quality and
eliminates tonic signaling at an early stage. The use of fully human single-chain fragment variable libraries lower risk of immunogenicity, and optimized intracellular signaling domains are designed to synergize with the invariant TCR and the array
of other native iNKT signaling receptors in driving tumor killing and limiting off-tumor toxicity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Bispecific iNKT cell engagers</I>: We utilize IgG-based, proprietary highly selective iNKT engager arms and a
fully human antibody discovery suite for developing targeting arms. Our experienced team of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
molecular biologists, genetic engineers and manufacturing experts has a track record of success in delivering now BLA-stage antibodies through Agenus and we are now focused on delivering iNKT
engagers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Access to I-O antibodies through Agenus collaboration</I>: We have access to Agenus&#146; pipeline of
immuno-oncology antibodies, both monospecific and bispecific, and immune stimulating adjuvants for our development activities, which creates the potential for rapid development of combinations and commercial flexibility. Agenus will not be obligated
to provide us access to their biological material in certain limited circumstances. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our platform has enabled our broad and wholly owned or exclusively licensed pipeline: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g19z56.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">In process of submitting an IND application. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidate </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>AGENT-797 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AGENT-797, our allogeneic, native iNKT cell therapy, is our most advanced product candidate and is currently in clinical development across multiple different
trials and indications, constituting a pipeline within a single product. We are also developing two preclinical CAR-iNKT programs targeting BCMA and a tumor stromal target. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>AGENT-797 &#150; Oncology </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preclinical studies we have
observed that AGENT-797 cells very effectively home to bone marrow, a key site for disease modulation and mitigation in multiple myeloma. We commenced a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">AGENT-797</FONT> for multiple myeloma
in March 2021. Despite recent approvals, there are no curative therapies for patients with multiple myeloma. We currently expect to report top-line data from this trial in the fourth quarter of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preclinical studies we have observed that AGENT-797 cells have the potential to reduce or eliminate hematologic and solid tumor cancers as a monotherapy
and in combination with checkpoint modulating antibodies, as they (1) home to sites of disease via CD1d and NK related ligands; (2) attack suppressive myeloid cells in the TME to eliminate tumor escape mechanisms; (3) recruit and activate NK cells
and T cells for enhanced tumor killing (a distinguishing feature not shared by other innate lymphocytes such as NK and gamma delta T cells); and (4) promote tumor killing without lymphodepletion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also advancing AGENT-797 in solid tumor indications, both as a monotherapy and in combination with
checkpoint antibodies. We received FDA clearance to commence a clinical study for the treatment of solid tumors in August 2021. We intend to commence Phase 1 studies in indications that are eligible for rapid development opportunities including, but
not limited to, non-small cell lung cancer (NSCLC), squamous cell cancer of the head and neck (SCCHN) and hepatocellular carcinoma (HCC). We expect to present preliminary data for solid tumor indications in the first half of 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>AGENT-797 &#150; GvHD </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">iNKT cells have the potential to
provide the following benefits in relation to GvHD: (1) promoting engraftment success; (2) mitigating or suppressing GvHD; and (3) promoting durable responses in patients with cancer. Our near-term plans are to advance the administration of
allogeneic iNKT cells in patients undergoing hematopoietic stem cell transplantation (HSCT) to enable a successful engraftment and prevention/suppression of acute GvHD. HSCT is a well-established treatment for more than 50,000 adults and children
with malignancies, autoimmune conditions and other serious diseases. The most common life-threatening complication, which occurs in approximately 50% of HSCTs, is graft failure and GvHD driven by immunocompetent T cells in the graft recognizing host
tissues. Current pre-conditioning therapies such as cytotoxic chemotherapies produce inferior responses in patients over 65 years old. Furthermore, failure to engraft and downstream GvHD are associated with cancer recurrence or death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to commence a Phase 1 clinical trial of AGENT-797 for the treatment of GvHD and engraftment conditioning without cytotoxic chemotherapy in the fourth
quarter of 2021. We currently expect to report top-line data from this trial in the second half of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>AGENT-797 &#150; ARDS Secondary to Infectious
Disease (i.e. COVID-19, Influenza) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preclinical models, iNKT cells have been shown to promote viral clearance and increase secondary anti-viral
responses, offering the potential to control inflammation and limit lung tissue damage resulting from ARDS secondary to infectious disease in humans. We commenced a Phase 1 clinical trial of AGENT-797 for the treatment of ARDS secondary to COVID-19
during the height of the COVID-19 pandemic in October 2020. We are preparing a protocol to expand this trial into ARDS secondary to other life-threatening infectious diseases, such as influenza. We have completed all dose cohorts up to 1 billion
cells/dose in our Phase 1 trial. Expansion cohorts are underway. We currently expect to report top-line data from this Phase&nbsp;1 trial in the fourth quarter of 2021 and top-line data from a Phase&nbsp;2 trial in the second half of 2022, and
intend to leverage our conclusions from the data to pursue ARDS secondary to infectious disease more broadly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Enhance iNKT Activity and Expand
Targeting through Engineering </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing a pipeline of allogeneic, engineered iNKT cell product candidates that leverage our proprietary
technologies to enhance iNKT activity and expand tumor targeting through CARs and bispecific iNKT engagers. Our two most advanced engineered programs are (1) BCMA-CAR-iNKT, and (2) stromal target-CAR-iNKT. These programs are both in preclinical
development and we expect to file IND applications for each in 2022. In addition, we plan to utilize our bispecific iNKT engager and CAR technologies, as well as our access to a large portfolio of proprietary targets, to further expand our pipeline
of novel allogeneic, engineered iNKT cell product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our CARs are designed to work in conjunction with the invariant TCR and the array of innate
receptors expressed natively by iNKT cells. They increase the range of tumor targets that can be addressed by iNKT cells and carry optimized intracellular domains that augment and expand native signaling. The resulting CAR-iNKT cells exhibit an
augmented and finely integrated response to the tumor through a combination of CAR target recognition, TCR activation and innate receptor activation by CD1d or stress ligands in the TME. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to genetically engineered CAR-expressing iNKT products, we are developing bispecific iNKT cell engagers. Our bispecific iNKT cell engagers are
designed to expand tumor targeting in tumors that are difficult to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treat due to immunologic or biologic factors, which may include low CD1d expression. Our engagers bind to the invariant TCR with one arm, and to tumor targets with the other arm. They extend the
range of tumor targets that can be engaged by iNKT cells and are designed to work in conjunction with allogeneic iNKT cells, CAR-iNKT cells as well as endogenous iNKT cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Data for iNKT Cell Therapy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proof of
concept of iNKT cells as a cancer treatment has been established in extensive public preclinical <I>in vivo</I> data sets. Such data has shown that iNKT cells can decrease tumor burden and improve survival in multiple animal models, including
through prophylactic and interventional administration of iNKT cells using xenograft, syngeneic and spontaneous tumor models of solid and hematologic tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our in-house research is consistent with these findings and we have observed that infused native human iNKT cells are persistent (detectable and active) in
mice for over 35 days. This persistence enables flexible clinical development. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g111280g22c03.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Healthy
mice &#150; Xenograft model</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;10 million AGENT-797 cells injected</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;iNKT Rapidly disappear from
circulation</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Migrate to
bone marrow and other tissues</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Detected in bone marrow for 35 days</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also observed that allogeneic human iNKT cells are beneficial in reducing tumor burden in an aggressive human leukemia
xenograft model. In this model we observed that our human iNKT cells were present in all tissues that contain tumor cells, and also were detected in blood throughout the treatment window. We believe this indicates that iNKT cells home to and are
activated at sites with tumor cells, which is different from the observations in healthy mice. This is in line with published data and supports that iNKT cells recognize and actively seek out tumor cells. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g111280g22d04.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Nalm6-CD1d
human leukemia xenograft model</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;10 million AGENT-797 cells injected</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Stay in circulation with
tumor cells</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Home to all
tissues with tumor cells</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;iNKT cells present and active for &gt;21 days</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Reduce tumor
burden</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A further active area of our internal research focuses on the combination of iNKT cell therapy and checkpoint inhibitors such
as anti-PD-1 and anti-CTLA4 antibodies. Agenus has an extensive pipeline of checkpoint </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
antibodies in development and we believe there is a strong rationale for combining cell therapy with checkpoint antibodies as these further potentiate the patient&#146;s own immune response to
cancer, which may increase impact and durability of the treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anti-PD-1 and anti-CTLA-4 antibody combinations have to date demonstrated potent
combinatorial effect in patients, especially in solid tumors. However, not all patients and types of solid tumors respond to these antibody treatments, making it necessary to find ways to further increase response rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our internal preclinical research indicates that the anti-tumor activity of iNKT cells can be further improved when used in combination with immuno-oncology
antibodies, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and <FONT STYLE="white-space:nowrap">anti-CTLA-4</FONT> antibodies. These increase the ability of iNKT cells to control tumors by further
increasing immune cell infiltration and reducing metastases. In a highly checkpoint inhibitor-resistant metastatic murine tumor model we have observed nearly complete tumor clearance when the mice are treated with a combination of anti-PD-1 and
Fc-enhanced CTLA4 antibodies, and endogenously expanded and activated murine iNKT cells. Endogenous iNKT cell expansion and activation is driven by co-administration of alpha-Galactosyl Ceramide, a potent CD1d ligand that stimulates expansion and
activation of iNKT cells in a manner similar to our <I>in vitro</I> manufacturing process. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g36z36.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to capitalize on our internal research
findings and actively pursue preclinical and clinical development of iNKT cells in combination with immuno-oncology antibodies for treatment of solid tumors. Our close relationship with Agenus is a key enabler for this strategy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Data for First Generation iNKT Cell Therapy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precedent data for autologous therapies in clinical trials using autologous iNKT cells for three different cancers have been published to date: melanoma, NSCLC
and SCCHN (certain of which are summarized in the table following this paragraph). Autologous iNKT cells were dosed at up to 1 billion cells per patient, comparable to currently approved <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies.
Among the 33 patients treated in the four previously published trials, there was only one report of a Grade 3 adverse event. In the NSCLC trial, stable disease was observed in 4 of 6 patients (67%). In the SCCHN trials, there was a 37.5% partial
response in one trial and a 50% overall response rate (ORR) in another trial of iNKT cells <FONT STYLE="white-space:nowrap">co-administered</FONT> with <FONT STYLE="white-space:nowrap">&#945;-GalCer</FONT> pulsed antigen presenting cells (APCs),
comparing favorably to currently available therapies in previously treated SCCHN, which have an ORR of 10% to 18%. Increased numbers of cells producing <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>, a key
activator of the cytotoxic immune response, were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
observed in most patients in all trials. Tumor targeting by iNKT cells was also predictive of response in SCCHN, with responding patients having five-fold greater iNKT tumor infiltration relative
to <FONT STYLE="white-space:nowrap">non-responders.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g72l45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to anti-cancer activity, iNKT cells can also regulate mechanisms combatting bacterial and viral infection,
indicating potential as an infectious disease therapy. In preclinical models of bacterial or viral infections in the lung (including bacterial pneumonia, influenza and respiratory syncytial virus), iNKT cells induced
<FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> immunity, including increased cytotoxic T cell and NK activity, leading to clearance of infection. In influenza models, iNKT cells have additionally been shown to indirectly enhance immunity
by reducing the immunosuppressive activity of myeloid-derived suppressor cells, similar to their immunomodulatory role in the TME. Moreover, in models of severe influenza with high-immune pathology, iNKT cells act to reduce lung injury by limiting
infiltrating inflammatory monocytes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Proprietary Manufacturing Process and Capabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our experienced management team and fully operational cGMP manufacturing facility, which we access through our Intercompany General &amp; Administrative
Services Agreement with Agenus, directly address and greatly de-risk the challenges often associated with capital intensive cell therapy companies. We believe this facility pioneered the industrialization and international distribution of autologous
cancer vaccines and later the customization of synthetic, off-the-shelf cancer vaccines, immune stimulating adjuvants and antibodies. We are currently in the process of transferring our manufacturing from a third-party to this cGMP facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our manufacturing process uses healthy, donor derived PBMCs collected by apheresis, which eliminates a key supply bottleneck compared to autologous cell
therapies. The donor cells are processed using a proprietary combination of iNKT cell enrichment, stimulant mediated cell activation and selective expansion, yielding highly pure iNKT cells essentially without potentially alloreactive T cells
(contaminating conventional &#945;&szlig; T cells). After robust testing to ensure product purity and potency, iNKT cells are cryopreserved for distribution and storage. We utilize a proprietary reagent composition and dosing for optimal activation
and expansion. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g22f06.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are in the process of scaling up our manufacturing process to ensure stable, robust and scalable
production for advanced clinical trials and commercialization. We plan to conduct all manufacturing for native iNKT cells and the engineered programs with our in-house capabilities, with the exception of lentiviral vector manufacturing. Using
healthy donor cells as the starting material eliminates the risk that such cells will be exhausted, or damaged, from prior chemotherapy or HSCT. Our automated, closed-system allogeneic cell product batch production is designed to provide rapid,
scalable, production with rigorous quality control and consistent and reproducible product release with minimal risk of batch failure. This closed-system process reduces hands-on time and optimizes personnel usage and facility qualification and
validation processes. Our proprietary reagents and process generate a product that is over 99% pure iNKT cells that can be stably cryopreserved with full retention of functional properties. We believe this will enable us to further increase
reproducibility, minimize run failures and greatly increase scalability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immuno-Oncology Combination Therapy Collaboration with Agenus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have retained the rights to develop our wholly owned or exclusively licensed pipeline independent of Agenus, we have entered into an agreement with
Agenus which provides us with access to immuno-oncology antibodies, adjuvants and other potential synergistic combinations, and intend to pursue the development of combination products between our allogeneic iNKT cell product candidates and products
in Agenus&#146; immuno-oncology portfolio. The Intellectual Property Assignment and License Agreement between us and Agenus would require us to enter into a seperate agreement governing the transfer of Agenus&#146; biological material and allows for
Agenus to refuse such a transfer in certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While there is significant development opportunity for iNKT cells as a monotherapy, we have
also demonstrated the benefits of these cells in combination with anti-PD-1 and/or enhanced anti-CTLA-4 antibodies in preclinical models. We believe current cancer therapy developments indicate that <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and <FONT STYLE="white-space:nowrap">anti-CTLA-4</FONT> immuno-oncology antibodies have the potential to become the standard of care for many tumor indications and will form the basis for most, if
not all, future combination therapies in cancer. Access to Agenus&#146; immuno-oncology products in this class provides us with flexibility in terms of clinical and commercial development strategy, and we believe there is a compelling scientific
rationale for pursuing combination products for achieving better long-term remissions and cures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">iNKT cell therapy adds critical new immune system
functionality to cancer patients whose immune system cannot effectively combat the tumor. Infused iNKT cells home to the tumor, where the iNKT cells attack the cancer cells and reshape the TME, attracting additional endogenous immune cells to the
tumor, such as T cells and NK cells, and diminishing the suppressive effect of infiltrating myeloid cells. Due to their allogeneic nature, infused iNKT cells disappear over time, at which point the endogenous immune system must continue to provide
effective immune surveillance to prevent relapse. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1</FONT></FONT> and <FONT STYLE="white-space:nowrap">anti-CTLA-4</FONT> immuno-oncology antibodies have been demonstrated to
be effective in enhancing endogenous immune responses. Access to Agenus&#146; immuno-oncology products allows us to combine our iNKT cells with immuno-oncology antibodies that are already in clinical development, creating more flexibility in our
clinical strategy, a better window for optimization dosing and timing, and more control over commercial pricing of the combination. We have observed strong synergistic effect of combining anti-PD-1 and CTLA-4 antibodies with expanded and activated
iNKT cells in a preclinical <I>in vivo</I> model, as discussed earlier in this document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agenus has a suite of key proprietary immune modulators that we
believe will enable clinical iNKT cell combination therapy development. Agenus has a deep pipeline of immuno-oncology antibodies that will be available to us through the collaboration, and we intend to initially focus on two of Agenus&#146; assets,
zalifrelimab and balstilimab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have significant operational expertise for preclinical and clinical research and development as a result of our shared
history with Agenus. Since 2015, we and Agenus combined have had 17&nbsp;INDs accepted. Agenus expects to receive BLA approval from the FDA for its current lead product candidate, balstilimab, in 2021, slightly over four years after the IND for the
product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our relationship with Agenus also provides access to its manufacturing capabilities. We believe access to
this manufacturing capability would enable us to eventually manufacture our iNKT products, if approved, <FONT STYLE="white-space:nowrap">in-house,</FONT> and moreover, within the same facilities that will manufacture Agenus&#146; immuno-oncology
antibodies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We protect our
intellectual property rights and proprietary technology with a combination of patent rights, trademark rights, proprietary procedures and contractual provisions. We seek to protect our intellectual property rights and proprietary technology in
select key global markets. Further, in order to supplement our existing intellectual property protection and support commercialization of current and future product candidates, we continue to seek protection for our technological innovations and
branding efforts by filing new patent and trademark applications when and where appropriate. As of September&nbsp;12, 2021, we own one issued U.S. patent and 25 pending U.S. and foreign patent applications. The issued patent is directed to a process
for the discovery of TCRs and the term of the patent will expire in 2029. There are two families of pending patent applications directed to TCRs as compositions of matter and filed in the U.S. and other major jurisdictions worldwide; these
applications were filed in 2018, and the basic term of any patents granted on the applications would expire in 2038. More specifically, these patent applications are intended to protect intellectual property relating to a TCR for cell therapy
targeting NY-ESO-1 and a TCR for cell therapy targeting a PTT. There is also a pending patent application directed to a process for TCR discovery that was filed in the United States in 2016; the basic term of any patent granted on this application
would expire in 2036. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our process to manufacture iNKT cells at scale from healthy donor PBMCs, using <FONT STYLE="white-space:nowrap">cGMP-grade</FONT>
proprietary resources, including a humanized iNKT-TCR mAb to enable iNKT cell isolation and an &#945;-GalCer lipid ligand to enable iNKT cell expansion, is proprietary technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to proprietary processes and patents on individual assets, we anticipate achieving a <FONT STYLE="white-space:nowrap">12-year</FONT> regulatory
exclusivity period for AGENT-797 upon receiving BLA approval from the FDA, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ongoing collaboration with Agenus provides access to
Agenus&#146; immuno-oncology antibodies, adjuvants and other biological material for use in combination with our therapeutic candidates. Agenus has a suite of key proprietary immune modulators, including but not limited to balstilimab and
zalifrelimab, to enable iNKT cell combination therapies. Agenus will not be obligated to provide us access to their biological material in certain limited circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a biopharmaceutical company, we
are subject to extensive regulation. Our iNKT cell product candidates, if approved, will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered and licensed facilities in
compliance with cGMPs for biologics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human immunotherapy products are a new category of therapeutics. The FDA categorizes human cell- or tissue-based
products as either minimally manipulated or more than minimally manipulated, and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for
marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions,
including the European Union, extensively regulate, among other things, the research, development, testing, manufacturing, packaging, labeling, storage, record keeping, reimbursement, advertising, promotion, distribution, <FONT
STYLE="white-space:nowrap">post-approval</FONT> monitoring and reporting and import and export, pricing and reimbursement of pharmaceutical products, including biological products. In the United States, the FDA regulates biological products under
the Public Health Service Act (the PHSA), the Federal Food, Drug and Cosmetic Act (the FDCA) and implementing regulations. Failure to comply with the applicable regulatory requirements at any time during
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the product development process or <FONT STYLE="white-space:nowrap">post-approval</FONT> may subject an applicant for marketing approval to delays in development or approval, as well as
administrative and judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters and similar public notice of alleged <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with laws, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, fines, refusals of government contracts, restitution,
disgorgement of profits or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions and compliance with applicable statutes and regulatory requirements, both <FONT STYLE="white-space:nowrap">pre-</FONT> and post-approval,
require the expenditure of substantial time and financial resources. The regulatory requirements applicable to drug and biological product development, approval and marketing are subject to change, and regulations and administrative guidance often
are revised or reinterpreted by the agencies in ways that may have a significant impact on our business. Ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations restricting
or prohibiting the processes we may use. We cannot predict whether legislative changes will be enacted or if regulatory authorities&#146; guidance or interpretations will change. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Product Development Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain FDA
approval of a product candidate, we must, among other things, submit clinical data providing substantial evidence of safety and efficacy of the product for its intended use, as well as detailed information on product composition, its manufacture and
controls, and proposed labeling. The testing and collection of data and the preparation of necessary applications are expensive and time-consuming. The FDA may not act quickly or favorably in reviewing these applications, and we may encounter
significant difficulties or costs in our efforts to obtain FDA approvals that could delay or preclude us from marketing our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our biological
product candidates must be approved by the FDA through the BLA process before they may be legally marketed in the United States. The process required before a biologic may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests and animal studies according to Good Laboratory Practices (GLPs), and
applicable requirements for the humane use of laboratory animals or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board (IRB), representing each clinical site before each clinical
trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials according to the FDA&#146;s regulations
commonly referred to as Good Clinical Practices (GCPs), and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its
intended use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of a BLA, for marketing approval that includes substantive evidence of
safety, purity and potency from results of nonclinical testing and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees for FDA review of the BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities where the drug
or biological product is produced to assess compliance with cGMP to assure that the facilities, methods and controls used in product manufacture are adequate to preserve the drug or biological product&#146;s identity, strength, quality and purity
and, if applicable, the FDA&#146;s current Good Tissue Practices (GTPs), for the use of human cellular and tissue products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the
BLA; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA acceptance, review and approval, or licensure, of the BLA, which might include review by an advisory
committee, a panel typically consisting of independent clinicians and other experts who provide recommendations as to whether the application should be approved and under what conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies and Investigational New Drug Applications </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before testing any drug or biological product candidate, including our product candidates, in humans, the product candidate must undergo rigorous preclinical
testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations as well as <I>in vitro </I>and animal studies to assess the potential safety and efficacy of the product candidate. After sufficient preclinical
testing has been conducted, the conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor must submit an IND to the FDA before clinical testing can begin in the United States.
An IND must contain the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or literature, a proposed clinical protocol, an investigator&#146;s brochure, a sample informed consent form, and other
materials. Some preclinical testing, such as toxicity studies, may continue even after the IND is submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An IND is an exemption from the FDCA that
allows an unapproved drug or biological product to be shipped in interstate commerce for use in an investigational clinical trial. The IND seeks FDA authorization to test the drug or biological product candidate in humans and automatically becomes
effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable
health risks. In that case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trials can begin. Preclinical or nonclinical testing typically continues even after the IND is submitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FDA may, at any time during the initial <FONT STYLE="white-space:nowrap">30-day</FONT> IND review period or while clinical trials are ongoing under the IND,
impose a partial or complete clinical hold based on concerns for patient safety and/or noncompliance with regulatory requirements. This order issued by the FDA would delay the initiation of a proposed clinical trial or cause suspension of an ongoing
trial until all outstanding concerns have been adequately addressed, and the FDA has notified the company that investigations may proceed. Imposition of a clinical hold could cause significant delays or difficulties in completing planned clinical
studies in a timely manner. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that require the suspension or termination of such trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expanded Access to an Investigational Drug for Treatment Use </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expanded access, sometimes called &#147;compassionate use,&#148; is the use of investigational products outside of clinical trials to treat patients with
serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. FDA regulations allow access to investigational products under an IND by the company or the treating physician
for treatment purposes on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis for: individual patients (single-patient IND applications for treatment in emergency settings and <FONT
STYLE="white-space:nowrap">non-emergency</FONT> settings); <FONT STYLE="white-space:nowrap">intermediate-size</FONT> patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND
application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no requirement for a manufacturer to provide expanded access to an investigational product. However, if a manufacturer decides to
make its investigational product available for expanded access, FDA reviews requests for expanded access and determines if treatment may proceed. Expanded access may be appropriate when all of the following criteria apply: patient(s) have a serious
or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the
treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requested treatment will not interfere with initiation, conduct or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential
development of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the FDCA, sponsors of one or more investigational products for the treatment of a serious disease(s) or condition(s)
must make publicly available their policy for evaluating and responding to requests for expanded access for individual patients. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3
study, or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product or regenerative medicine advanced therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides an additional mechanism for patients with a
life-threatening condition who have exhausted approved treatments and are unable to participate in clinical trials to access certain investigational products that have completed a Phase 1 clinical trial, are the subject of an active IND, and are
undergoing investigation for FDA approval. Unlike the expanded access framework described above, the Right to Try Pathway does not require FDA to review or approve requests for use of the investigational product. There is no obligation for a
manufacturer to make its investigational products available to eligible patients under the Right to Try Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Human Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials must be conducted and monitored in accordance with the FDA&#146;s regulations comprising the GCP requirements, including the requirement that all
research patients provide informed consent. Clinical trials are conducted under study protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the
effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an
IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain FDA
regulatory requirements in order to use the trial as support for an IND or application for marketing approval in the United States. Specifically, the FDA requires that such trials be conducted in accordance with GCP requirements intended to ensure
the protection of human subjects and the quality and integrity of the study data, including requirements for review and approval by an independent ethics committee and obtaining subjects&#146; informed consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clinical trials conducted in the United States, an IND is required, and each clinical trial must be reviewed and approved by an IRB either centrally or
individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of
the institution. An IRB must operate in compliance with FDA regulations. Clinical trials must also comply with extensive GCP rules and the requirements for obtaining subjects&#146; informed consent. The FDA, IRB or the clinical trial sponsor may
suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements, including GCP, or the subjects or patients are being exposed to an
unacceptable health risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial
sponsor, known as a data safety monitoring board or committee. This group may recommend continuation of the study as planned, changes in study conduct, or cessation of the study at designated checkpoints based on access to certain data from the
study. Finally, research activities involving infectious agents, hazardous chemicals, recombinant DNA and genetically altered organisms and agents may be subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
review and approval of an Institutional Biosafety Committee (IBC), in accordance with National Institute of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid
Molecules. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are
typically conducted in three sequential phases that may overlap or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1</I>. The biological product is initially introduced into healthy human subjects and tested for safety.
In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the target
disease or condition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2</I>. The biological product is evaluated in a limited patient population to identify possible adverse
effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3</I>. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency and safety
in an expanded patient population, generally at geographically dispersed clinical trial sites. These clinical trials are intended to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the
overall risk to benefit profile of the product and to provide an adequate basis for product labeling. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phase 1, Phase 2 and Phase 3
clinical trials may not be completed successfully within any specified period, if&nbsp;at&nbsp;all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may approve a BLA for a
product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#146;s safety or effectiveness after approval. Such post approval trials are typically referred to as Phase 4 clinical trials.
These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs or biologics approved under accelerated approval regulations. Failure
to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During all phases of
clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to
the FDA. Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or <I>in vitro</I> testing that suggest
a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15
calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s
initial receipt of the information. The FDA or the sponsor or its data safety monitoring board, an independent group of experts that evaluates study data for safety and makes recommendations concerning continuation, modification or termination of
clinical trials, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy
trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the biological product has been associated with
unexpected serious harm to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as
to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of immunotherapy products, or that the data generated in these trials will be
acceptable to the FDA to support marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act of 2003 (the PREA), a BLA or supplement thereto must contain
data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must submit a pediatric study plan to FDA
outlining the proposed pediatric study or studies they plan to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The FDA must then review the information submitted, consult
with the sponsor and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For products intended to treat a
serious or life-threatening disease or condition, the FDA must, upon the request of an applicant, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, FDA will meet
early in the development process to discuss pediatric study plans with sponsors and FDA must meet with sponsors by no later than the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 1 meeting for serious
or life-threatening diseases and by no later than 90 days after FDA&#146;s receipt of the study plan. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after
approval of the product for use in adults, or full or partial waivers from the pediatric data requirements, under specified circumstances. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan
designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its
ClinicalTrials.gov website. Similar requirements for posting clinical trial information in clinical trial registries exist in the European Union and in other countries outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with clinical trials, companies usually complete additional nonclinical studies and must also develop additional information about the physical
characteristics of the drug or biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use
of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability
studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Review and Approval Processes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the
completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the product. The BLA must include results of product development, laboratory and animal studies, human trials, information
on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the premarketing
application for filing and, even if filed, that any approval will be granted on a timely basis, if at all as the FDA has significant discretion to approve or reject BLAs and to require additional preclinical or clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act, as amended (PDUFA), each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on
an annual basis. PDUFA also imposes an annual program fee for approved prescription biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a
small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts
it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission has been
accepted for filing, the FDA begins an in depth review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from filing in which to complete its initial review of a standard application and
respond to the applicant, and six months for a priority review application. A major amendment to a BLA submitted at any time during the review cycle, including in response to a request from the FDA, may extend the goal date by three months. The FDA
does not always meet its PDUFA goal dates for standard and priority applications. The FDA reviews the application to determine, among other things, whether the proposed product is safe, potent and/or effective for its intended use, and has an
acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity, safety, strength, quality, potency and purity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During its review of a BLA, the FDA may refer the application to an advisory committee for review, evaluation, and recommendation as to whether the
application should be approved and under what conditions. In particular, the FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee. Typically,
an advisory committee is a panel of independent experts, including clinicians and other scientific experts. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions
about a BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product
unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For immunotherapy products, the FDA also will
not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of
human cells, tissues, and cellular and tissue based products (HSCT/Ps), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that
cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA GTP regulations also require tissue establishments to register and list their HSCT/Ps with the FDA
and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND and GCP
requirements. To assure cGMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, recordkeeping, production and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for
approval and deny approval. If the agency decides not to approve the BLA in its present form, the FDA will issue a Complete Response Letter, which generally outlines the specific deficiencies in the application identified by the FDA and may require
additional clinical or other data or impose other conditions that must be met in order to secure final approval of the application. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring
additional clinical trials. Even with the submission of additional information, the FDA may ultimately decide that the application does not satisfy the regulatory criteria for approval. If a Complete Response Letter is issued, the applicant may
either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA approves a new product, it
may limit the approved indications for use of the product. It may also require that contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require post approval studies, including Phase 4 clinical
trials, to further assess the product&#146;s safety or efficacy after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution
restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to
assure safe use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of
patent registries. The FDA may prevent or limit further marketing of a product based on the results of post market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications,
manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited
Development and Review Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has several programs designed to expedite the development and approval of drugs and biological products
intended to treat serious or life-threatening diseases or conditions. These programs include fast track designation, breakthrough therapy designation, priority review designation, accelerated approval, and regenerative medicine advanced therapy
(RMAT) designation. These designations are not mutually exclusive, and a product candidate may qualify for one or more of these programs. While these programs are intended to expedite product development and approval, they do not alter the standards
for FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other
products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have more frequent
interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#146;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical
data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However,
the FDA&#146;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the
designation is no longer supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Second, a product may be designated as a Breakthrough Therapy if it is
intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the
sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and
taking other steps to design the clinical trials in an efficient manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third, the FDA may designate a product for priority review if it is a product
that treats a serious disease or condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT>
basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or
substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is
intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fourth, a product may be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage
over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM),
that is reasonably likely to predict an effect on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled
post-marketing clinical trials to confirm efficacy using a clinically meaningful endpoint, thereby confirming efficacy observed <FONT STYLE="white-space:nowrap">pre-approval</FONT> using a surrogate endpoint. If the FDA concludes that a drug or
biologic shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. If the FDA determines that the conditions of
approval are not being met, the FDA can withdraw its accelerated approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fifth, a product may receive RMAT designation, which provides for an expedited
program for the advancement and approval of regenerative medicine therapies that are intended to treat, modify, reverse or cure a serious condition and where preliminary clinical evidence indicates the potential to address unmet medical needs for
life-threatening diseases or conditions. Similar to Breakthrough Therapy designation, the RMAT designation allows companies developing regenerative medicine therapies to work earlier, more closely, and frequently with the FDA, and RMAT-designated
products may be eligible for priority review and accelerated approval. Regenerative medicine therapies include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies
or products, except for those regulated solely under section 361 of the PHS Act and Title 21 of the Code of Federal Regulations Part 1271. The FDA confirmed that gene therapies, including genetically modified cells that lead to a sustained effect on
cells or tissues, may meet the definition of a regenerative medicine therapy. For product candidates that have received a RMAT designation, interaction and communication between the FDA and the sponsor of the trial can help to identify the most
efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The timing of a sponsor&#146;s request for designation and FDA response are the same as for the Breakthrough Therapy designation
program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that any of our product candidates will qualify for any of these expedited development, review and approval programs, or that,
if a product candidate does qualify, that it will be approved, will be accepted as part of any such program or that the review time will be shorter than a standard review. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon FDA approval of a
BLA, the sponsor must comply with extensive post approval regulatory requirements applicable to drugs and biological products, including any additional post approval requirements that the FDA may impose as part of the approval process. These
post-approval requirements include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">record keeping requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reporting of certain adverse experiences with the product and production problems to the FDA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission of updated safety and efficacy information to the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug sampling and distribution requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">notifying FDA and gaining its approval of specified manufacturing and labeling changes; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with requirements concerning advertising, promotional labeling, industry-sponsored scientific and
educational activities and other promotional activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the sponsor and its third-party manufacturers are subject to
periodic unannounced regulatory inspections for compliance with ongoing regulatory requirements, including cGMP and pharmacovigilance regulations. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and
effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA strictly
regulates the advertising and labeling of prescription drug products, including both prescription drugs and biological products. Promotional claims about a drug&#146;s safety or effectiveness are prohibited before the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drug is approved. In addition, the sponsor of an approved drug in the United States may not promote that drug for unapproved, or <FONT STYLE="white-space:nowrap">off-label,</FONT> uses, although
a physician may prescribe a drug for an <FONT STYLE="white-space:nowrap">off-label</FONT> use in accordance with the practice of medicine. If a company is found to have promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, it may become
subject to administrative and judicial enforcement by the FDA, the DOJ, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that
could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal
fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After approval, some types of changes to the approved product, such as adding new indications or dosing regimens, manufacturing changes, or additional
labeling claims, are subject to further FDA review and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or
limit further marketing of a product based on the results of these post-marketing programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may withdraw product approval if compliance with
regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency or
issues with manufacturing processes, may result in revisions to the approved labeling to add new safety information; imposition of post market studies or clinical trials to assess new safety signals; or imposition of distribution or other
restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recall, seizure, or detention or refusal to permit the import or export of products; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan drug designation
in the United States is designed to encourage sponsors to develop drug and biological products intended for the treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that
affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available for the
disease or condition will be recovered from sales of the product in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan drug designation qualifies a company for certain tax
credits. In addition, if a drug candidate that has orphan drug designation subsequently receives the first FDA approval for that drug for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means
that the FDA may not approve any other applications to market the same drug for the same indication for seven years following product approval unless the subsequent product candidate is demonstrated to be clinically superior. Absent a showing of
clinical superiority, the FDA cannot approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient
quantities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In
addition, a sponsor of a product that is otherwise the same product as an already </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be
clinically superior to the first drug or biologic. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request
for designation. To qualify for orphan exclusivity, however, the drug must be clinically superior to the previously approved product that is the same drug for the same condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric Exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is
another type of <FONT STYLE="white-space:nowrap">non-patent</FONT> regulatory exclusivity in the United States. Specifically, the Best Pharmaceuticals for Children Act provides for the attachment of an additional six months of exclusivity, which is
added on to the term of any remaining regulatory exclusivity or patent periods at the time the pediatric exclusivity is granted. This six month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written
request from the FDA for such data, even if the data do not show the product to be effective in the pediatric population studied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and
Exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2010 Patient Protection and Affordable Care Act (the PPACA), which was signed into law in March 2010, included a subtitle called
the Biologics Price Competition and Innovation Act of 2009 (the BPCIA). The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. FDA has approved over 20 biosimilar products for use in the
United States to date. No interchangeable biosimilars, however, have been approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, a manufacturer may submit an application for
licensure of a biological product that is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a previously approved biological product or &#147;reference product.&#148; In order for the FDA to approve a biosimilar product, it must find
that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the
agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has
been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12&nbsp;years from the date on which the
reference product was first licensed. This <FONT STYLE="white-space:nowrap">12-year</FONT> exclusivity period is referred to as the reference product exclusivity period and bars approval of a biosimilar but notably does not prevent approval of a
competing product pursuant to a full BLA (i.e., containing the sponsor&#146;s own preclinical data and data from adequate and well controlled clinical trials to demonstrate the safety, purity and potency of the product). The BPCIA also created
certain exclusivity periods for biosimilars approved as interchangeable products. The law also includes an extensive process for the innovator biologic and biosimilar manufacturer to litigate patent infringement, validity and enforceability prior to
the approval of the biosimilar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been ongoing federal legislative and administrative efforts as well as judicial challenges seeking to repeal,
modify or invalidate some or all of the provisions of the PPACA. While none of those efforts have focused on changes to the provisions of the Affordable Care Act (ACA) related to the biosimilar regulatory framework, if those efforts continue and if
the ACA is repealed, substantially modified or invalidated, it is unclear what, if any, impact such action would have on biosimilar regulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Restoration and Extension </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A patent
claiming a new drug or biological product may be eligible for a limited patent term extension under the Hatch Waxman Act, which permits a patent restoration of up to five years for a single patent for an approved
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product as compensation for patent term lost during product development and FDA regulatory review. The restoration period granted on a patent covering a product is typically one half the time
between the effective date a clinical investigation involving human beings is begun and the submission date of a marketing application less any dime during which the applicant failed to exercise due diligence, plus the time between the submission
date of an application and the ultimate approval date less any dime during which the applicant failed to exercise due diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the
product&#146;s approval date. Only one patent applicable to an approved product is eligible for the extension, only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application
for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves
the application for any patent term extension or restoration in consultation with the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry, and particularly the immuno-oncology field, is characterized by rapidly advancing and changing technologies with intense
competition. Cell therapy is one of the most active areas for the discovery and clinical development of new anti-cancer therapies. It involves the delivery of immune cells to the site of the tumor to mediate killing. We face substantial competition
from many different entities, including large pharmaceutical companies, small and midsize biotechnology companies, and academic research institutions. These competitors are focused on engineering multiple immune cell types including NK cells, &#945;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> T cells and <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells, in addition to iNKT cells. These products are both autologous and allogeneic (i.e., derived
from a donor) in nature and are unmodified or genetically engineered to target ligands with CARs or TCRs. Several companies are also using induced pluripotent stem cells as an allogeneic cell source, which could theoretically have enhanced
scalability. Other modalities such as bispecific antibodies, antibody drug conjugates, as well as novel immuno-oncology antibodies, are also capable of enabling infiltration of immune cells to the site of the tumor. For example, many bispecific
approaches simultaneously bind one immune cell antigen and one tumor cell antigen, thereby redirecting a patient&#146;s endogenous NK or T cells to the site of a tumor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key competitor companies developing autologous <FONT STYLE="white-space:nowrap">CAR-T</FONT> or TCR cell therapies include, but are not limited to,
Bristol-Myers Squibb Company (Celgene/Juno Therapeutics), Gilead Sciences, Inc. (Kite Pharma), GlaxoSmithKline plc, Janssen Pharmaceutica N.V., Novartis AG, Kuur Therapeutics Limited, which was acquired by Athenex, Inc. in May 2021, Appia Bio, Inc.
and Suda Pharmaceuticals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key competitors developing allogeneic T cell therapies include, but are not limited to, Allogene Therapeutics, Inc., Atara
Biotherapeutics, Inc., Cellectis S.A., Celularity, Inc., Celyad Oncology SA, CRISPR Therapeutics AG, Poseida Therapeutics, Inc. and Precision BioSciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key competitors in the NK cell therapy space include, but are not limited to, Fate Therapeutics, Inc., Glycostem Therapeutics B.V., Nkarta, Inc., Sanofi and
Takeda Pharmaceutical Company Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other key competitors in the
<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cell therapy space include, but are not limited to, Adicet Bio, Inc., GammaDelta Therapeutics Limited, In8bio, Inc. and TC BioPharm Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors have initiated clinical trials for GvHD and multiple myeloma, settings in which our iNKT cell therapy platform is currently being
investigated. We are also aware of competitors pursuing cell therapy drug candidates, including but not limited to stem cell-based approaches, for the treatment of ARDS secondary to COVID-19. Competitors may compete with us in hiring scientific and
management personnel, establishing clinical trial sites, recruiting patients for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Many of our current or potential competitors have significantly greater
financial, technical and human resources, as well as more expertise in research and development, manufacturing, conducting clinical trials and commercializing and marketing approved products. Early-stage companies may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also prove to be significant competitors, either alone or through collaborative arrangements with large established companies. Our commercial opportunity could be reduced if our competitors
develop and commercialize products that are safer, more effective, more convenient or less expensive. Our competitors also may obtain regulatory approval more rapidly than we may obtain approval for ours, which could result in them establishing a
dominant market position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;28, 2021, we had 31 full-time employees and consultants, 68% of whom have M.D. or Ph.D. degrees. Our ability to manage growth effectively will require us to continue to implement and improve our management systems, recruit and train
new employees and select qualified independent contractors. Functions in&nbsp;legal, finance, information technology and human resources are provided by Agenus pursuant to our services agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently utilize a combined 3,500 square
feet of Agenus&#146; facilities in Lexington, MA, New&nbsp;York, NY and Cambridge, United&nbsp;Kingdom. The space supports our research, clinical and administrative functions. There is current capacity to expand our operations within existing Agenus
facilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not currently
a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, litigation can have a material adverse
effect on us because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets
forth the name, age (as of September 28, 2021) and position of each of our executive officers and directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer S. Buell, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc van Dijk, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Technology Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christine M. Klaskin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Treasurer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Garo H. Armen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walter Flamenbaum, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Behner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Baldoni, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Corvese</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barbara Ryan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ulf Wiinberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Team </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Jennifer S. Buell, Ph.D.</I></B> has served as our President, Chief Executive Officer and a member of our board of directors since February 2021.
Dr.&nbsp;Buell also serves as the Chief Operating Officer and President of Agenus, the Company&#146;s parent, where she has served in such roles since 2018 and December 2019, respectively. Dr.&nbsp;Buell has more than 20 years of biopharmaceutical
R&amp;D experience. From September 2013 to August 2016, Dr.&nbsp;Buell was Agenus&#146; Vice President, Research and Development Operations and Program Management. From July 2016 to March 2018, she was Agenus&#146; Vice President, Research and
External Affairs, and from November 2017 to November 2018, she served as the Chief Communications and External Affairs Officer. Dr. Buell currently serves on the board of directors of Protagenic Therapeutics, Inc., a publicly held biotechnology
company. Dr.&nbsp;Buell obtained her Ph.D. in Cellular, Biochemical and Molecular Biochemistry with an MS in Biostatistics from Tufts University. We believe Dr. Buell is qualified to serve as a member of our board of directors due to her extensive
experience in the life sciences industry, including as an executive, and her familiarity with MiNK from her role as an executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marc van
Dijk, Ph.D.</I></B> has served as our Chief Technology Officer since March 2020. Since 2014, Dr. van Dijk has served as executive director and vice president of platform technology and as Chief Technology Officer at Agenus. Previously, he served as
Chief Technology Officer of 4-Antibody, from 2008 until 2014, when it became a subsidiary of Agenus. Prior to this, Dr. van Dijk was Vice President, Antibody Technology at Genmab from 1999 to 2005, and Director of Applied Research at Innogenetics
(now Fujirebio) from 2005 to 2007. Dr.&nbsp;van Dijk holds a Ph.D. in molecular biology from Utrecht University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Christine M. Klaskin</I></B> has
served as our Treasurer since July 2017. Since October 2006, Ms.&nbsp;Klaskin has also served as Vice President, Finance of Agenus. Since joining Agenus in 1996 as finance manager, Ms.&nbsp;Klaskin has held various positions within Agenus&#146;s
finance department. From 2012 until 2017, Ms.&nbsp;Klaskin was a member of the board of directors of American DG Energy Inc. until its sale to Tecogen Inc. Prior to joining Agenus, Ms.&nbsp;Klaskin was employed by Arthur Andersen as an audit
manager. Ms.&nbsp;Klaskin received her Bachelor of Accountancy from The George Washington University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Non-Employee Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Garo H. Armen, Ph.D.</I></B> has served as Chairman of our board of directors since July 2017. Dr. Armen also serves as Chairman and Chief Executive
Officer of Agenus, which he co-founded in 1994. Dr. Armen serves as the sole director and Chief Executive Officer of AgenTus Therapeutics Limited, a wholly owned subsidiary of the Company. He previously served as President of Agenus from the
company&#146;s founding until December 2019. From mid-2002 through 2004, Dr. Armen was Chairman of the board of directors for the biopharmaceutical company Elan Corporation, plc, which he helped restructure. Dr. Armen currently serves as Executive
Chairman of the board of directors of Protagenic Therapeutics, Inc. Dr. Armen is also the founder and Chairman of the Children of Armenia Fund, a philanthropic organization established in 2000 that is dedicated to the positive development of the
children and youth of rural Armenia. He holds a Ph.D. degree in physical organic chemistry from the City University of New York. We believe Dr. Armen is qualified to serve as a member of our board of directors due to his extensive experience in the
life sciences industry, including serving as an executive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Walter Flamenbaum, M.D.</I></B> has served as a member of our board of directors since
November 2019 and Dr.&nbsp;Flamenbaum has notified us that he intends to retire from our board of directors on December 31, 2021. Dr.&nbsp;Flamenbaum also served as our Chief Executive Officer from November 2019 until January 2021.
Dr.&nbsp;Flamenbaum has been a Managing Director of The Channel Group since 2014 and a member of the board of Stuart Therapeutics since 2019. Dr.&nbsp;Flamenbaum also served as a Director of Ose Pharma. From 1999 until November 2019, he was a
Partner Emeritus at Paul Capital Partners, a private equity investment firm, and the Founding Partner of Paul Capital Healthcare Funds. Dr. Flamenbaum served as the Chief Executive Officer of The Plumtree Group, Ltd. from 1996 until 2000.
Dr.&nbsp;Flamenbaum has been board certified in internal medicine, nephrology and clinical pharmacology and was a professor of medicine at the Mt. Sinai School of Medicine and Tufts University School of Medicine. Dr.&nbsp;Flamenbaum served in the
U.S. Army at the Walter Reed Army Institute of Research and the Walter Reed Army Medical Center from 1970 until 1976. He completed his training in internal medicine at the Hospital of the University of Pennsylvania, and his fellowship in nephrology
at the Peter Bent Brigham Hospital. He earned his M.D. from Columbia University&#146;s College of Physicians&nbsp;&amp; Surgeons and his B.A. from Washington&nbsp;&amp; Jefferson College. We believe Dr.&nbsp;Flamenbaum is qualified to serve as a
member of our board of directors due to his broad-based medical knowledge and investment experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>John Baldoni, Ph.D.</I></B> has served as a
member of our board of directors since February 2021. Since September 2020, Dr. Baldoni has provided consulting services to Agenus. Dr. Baldoni has over 40 years of experience in the pharmaceutical industry and has since October 2020 served as
President of Scinovo Consulting LLC. Prior to that role, Dr.&nbsp;Baldoni served as Chief Technology Officer of Integral Health, Inc. from April 2019 to May 2020. Previously, Dr. Baldoni spent 29 years serving in various roles at GlaxoSmithKline
plc&#146;s (GSK) research and development organization, including leadership of GSK&#146;s Platform Technology and Science Organization and 11&nbsp;years on GSK&#146;s Executive Leadership Team. Dr.&nbsp;Baldoni conceptualized and is currently
Senior Science Advisor to the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, a public/private partnership with the mission of transforming drug discovery by accelerating the development of more effective therapies for
patients. Dr. Baldoni previously served on the board of directors of TARA Biosystems, Inc. Dr. Baldoni received his Ph.D. from Penn State University in biological chemistry. We believe Dr. Baldoni is qualified to serve as a member of our board of
directors due to his extensive experience as a senior leader in the pharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Peter Behner</I></B> has served as a member of our
board of directors since April 2021. Since July 2020, Mr. Behner has served as Global Health Sciences &amp; Wellness Strategy and Transactions Leader at Ernst &amp; Young. Mr.&nbsp;Behner joined Ernst &amp; Young in September 2018 as the Global
Transaction Services Leader for the Pharmaceutical and Life Sciences Industries. From 2013 to June 2018, Mr. Behner was European Head of Health Industries and Consulting Leader for the Pharma &amp; Lifesciences Industries for the EMEA region for
Strategy&amp;, a PricewaterhouseCoopers (PwC) company. From 2005 until its 2013 acquisition by PwC, Mr. Behner was an equity partner at Booz &amp; Company (BC), together with Booz Allen Hamilton (BAH), prior to BC&#146;s spin-out from BAH. From 2003
to 2005, Mr. Behner was a partner at A.T. Kearney in its German Division, and, from 2004 to 2005, he was Head of A.T. Kearney&#146;s European Pharmaceutical and Life Science Industry group. Additionally,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
since April 2015, Mr. Behner has served as a Principal of Rottendorf GmbH, a pharmaceutical contract development and manufacturing company. He holds a combined BE &amp; ME degree in Mechanical
Engineering for RWTH Aachen University in Germany. We believe Mr. Behner is qualified to serve as a member of our board of directors due to his extensive experience as a consultant in the life science and pharmaceuticals industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Brian Corvese</I></B> has served as a member of our board of directors since July 2017. Since 1999, Mr.&nbsp;Corvese has been the President and Founder
of Vencor Capital, a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr.&nbsp;Corvese worked on investments in the United States and global equity
markets as a Managing Director and partner at Soros Fund Management, one of the largest hedge funds in the world at the time. From 1988 to 1996, Mr.&nbsp;Corvese was a partner at Chancellor Capital Management, a $25.0&nbsp;billion money management
firm. While at Chancellor, Mr.&nbsp;Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge
fund. From 1981 to 1988, Mr.&nbsp;Corvese was with Drexel Burnham Lambert as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel,
Mr.&nbsp;Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr.&nbsp;Corvese currently serves on the board of directors of the National Telecommunications Corporation, based in Cairo,
Egypt, and Protagenic Therapeutics, Inc. based in Ontario, Canada. Mr.&nbsp;Corvese has served on the board of directors of Agenus since 2007. Mr.&nbsp;Corvese earned degrees in finance and political science from The University of Rhode Island and
attended New&nbsp;York University Graduate School. We believe Mr.&nbsp;Corvese is qualified to serve as a member of our board of directors due to his over 30 years of experience in the financial industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Barbara Ryan</I></B> has served as a member of our board of directors since September 2021. Ms.&nbsp;Ryan founded Barbara Ryan Advisors, a capital
markets and communications firm, in 2012 following a more than 30-year career on Wall Street as a sell-side research analyst covering the U.S. large-cap pharmaceutical industry. Ms.&nbsp;Ryan has deep experience in equity and debt financings,
M&amp;A, valuation, SEC reporting, financial analysis and corporate strategy across a broad range of life sciences companies. Ms.&nbsp;Ryan has been involved in several of the pharmaceutical industry&#146;s largest M&amp;A transactions: Shire&#146;s
defense against a hostile takeover attempt by Abbvie, Shire&#146;s takeover of Baxalta, Allergan&#146;s defense against Valeant and Perrigo&#146;s defense against Mylan. Ms.&nbsp;Ryan served as an executive team member and on the disclosure
committee of Radius Health from January 2014 to December 2017 and played a critical role in Radius&#146; initial public offering and subsequent follow-on offerings which raised approximately $1&nbsp;billion. Ms.&nbsp;Ryan has also served as an
executive team member at Eloxx Pharmaceuticals, a development-stage rare disease company, where she played a critical role in Eloxx&#146;s uplisting to Nasdaq and subsequent follow-on offering. Previously, Ms.&nbsp;Ryan was a Managing Director at
Deutsche Bank/Alex Brown and head of the company&#146;s Pharmaceutical Research Team for 19&nbsp;years. She began her research career covering the pharmaceutical industry at Bear Stearns in 1982. Ms.&nbsp;Ryan also covered drug wholesalers and PBMs,
and was the lead-analyst on many high-profile initial public offerings, including Express Scripts, PSSI, Henry Schein, and Flamel Technologies. Ms.&nbsp;Ryan currently serves as a director of Gilda&#146;s Club NYC, a non-profit organization, and is
the founder of Fabulous Pharma Females, a non-profit whose mission is to advance women in the biopharma industry. Ms.&nbsp;Ryan has also led the development of women leadership programs at Radius Health and Eloxx Pharmaceuticals. We believe Ms. Ryan
is qualified to serve as a member of the board of directors due to her extensive experience as an executive and consultant in the life science industry and research analyst covering the pharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ulf Wiinberg </I></B>has served as a member of our board of directors since July 2017 and Mr.&nbsp;Wiinberg has notified us that he intends to retire
from our board of directors on December&nbsp;31, 2021. Mr.&nbsp;Wiinberg has also served as a Director of AgenTus Therapeutics SA, a subsidiary of the Company, since 2018. Mr.&nbsp;Wiinberg has almost 20&nbsp;years of senior leadership experience
and currently serves as the Chief Executive Officer of <FONT STYLE="white-space:nowrap">X-Vax</FONT> Technology, Inc., preclinical vaccine research company. Prior to <FONT STYLE="white-space:nowrap">X-Vax,</FONT> Mr.&nbsp;Wiinberg served as Chief
Executive Officer of H. Lundbeck A/S from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
boards of several health care industry associations and held multiple executive roles at Wyeth, one of the world&#146;s largest research-driven pharmaceutical companies that was acquired by
Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr.&nbsp;Wiinberg currently serves on the boards of UCB SA, a
global biopharmaceutical company based in Belgium, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, and Alfa Laval AB, a Swedish industrial company. Mr.&nbsp;Wiinberg has served on the board of directors of Agenus since 2016. We
believe Mr.&nbsp;Wiinberg is qualified to serve as a member of our board of directors due to his years of experience in the biotechnology, pharmaceutical and healthcare industries internationally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors and executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with
our amended and restated certificate of incorporation, which will be in effect upon the closing of this offering, our board of directors will be divided into three classes of directors. At each annual meeting of stockholders, a class of directors
will be elected for a three-year term to succeed the class whose terms are then expiring, to serve from the time of election and qualification until the third annual meeting following their election or until their earlier death, resignation or
removal. Upon the closing of this offering, our directors will be divided among the three classes as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;I directors will be Mr.
Behner, Dr. Buell and Mr. Wiinberg, and their terms will expire at our first annual meeting of stockholders following this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;II
directors will be Drs. Armen and Flamenbaum, M.D. and Ms. Ryan, and their terms will expire at our second annual meeting of stockholders following this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;III directors will be Dr. Baldoni and Mr. Corvese, and their terms will expire at our third annual meeting of stockholders following this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide that the authorized number of directors may be changed only by resolution of
our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of
<FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. See the section of
this prospectus captioned &#147;Description of Capital Stock&#151;Anti-takeover Effects of Our Certificate of Incorporation and Our <FONT STYLE="white-space:nowrap">By-laws&#148;</FONT> for a discussion of these and other anti-takeover provisions
found in our amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws,</FONT> which will become effective upon the closing of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the rules of the
Nasdaq Stock Market, we are a &#147;controlled company&#148; and are not required to have, and do not have, (i)&nbsp;a majority of independent directors on our board of directors, (ii)&nbsp;a nominating and corporate governance committee composed
entirely of independent directors, or (iii)&nbsp;a compensation committee composed entirely of independent directors. We intend to rely on these exemptions for the foreseeable future. Accordingly, you will not have the same protections afforded to
stockholders of companies that are not controlled companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the rules of the Nasdaq Stock Market, a director will only qualify as
&#147;independent&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that
such person is &#147;independent&#148; as defined under Nasdaq Stock Market and the Exchange Act rules. Audit committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the
Exchange Act. To be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from
the listed company or any of its subsidiaries or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon
information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that each of Dr. Baldoni, Mr. Behner, Mr. Corvese, Ms. Ryan
and Mr. Wiinberg is an &#147;independent director&#148; as defined under applicable rules of the Nasdaq Stock Market, including, in the case of all members of our audit and finance committee the independence criteria set forth in Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and all members of our compensation committee satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act and are
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; as defined in <FONT STYLE="white-space:nowrap">Section&nbsp;16b-3</FONT> of the Exchange Act. In making such determination, our board of directors considered the
relationships that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our Company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the
beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Committees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has established an audit and finance committee, a compensation committee and a corporate governance and nominating committee, each of
which will operate pursuant to a charter adopted by our board of directors. The board of directors may also establish other committees from time to time to assist us and the board of directors in their duties. The composition and functioning of all
of our committees each comply with all applicable requirements of Sarbanes-Oxley, the Nasdaq Stock Market and the Exchange Act. Each committee&#146;s charter is available on the corporate governance section of our website at
www.minktherapeutics.com. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase
shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit and Finance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit and finance committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, approving the compensation of, and evaluating the qualifications, performance and independence of our
independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the work of our independent registered public accounting firm, including through the receipt and
consideration of reports from such firm, and <FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and permitted <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and
quarterly financial statements and related disclosures, including earnings releases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm any material
issues regarding accounting principles and financial statement presentations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating our board of directors&#146; oversight of our internal control over financial reporting, disclosure
controls and procedures, code of ethics, procedures for complaints and legal and regulatory matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing our risk management policies with management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt and retention of accounting related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting independently with our independent registered public accounting firm and management;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving any related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing our guidelines and policies governing risk assessment and risk management; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the audit committee report required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing, at least annually, the adequacy of the audit and finance committee&#146;s charter; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performing, at least annually, an evaluation of the performance of the audit and finance committee.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All audit services and all <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be provided to us by our independent
registered public accounting firm must be approved in advance by our audit and finance committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of our audit and finance committee are Mr.
Behner, Mr. Corvese and Ms. Ryan. Ms. Ryan chairs the audit and finance committee. Our board of directors has determined that each member of our audit and finance committee has sufficient knowledge in financial and auditing matters to serve on the
audit and finance committee. Our board of directors has also determined that Ms. Ryan is an &#147;audit committee financial expert,&#148; as defined under Item 407 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to satisfy the member independence requirements for the audit and finance committee prior to the end of the transition period provided under current
Nasdaq Listing Rules and SEC rules and regulations for companies completing their initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our overall compensation strategy, including base salary, incentive compensation and equity-based
grants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving corporate goals and objectives relevant to compensation of our chief executive officer
and our other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our board of directors the compensation of our chief executive officer and other executive
officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the board of directors with respect to director compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing and administering our cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, considering and selecting, to the extent determined to be advisable, a peer group of appropriate
companies for purposing of benchmarking and analysis of compensation for our executive officers and directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving all employment contract and other compensation, severance and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our board of directors any stock ownership guidelines for our executive officers and <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retaining, appointing or obtaining advice of a compensation consultant, legal counsel or other advisor, and
determining the compensation and independence of such consultant or advisor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing our compliance with applicable SEC rules regarding stockholder approval of certain executive
compensation matters; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the risks associated with our compensation policies and practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing, at least annually, the adequacy of the compensation committee&#146;s charter; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performing, on an annual basis, an evaluation of the performance of the compensation committee.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are Mr. Corvese, Ms. Ryan and Mr. Wiinberg. Mr. Corvese chairs the compensation committee.
Prior to establishing a compensation committee, our board of directors made decisions relating to the compensation of our executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Governance and Nominating </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate
governance and nominating committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying individuals qualified to become members of our board of directors consistent with criteria approved
by the board and receiving nominations for such qualified individuals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our board of directors the persons to be nominated for election as directors and to each
committee of the board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending committee slates on an annual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our board of directors qualified candidates to fill vacancies on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to our board of directors a set of corporate governance principals applicable to us
and reviewing the principles on at least an annual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to our board with respect to our board leadership structure and board
committee structure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, in concert with our board of directors, our policies with respect to significant issues of corporate
public responsibility such as our code of ethics and our insider trading policy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to our board of directors processes for annual evaluations of the performance of our board
of directors, our chief executive officer and committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the process for annual evaluations of our board of directors, chief executive officer and committees
of our board of directors and certifying that performance of our chief executive officer and other members of executive management is being properly evaluated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and reporting to our board of directors any questions of possible conflicts of interest of members of
our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing new director orientation and continuing education for existing directors on a periodic basis;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the maintenance and presentation to our board of directors of management&#146;s plans for succession
to senior management positions in the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing, periodically, the adequacy of the corporate governance and nominating committee&#146;s
charter; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">periodically performing an evaluation of the performance of the corporate governance and nominating committee.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of our corporate governance and nominating committee are Dr. Baldoni, Mr. Behner and Mr.&nbsp;Corvese. Dr. Baldoni chairs
the corporate governance and nominating committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors may establish other committees from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our board of directors is
responsible for general oversight of risks and regular review of information regarding our risks, including credit risks, liquidity risks and operational risks. The compensation committee is responsible for overseeing the management of risks
relating to our executive compensation plans and arrangements. The audit and finance committee is responsible for overseeing the management of risks relating to accounting matters and financial reporting. The corporate governance and nominating
committee is responsible for overseeing the management of risks associated with the independence of our board of directors and potential conflicts of interest. Although each committee is responsible for evaluating certain risks and overseeing the
management of such risks, the entire board of directors is regularly informed through discussions from committee members about such risks. Our board of directors believes its administration of its risk oversight function has not negatively affected
our board of directors&#146; leadership structure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2021, we adopted a written code of ethics that applies to our directors, officers and employees, including our principal executive officer,
principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the investor section of our website. The information on our website is deemed not to be
incorporated in this prospectus or to be a part of this prospectus. In addition, we intend to post on our website all disclosures that are required by law or Nasdaq Stock Market rules concerning any substantive amendments to, or waivers from, any
provision of the code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_14"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion contains
forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we
adopt in the future may differ materially from the programs summarized in this discussion. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables and discussion describe the material
elements of the compensation awarded to, earned by, or paid to Jennifer S. Buell, Ph.D., our President and Chief Executive Officer, who also currently serves as a member of our board of directors and the President and Chief Operating Officer of
Agenus, Garo H. Armen, Ph.D., our Chairman of the Board, who also currently serves as the Chairman and Chief Executive Officer of Agenus, Walter Flamenbaum, M.D., our Vice Chairman and former Chief Executive Officer, and Patrick N. Jordan, our
current Vice President of Business Operations and former Chief Operating Officer, by us under our compensation and benefit plans and programs in respect of their service to us for the fiscal year ended December&nbsp;31, 2020. These individuals are
referred to collectively in this prospectus as our &#147;named executive officers.&#148; Amounts in the tables below do not include any amounts awarded to, earned by, or paid to our named executive officers by Agenus in respect of their employment
with or services provided to Agenus, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Flamenbaum served as our Chief Executive Officer for all of fiscal year 2020. Effective as
of January&nbsp;1, 2021, Dr.&nbsp;Flamenbaum transitioned to a role on our board of directors as Vice Chairman and Dr.&nbsp;Buell was appointed to serve as our Chief Executive Officer. During 2020, and prior to her appointment as our Chief Executive
Officer, Dr.&nbsp;Buell had not been formally appointed to any official title with MiNK, but had a lead role in the management of our Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With
respect to our named executive officers that are also officers of Agenus, and other than with respect to grants of Company awards, Agenus and the compensation committee of Agenus were responsible for determining the compensation of such executive
officers for fiscal year 2020 and have continued to be responsible for doing so in fiscal year 2021. With respect to our named executive officers that are not officers of Agenus, and with respect to all grants of Company equity awards to any of our
named executive officers, our board of directors was responsible for determining the compensation of such executive officers for fiscal year 2020 and has continued to be responsible for doing so in fiscal year 2021. Following this offering, the
compensation committee of our board of directors will generally be responsible for making such determinations. Our former Chief Executive Officer also made recommendations with respect to the compensation of his direct reports for fiscal year 2020,
and our current Chief&nbsp;Executive Officer is expected to do so for fiscal year 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table</B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the compensation awarded to, earned by, or paid to our named executive officers in respect of their service to us for the fiscal
year ended December&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and principal&nbsp;position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>awards<BR>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>awards<BR>($)(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All other<BR>compensation<BR>($)(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer S. Buell, Ph.D.<BR><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Garo H. Armen, Ph.D.<BR><I>Chairman of the Board</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walter Flamenbaum, M.D.<BR><I>Vice Chairman</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick N. Jordan<BR><I>Vice President of Business Operations</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Jordan originally commenced employment with Agenus on June&nbsp;29, 2020 and formally transitioned to
employment by us as our Chief Operating Officer on November&nbsp;12, 2020. The amounts in the table above </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
reflect his compensation from Agenus allocated to services he provided to the Company from August&nbsp;2020 through November 2020 and from the Company for services provided to the Company since
November 2020. Mr. Jordan currently serves as our Vice President of Business Operations. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Dr. Flamenbaum nor Mr. Jordan were awarded cash bonuses for 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount shown reflects the aggregate grant date fair value of performance-based restricted shares of our
common stock granted to Mr.&nbsp;Jordan in fiscal year 2020, computed in accordance with FASB ASC Topic 718, disregarding the effect of estimated forfeitures. The assumptions used to value the restricted stock for this purpose are set forth in Note
8 to our consolidated financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown reflect the aggregate grant date fair value of options to purchase our common stock granted
to Drs. Buell, Armen and Flamenbaum in fiscal year 2020, computed in accordance with FASB ASC Topic 718, disregarding the effects of estimated forfeitures. The assumptions used to value our options for this purpose are set forth in Note 8 to our
consolidated financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported reflect matching contributions made to Dr.&nbsp;Flamenbaum and Mr.&nbsp;Jordan under the
Agenus 401(k) Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officer Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with Our Named Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
of Dr.&nbsp;Flamenbaum and Mr.&nbsp;Jordan is party to a letter agreement with us that sets forth the terms and conditions of his employment. The material terms of the agreements are described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;14, 2019, we entered into a letter agreement with Dr.&nbsp;Flamenbaum that provides for a base salary of $360,000 per year, subject to
periodic review. The letter agreement also provided for a <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of $30,000, which was paid in 2019, and for the grant of an option to purchase 166,980 shares of our common stock, which was granted to
him in 2019 as described under &#147;Equity Compensation&#148; below, and an option to purchase 41,745 shares of Agenus common stock, which was granted to him on November&nbsp;14, 2019. Dr.&nbsp;Flamenbaum&#146;s letter agreement also provides for a
<FONT STYLE="white-space:nowrap">one-time</FONT> performance bonus opportunity of up to $2,000,000, contingent upon the Company&#146;s achievement of specified milestones related to clinical trials and equity financing, as determined by mutual
agreement with the chairman of the Company&#146;s board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January 1, 2021, in connection with his transition to Vice Chairman of
our board of directors, Dr.&nbsp;Flamenbaum began to receive a $100,000 annual cash retainer and, effective March 31, 2021, all of Dr.&nbsp;Flamenbaum&#146;s outstanding stock options were vested in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Flamenbaum also entered into an Employee Nondisclosure Agreement under which he has agreed to a perpetual confidentiality covenant and an assignment
of intellectual property covenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into a letter agreement with Mr.&nbsp;Jordan on November&nbsp;12, 2020 that provides for a base salary of
$360,000 per year and a target annual bonus equal to 35% of his base salary. The letter agreement also provided for the grant of 55,660 restricted shares of our common stock. Mr.&nbsp;Jordan was granted restricted shares in satisfaction of this
letter agreement provision in fiscal year 2020, as described below under &#147;Equity Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jordan also entered into a Restrictive
Covenant and Intellectual Property Agreement under which he has agreed not to solicit our employees, independent contractors, customers or suppliers during employment and for one year following his termination of employment and to a perpetual
confidentiality covenant and an assignment of intellectual property covenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We granted stock options to each of Drs. Buell and Armen as compensation
for their services to us, as described in &#147;Equity Compensation&#148; below, but we have not provided any other form of compensation to these named executive officers, who are also named executive officers of Agenus. No portion of Drs.
Buell&#146;s and Armen&#146;s compensation from Agenus was allocated to us during 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any employment or services agreement with Dr.&nbsp;Armen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Severance Upon Termination of Employment; Change in Control </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under his letter agreement, if Dr.&nbsp;Flamenbaum&#146;s employment is terminated by the Company, he will be entitled to receive continued payment of his
initial base salary for a period of three months following termination, conditioned on Dr.&nbsp;Flamenbaum&#146;s execution of a separation agreement that includes a customary release of claims. Dr.&nbsp;Flamenbaum&#146;s letter agreement also
provides that upon a termination of his employment for any reason other than cause (as defined in his letter agreement), his options to purchase 166,980 shares of our common stock and 41,745 shares of Agenus common stock will fully and immediately
vest. In addition, pursuant to the letter agreement, these options will fully and immediately vest upon a change of control of either Agenus or the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not provided any severance or change in control related benefits to any of our other named executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drs. Buell, Armen and Flamenbaum
each hold options to purchase shares of our common stock, and Mr.&nbsp;Jordan holds restricted shares of our common stock, in each case, granted under the 2018 Plan. Dr.&nbsp;Flamenbaum, in years prior to 2020, also received options to purchase
shares of Agenus common stock granted under the Agenus 2019 Equity Incentive Plan (the Agenus 2019 Plan). The terms of the named executive officers&#146; outstanding equity awards and the applicable plans are described below under &#147;Equity
Incentive Plans.&#148; Drs. Buell&#146;s and Armen&#146;s participation in the Agenus equity incentive plans is solely related to the services they provide to that entity and awards under those plans are not disclosed or otherwise discussed in this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our named executive officers received incentive equity grants during fiscal 2020, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;30, 2020, Dr.&nbsp;Buell was granted an option to purchase 347,875 shares of our common stock, which vested as to 33% of the underlying shares
on January&nbsp;30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to Dr.&nbsp;Buell&#146;s continued employment with us or our affiliates through the applicable vesting
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;30, 2020, Dr.&nbsp;Armen was granted an option to purchase 695,750 shares of our common stock, which vested as to 33% of the
underlying shares on January&nbsp;30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to Dr.&nbsp;Armen&#146;s continued employment with us or our affiliates through the
applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November 14, 2019, Dr.&nbsp;Flamenbaum was granted an option to purchase 166,980 shares of our common stock, which vests as
to 25% of the underlying shares upon the achievement of a development milestone related to clinical trials, as to 25% upon the achievement of another development milestone related to clinical trials and as to 50% upon the achievement of an equity
financing, in each case, generally subject to Dr.&nbsp;Flamenbaum&#146;s continued employment or service with us through the applicable vesting date. On January&nbsp;30, 2020, Dr.&nbsp;Flamenbaum was granted an option to purchase 139,150 shares of
our common stock, which vests as to 33% of the underlying shares on January&nbsp;30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to Dr.&nbsp;Flamenbaum&#146;s continued
employment or service with us through the applicable vesting date. On March 31, 2021, in connection with his transition to Vice Chairman of our board of directors, Dr. Flamenbaum&#146;s stock options were vested in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;5, 2020, Mr.&nbsp;Jordan was granted 27,830 restricted shares of our common stock, which vest as to 6,958 shares on each of August&nbsp;31,
2021, August&nbsp;31, 2022, August&nbsp;31, 2023 and August&nbsp;31, 2024, in each case, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generally subject to Mr.&nbsp;Jordan&#146;s continued employment through the applicable vesting date. On November&nbsp;5, 2020, Mr.&nbsp;Jordan was also granted 27,830 restricted shares of our
common stock, which vest upon the achievement of an equity financing on or before December&nbsp;31, 2021 and prior to an initial public offering of our common stock (including this offering), generally subject to Mr.&nbsp;Jordan&#146;s continued
employment through the vesting date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Severance and Change of Control Payments and Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Flamenbaum is entitled to severance benefits under his letter agreement upon a termination of employment in certain circumstances or upon the
occurrence of a change in control, as described above under &#147;Named Executive Officer Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the other named executive officers
is party to an employment or letter agreement with us under which they are entitled to payments or benefits in connection with a termination of their employment with us or a change of control of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee and Retirement Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2020, our named
executive officers participated in broad-based health and welfare benefit plans offered by Agenus that are also available to all of our full-time employees, including health, life, disability, vision and dental insurance plans. Our named executive
officers participate in these plans on the same basis as other eligible employees, and we do not maintain any supplemental health and welfare plans for our named executive officers. In addition, during fiscal year 2020, our named executive officers
participated in the Agenus 401(k) retirement plan. The 401(k) plan is intended to be a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> defined contribution retirement plan under which eligible employees may defer their eligible compensation,
subject to the limits imposed by the Internal Revenue Code. Other than the 401(k) plan, our employees, including our named executive officers, do not participate in any qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> retirement or
deferred compensation benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may provide limited personal benefits or perquisites to our executive officers from time to time. During 2020, the
Company reimbursed Dr.&nbsp;Flamenbaum for the cost of wireless internet for his home. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2020 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows outstanding Company (and, in the case of Dr.&nbsp;Flamenbaum, Agenus) equity awards held by the named executive officers as of
December&nbsp;31,&nbsp;2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options<BR>exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options<BR>unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>incentive<BR>plan<BR>awards:<BR>Number of<BR>securities<BR>underlying<BR>unexercised<BR>unearned<BR>options</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>exercise<BR>price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>expiration<BR>date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;shares<BR>or units<BR>of stock<BR>that&nbsp;have<BR>not<BR>vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>value<BR>of<BR>shares<BR>or<BR>units<BR>of<BR>stock<BR>that<BR>have<BR>not<BR>vested<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>incentive<BR>plan<BR>awards:<BR>Number<BR>of<BR>unearned<BR>shares,<BR>units or<BR>other<BR>rights<BR>that
have<BR>not<BR>vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>incentive<BR>plan<BR>awards:<BR>market<BR>or<BR>payout<BR>value of<BR>unearned<BR>shares,<BR>units or<BR>other<BR>rights<BR>that
have<BR>not<BR>vested</B><br><B>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jennifer S. Buell, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/30/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347,875</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/30/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Garo H. Armen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/19/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,830</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/19/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/19/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,830</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/19/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/30/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">695,750</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/30/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Walter Flamenbaum, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/14/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/14/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/22/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,980</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/22/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/30/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,150</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/30/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Patrick N. Jordan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/05/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,830</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/05/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,830</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Stock awards were valued based on the fair market value of our common stock as of December&nbsp;31, 2020, which
was determined by our board of directors to be $0.01 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase 347,875 shares of our common stock, which vested as to 33% of the underlying
shares on January&nbsp;30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase 27,830 shares of our common stock, which vests as to 30% of the underlying
shares on November&nbsp;19, 2021 and as to the remaining 70% of the underlying shares on November&nbsp;19, 2022, in each case, generally subject to continued employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase 27,830 shares of our common stock, which vests on or about December&nbsp;31,
2022, as to a portion of the underlying shares as determined by the achievement of certain milestones between January&nbsp;1, 2019 and December, 31, 2022, with 20% vesting upon achievement of five milestones, and an additional 5% vesting for each
additional milestone achieved. The option will also fully vest to the extent the Company undergoes a change of control prior to December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase 695,750 shares of our common stock, which vested as to 33% of the underlying
shares on January&nbsp;30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase 15,000 shares of Agenus common stock, which vests as to 25% of the underlying
shares upon our achievement of a development milestone related to clinical trials, as to 25% upon our achievement of another development milestone related to clinical trials and as to 50% upon our achievement of an equity financing, in each case,
generally subject to continued employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase 166,980 shares of our common stock, generally subject to continued employment.
The vesting of all such options was accelerated on March 31, 2021 and were fully-vested as of such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase 139,150 shares of our common stock, generally subject to continued employment.
The vesting of all such options was accelerated on March 31, 2021 and were fully-vested as of such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 27,830 restricted shares of our common stock, which vest as to 25% of the underlying shares on each
of August&nbsp;31, 2021, August&nbsp;31, 2022, August&nbsp;31, 2023 and August&nbsp;31, 2023, in each case, generally subject to continued employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 27,830 performance shares granted by the Company that are eligible to vest upon the achievement of an
equity financing on or before December&nbsp;31, 2021 and prior to an initial public offering (including this offering), generally subject to continued employment. The number of shares reported in the table represent the number of performance shares
that would be earned assuming the performance condition was satisfied in full. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the compensation awarded to, earned by or paid to our non-employee directors for services to us for the fiscal year ended
December&nbsp;31,&nbsp;2020. Any compensation Drs.&nbsp;Armen, Buell and Flamenbaum received for 2020 is described in the &#147;Summary Compensation Table&#148; above. Drs.&nbsp;Armen, Buell and Flamenbaum did not receive any additional compensation
for their services as members of our board of directors. Dr.&nbsp;Baldoni, Mr.&nbsp;Behner and Ms.&nbsp;Ryan joined our board of directors in February, April and September 2021, respectively, and did not receive any compensation from the Company in
the fiscal year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>earned&nbsp;or<BR>paid in<BR>cash&nbsp;($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>awards</B><br><B>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Corvese</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ulf Wiinberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown reflect cash fees earned in fiscal year 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown reflect the grant date fair value of options to purchase our common stock computed in
accordance with FASB ASC Topic&nbsp;718. The assumptions used to value the options for this purpose are set forth in Note&nbsp;8 to our consolidated financial statements included elsewhere in this prospectus. As of December&nbsp;31, 2020,
Mr.&nbsp;Corvese held an option to purchase 236,555 shares of our common stock and Mr.&nbsp;Wiinberg held an option to purchase 139,150 shares of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In respect of their service on our board of directors in fiscal year 2020, Messrs.&nbsp;Corvese and Wiinberg were each entitled to receive a $50,000 cash
retainer and stock options as determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In respect of his service as a member of our board of directors, Mr.&nbsp;Corvese
received a grant of an option to purchase 208,725 shares of our common stock on January&nbsp;30, 2020, which vested as to 33% of the underlying shares on January&nbsp;30, 2021, and with respect to the remainder, in eight equal quarterly installments
thereafter, generally subject to Mr.&nbsp;Corvese&#146;s continued service with us through the applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In respect of his service as a
member of our board of directors, Mr.&nbsp;Wiinberg received a grant of an option to purchase 111,320 shares of our common stock on January&nbsp;30, 2020, which vested as to 33% of the underlying shares on January&nbsp;30, 2021, and with respect to
the remainder, in eight equal quarterly installments thereafter, generally subject to Mr.&nbsp;Wiinberg&#146;s continued service with us through the applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2021, our board of directors established an additional $50,000 retainer for the role of Vice Chairman of our board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with or following the completion of this offering, we plan to establish a formal policy governing the compensation of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;2018, our board of directors
approved the 2018 Plan. The 2018 Plan permits the grant of incentive stock options to our employees and the grant of nonqualified stock options, restricted stock awards, restricted stock units, unrestricted stock, stock appreciation rights and
performance awards to our and our affiliates&#146; employees, directors and consultants. Subject to adjustment, the maximum number of shares that may be granted under the 2018 Plan as of June&nbsp;30, 2021 was 13,915,000. As of June&nbsp;30, 2021,
options to purchase 4,845,203 shares of our common stock were outstanding under the 2018 Plan and 4,373,485 options remained available for future issuance. In addition, 695,750 restricted stock units convertible into an equivalent number of shares
of our common stock are outstanding. Shares underlying awards that are settled in cash, expire or become unexercisable without having been exercised, or that are forfeited to or repurchased by us for cash and shares that are withheld in payment of
an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise price of an award or in satisfaction of tax withholding requirements will become available for subsequent awards under the 2018 Plan. It is anticipated that no further awards will be
made under the 2018 Plan following the completion of this offering. In connection with this offering, we adopted a new omnibus equity plan under which we will grant equity based awards in connection with and following this offering. This summary is
not a complete description of all provisions of the 2018 Plan and is qualified in its entirety by reference to the 2018 Plan, which is filed as an exhibit to the registration statement of which this prospectus is part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors, or one or
more committees of our board of directors, administers the 2018 Plan. As used in this summary, the term &#147;administrator&#148; refers to our board of directors and its authorized delegates, as applicable. Subject to the provisions of the 2018
Plan, the administrator has the authority to, among other things, interpret the 2018 Plan, determine eligibility for and grant awards under the 2018 Plan, determine the form of settlement of awards under the 2018 Plan, prescribe forms, rules and
procedures and otherwise do all things necessary or desirable to carry out the purposes of the 2018 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards.</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2018 Plan generally does not allow for the transfer of awards and awards may generally be exercised only by the holder of an award, during his or her
lifetime. However, the administrator may, in its discretion, permit the gratuitous transfer of an award other than an incentive stock option, subject to applicable securities and other laws and such other limitations as the administrator may impose.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adjustments Upon Changes in Capitalization, Merger or Certain Other Transactions. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2018 Plan provides that in the event of any stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or
other similar change in the Company&#146;s capital structure, the administrator will make appropriate adjustments to the maximum number of shares reserved for issuance under the 2018 Plan, the number and kind of shares or securities subject to any
then outstanding or subsequently granted awards under the 2018 Plan, any exercise prices or purchase prices (or base values) relating to awards under the 2018 Plan and any other provision of awards affected by such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of a covered transaction (which does not include this offering), except as otherwise expressly provided in an award agreement or by the
administrator, the administrator may, in its sole discretion, take the following actions: (i)&nbsp;if the covered transaction is one in which there is an acquiring or surviving entity, the administrator may provide for the assumption or continuation
of some or all outstanding awards or any portion thereof or for the grant of substitute awards by the acquirer or survivor or an affiliate of the acquirer or survivor; (ii)&nbsp;the administrator may provide for the cash out of awards; and
(iii)&nbsp;the administrator may provide for acceleration of awards. Except as the administrator may otherwise determine, each award will automatically terminate or be forfeited immediately upon the consummation of the covered transaction, other
than awards that are assumed, continued or substituted for following the covered transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator may, at any time, amend the 2018 Plan or any outstanding award, and may, at any time, terminate the 2018 Plan as to any future grants of
awards, provided, however, that no such action may adversely affect rights under any outstanding award without the consent of the holder of the award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agenus 2019 Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2019, the
board of directors of Agenus adopted, and on June&nbsp;19, 2019, the stockholders of Agenus approved, the Agenus 2019 Plan. The Agenus 2019 Plan provides for the grant of incentive stock options intended to qualify under Section&nbsp;422 of the
Code, nonqualified stock options, restricted stock, unrestricted stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other equity-based awards, such as stock appreciation rights, phantom stock awards and restricted stock units, for up to 35,917,776 shares of Agenus common stock (subject to adjustment in the
event of stock splits and other similar events). The board of directors of Agenus appointed the compensation committee of Agenus to administer the Agenus 2019 Plan. No awards will be granted under the Agenus 2019 Plan after June&nbsp;19, 2029. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
this offering, our board of directors adopted the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (the 2021 Plan), and, in connection with and following this offering, all equity-based awards to our employees, directors and consultants will be
granted under the 2021 Plan. The following summary describes the material terms of the 2021 Plan. This summary is not a complete description of all provisions of the 2021 Plan and is qualified in its entirety by reference to the 2021 Plan, which is
filed as an exhibit to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the 2021 Plan is to advance our interests by providing for the grant of stock and stock-based awards to our employees, directors and
consultants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan
will generally be administered by the compensation committee. The compensation committee (or our board of directors, as applicable) will have the discretionary authority to interpret the 2021 Plan and any awards granted under it, determine
eligibility for and grant awards, determine the exercise price, base value from which appreciation is measured, or purchase price, if any, applicable to any award, determine, modify, accelerate and waive the terms and conditions of any award,
determine the form of settlement of awards, prescribe forms, rules and procedures relating to the 2021 Plan and awards and otherwise do all things necessary or desirable to carry out the purposes of the 2021 Plan or any award. The compensation
committee may delegate such of its duties, powers and responsibilities as it may determine to one or more of its members, members of our board of directors and, to the extent permitted by law, our officers, and may delegate to employees and other
persons such ministerial tasks as it deems appropriate. As used in this summary, the term &#147;Administrator&#148; refers to the compensation committee and its authorized delegates, as applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our employees, directors and consultants
are eligible to participate in the 2021 Plan. Eligibility for stock options intended to be incentive stock options, or ISOs, is limited to our employees or employees of certain affiliates. Eligibility for stock options, other than ISOs, and stock
appreciation rights, or SARs, is limited to individuals who are providing direct services to us or certain affiliates on the date of grant of the award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to adjustment as described
below, the maximum number of shares of our common stock that may be delivered in satisfaction of awards under the 2021 Plan is 2,000,000 shares (the &#147;initial share pool&#148;), plus the number of shares of our common stock underlying awards
under the 2018 Plan (not to exceed 4,113,487 shares) that on or after the date the 2021 Plan is adopted expire or become unexercisable without delivery of shares, are forfeited to, or repurchased for cash by, us, are settled in cash, or otherwise
become available again for grant under the 2018 Plan, in each case, in accordance with its terms. The initial share pool will automatically increase on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year from 2022 to 2031
by the lesser of (i)&nbsp;four percent of the number of shares of our common stock outstanding as of the close of business on the immediately preceding December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> and (ii)&nbsp;the number of
shares determined by our board of directors on or prior to such date for such year (as so increased, the &#147;share pool&#148;). Up to 14,577,893 shares from the share pool may be delivered in satisfaction of ISOs. The number
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of shares of our common stock delivered in satisfaction of awards under the 2021 Plan is determined (i)&nbsp;by excluding shares withheld by us in payment of the exercise price or purchase price
of the award or in satisfaction of tax withholding requirements with respect to the award, (ii)&nbsp;by including only the number of shares delivered in settlement of a SAR that is settled in shares of our common stock, and (iii)&nbsp;by excluding
any shares underlying awards settled in cash or that expire, become unexercisable, terminate or are forfeited to or repurchased by us, in each case, without the delivery of shares of our common stock (or retention, in the case of restricted stock or
unrestricted stock). The number of shares available for delivery under the 2021 Plan will not be increased by any shares that have been delivered under the 2021 Plan and are subsequently repurchased using proceeds directly attributable to stock
option exercises. <I></I>Shares that may be delivered under the 2021 Plan may be authorized but unissued shares, treasury shares or previously issued shares acquired by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Types of Awards. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan provides for the grant of
stock options, SARs, restricted and unrestricted stock and stock units, performance awards and other awards that are convertible into or otherwise based on our common stock. Dividend equivalents may also be provided in connection with awards under
the 2021 Plan. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock Options and SARs</I>. The Administrator may grant stock options, including ISOs, and SARs. A stock
option is a right entitling the holder to acquire shares of our common stock upon payment of the applicable exercise price. A SAR is a right entitling the holder upon exercise to receive an amount (payable in cash or shares of equivalent value)
equal to the excess of the closing price of the shares subject to the right over the base value from which appreciation is measured. The exercise price per share of each stock option, and the base value of each SAR, granted under the 2021 Plan will
not be less than 100% of the closing price of a share on the date of grant (or, if no closing price is reported on that date, the closing price on the immediately preceding date on which a closing price was reported) (110% in the case of certain
ISOs granted to a 10-percent stockholder). Other than in connection with certain corporate transactions or changes to our capital structure, stock options and SARs granted under the 2021 Plan may not be repriced, amended, or substituted for with new
stock options or SARs having a lower exercise price or base value, nor may any consideration be paid upon the cancellation of any stock options or SARs that have a per share exercise or base price greater than the closing price of a share on the
date of such cancellation (or, if no closing price is reported on that date, the closing price on the immediately preceding date on which a closing price was reported), in each case, without stockholder approval. Each stock option and SAR will have
a maximum term of not more than ten years from the date of grant (or five years, in the case of certain ISOs granted to a 10-percent stockholder). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted and Unrestricted Stock and Stock Units</I>. The Administrator may grant awards of stock, stock
units, restricted stock and restricted stock units. A stock unit is an unfunded and unsecured promise, denominated in shares, to deliver shares or cash measured by the value of shares in the future, and a restricted stock unit is a stock unit that
is subject to the satisfaction of specified performance or other vesting conditions. Restricted stock are shares subject to restrictions requiring that they be forfeited, redelivered or offered for sale to us if specified performance or other
vesting conditions are not satisfied. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Performance Awards</I>. The Administrator may grant performance awards, which are awards that vest subject to
the achievement of performance criteria. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Share-Based Awards</I>. The Administrator may grant other awards that are convertible into or otherwise
based on shares of our common stock, subject to such terms and conditions as it determines. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Substitute Awards</I>. The Administrator may grant substitute awards in connection with certain corporate
transactions, which may have terms and conditions that are different from the terms and conditions of the 2021 Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Limits. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate value of all compensation granted or paid to any director with respect to any calendar year, including the grant date fair value of awards
granted under the 2021 Plan and cash fees or other compensation paid by us to such director outside of the 2021 Plan for services as a director during such calendar year (which, for the avoidance of doubt, will not include compensation granted or
paid to a director for services other than as a director, including without limitation, for services as a consultant or advisor to the Company), may not exceed $750,000 in the aggregate ($1,000,000 in the aggregate with respect to a director&#146;s
first year of service on our board of directors). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vesting; Terms of Awards. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Administrator determines the terms and conditions of all awards granted under the 2021 Plan, including the time or times an award vests or becomes
exercisable, the terms and conditions on which an award remains exercisable, and the effect of termination of a participant&#146;s employment or service on an award. The Administrator may at any time accelerate the vesting or exercisability of an
award. Unless the Administrator expressly provides otherwise the following rules will apply in the case of the cessation of the participant&#146;s employment: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately upon the termination of the participant&#146;s employment, each stock option and SAR then held by the
participant or a permitted transferee shall cease to be exercisable and will terminate and all unvested stock options and SARs will be forfeit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each stock option and SAR held by the participant or the participant&#146;s permitted transferees immediately
prior to the cessation of the participant&#146;s employment, to the extent then vested and exercisable, will remain exercisable for the lesser of (i) a period of three months following such cessation of employment or (ii) the period ending on the
latest date on which such stock option or SAR could have been exercised; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each stock option and SAR held by a participant or the participant&#146;s permitted transferees immediately prior
to the cessation of the participant&#146;s employment due to the participant&#146;s death or by the Company due to the participant&#146;s disability, to the extent then vested and exercisable, will remain exercisable for the lesser of (i) the
one-year period ending on the first anniversary of such cessation of employment or (ii) the period ending on the latest date on which such stock option or SAR could have been exercised; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all awards (whether or not vested or exercisable) held by a participant or the participant&#146;s permitted
transferees, if any, immediately prior to the cessation of the participant&#146;s employment will immediately terminate upon (i) such termination of employment is for cause or occurs in circumstances that in the determination of the Administrator
would have constituted grounds for the participant&#146;s employment to be terminated for cause or (ii) the participant&#146;s violation of any non-competition, non-solicitation, no-hire, non-disparagement, confidentiality, invention assignment, or
other restrictive covenant in favor of the Company or any of its affiliates by which the participant is bound. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Non transferability
of Awards. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as the Administrator may otherwise determine, awards may not be transferred other than by will or by the laws of descent and
distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adjustments upon Certain Covered Transactions. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of certain covered transactions (including the consummation of a consolidation, merger or similar transaction, the sale of all or substantially
all of our assets or shares of our common stock, our dissolution or liquidation, or such other transaction or event as the Administrator determines), the Administrator may, with respect to outstanding awards, provide for (in each case, on such terms
and subject to such conditions as it deems appropriate): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The assumption, substitution or continuation of some or all awards (or any portion thereof) by the acquiror or
surviving entity; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The acceleration of exercisability or delivery of shares in respect of any award, in full or in part; and/or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The cash payment in respect of some or all awards (or any portion thereof) equal to the difference between the
fair market value of the shares subject to the award and its exercise or base price, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as the Administrator may otherwise
determine, each award will automatically terminate or be forfeited immediately upon the consummation of the covered transaction, other than awards that are substituted for, assumed, or that continue following the covered transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adjustments upon Changes in Capitalization. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event
of certain corporate transactions, including a stock dividend, extraordinary cash dividend, stock split or combination of shares (including a reverse stock split), recapitalization, reorganization, merger, consolidation, combination, exchange of
shares, liquidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> <FONT STYLE="white-space:nowrap">split-up,</FONT> or other similar change in our capital structure, the Administrator will make appropriate adjustments to the maximum number of
shares that may be delivered under the 2021 Plan, the number and kind of securities subject to, and, if applicable, the exercise or purchase prices (or base values) of, outstanding awards, and any other provisions affected by such event. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recovery of Compensation. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Administrator may provide
that any outstanding award, the proceeds of any award or shares acquired thereunder and any other amounts received in respect of any award or shares acquired thereunder will be subject to forfeiture and disgorgement to us, with interest and other
related earnings, if the participant to whom the award was granted is not in compliance with any provision of the 2021 Plan or any award, or violates any <FONT STYLE="white-space:nowrap">non-competition,</FONT>
<FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">no-hire,</FONT> <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> confidentiality, invention assignment or other restrictive covenant in favor of the
Company or any of its affiliates, or any Company policy that relates to trading on <FONT STYLE="white-space:nowrap">non-public</FONT> information and permitted transactions with respect to shares of our common stock or provides for forfeiture,
disgorgement or clawback, or as otherwise required by law or applicable stock exchange listing standards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Administrator may at any time amend the 2021 Plan or any outstanding award and may at any time terminate the 2021 Plan as to future awards. However, except
as expressly provided in the 2021 Plan, the Administrator may not alter the terms of an award so as to materially and adversely affect a participant&#146;s rights without the participant&#146;s consent (unless the Administrator expressly reserved
the right to do so in the 2021 Plan or at the time the award was granted). Any amendments to the 2021 Plan will be conditioned on stockholder approval to the extent required by applicable law or stock exchange requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Employee Stock Purchase Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection
with this offering, our board of directors adopted the MiNK Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the ESPP). The following summary describes the material terms of the ESPP. This summary is not a complete description of all provisions
of the ESPP and is qualified in its entirety by reference to the ESPP, which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the ESPP is to enable eligible
employees of us and our participating subsidiaries to use payroll deductions to purchase shares of our common stock, and thereby acquire an interest in us. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; under
Section&nbsp;423 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP will be administered by the compensation committee, which will have the discretionary authority to administer and interpret the ESPP, determine
eligibility under the ESPP, prescribe forms, rules and procedures relating to the ESPP, and otherwise do all things necessary or desirable to carry out the purposes of the ESPP. The compensation committee may delegate such of its duties, powers and
responsibilities as it may determine to one or more of its members, members of our board of directors and our officers and employees, in each case, to the extent permitted by law. As used in this summary, the term &#147;Administrator&#148; refers to
the compensation committee and its authorized delegates, as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shares Subject to the ESPP. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to adjustment as described below, the aggregate number of shares of our common stock available for purchase pursuant to the exercise of options under
the ESPP is 375,000 shares, plus an automatic annual increase, as of January 1st of each year beginning in 2022 and continuing through and including 2031, equal to the lesser of (i)&nbsp;one percent of the number of shares of our common stock
outstanding as of the close of business on the immediately preceding December 31st and (ii)&nbsp;the number of shares determined by our board of directors on or prior to such date for such year, up to a maximum of 3,519,473 shares in the aggregate.
Shares to be delivered upon exercise of options under the ESPP may be authorized but unissued shares, treasury shares, or previously issued shares acquired by us. If any option granted under the ESPP expires or terminates for any reason without
having been exercised in full or ceases for any reason to be exercisable in whole or in part, the unpurchased shares subject to such option will again be available for purchase under the ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participation in the ESPP will generally be
limited to our employees and employees of our subsidiaries (i)&nbsp;who have been continuously employed by us or one of our subsidiaries, as applicable, for a period of at least 30 days as of the first day of an applicable option period,
(ii)&nbsp;whose customary employment with us or one of our subsidiaries, as applicable, is for more than five months per calendar year, (iii)&nbsp;who customarily work 20 hours or more per week, and (iv)&nbsp;who satisfy the requirements set forth
in the ESPP. The Administrator may establish additional or other eligibility requirements, or change the requirements set forth in the ESPP, to the extent consistent with Section&nbsp;423 of the Code. Any employee who owns (or is deemed under
statutory attribution rules to own) shares possessing five percent or more of the total combined voting power or value of all classes of shares of us or our parent or subsidiaries, if any, will not be eligible to participate in the ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General Terms of Participation. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP allows eligible
employees to purchase shares of our common stock during specified offering periods, which we refer to as option periods. On the first day of each option period, eligible employees will be granted an option to purchase shares of our common stock on
the last business day of the option period. A participant may purchase a maximum of 25,000 shares with respect to any option period (or such other number as the Administrator may prescribe). No participant will be granted an option under the ESPP
that permits the participant&#146;s right to purchase shares of our common stock under the ESPP and under all other employee stock purchase plans of us or our parent or subsidiaries, if any, to accrue at a rate that exceeds $25,000 in fair market
value (or such other maximum as may be prescribed by the Code) for each calendar year during which any option granted to the participant is outstanding at any time, determined in accordance with Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price of each share issued pursuant to the exercise of an option under the ESPP on an exercise date will be 85% (or such greater percentage as
specified by the Administrator) of the lesser of: (a)&nbsp;the closing price of a share of our common stock on the date the option is granted (or, if no closing price is reported on that date, the closing price on the immediately preceding date on
which a closing price was reported), which will be the first day of the option period, and (b)&nbsp;the closing price of a share of our common stock on the exercise date (or, if no closing price is reported on that date, the closing price on the
immediately preceding date on which a closing price was reported), which will be the last business day of the option period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Administrator has the discretion to change the commencement and exercise dates of option periods, the
purchase price, the maximum number of shares that may be purchased with respect to any option period, the duration of any option periods and other terms of the ESPP, in each case, without stockholder approval, except as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participants in the ESPP will pay for shares purchased under the ESPP through payroll deductions. Participants may elect to authorize payroll deductions in an
amount equal to a <FONT STYLE="white-space:nowrap">pre-established</FONT> percentage of the participant&#146;s eligible compensation each payroll period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transfer Restrictions. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For participants who have
purchased shares under the ESPP, the Administrator may impose restrictions prohibiting the transfer, sale, pledge or alienation of such shares, other than by will or by the laws of descent and distribution, for such period as may be determined by
the Administrator. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adjustments upon Changes in Capitalization. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a stock dividend, extraordinary cash dividend, stock split or combination of shares (including a reverse stock split), recapitalization,
reorganization, merger, consolidation, combination, exchange of shares, liquidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> <FONT STYLE="white-space:nowrap">split-up,</FONT> or other similar change in our capital structure or event that
constitutes an equity restructuring, the Administrator will make appropriate adjustments to the maximum number and type of shares available for purchase under the ESPP, the number and type of shares granted under any outstanding options, the maximum
number and type of shares purchasable under any outstanding option and/or the purchase price per share under any outstanding option. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate
Transactions. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a sale of all or substantially all of the Company&#146;s common stock or a sale of all or substantially all of the
assets of the Company, or a merger or similar transaction in which the Company is not the surviving corporation or that results in the acquisition of the Company by another person, the Administrator may provide that each outstanding option will be
assumed or substituted for or will be cancelled and the balances of participants&#146; accounts returned, or that the option period will end before the date of the proposed sale, merger or similar transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Administrator has
discretion to amend the ESPP to any extent and in any manner it may deem advisable, provided that any amendment that would be treated as the adoption of a new plan for purposes of Section&nbsp;423 of the Code will require stockholder approval. Upon
the termination of a participant&#146;s employment for any reason (including the death of a participant during an option period prior to an exercise date) or in the event the participant ceases to qualify as an eligible employee, the participant
will cease to be a participant, any option held by the participant under the ESPP will be canceled, the balance in the participant&#146;s account will be returned to the participant (or the participant&#146;s estate or designated beneficiary in the
event of the participant&#146;s death), without interest, as soon as administratively practicable thereafter, and the participant will have no further rights under the ESPP. The Administrator may suspend or terminate the ESPP at any time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Cash Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this
offering, our board of directors adopted the MiNK Therapeutics, Inc. 2021 Cash Incentive Plan (the Cash Incentive Plan). Following its adoption, the Cash Incentive Plan will provide for the grant of cash-based incentive awards to our executive
officers and other key employees. The following summary describes the material terms of the Cash Incentive Plan. This summary is not a complete description of all provisions of the Cash Incentive Plan and is qualified in its entirety by reference to
the Cash Incentive Plan, which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Cash Incentive Plan is to advance our interests by providing for the grant of cash-based incentive awards to our executive officers and
other key employees that will attract, retain, and reward such persons and incentivize them to attain key Company performance criteria and metrics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cash Incentive Plan will be
administered by the compensation committee and its delegates. As used in this summary, the term &#147;Administrator&#148; refers to the compensation committee and its authorized delegates, as applicable.<I> </I>The Administrator will have the
discretionary authority to administer and interpret the Cash Incentive Plan and any awards; determine eligibility for and grant awards; adjust the performance criterion or criteria applicable to awards; determine, modify or waive the terms and
conditions of any award; prescribe forms, rules and procedures relating to the Cash Incentive Plan and awards, and otherwise do all things necessary or desirable to carry out the purposes of the Cash Incentive Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility and Participation. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive officers and
other key employees of us and our subsidiaries will be eligible to participate in the Cash Incentive Plan and will be selected from time to time by the Administrator to participate in the Cash Incentive Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards; Performance Criteria. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards under the Cash
Incentive Plan will be made based on, and subject to achieving, specified criteria established by the Administrator. For each award granted under the Cash Incentive Plan, the Administrator will establish the performance criteria applicable to the
award, the amount or amounts payable if the performance criteria are achieved and such other terms and conditions as the Administrator deems appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Payments under an Award. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A participant will be entitled
to payment under an award only if all conditions to payment have been satisfied in accordance with the Cash Incentive Plan and the terms of the award. Following the end of a performance period, the Administrator will determine whether and to what
extent the applicable performance criteria have been satisfied and will determine the amount payable under each award. The Administrator has the discretionary authority to increase or decrease the amount actually paid under any award. A payment will
not be made unless the participant has remained employed with us through the date of payment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recovery of Compensation. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments in respect of an award will be subject to forfeiture and disgorgement to us if the participant is not in compliance with any provision of the Cash
Incentive Plan or any applicable award, or, violates a <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other restrictive covenant or to the extent provided in any
applicable Company policy that provides for forfeiture or disgorgement, or as otherwise required by law or applicable stock exchange listing standards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Administrator may amend
the Cash Incentive Plan or any outstanding award for any purpose, and may at any time terminate the Cash Incentive Plan as to any future grant of awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the transactions since January&nbsp;1, 2018 to which we have been a party in which the amount involved exceeded $120,000 and in
which any of our executive officers, directors, promoters or beneficial holders of more than 5% of our capital stock had or will have a direct or indirect material interest, other than compensation arrangements which are described under the section
of this prospectus captioned &#147;Executive and Director Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Agenus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently dependent upon Agenus for all of our working capital requirements. Certain of our operations are currently fully integrated with Agenus,
including, but not limited to, corporate functions such as finance, human resources, information technology and legal functions. In September 2018, we entered into an Amended and Restated Intercompany License and Services Agreement (the Intercompany
Agreement), which amended and restated the original Intercompany License and Services Agreement effective March&nbsp;1, 2018, under which (i)&nbsp;for consideration of $600,000, we were granted a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> field-limited, nontransferable license to certain licensed technology, (ii)&nbsp;Agenus performed research and business services (Agenus Services) to support our operations on a cost plus basis
and (iii)&nbsp;we performed research services to Agenus, also on a cost plus basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2021, we entered into a new Intercompany General &amp;
Administrative Services Agreement with Agenus (the New Intercompany Service Agreement). The New Intercompany Service Agreement provides us with administrative support, including, without limitation, financial, legal, information technology and human
resources administrative support and non-administrative services as may be agreed to between the parties from time to time. Agenus provides the services under the New Intercompany Service Agreement on a cost plus basis and we are required to pay
105% of Agenus&#146; costs. Under the New Intercompany Service Agreement, we are also entitled to use Agenus&#146; business offices and laboratory space and equipment in exchange for us contributing a proportionate payment for the use of such
facilities and equipment. Either party may terminate the New Intercompany Service Agreement upon 30 days&#146; prior written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2021,
we entered into a new Intellectual Property Assignment and License Agreement with Agenus (the New Assignment and License Agreement), upon which the Intercompany Agreement was terminated. Pursuant to the New Assignment and License Agreement, Agenus
assigned to us certain patent rights and know-how related to our iNKT product candidates and other patents and know-how related to our business. In addition to the patent rights assigned to us by Agenus, we also received an exclusive, royalty-free,
sublicensable license to research, develop, manufacture and commercialize certain licensed technology in the field. The New Assignment and License Agreement further provides for us to grant Agenus a field-limited, non-exclusive, royalty-free license
under the assigned patent rights. Agenus has also agreed to provide us with Agenus&#146; biological material upon written request in order for us to use such material in our development activities of a combination therapy. Agenus may withhold the
transfer of biological material for various reasons, including if such transfer would reasonably result in a disruption of planned Agenus activities. For any materials Agenus does share with us, we have agreed to enter into a separate agreement
governing the transfer and providing for joint ownership of the data. Agenus has agreed that during the term of the New Assignment and License Agreement, and for three years thereafter, it will not develop, manufacture or commercialize an iNKT cell
therapy, directly or indirectly by transferring such technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the sole responsibility to develop, manufacture and commercialize products under
this New Assignment and License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may terminate the New Assignment and License Agreement without cause upon 90 days&#146; prior written
notice to Agenus. Either party may terminate if they believes there has been a material breach which has not been cured within 90 days (or 45 days for breach of payment obligations) of receiving such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allocated Agenus Services primarily include payroll related expenses, facility costs and stock based compensation. Allocation of Agenus Services, net of
$1.3&nbsp;million and $1.4&nbsp;million for the periods ended December&nbsp;31, 2020 and 2019, respectively, is included in Operating expenses in our statement of operations and comprehensive loss and Due to related parties in our consolidated
balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2018, our Board of Directors awarded 4,230,160 of our common shares to directors and
certain officers and employees of us and Agenus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agenus is our parent and we will remain a subsidiary of Agenus upon the completion of this offering.
Agenus has agreed to purchase 1,400,000 shares of common stock in this offering at the initial public offering price for an aggregate purchase price of $16.8 million. Agenus currently owns 81% of our outstanding shares and upon the completion of the
offering will own 79.8%. Agenus has informed us that it has no present intent to transfer any of our outstanding shares that it owns, but will evaluate its options, including a potential distribution of such shares to its stockholders following the
expiration of its lock-up agreement described under &#147;Shares Eligible for Future Sale &#151; Lock-Up Agreements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Promissory Note
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;1, 2019, we issued a convertible promissory note to Agenus (the Note). The Note will be converted upon completion of this offering. In
accordance with the terms of the Note, interest is computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year at 8% and shall accrue and not be payable until converted or paid. In July 2020, the Note was canceled and we entered
into a new convertible promissory note (the July Note) to increase the amount of borrowing to up to $35.0 million and extend the maturity to July 1, 2021. In February 2021, the July Note was canceled and we entered into a new convertible promissory
note (the New Note) to increase the amount of borrowing to up to $50.0&nbsp;million and extend the maturity to July&nbsp;1, 2022. The New Note had a principal balance of $42.8 million at June&nbsp;30, 2021. We amended the New Note on September 28,
2021 to provide, among other things, that the New Note will be automatically converted into our common stock upon completion of this offering at a rate equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii)
80% of the per share price of our common stock sold in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment or Offer Letter Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into employment or offer letter agreements with certain of our executive officers. See &#147;Executive and Director Compensation&#151;Named
Executive Officer Compensation&#148; for a further discussion of these arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted stock options and/or restricted stock to our named
executive officers, other executive officers and certain of our directors. See the section of this prospectus captioned &#147;Executive and Director Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director and Officer Indemnification and Insurance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have agreed to indemnify each of our directors and executive officers against certain liabilities, costs and expenses, and maintain directors&#146; and officers&#146; liability insurance. We intend to enter into agreements with each of our directors
and officers that provide for the indemnification of such directors and officers for certain expenses and liabilities incurred in connection with certain proceedings to which they are a party, or are threatened to be made a party, by reason of the
fact that they are or were a director, officer, employee, agent or fiduciary of us or any of our subsidiaries, by reason of any action or inaction by them while serving as an officer, director, agent or fiduciary, or by reason of the fact that they
were serving at our request as a director, officer, employee, agent or fiduciary of another entity. We also maintain a general liability insurance policy which covers certain liabilities of directors and officers arising out of claims based on acts
or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a written related person transaction policy, to be effective upon the effectiveness of the amended and restated certificate
of incorporation to be effective upon the closing of this offering, setting forth the policies and procedures for the review and approval or ratification of related person </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act of 1933, as amended, any
transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year and a related person had, has
or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness
and employment by us of a related person. In reviewing and approving any such transactions, our audit and finance committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on
terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this
policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock at September 28, 2021, as adjusted to reflect
the sale of common stock offered by us in this offering, for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, who we know beneficially owns more than 5% of our outstanding common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares beneficially owned by each stockholder is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be
a &#147;beneficial&#148; owner of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. Except as indicated in the footnotes below, we believe,
based on the information furnished to us, that the individuals and entities named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned by them, subject to any applicable community
property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Percentage ownership of our common stock before this offering is based on 29,671,015 shares of our common stock outstanding as of
September 28, 2021 and the conversion of our convertible affiliated note, as amended, in accordance with the terms of the note using the initial public offering price of $12.00 per share. Percentage ownership of our common stock after this offering
is based on 33,004,349 shares of our common stock outstanding as of September 28, 2021, after giving effect to our issuance of 3,333,334 shares of our common stock in this offering. In computing the number of shares beneficially owned by an
individual or entity and the percentage ownership of that person, shares of common stock subject to options, warrants or other rights held by such person that are currently exercisable or that will become exercisable within 60&nbsp;days of September
28, 2021 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Unless noted otherwise, the address of all listed stockholders is 149 Fifth Avenue
Suite&nbsp;500, New York, NY 10010. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>shares</B><br><B>beneficially</B><br><B>owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;shares</B><br><B>beneficially&nbsp;owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name&nbsp;of&nbsp;beneficial&nbsp;owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before</B><br><B>offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After</B><br><B>offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5%&nbsp;or&nbsp;greater&nbsp;stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agenus Inc.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,332,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer S. Buell, Ph.D.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Garo H. Armen, Ph.D.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,639,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick N. Jordan(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Corvese(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ulf Wiinberg(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walter Flamenbaum(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Baldoni(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Behner(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barbara Ryan(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All executive officers and directors as a group (11 persons)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,360,079</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.07</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12.71</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent of our outstanding common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 19,481,000 shares of common stock held of record by Agenus Inc., Agenus&#146; purchase of 1,400,000
shares of common stock in this offering and 5,451,958 shares of common stock issuable upon the automatic conversion of the New Note, as described below. The address of Agenus is 3 Forbes Road, Lexington, MA&nbsp;02421. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 208,725&nbsp;shares of common stock and options to purchase 202,196&nbsp;shares of common stock
that are exercisable as of September 28, 2021, or will become exercisable within 60&nbsp;days of such date. Dr.&nbsp;Buell is an executive officer of Agenus. She may influence voting and disposition of the shares of our common stock held by Agenus.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,226,400&nbsp;shares of common stock and options to purchase 412,750&nbsp;shares of common stock
that are exercisable as of September 28, 2021, or will become exercisable within 60&nbsp;days of such date. Dr.&nbsp;Armen is a director and executive officer of Agenus. He may influence voting and disposition of the shares of our common stock held
by Agenus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 6,958 shares of restricted stock that are exercisable as of September 28, 2021, or will become
exercisable within 60 days of such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 278,300&nbsp;shares of common stock and options to purchase 149,149&nbsp;shares of common stock
that are exercisable as of September 28, 2021, or will become exercisable within 60 days of such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 278,300&nbsp;shares of common stock and options to purchase 92,535&nbsp;shares of common stock that
are exercisable as of September 28, 2021, or will become exercisable within 60&nbsp;days of such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 347,875&nbsp;shares of common stock that are exercisable as of
September&nbsp;28, 2021, or will become exercisable within 60&nbsp;days of such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Baldoni became a member of our board of directors in February&nbsp;2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Behner became a member of our board of directors in April&nbsp;2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Ryan became a member of our board of directors in September&nbsp;2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of our
capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> are summaries and are qualified by reference to the amended and restated
certificate of incorporation and the amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> that will be in effect upon the closing of this offering. Copies of these documents will be filed with the SEC as exhibits to our registration
statement, of which this prospectus forms a part. The descriptions of our common stock and preferred stock reflect changes to our capital structure that will occur upon the closing of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, our authorized
capital stock will consist of 155,000,000 shares, all with a par value of $0.00001 per share, of which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">150,000,000 shares are designated as common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,000,000 shares are designated as preferred stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2021 after giving effect to
the conversion of our convertible affiliated note, as amended, based on the initial public offering price of $12.00 per share, we had outstanding 29,253,967 shares of common stock held of record by 34&nbsp;stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting
rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive any dividends as may be declared by our
board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior
rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and
paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we
may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2021, we had no shares of preferred stock outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of our amended and restated certificate of incorporation that will become effective upon closing of this offering, our board of directors is
authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights,
dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of authorizing our
board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with
possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting
stock. Upon the closing of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this offering, there will be no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2021, options to purchase
4,845,203 shares of our common stock were outstanding under our 2018 Equity Incentive Plan, of which 1,347,292 options were vested as of that date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Our Certificate of Incorporation and Our <FONT STYLE="white-space:nowrap">By-Laws</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> will contain certain provisions that are intended to
enhance the likelihood of continuity and stability in the composition of our board of directors but which may have the effect of delaying, deferring or preventing a future takeover or change in control of us unless such takeover or change in control
is approved by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions include: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Classified board.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation will provide that our board of directors will be divided into three classes
of directors, with the classes as nearly equal in number as possible. As a result, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of our board of directors will be elected each year. The classification of directors will have the
effect of making it more difficult for stockholders to change the composition of our board. Our certificate of incorporation will also provide that, subject to any rights of holders of preferred stock to elect additional directors under specified
circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by our board of directors. Upon completion of this offering, we expect that our board of directors will have eight members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Action by written consent; special meetings of stockholders.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation will provide that stockholder
action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in lieu of a meeting. Our certificate of incorporation and the <FONT STYLE="white-space:nowrap">by-laws</FONT> will also provide that,
except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted by a majority of our board of directors, the Chairman of our board of directors or our Chief Executive Officer. Except as
described above, stockholders will not be permitted to call a special meeting or to require our board of directors to call a special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Removal
of directors.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation will provide that our directors may be removed only for cause by the affirmative vote of at least a majority of the voting power entitled to vote for the election of
directors. Our by-laws also provide that unless and until filled by the stockholders and except as otherwise determined by our board of directors in establishing a series of preferred stock as to directors elected by the holders of such series, any
vacancy in our of board of directors, however occurring, may be filled by vote of a majority of the directors then in office although less than a quorum, or by the sole remaining director. Each director so chosen to fill a vacancy shall serve for a
term determined in the manner provided in the Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advance notice procedures.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our <FONT
STYLE="white-space:nowrap">by-laws</FONT> will establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of
directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or, with respect to a director
nomination, by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Chairman of the Board, President or Secretary timely written notice, in proper form, of the
stockholder&#146;s intention to bring that business before the meeting. Although the <FONT STYLE="white-space:nowrap">by-laws</FONT> will not give our board of directors the power to approve or disapprove stockholder nominations of candidates or
proposals regarding other business to be conducted at a special or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
annual meeting, the <FONT STYLE="white-space:nowrap">by-laws</FONT> may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may
discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Supermajority approval requirements.</I>&nbsp;&nbsp;&nbsp;&nbsp;The DGCL generally provides that the affirmative vote of a majority of the shares entitled
to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> unless either a corporation&#146;s certificate of incorporation or
<FONT STYLE="white-space:nowrap">by-laws</FONT> requires a greater percentage. Our certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> will provide that the affirmative vote of holders of at least 75% of the total votes
eligible to be cast in the election of directors will be required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to our certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws</FONT> could enable a minority of our stockholders to exercise veto power over any such amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized but
unissued shares.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate
purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage
an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive
forum.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation will require, to the fullest extent permitted by law, that derivative actions brought in the name of the Company, actions against directors, officers and employees for breach of a
fiduciary duty and other similar actions may be brought only in specified courts in the State of Delaware. Under our certificate of incorporation, this exclusive forum provision will not apply to claims that are vested in the exclusive jurisdiction
of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction and explicitly does not apply to actions arising under federal
securities laws, including suits brought to enforce any liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Furthermore, our amended and restated certificate of incorporation will also provide that
unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any compliant asserting a cause of action arising under the Securities Act.
Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, these provisions may have the effect of discouraging lawsuits against our directors
and officers. See &#147;Risk Factors&#151;Our amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> designate the state or federal courts within the State of Delaware as the
exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or
employees.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the DGCL </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly-held
Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination
is approved in a prescribed manner. A &#147;business combination&#148; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#147;interested
stockholder&#148; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#146;s voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following
conditions: before the stockholder became interested, our board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in
the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock
outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by our board of directors of the
corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of incorporation or an express
provision in its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these
provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock has been approved for listing
on the Nasdaq Global Market under the symbol &#147;INKT.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, there was no public market for our common stock, and no predictions can be made about the effect, if any, that market sales
of our common stock or the availability of such shares for sale will have on the market price prevailing from time to time. Nevertheless, future sales of our common stock in the public market, or the perception that such sales may occur, could
adversely affect the market price of our common stock and could impair our ability to raise capital through future sales of our securities. See &#147;Risk Factors&#151;Risks related to this offering and ownership of our common stock&#151;A
significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is
doing well.&#148; Furthermore, although we have applied to have our common stock approved for listing on the Nasdaq Stock Market, we cannot assure you that there will be an active public trading market for our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, based on the number of shares of our common stock outstanding as of June&nbsp;30, 2021, we will have an aggregate of
32,587,301 shares of our common stock outstanding (or 33,087,301 shares of our common stock if the underwriters exercise in full their option to purchase additional shares). Of these shares of our common stock, all of the 3,333,334 shares sold in
this offering (or 3,833,334 shares if the underwriters exercise in full their option to purchase additional shares) will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our
&#147;affiliates,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act, whose sales would be subject to the Rule 144 resale restrictions described below, other than the holding period requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The remaining 29,253,967 shares of our common stock will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act.
These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules&nbsp;144 or 701 under the Securities Act, which are summarized below. We
expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
described below. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, we estimate that approximately 32,587,301 shares of our common stock will be available for sale in the public market, subject in some cases to applicable
volume limitations under Rule&nbsp;144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc111280_18"></A>We and each of our directors and executive officers and holders of substantially all of our outstanding capital stock, have agreed
not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Evercore Group
L.L.C. and William Blair &amp; Company, L.L.C. The lock-ups are subject to customary exceptions to such restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. For a further
description of these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, please see &#147;Underwriting.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliate Resales of Restricted Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially
owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of shares within any three-month period
that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal&nbsp;approximately
325,873&nbsp;shares (or 330,873 shares if the underwriters exercise their option to purchase additional shares in full) of our common stock immediately after this offering; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume in shares of our common stock on the Nasdaq Stock Market during the four
calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Affiliate resales under Rule 144 are also
subject to the availability of current public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of
$50,000, the seller must file a notice on Form 144 with the SEC and the Nasdaq Stock Market concurrently with either the placing of a sale order with the broker or the execution directly with a market maker. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate of
ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell such shares
subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule&nbsp;144(b)(1) without regard to any Rule 144 restrictions, including the <FONT
STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of
Rule&nbsp;144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, under Rule 701,
any of an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration
statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period
requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule 144 without having to comply with the current public information and holding period requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has indicated that Rule 701 will apply to typical options granted by an issuer before it becomes subject to the reporting requirements of the Exchange
Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration
statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all shares of our common stock subject to outstanding options and shares of our common stock issued or issuable under our incentive plans. We expect
to file the registration statement covering shares offered pursuant to our incentive plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market
without restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule 144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax
consequences of the purchase, ownership and disposition of our common stock to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) that acquire such common stock pursuant to this offering. It does not purport to be a complete
analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is
based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in
each case, in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance that the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is
limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not
address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the alternative minimum tax. In addition, it does not address consequences relevant to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a
conversion transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and
investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of
the interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not address the tax treatment of partnerships
or other pass-through entities or arrangements, or persons who hold our common stock through partnerships or other pass-through entities or arrangements, for U.S. federal income tax purposes. If an entity or arrangement treated as a partnership for
U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly,
partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF
THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS, AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE AND GIFT TAX LAWS, UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION
AND UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that is
neither a &#147;U.S. person&#148; nor an entity or arrangement treated as a partnership for U.S. federal income tax purposes (or a partner thereof). A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a domestic corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more
&#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code) or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the section entitled
&#147;Dividend Policy,&#148; we do not anticipate declaring or paying any distributions to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will
constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax
purposes will constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any remaining portion of a distribution
will be treated as capital gain and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition of Our Common Stock.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, FATCA and backup withholding, dividends paid to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by an applicable income tax treaty,
provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other
applicable documentation) certifying qualification for the lower treaty rate. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain
a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under any
applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent
establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or successor form), certifying that the dividends are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any such effectively connected
dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30%
(or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits attributable to such dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should
consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on backup withholding and FATCA, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal
income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct
of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a &#147;U.S.
real property holding corporation,&#148; or USRPHC, at any time within the shorter of the five-year period preceding the disposition and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period for our shares (the relevant
period) and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (i)&nbsp;disposes of our shares during a calendar year when our shares are no longer regularly traded on an established securities market or (ii)&nbsp;owned (directly,
indirectly, and constructively) more than 5% of our shares at any time during the relevant period, in which case such a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to tax on the gain on the disposition of shares generally
as if the gain were effectively connected with the conduct of a trade or business in the United States, except that the &#147;branch profits tax&#148; will not apply. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits
attributable to such gain, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a
rate of 30% (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.-source capital losses (even though the individual is not considered a resident of the United States), provided that the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe we currently
are not, and we do not anticipate becoming, a USRPHC. Generally, a corporation is a USRPHC only if the fair market value of its United States real property interests (as defined in the Code) equals or exceeds 50% of the sum of the fair market value
of its worldwide real property interests and its other assets used or held for use in a trade or business. Because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair market value of our <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there can be no assurance we are not currently a USRPHC or will not become a USRPHC in the future. Even if we are or were to become a USRPHC, gain
arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded&#148; (as defined by
applicable Treasury Regulations) on an established securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period
ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments of
dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status by furnishing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT
STYLE="white-space:nowrap">W-8ECI</FONT> (or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successor forms) or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any distributions on our common stock paid to the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any distributions constitute dividends or whether any tax was actually withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. However, a sale of our shares by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is effected at a
foreign office of a broker will be subject to information reporting and backup withholding if: (1)&nbsp;the proceeds are transferred to an account maintained by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States;
(2)&nbsp;the payment of proceeds or the confirmation of the sale is mailed to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder at a United States address; or (3)&nbsp;the sale has some other specified connection with the United States as
provided in the Treasury regulations, unless the broker does not have actual knowledge or reason to know that the holder is a United States person and the documentation requirements described above are met or the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder otherwise establishes an exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a sale of shares will be subject to information
reporting if it is effected at a foreign office of a broker that is: (1)&nbsp;a United States person; (2)&nbsp;a &#147;controlled foreign corporation&#148; for United States federal income tax purposes; (3)&nbsp;a foreign person 50% or more of whose
gross income is effectively connected with the conduct of a United States trade or business for a specified three-year period; or (4)&nbsp;a foreign partnership, if at any time during its tax year (a)&nbsp;one or more of its partners are &#147;U.S.
persons&#148;, as defined in U.S. Treasury regulations, who in the aggregate hold more than 50% of the income or capital interest in the partnership, or (b)&nbsp;such foreign partnership is engaged in the conduct of a trade or business in the United
States, unless the broker does not have actual knowledge or reason to know that the holder is a United States person and the documentation requirements described above are met or an exemption is otherwise established. Backup withholding will apply
if the sale is subject to information reporting and the broker has actual knowledge that the holder is a United States person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of information
returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is
established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code and related Treasury Regulations and guidance, or FATCA, on certain types of payments
made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on our common stock paid to
a foreign entity if the foreign entity is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A &#147;foreign financial institution&#148; (as defined under FATCA) that does not furnish proper documentation,
typically on IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> evidencing either (i)&nbsp;an exemption from FATCA withholding or (ii)&nbsp;its compliance (or deemed compliance) with specified due
diligence, reporting, withholding and certification obligations under FATCA or (iii)&nbsp;residence in a jurisdiction that has entered into an intergovernmental agreement with the United States relating to FATCA and compliance with the diligence and
reporting requirements of the intergovernmental agreement and local implementing rules; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (as defined under FATCA) that
does not provide sufficient documentation, typically on IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> evidencing either (i)&nbsp;an exemption from FATCA or (ii)&nbsp;adequate information regarding
substantial United States beneficial owners of such entity (if any). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative
guidance, withholding under FATCA generally applies to payments of dividends on our common stock. Under proposed Treasury Regulations, FATCA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withholding would not apply to payments of gross proceeds. Parties obligated to withhold under FATCA generally may rely on these proposed Treasury Regulations until final Treasury Regulations are
issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under certain circumstances, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be eligible for refunds or credits of withholding
taxes imposed under FATCA by filing a United States federal income tax return. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective investors should consult their tax advisors regarding the
potential application of withholding under FATCA to their investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement among us, Agenus and Evercore Group L.L.C. and William Blair &amp; Company, L.L.C.
as the representatives of the underwriters named below and the book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the
respective number of shares of common stock shown opposite its name below:<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair &amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B. Riley Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Baird &amp; Co. Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,333,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agenus Inc. has agreed to purchase 1,400,000 shares of our common stock in this offering at the initial public offering price.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by
the underwriters of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are
purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. We
have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of
those liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common
stock as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no
assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The
underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they
exercise discretionary authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commission and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the
cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $0.504 per share of common stock. After the offering, the initial public offering price and concession to
dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, the underwriting discounts and commissions that we are
to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without</B><br><B>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With</B><br><B>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without</B><br><B>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With</B><br><B>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,000,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,800,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,220,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,200,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,780,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions
referred to above, will be approximately $2.9 million. We also have agreed to reimburse the underwriters for up to $45,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, these reimbursed fees and expenses are deemed underwriting
compensation for this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of Offering Price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our common stock will be
determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the
underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We offer no assurances that the initial public offering price will correspond to the price at which the common stock will trade in the public market
subsequent to the offering or that an active trading market for the common stock will develop and continue after the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock has been approved for listing on the Nasdaq Global Market under the trading symbol &#147;INKT&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stamp Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you purchase shares of common stock
offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted to
the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of 500,000 shares from us at the public offering price set forth on the cover page of this
prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that
underwriter&#146;s initial purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, our officers, directors and holders of all or substantially all our outstanding common stock or of securities convertible into or exchangeable or
exercisable for shares of our common stock have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-l(h)</FONT> under the Securities Exchange Act of 1934, as amended, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or
securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this
prospectus without the prior written consent of the representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This restriction terminates after the close of trading of the
common stock on and including the 180th day after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The representatives may, in their sole discretion and at any time or from
time to time before the termination of the <FONT STYLE="white-space:nowrap">180-day</FONT> period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements
between the underwriters and any of our stockholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised
us that they, pursuant to Regulation M under the Exchange Act, and certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in
connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may
involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Covered&#148; short sales are sales made in an amount not greater
than the underwriters&#146; option to purchase additional shares of our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or
purchasing shares of our common stock in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market
as compared to the price at which they may purchase shares through the option to purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Naked&#148; short sales are sales in
excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are
concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the
common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase
transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a
result, the price of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise
accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions
described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters may also engage in passive market making transactions in our common stock on the Nasdaq Global Market in accordance with Rule&nbsp;103 of
Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of
the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus in electronic
format may be made available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering
terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be
made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site maintained by any of the
underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Activities and Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters and
certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal
investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services
for us and our affiliates, for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business
activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their
own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending
relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of
either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future
trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research
views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclaimers About <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canada </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Resale Restrictions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of the securities in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis
exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the securities in Canada must be made under applicable securities
laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory authority.
Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Representations of Canadian Purchasers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By purchasing the securities in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the
purchase confirmation is received that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchaser is entitled under applicable provincial securities laws to purchase the securities without the
benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;Prospectus</FONT> Exemptions, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where required by law, the purchaser is purchasing as principal and not as agent, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of Interest </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canadian purchasers are
hereby notified that the underwriters are relying on the exemption set out in section&nbsp;3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;Underwriting</FONT> Conflicts from having to provide certain
conflict of interest disclosure in this document. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Statutory Rights of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus
(including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enforcement of Legal Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian
purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a
judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation and Eligibility for Investment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canadian
purchasers of the securities should consult their own legal and tax advisors with respect to the tax consequences of an investment in the securities in their particular circumstances and about the eligibility of the securities for investment by the
purchaser under relevant Canadian legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been
lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You confirm and warrant that you are either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you
have provided an accountant&#146;s certificate to the company which complies with the requirements of section&nbsp;708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person associated with the company under section&nbsp;708(12) of the Corporations Act; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or
professional investor under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. You warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus for
resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member State
of the European Economic Area (each, a Relevant State), no offer of securities that are the subject of the offering has been, or will be made to the public in that Relevant State, except that an offer of shares to the public in that Relevant State
may be made at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined in the Prospectus Regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of securities shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article 3 of
the Prospectus Regulation or to supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the
expression an &#147;offer to the public&#148; in relation to any securities in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to
enable an investor to decide to purchase or subscribe for any securities, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hong Kong </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities have been offered or sold, and
no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in
the Securities and Futures Ordinance (Cap. 571) of Hong Kong, or SFO, and any rules made under that Ordinance; or in other circumstances which do not result in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong, or CO, or which do not constitute an offer or invitation to the public for the purpose of
the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is
directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only
to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO of Hong Kong and any rules made under that Ordinance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or
distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is
aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Japan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering has not been and will not be
registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended) (the FIEL), and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit
of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale,
directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and
ministerial guidelines of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for
subscription or purchase of the securities may not be issued, circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in
Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the SFA), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor as defined in Section&nbsp;4A of the SFA) the sole business of
which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of
that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities under Section&nbsp;275 of the SFA except:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person
arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (SIX), or on any other stock exchange or regulated
trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or
the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this prospectus nor any other offering or marketing
material relating to the offering, the company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised
by, the Swiss Financial Market Supervisory Authority FINMA and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of
interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Israel </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968 (the Israeli Securities Law), and has not been filed with or
approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the shares is directed only at, investors listed in the first addendum (the Addendum), to the
Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds,
entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals&#148;, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their
own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are
aware of the meaning of same and agree to it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is only being distributed to, and is only directed at, persons in the U.K. that are qualified investors (as defined in the U.K. Prospectus
Regulation) that are also (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) and/or (ii)&nbsp;high net worth entities falling within
Article 49(2)(a) to (d)&nbsp;of the Order and other persons to whom it may lawfully be communicated or caused to be communicated. Each such person is referred to herein as a &#147;Relevant Person.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to
any other persons in the U.K. Any person in the U.K. that is not a Relevant Person should not act or rely on this document or any of its contents. Any invitation or inducement to engage in investment activity within the meaning of Section&nbsp;21 of
the Financial Services and Markets Act 2000 (the FSMA) may only be communicated or caused to be communicated in connection with the issue or sale of the securities in circumstances in which Section&nbsp;21(1) of the FSMA does not apply. All
applicable provisions of the FSMA must be complied with in respect of anything done by any person in relation to the securities in, from or otherwise involving the U.K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No offer of securities that are the subject of the offering has been, or will be made to the public in the
U.K., except that an offer of shares to the public in the U.K. may be made at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined in the U.K. Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons in the U.K. (other than qualified investors as defined in the U.K.
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of securities shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to
Section&nbsp;85 of the FSMA or to supplement a prospectus pursuant to Article 23 of the U.K. Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision,
the expression an &#147;offer to the public&#148; in relation to any securities means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to
decide to purchase or subscribe for any securities, and the expression &#147;U.K. Prospectus Regulation&#148; means Regulation (EU) 2017/1129, as it applies in the U.K. pursuant to the European Union (Withdrawal) Act 2018, as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cayman Islands </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is prohibited from making any
invitation to the public of the Cayman Islands to subscribe for shares of its common stock and this prospectus does not constitute an invitation or offer to the public in the Cayman Islands with respect to the common stock, whether by way of sale or
subscription. &#147;Public&#148; for these purposes shall have the same meaning as &#145;public in the Islands&#146; as defined in the Cayman Islands Mutual Funds Law. However, shares of our common stock may be beneficially owned by persons
resident, domiciled, established, incorporated or registered pursuant to the laws of the Cayman Islands. The company will not undertake business with any person in the Cayman Islands except in furtherance of the business of the company carried on
outside of the Cayman Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts.
Covington&nbsp;
&amp; Burling LLP, New York, New York is counsel to the underwriters in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_22"></A>EXPERTS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of MiNK Therapeutics, Inc. as of December&nbsp;31, 2020 and 2019 and for the years ended December&nbsp;31, 2020
and 2019, have been included herein and in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit report covering the December&nbsp;31, 2020 consolidated financial statements contains an explanatory paragraph that states that the Company&#146;s
recurring losses from operations and net capital deficiency raise substantial doubt about the entity&#146;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the
outcome of that uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_23"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act, with respect to the shares of
common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further
information about us and the shares of common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other
document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the
registration statement. The SEC also maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is<I> www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Exchange Act, and, in accordance with the Exchange Act, will file reports, proxy and information
statements and other information with the SEC. Such annual, quarterly and special reports, proxy and information statements and other information can be inspected and copied at the locations set forth above. We intend to make this information
available on the investor relations section of our website, which is located at www.minktherapeutics.com. Information on, or accessible through, our website is not part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111280_24"></A><A NAME="index"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audited Consolidated Financial Statements for the Years Ended December 31, 2019 and 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_2">Consolidated Balance Sheet</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_3">Consolidated Statement of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_4">Consolidated Statement of Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_5">Consolidated Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unaudited Condensed Consolidated Interim Financial Statements for the Six Months Ended
June&nbsp;30, 2020 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_7">Condensed Consolidated Balance Sheet</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_8">Condensed Consolidated Statement of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_9">Condensed Consolidated Statement of Stockholders&#146; Deficit</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_10">Condensed Consolidated Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin111280_11">Notes to Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin111280_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MiNK Therapeutics,
Inc.: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Opinion on the Consolidated Financial Statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheet of MiNK Therapeutics, Inc. and subsidiaries (the Company) as of December&nbsp;31, 2020 and 2019,
the related consolidated statement of operations and comprehensive loss, stockholders&#146; deficit, and cash flows for each of the years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2020, and the related
notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020 and 2019, and the results
of its operations and its cash flows for the years ended December&nbsp;31, 2020 and 2019, in conformity with U.S.&nbsp;generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Going Concern </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency
that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result
from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis for Opinion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our
audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to
error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 17, 2021, except for Note&nbsp;16,
as to which the date is October 12, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_2"></A>MiNK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEET </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">ASSETS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,691,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">299,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">913,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,096,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment, net of accumulated depreciation of $98,160 and $36,816 as of December&nbsp;31, 2020 and
2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,555,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,308,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,141,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,456,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,859,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,690,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,530,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,171,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,222,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,418,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,824,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,790,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,433,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.00001 per share, 35,000,000 shares authorized, 24,177,313 and
24,059,035 shares issued and outstanding as of December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,523,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,735,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,496,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,874,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,333,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,555,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,308,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated
financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_3"></A>MiNK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">689,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,509,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,654,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,828,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,840,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,637,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,284,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,440,903</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,560,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,238,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,802,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per common share data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,108,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,059,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,390,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(269,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;(17,629,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;(24,071,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_4"></A>MiNK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENT OF STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2019 AND 2020 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Par</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other</B><br><B>Comprehensive</B><br><B>Income (Loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,059,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,694,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,481,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,802,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,802,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(269,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(269,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant and recognition of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of parent stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,059,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">294,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(132,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,496,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,333,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,238,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,238,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,390,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,390,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Option Exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant and recognition of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of parent stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,177,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,523,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,735,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,874,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_5"></A>MiNK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENT OF CASH FLOWS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;(16,238,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;(23,802,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest accrued on convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,440,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,840,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">507,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">886,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(194,371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(802,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayable advance received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,801,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,433,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,110,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,337,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,944,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,749,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,436,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,106,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,436,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(281,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,392,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,056,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,355,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,691,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">299,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_6"></A>MiNK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(1) Description of Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MiNK
Therapeutics, Inc. (&#147;MiNK,&#148; &#147;the Company,&#148; &#147;we&#148; or &#147;our&#148;) is a clinical stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (&#147;iNKT&#148;) cell therapies to treat
cancer and other life-threatening illnesses. We are a majority-owned subsidiary of Agenus Inc. (&#147;Agenus&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred
losses since inception and, as of December&nbsp;31, 2020, had an accumulated deficit of $52.7&nbsp;million. Since inception, we have financed our operations primarily through funding from Agenus. We expect to continue to incur operating losses and
negative cash flows for the foreseeable future. Until we are successful in our efforts for capital infusion, and because the completion of such is not entirely within our control, a substantial doubt exists about our ability to continue as a going
concern for a period of one year after the date these financial statements were issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management continually addresses our liquidity
position and adjusts spending as needed in order to preserve liquidity. Our future liquidity needs will be determined primarily by the success of our operations with respect to the progression of our product candidates and key development and
regulatory events in the future. Potential sources of additional funding include: (1)&nbsp;pursuing collaboration, <FONT STYLE="white-space:nowrap">out-licensing</FONT> and/or partnering opportunities for our portfolio programs and product
candidates with one or more third parties, (2)&nbsp;securing additional debt financing and/or (3)&nbsp;selling equity securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
product candidates are in various stages of development and significant additional expenditures will be required if we start new trials, encounter delays in our programs, apply for regulatory approvals, continue development of our technologies,
expand our operations and/or bring our product candidates to market. The eventual total cost of each clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites and number of patients. The
process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive and uncertain. Because all of our programs are early stage, we are unable to reliably estimate the cost of completing our research and
development programs or the timing for bringing such programs to various markets or substantial partnering or <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements, and, therefore, when, if ever, material cash inflows are likely to
commence. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(2) Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(a) Basis of Presentation and Principles of Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and
include the accounts of us and our subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(b) Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are managed and operated as one business segment. The entire business is managed by a single executive operating committee that reports to
the chief executive officer. We do not operate separate lines of business with respect to any of our product candidates or geographic locations. Accordingly, we do not prepare discrete financial information with respect to separate product areas or
by location and do not have separately reportable segments as defined by Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 280, <I>Segment Reporting.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(c) Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires us to make
estimates and assumptions that affect the reported amounts of assets and liabilities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base
those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(d) Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equipment is carried at cost, $458,000 and $391,000 at December&nbsp;31, 2020, and 2019, respectively. Depreciation is computed using the
straight-line method over the estimated useful lives of the assets, typically <FONT STYLE="white-space:nowrap">4-10</FONT> years. Additions are capitalized, while repairs and maintenance are charged to expense as incurred. Depreciation of equipment
was $98,000 and $37,000, for the years ended December&nbsp;31, 2020 and 2019, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(e) Fair Value Option </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Fair Value Option subsection of ASC Subtopic <FONT STYLE="white-space:nowrap">825-10,</FONT> <I>Financial Instruments &#150;
Overall,</I> the Company has the irrevocable option to report most financial assets and liabilities at fair value on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">instrument-by-instrument</FONT></FONT> basis with changes in
fair value reported in earnings. The Company elected to report the convertible affiliated note it issued to Agenus on July 1, 2020 (the &#147;Note&#148;) at fair value. The fair value of the Note is determined on a scenario based present value
methodology. The outstanding principal amount of the Note was $36.1&nbsp;million at December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(f) Fair Value
Measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that
would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation
techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three
levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets
for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to
determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash and convertible affiliate note are carried at fair value (a Level&nbsp;1 measurement and Level&nbsp;2 measurement,
respectively), determined according to the fair value hierarchy described above (see Note&nbsp;12). The carrying values of the Company&#146;s, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these
liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(g) Foreign Currency Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gains and losses from our foreign currency-based accounts and transactions, such as those resulting from the translation and settlement of
receivables and payables denominated in foreign currencies, are included in the consolidated statements of operations within other income (expense). We do not currently use derivative financial instruments to manage the risks associated with foreign
currency fluctuations. We recorded foreign currency gains of $487,000 and $43,000 for the years ended December&nbsp;31, 2020 and 2019, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(h) Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue includes grant income recognized under our agreement with the Belgium Walloon Region Government (see Note 9) in accordance with ASC <FONT
STYLE="white-space:nowrap">958-605,</FONT> <I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Not-for-Profit</FONT></FONT> Entities, Revenue Recognition </I>as we considered the arrangement as a nonexchange transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(i) Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses include the costs associated with our internal research and development activities, including salaries and
benefits, share-based compensation, occupancy costs, clinical manufacturing costs, related administrative costs and research and development conducted for us by outside advisors. Research and development expenses also include the cost of clinical
trial materials shipped to our research partners. Research and development costs are expensed as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(j) Share-Based
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for share-based compensation in accordance with the provisions of ASC 718, <I>Compensation&#151;Stock
Compensation.</I> Share-based compensation expense is recognized based on the estimated grant date fair value. Compensation cost is recognized on a straight-line basis over the requisite service period of the award. Forfeitures are recognized as
they occur. See Note 8 for a further discussion on share-based compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(k) Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations were historically included in the consolidated U.S. Federal and state income tax returns of Agenus. The provision for income
taxes has been determined based on the separate return method for the period presented. Income taxes are accounted for under the asset and liability method with deferred tax assets and liabilities recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which such items are expected to be reversed or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated
statement of operations in the period that includes the enactment date. Deferred tax assets are recognized when they are more likely than not expected to be realized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(l) Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic income and loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average
number of common shares outstanding. Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding plus the dilutive effect of outstanding
instruments such as stock options. Because we reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted
share count would have reduced the net loss per common share. Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December&nbsp;31, 2020 and 2019, as
they would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,713,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,118,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonvested shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(l) Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued and Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation &#150; Stock Compensation (Topic
718): Improvements to Nonemployee Share-Based Payment Accounting </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2018-07&#148;).</FONT> The amendments in ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> simplify the accounting for share-based
payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. We adopted the new standard on January&nbsp;1, 2019. The adoption did not have a material impact on our consolidated
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair Value
Measurement (Topic 820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2018-13&#148;).</FONT> The amendments in ASU
<FONT STYLE="white-space:nowrap">2018-13</FONT> modify the disclosure requirements of fair value measurements. The standard is effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within those fiscal years, with
early adoption permitted. Certain disclosures are required to be applied on a retrospective basis and others on a prospective basis. We adopted the new standard on January&nbsp;1, 2019. The adoption did not have a material impact on our consolidated
financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued, Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the
Accounting for Income Taxes</I>&nbsp;(&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> enhances and simplifies multiple aspects of the income tax accounting guidance in ASC 740.
The standard will be effective for fiscal years beginning after December&nbsp;15, 2020, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact of adoption of ASU <FONT
STYLE="white-space:nowrap">2019-12</FONT> on our consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No other new accounting pronouncement issued or
effective during the year ended December&nbsp;31, 2020 had or is expected to have a material impact on our consolidated financial statements or disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(3) Other Current Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other current
assets consist of the following as of December&nbsp;31, 2020 and 2019 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance recovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(4) Equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net, consist of the following as of December&nbsp;31, 2020 and 2019 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(5) Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to taxation in the United States and in various state, local and foreign jurisdictions. We remain subject to examination by U.S.
Federal, state, local and foreign tax authorities for tax years 2017 through 2020. Our policy is to recognize income tax related penalties and interest, if any, in our provision for income taxes and, to the extent applicable, in the corresponding
income tax assets and liabilities, including any amounts for uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had available net
operating loss carryforwards of $25.4&nbsp;million for Federal and state income tax purposes, respectively, which are available to offset future Federal and state taxable income, if any. $25.2&nbsp;million of these Federal net operating loss
carryforwards do not expire, while the remaining net operating loss carryforwards expire in 2037. Our ability to use these net operating losses is limited by change of control provisions under Internal Revenue Code Section&nbsp;382 and may expire
unused. We also have foreign net operating loss carryforwards, which do not expire, available to offset future foreign taxable income of $8.9&nbsp;million in the United Kingdom, $8.9&nbsp;million in Belgium, and $359,000 in Hong Kong. The potential
impacts of such provisions are among the items considered and reflected in management&#146;s assessment of our valuation allowance requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax effect of temporary differences and net operating loss carryforwards that give rise to significant portions of the deferred tax assets
and deferred tax liabilities as of December&nbsp;31, 2020 and 2019 are presented below (in thousands). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Federal and state net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,520</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that
some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the net operating loss and tax credit
carryforwards can be utilized or the temporary differences become deductible. We consider projected future taxable income and tax planning strategies in making this assessment. To fully realize the deferred tax asset, we will need to generate future
taxable income sufficient to utilize net operating losses prior to their expiration. Based upon our history of not generating taxable income, we believe that it is more likely than not that deferred tax assets will not be realized through future
earnings. Accordingly, a valuation allowance has been established for the full value of the deferred tax assets. The valuation allowance on the deferred tax assets increased by $2.8 million and $5.6&nbsp;million during the years ended
December&nbsp;31, 2020 and 2019, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax benefit was nil for the years ended December&nbsp;31, 2020 and 2019. Income taxes
recorded differed from the amounts computed by applying the U.S. Federal income tax rate of 21% in 2020 and 2019 to loss before income taxes as a result of the following (in thousands). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computed &#147;expected&#148; Federal tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Increase) reduction in income taxes benefit resulting from:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Uncertain tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State and local income benefit, net of Federal income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(6) Accrued Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following as of December&nbsp;31, 2020 and 2019 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(7) Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 35,000,000 shares of common stock, $0.00001 par value per share. At our inception, Agenus Inc. owned
100&nbsp;percent of our outstanding shares of our common stock. Under our 2018 Equity Incentive Plan (the &#147;2018 Plan&#148;), in February 2018, our Board of Directors issued 4,230,160 shares of our common stock with value of $0.02 per share, see
Note 10. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(8) Share-based Compensation Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Plan provides for the grant of incentive stock options intended to qualify under Section&nbsp;422 of the Internal Revenue Code,
nonstatutory stock options, restricted stock, unrestricted stock and other equity-based awards, such as stock appreciation rights, and stock units including restricted stock units for up to 8,349,000 shares of our common stock (subject to adjustment
in the event of stock splits and other similar events). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We primarily use the Black-Scholes option pricing model to value options granted
to employees and <FONT STYLE="white-space:nowrap">non-employees,</FONT> as well as options granted to members of our Board of Directors. All stock option grants have <FONT STYLE="white-space:nowrap">10-year</FONT> terms and generally vest ratably
over a 3 or <FONT STYLE="white-space:nowrap">4-year</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option granted during the period was estimated on the date of grant
using the following weighted average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected term of stock options granted is based on historical data and other factors and represents the
period of time that stock options are expected to be outstanding prior to exercise. The risk-free interest rate&nbsp;is based on U.S. Treasury strips with maturities that match the expected term on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of option activity for 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,118,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,420,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(763,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,713,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested or expected to vest at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average grant-date fair values of options granted during the year ended December&nbsp;31, 2020,
was $0.01. During 2020, all options were granted with exercise prices equal to the market value of the underlying shares of common stock on the grant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, there was $5,398 of unrecognized share-based compensation expense related to stock options granted to employees,
consultants and directors which, if all milestones are achieved, will be recognized over a weighted average period of 3.4 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock activity for 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonvested</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Grant&nbsp;Date</B><br><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock based compensation expense also includes expense related to awards to employees of the
Company from the Agenus 2019 Equity Incentive Plan. The impact on our results of operations from share-based compensation for the year ended December&nbsp;31, 2020 and 2019, was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">219,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(9) Research and Development Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2018, we entered into an agreement with the Belgium Walloon Region Government in which the Walloon Region agreed to provide a grant
of &#128;1.3&nbsp;million and a repayable advance of &#128;8.3&nbsp;million for the development of one of our research programs. As of December&nbsp;31, 2019, we received $881,000 of the grant portion and $3.4&nbsp;million of the repayable advance.
During the year ended December&nbsp;31, 2019 we recognized grant revenue of $690,000 in accordance with ASC <FONT STYLE="white-space:nowrap">958-605</FONT> and included in our balance sheet at December&nbsp;31, 2019 deferred revenue of $191,000
related to the grant funds received and a long-term liability of $3.4&nbsp;million related to the repayable advance received. During 2020, we discontinued research efforts related to this program and are evaluating our options in accordance with the
terms of the agreement. Accordingly, we recorded the balance of the deferred revenue as other income in our consolidated statement of operations. In addition, due to the uncertainty of the terms of the termination of the agreement, we have included
the refundable advance balance of $5.7&nbsp;million in other current liabilities in our consolidated balance sheet at December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(10)
Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent upon Agenus for all of our working capital requirements. For the periods presented,
certain of our operations were fully integrated with Agenus, including, but not limited to, corporate functions such as finance, human resources, information technology and legal functions. Our consolidated financial statements reflect all costs of
doing business related to these operations. We are party to an Amended and Restated Intercompany License and Services Agreement effective September&nbsp;14, 2018 (the &#147;Intercompany Agreement&#148;), which amended and restated the original
Intercompany License and Services Agreement effective March&nbsp;1, 2018, under which (i)&nbsp;for consideration of $600,000, we were granted a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> field-limited, nontransferable license to Licensed
Technology (as defined in the Intercompany Agreement), (ii) Agenus is to perform research and business services (&#147;Agenus Services&#148;) to support our operations on a cost plus basis and (iii)&nbsp;we are to perform research services to
Agenus, also on a cost plus basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allocated Agenus Services primarily include payroll related expenses, facility costs and stock-based
compensation and are included in the accompanying financial statements based on certain estimates and allocations. The allocation methods primarily include time devoted to activities and headcount-based allocations. Agenus business services and
occupancy costs are allocated to us based on our headcount as a percentage of Agenus&#146;s. Research services are charged between the entities based on hours spent on specific projects applied to hourly wage rates. While we believe our allocation
methods are reasonable, these allocations may not be indicative of the actual amounts that would have been recorded had we operated as an independent, publicly traded company for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allocation of Agenus Services, net of $1.3 and $1.4&nbsp;million for the periods ended December&nbsp;31, 2020 and 2019, respectively, is
included in Operating expenses in our statement of operations and comprehensive loss and Due to related parties in our consolidated balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Note had a principal balance of $36.1&nbsp;million at December&nbsp;31, 2020. The Note is convertible upon a qualified financing, sale by
us of our equity securities resulting in aggregate proceeds to us of at least $50.0&nbsp;million, or upon a change of control, provided that a qualified financing does not constitute a change of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
control. Upon a qualified financing, the outstanding principal amount of the Note plus accrued and unpaid interest shall, at Agenus&#146; election, either be paid in full or converted into equity
shares equal to the quotient obtained by dividing (i)&nbsp;the amount due on the date of conversion by (ii)&nbsp;80% of the per share price of the equity securities sold in the qualified financing. Upon a change of control, we will pay Agenus an
amount equal to (i)&nbsp;1.5 times the principal then outstanding under the Note and (ii)&nbsp;the amount of accrued interest then outstanding immediately prior to the closing of such change of control. In accordance with the terms of the Note,
interest is computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year at 8% and shall accrue and not be payable until converted or paid. In February 2021, the Note was canceled and we entered into a new convertible promissory
note. See Note 16 Subsequent Events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2018, our Board of Directors awarded 4,230,160 of our common shares to
directors and certain officers and employees of us and Agenus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(11) Other Long-Term Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2020, we entered into a promissory note with Bank of America, NA for aggregate loan proceeds of $356,000 (the &#147;Loan&#148;) under
the Small Business Administration (the &#147;SBA&#148;) Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the &#147;CARES Act&#148;). We believe we used at least 60% of the Loan proceeds for covered
payroll costs in accordance with the relevant terms and conditions of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act. The Loan has a <FONT STYLE="white-space:nowrap">two-year</FONT> term and bears interest at a rate of
1% per annum. The Loan may be forgiven partially or fully if the Loan proceeds are used for covered costs provided that such amounts are incurred during the covered period commencing on receipt of the Loan proceeds and at least 60% of any forgiven
amount has been used for covered payroll costs. Any forgiveness of the Loan will be subject to approval by the SBA and will require us to apply for such treatment in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(12) Fair Value Measurement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure
the Note at fair value. The fair value of our Note at December&nbsp;31, 2020 was $43.8&nbsp;million, based on the Level&nbsp;2 valuation hierarchy of the fair value measurements standard using a scenario based present value methodology that was
derived by evaluating the nature and terms of each note and considering the prevailing economic and market conditions at the balance sheet date. The principal amount of the Note at December&nbsp;31, 2020 was $36.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(13) Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may currently be,
or may become, a party to legal proceedings. While we currently believe that the ultimate outcome of any of these proceedings will not have a material adverse effect on our financial position, results of operations, or liquidity, litigation is
subject to inherent uncertainty. Furthermore, litigation consumes both cash and management attention. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(14) Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our employees are eligible to participate in the Agenus Inc. 401(k) Savings Plan in the United States and a defined contribution Group Personal
Pension Plan in the United Kingdom (the &#147;Plans&#148;) for all eligible employees, as defined in the Plans. Participants may contribute a portion of their compensation, subject to a maximum annual amount, as established by the applicable taxing
authority. Each participant is fully vested in his or her contributions and related earnings and losses. For the years ended December&nbsp;31, 2020 and 2019, we expensed $84,000 and $101,000, respectively, related to the discretionary contribution
to the Plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(15) Geographic Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue for the year ended December&nbsp;31, 2019 was earned in Europe based on the domicile of the related business operation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(16) Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, we entered into a fifth convertible promissory note with Agenus with terms identical to the Note but increasing the amount of
borrowing to up to $50.0&nbsp;million and extending the maturity to July&nbsp;1, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2021, we entered into a new
Intercompany General &amp; Administrative Services Agreement with Agenus (the &#147;New Intercompany Service Agreement&#148;). The New Intercompany Service Agreement provides us with administrative support, including, without limitation, financial,
legal, information technology and human resources administrative support and non-administrative services as may be agreed to between the parties from time to time. Agenus provides the services under the New Intercompany Service Agreement on a cost
plus basis and we are required to pay 105% of Agenus&#146; costs. Under the New Intercompany Service Agreement, we are also entitled to use Agenus&#146; business offices and laboratory space and equipment in exchange for us contributing a
proportionate payment for the use of such facilities and equipment. Either party may terminate the New Intercompany Service Agreement upon 30 days&#146; prior written notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2021, we entered into a new Intellectual Property Assignment and License Agreement with Agenus (the &#147;New Assignment and
License Agreement&#148;), upon which the Intercompany Agreement was terminated. Pursuant to the New Assignment and License Agreement, Agenus assigned to us certain patent rights and know-how related to our iNKT product candidates and other patents
and know-how related to our business. In addition to the patent rights assigned to us by Agenus, we also received an exclusive, royalty-free, sublicensable license to research, develop, manufacture and commercialize certain licensed technology in
the field. The New Assignment and License Agreement further provides for us to grant Agenus a field-limited, nonexclusive, royalty-free license under the assigned patent rights. Agenus has also agreed to provide us with Agenus&#146; biological
material upon written request in order for us to use such material in our development activities of a combination therapy. Agenus may withhold the transfer of biological material for various reasons, including if such transfer would reasonably
result in a disruption of planned Agenus activities. For any materials Agenus does share with us, we have agreed to enter into a separate agreement governing the transfer and providing for joint ownership of the data. Agenus has agreed that during
the term of the New Assignment and License Agreement, and for three years thereafter, it will not develop, manufacture or commercialize an iNKT cell therapy, directly or indirectly by transferring such technology. We have the sole responsibility to
develop, manufacture and commercialize products under this New Assignment and License Agreement. We may terminate the New Assignment and License Agreement without cause upon 90 days&#146; prior written notice to Agenus. Either party may terminate if
they believes there has been a material breach which has not been cured within 90 days (or 45 days for breach of payment obligations) of receiving such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2021, the Company received notification from Bank of America, NA that the full amount ($356,000) of the Loan was forgiven by the
SBA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 28, 2021, the Company entered into an amendment to the convertible promissory note with Agenus to provide, among other
things, that the Note will be automatically converted into the Company&#146;s common stock upon the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September 28, 2021, the Company&#146;s stockholders approved an amendment to the Company&#146;s Amended and Restated Certificate of Incorporation, to increase the number of authorized shares of common stock to 35,000,000. This has been reflected on
the consolidated balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 28, 2021, the Company&#146;s stockholders approved the 2021 Equity Incentive Plan
(&#147;2021 Plan&#148;). The 2021 Plan provides for the granting of equity-based awards to the Company&#146;s employees, directors and consultants. The provisions of the plan allow for automatic annual increases for the shares reserved under the
2021 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 28, 2021, the Company&#146;s stockholders approved the 2021 Employee Stock
Purchase Plan (&#147;2021 ESPP&#148;). The 2021 ESPP initially provides for the issuance of 375,000 shares of common stock to employees. The provisions of the 2021 ESPP provide for automatic annual increases for shares reserved under the 2021 ESPP.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 29, 2021, the Company effected a 2.783-for-one split of the Company&#146;s common stock. All common share, per share and
related information included in the accompanying financial statements have been adjusted retroactively, where applicable, to reflect the split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events from the balance sheet date through March 17, 2021, the date at which the consolidated financial
statements were available to be issued and has evaluated for disclosures and subsequent events occurring after such date through October 12, 2021, which is the date these financial statements were available for reissuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_7"></A>MINK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,658,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,691,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,371,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">913,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,200,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,096,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment, net of accumulated depreciation of $129,283 and $98,160 at June&nbsp;30, 2021 and
December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">552,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,753,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,555,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,268,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,141,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,451,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,859,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,511,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,690,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible affiliated note, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,526,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,789,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,530,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,547,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,222,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,824,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STOCKHOLDERS&#146; DEFICIT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.00001 per share; 35,000,000 shares authorized; and 24,177,313 shares
issued at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,074,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,335,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,523,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,916,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,735,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,177,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,874,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,753,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,555,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_8"></A>MINK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,682,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,217,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,462,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,620,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,188,598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,548,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,115,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356,988</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,181,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,660,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per common share data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,177,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,077,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">450,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,993,765</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,210,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_9"></A>MINK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Income (Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Par</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,177,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,523,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,735,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,874,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,181,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,181,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant and recognition of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">619,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">619,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of parent stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,177,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,074,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,335,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(62,916,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,177,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MINK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF&nbsp;STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Par</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Income (Loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,059,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">294,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(132,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,496,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,333,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,660,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,660,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant and recognition of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of parent stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,097,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">338,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">317,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,156,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,500,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_10"></A>MINK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,181,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,660,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">690,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest accrued on convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,548,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,115,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(890,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,739,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(883,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayable advance received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,739,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,628,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,037,675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible affiliated note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,676,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,886,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,676,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,242,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,032,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,071,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,691,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,658,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,370,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited
condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin111280_11"></A>MINK THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(1) Description of
Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MiNK Therapeutics, Inc. (&#147;MiNK&#148; or &#147;the Company&#148;) is a clinical stage biopharmaceutical company focused
on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses. MiNK is a majority-owned subsidiary of Agenus Inc. (&#147;Agenus&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred losses since inception and, as of June&nbsp;30, 2021, had an accumulated deficit of $62.9&nbsp;million. Since
inception, the Company has financed its operations primarily through funding from Agenus. MiNK expects to continue incurring operating losses and negative cash flows for the foreseeable future. Until the Company is successful in its efforts to raise
capital, or until there is a commitment from Agenus to fund operations for the next 12 months, and because the completion of such is not entirely within the Company&#146;s control, a substantial doubt exists about the Company&#146;s ability to
continue as a going concern for a period of one year after the date these financial statements were issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management continually
addresses the Company&#146;s liquidity position and adjusts spending as needed in order to preserve liquidity. The Company&#146;s future liquidity needs will be determined primarily by the success of its operations with respect to the progression of
the Company&#146;s product candidates and key development and regulatory events in the future. Potential sources of additional funding for the Company include: (1)&nbsp;pursuing collaboration, <FONT STYLE="white-space:nowrap">out-licensing</FONT>
and/or partnering opportunities for the Company&#146;s portfolio programs and product candidates with one or more third parties, (2)&nbsp;securing additional debt financing and/or (3)&nbsp;selling equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MiNK&#146;s product candidates are in various stages of development and significant additional expenditures will be required if the Company
starts new trials, encounters delays in its programs, applies for regulatory approvals, continues development of its technologies, expands its operations, and/or brings its product candidates to market. The eventual total cost of each clinical trial
is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, and number of patients. The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive, and
uncertain. Because all of the Company&#146;s programs are at an early stage of clinical development, the Company is unable to reliably estimate the cost of completing its research and development programs or the timing for bringing such programs to
various markets or substantial partnering or <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements, and, therefore, when, if ever, material cash inflows are likely to commence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(2) Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s significant accounting policies are disclosed in the audited consolidated financial statements for the years ended December&nbsp;31, 2020 and 2019 (&#147;annual financial statements&#148;), included elsewhere in this prospectus. Since
the date of those financial statements, there have been no changes to the Company&#146;s significant accounting policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#147;U.S. GAAP&#148;) for interim financial information and with the instructions to
Article 8 of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual consolidated financial statements. In the opinion of the
Company&#146;s management, the condensed consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company&#146;s financial position and operating results. All significant
intercompany transactions and accounts have been eliminated in consolidation. Operating results for the six months ended June&nbsp;30, 2021, are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31,
2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(3) Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic income and loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average
number of common shares outstanding. Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding plus the dilutive effect of outstanding
instruments such as stock options. Because the Company reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully
diluted share count would have reduced the net loss per common share. Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of June&nbsp;30, 2021 and 2020,
as they would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,845,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,819,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(4) Other Current Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other current assets consist of the following as of June&nbsp;30, 2021 and December&nbsp;31, 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance recovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(5) Accrued and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following as of June&nbsp;30, 2021 and December&nbsp;31, 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other current liabilities of $5.5&nbsp;million and $5.7&nbsp;million as of June&nbsp;30, 2021 and
December&nbsp;31, 2020, respectively, consist entirely of the repayable advance received under the Company&#146;s research and development agreement with the Belgium Walloon Region Government. During 2020, the Company discontinued research efforts
related to this program and is evaluating its options in accordance with the terms of the agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(6) Share-based Compensation Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2018 EIP provides for the grant of incentive stock options intended to qualify under Section&nbsp;422 of the Internal
Revenue Code, nonstatutory stock options, restricted stock, unrestricted stock and other equity-based awards, such as stock appreciation rights, and stock units including restricted stock units for up to 13,915,000 shares of the Company&#146;s
common stock (subject to adjustment in the event of stock splits and other similar events). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company primarily uses the Black-Scholes option pricing model to value options granted
to employees and <FONT STYLE="white-space:nowrap">non-employees,</FONT> as well as options granted to members of the Company&#146;s Board of Directors. All stock option grants have <FONT STYLE="white-space:nowrap">10-year</FONT> terms and generally
vest ratably over a 3 or <FONT STYLE="white-space:nowrap">4-year</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of option activity for the <FONT
STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2021 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B><br><B>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,713,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,131,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">( &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,845,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,202,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested or expected to vest at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,845,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,202,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,947,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average grant-date fair values of options granted during the
<FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2021, was $1.76. During the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2021, all options were granted with exercise prices equal to the
market value of the underlying shares of common stock on the grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2021, there was $3.2&nbsp;million of
unrecognized share-based compensation expense related to stock options granted to employees, consultants and directors which, if all milestones are achieved, will be recognized over a weighted average period of 2.5 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock activity for the <FONT STYLE="white-space:nowrap">six-month</FONT>
period ended June&nbsp;30, 2021 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonvested</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Grant&nbsp;Date</B><br><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock based compensation expense also includes expense related to awards to employees of the Company from the
Agenus 2019 Equity Incentive Plan. The impact on the Company&#146;s results of operations from share-based compensation for the six months ended June&nbsp;30, 2021 and 2020, was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 85,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">690,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(7) Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the Company has been reliant on Agenus for all of its working capital requirements. For the periods presented, certain of the
Company&#146;s operations were fully integrated with Agenus, including, but not limited to, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporate functions such as finance, human resources, information technology and legal functions. The Company&#146;s consolidated financial statements reflect the costs of doing business related
to these operations. The Company is party to an Amended and Restated Intercompany License and Services Agreement effective September&nbsp;14, 2018 (the &#147;Intercompany Agreement&#148;), which amended and restated the original Intercompany License
and Services Agreement effective March&nbsp;1, 2018, under which (i)&nbsp;for consideration of $600,000, MiNK was granted a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> field-limited, nontransferable license to Licensed Technology (as
defined in the Intercompany Agreement), (ii) Agenus is to perform research and business services (&#147;Agenus Services&#148;) to support MiNK&#146;s operations on a cost plus basis and (iii)&nbsp;MiNK is to perform research services to Agenus, also
on a cost plus basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allocated Agenus Services primarily include payroll related expenses, facility costs and stock-based compensation
and are included in the accompanying financial statements based on certain estimates and allocations. The allocation methods primarily include time devoted to activities and headcount-based allocations. Agenus business services and occupancy costs
are allocated to the Company based on the Company&#146;s headcount as a percentage of Agenus&#146;. Research services are charged between the entities based on hours spent on specific projects applied to hourly wage rates. As such, these allocations
may not be indicative of the actual amounts that would have been recorded had the Company operated as an independent, publicly traded company for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allocation of Agenus Services, net of approximately $1.2&nbsp;million and $635,000 for the six months ended June&nbsp;30, 2021 and 2020,
respectively, is included in Operating expenses in the Company&#146;s statement of operations and Due to related parties in the Company&#146;s consolidated balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, the Company entered into a fifth Convertible Promissory Note (the &#147;Note&#148;) with Agenus with terms identical to the
convertible promissory note, as amended, issued to Agenus on April&nbsp;1, 2019, increasing the amount of borrowing to up to $50.0&nbsp;million and extending the maturity to July&nbsp;1, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Note had a principal balance of $42.8&nbsp;million at June&nbsp;30, 2021. The Note is convertible upon a qualified financing, sale by the
Company of its equity securities resulting in aggregate proceeds to the Company of at least $50.0&nbsp;million, or upon a change of control, provided that a qualified financing does not constitute a change of control. Upon a qualified financing, the
outstanding principal amount of the Note plus accrued and unpaid interest shall, at Agenus&#146; election, either be paid in full or converted into equity shares equal to the quotient obtained by dividing (i)&nbsp;the amount due on the date of
conversion by (ii)&nbsp;80% of the per share price of the equity securities sold in the qualified financing. Upon a change of control, the Company will pay Agenus an amount equal to (i)&nbsp;1.5 times the principal then outstanding under the Note
and (ii)&nbsp;the amount of accrued interest then outstanding immediately prior to the closing of such change of control. In accordance with the terms of the Note, interest is computed on the basis of a
<FONT STYLE="white-space:nowrap">360-day</FONT> year at 8% and shall accrue and not be payable until converted or paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(8) Other Long-term
Liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2020, the Company entered into a promissory note with Bank of America, NA for aggregate loan proceeds of $356,000
(the &#147;Loan&#148;) under the Small Business Administration (the &#147;SBA&#148;) Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the &#147;CARES Act&#148;). The Company believes it used at least 60%
of the Loan proceeds for covered payroll costs in accordance with the relevant terms and conditions of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act. The Loan has a <FONT STYLE="white-space:nowrap">two-year</FONT> term
and bears interest at a rate of 1% per annum. The Loan may be forgiven partially or fully if the Loan proceeds are used for covered costs provided that such amounts are incurred during the covered period commencing on receipt of the Loan proceeds
and at least 60% of any forgiven amount has been used for covered payroll costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(9) Fair Value Measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the Note at fair value. The fair value of the Company&#146;s Note at June&nbsp;30, 2021 and December&nbsp;31, 2020 was
$52.5&nbsp;million and $43.8&nbsp;million, respectively, based on the Level&nbsp;2 valuation hierarchy of the fair value measurements standard using a scenario based present value methodology that was derived by evaluating the nature and terms of
each note and considering the prevailing economic and market conditions at the balance sheet date. The principal amount of the Note at June&nbsp;30, 2021 and December&nbsp;31, 2020 was $42.8&nbsp;million and $36.1&nbsp;million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(10) Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may
currently be, or may become, a party to legal proceedings. While the Company currently believes that the ultimate outcome of any of these proceedings will not have a material adverse effect on its financial position, results of operations, or
liquidity, litigation is subject to inherent uncertainty and consumes both cash and management attention. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(11) Recent Accounting Pronouncements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Recently Issued and Adopted </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the Financial Accounting Standards Board (&#147;FASB&#148;) issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> Income Taxes (Topic 740): simplifying the Accounting for Income Taxes. This ASU enhances and simplifies multiple aspects of the income tax accounting guidance in ASC 740. The Company adopted
the standard on January&nbsp;1, 2021. The adoption did not have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No other new accounting pronouncement issued or effective during the six months ended June&nbsp;30, 2021 had or is expected to have a material
impact on the Company&#146;s consolidated financial statements or disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(12) Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2021, the Company entered into a new Intercompany General &amp; Administrative Services Agreement with Agenus (the &#147;New
Intercompany Service Agreement&#148;). The New Intercompany Service Agreement provides MiNK with administrative support, including, without limitation, financial, legal, information technology and human resources administrative support and
non-administrative services as may be agreed to between the parties from time to time. Agenus provides the services under the New Intercompany Service Agreement on a cost plus basis and the Company is required to pay 105% of Agenus&#146; costs.
Under the New Intercompany Service Agreement, the Company is also entitled to use Agenus&#146; business offices and laboratory space and equipment in exchange for us contributing a proportionate payment for the use of such facilities and equipment.
Either party may terminate the New Intercompany Service Agreement upon 30 days&#146; prior written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2021, the Company
entered into a new Intellectual Property Assignment and License Agreement with Agenus (the &#147;New Assignment and License Agreement&#148;), upon which the Intercompany Agreement was terminated. Pursuant to the New Assignment and License Agreement,
Agenus assigned to the Company certain patent rights and know-how related to its iNKT product candidates and other patents and know-how related to its business. In addition to the patent rights assigned to the Company by Agenus, the Company also
received an exclusive, royalty-free, sublicensable license to research, develop, manufacture and commercialize certain licensed technology in the field. The New Assignment and License Agreement further provides for the Company to grant Agenus a
field-limited, non-exclusive, royalty-free license under the assigned patent rights. Agenus has also agreed to provide the Company with Agenus&#146; biological material upon written request in order for the Company to use such material in its
development activities of a combination therapy. Agenus may withhold the transfer of biological material for various reasons, including if such transfer would reasonably result in a disruption of planned Agenus activities. For any materials Agenus
does share with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company, the parties have agreed to enter into a separate agreement governing the transfer and providing for joint ownership of the data. Agenus has agreed that during the term of the New
Assignment and License Agreement, and for three years thereafter, it will not develop, manufacture or commercialize an iNKT cell therapy, directly or indirectly by transferring such technology. The Company has the sole responsibility to develop,
manufacture and commercialize products under this New Assignment and License Agreement. The Company may terminate the New Assignment and License Agreement without cause upon 90 days&#146; prior written notice to Agenus. Either party may terminate if
they believes there has been a material breach which has not been cured within 90 days (or 45 days for breach of payment obligations) of receiving such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2021, the Company received notification from Bank of America, NA that the full amount ($356,000) of its loan was forgiven by the
SBA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2021, the Company entered into an amendment to the convertible promissory note with Agenus to provide, among
other things, that the Note will be automatically converted into the Company&#146;s common stock upon the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;28, 2021, the Company&#146;s stockholders approved an amendment to the Company&#146;s Amended and Restated Certificate of Incorporation, to increase the number of authorized shares of common stock to 35,000,000. This has been
reflected on the consolidated balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2021, the Company&#146;s stockholders approved the 2021 Equity
Incentive Plan (&#147;2021 Plan&#148;). The 2021 Plan provides for the granting of equity-based awards to the Company&#146;s employees, directors and consultants. The provisions of the plan allow for automatic annual increases for the shares
reserved under the 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2021, the Company&#146;s stockholders approved the 2021 Employee Stock Purchase Plan
(&#147;2021 ESPP&#148;). The 2021 ESPP initially provides for the issuance of 375,000 shares of common stock to employees. The provisions of the 2021 ESPP provide for automatic annual increases for shares reserved under the 2021 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2021, the Company effected a 2.783-for-one split of the Company&#146;s common stock. All common share, per share and
related information included in the accompanying financial statements have been adjusted retroactively, where applicable, to reflect the split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events from the balance sheet date through September&nbsp;13, 2021, the date at which the consolidated
financial statements were available to be issued, and has evaluated for disclosures and subsequent events occurring after such date through October&nbsp;12, 2021, which is the date these financial statements were available for reissuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>3,333,334 shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MiNK Therapeutics, Inc. </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111280g45c49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><I></I></B><B>Common stock</B><B><I> </I></B></P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Evercore
ISI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;William Blair </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:15pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="65%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:15pt">
<TD VALIGN="top" ALIGN="center"><B>B.&nbsp;Riley&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Baird</B></TD></TR>
</TABLE> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October 14, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Through
and including November 8, 2021 (the 25th day after the date of this prospectus), all dealers effecting transactions in the common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery
requirement is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g111280g13a26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g13a26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2C&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    **J^$$$#A"24T$!       #QP!6@ #&R5'' (   ('_P X0DE-!"4
M   !"A6VRSV]-W6D\;SL\E9.N:.$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  @$L
M   0 ".$))300F       .             #^    X0DE-! T       0
M >.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "
MT    &       !.$))30/X      !P  #___________________________
M__ ^@     _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@  #
MA"24T$"       $     $   )    "0      X0DE-!!X       0     .$
M))300:      ,U    !@             #^P  !U           0
M                 !              =0   #^P
M !                         !     !        ;G5L;     (    &8F
M]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M  3&5F=&QO;F<          $)T;VUL;VYG   #^P    !29VAT;&]N9P  !U
M     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M=S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F
M5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP96
M5N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M      4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M    !"=&]M;&]N9P   _L     4F=H=&QO;F<   =0     W5R;%1%6%0
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MEC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M  "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M  .$))3001       ! 0 X0DE-!!0       0    #.$))300,     !Y$
M   0   *    !7   !X   HR   !XH !@  ?_8_^(,6$E#0U]04D]&24Q%
M$!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E
M0     245#('-21T(               $  /;6  $     TRU(4" @
M                                                         18W
M!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0
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M(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M   %A96B        #S40 !     1;,6%E:(                     !865
MH@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M   "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V
M@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                              9&5S8P
M N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D
M="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7
M(@<W!A8V4@+2!S4D="                             &1E<V,
M  +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C
M$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@24
M5#-C$Y-C8M,BXQ                                  !V:65W
M 3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %
M<?YVUE87,          0                        */     G-I9R
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M$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-=
MV.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^
MP0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!
M*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7
M@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BA
MBO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'
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M$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %& E<# 1$
M A$! Q$!_\0 'P !  (" @,! 0            <(!08!"0($"@,+_\0 5Q
M 00" @ #! ,,!P4$" (+!0(#! 8!!P ("1$2$Q05%B$Q5AD:05=WEI>8M]+7
MV!<B-3A1MO C)&%Q@0H8,I$E)D9XH;'!\3EU)S,T-D-89X>GT=;_Q  = 0$
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MEYX\_P##\/-:R1R*MD;NU5J,A1 ^P[S7ZN;V=< 5"U\#(S/,W;K99"T$(*%
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M)>:89;0I;KB$8RK%R*&:Q+'!7AEGGE=8X8(4:6661CPD<<:!G=V) 554L2>
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MZNW7>ZB.;81R7'2 5K B3M@<-V,YC\$*W=/W2CE#P" ..W@7DVGV7[Y[M[9
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MDLH\DJ?5@4KH@5!(W=A]/VNI-QX=AMA$E2K;"3]T,0FLIRKRQ^YA*>YC(5"
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M0RW[I!D9^UINZ%'53 07=&6.V]N2[9UOT0U)T59;'$EOP7:0@]I[?$6"$CL
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MWQY@W;'5[?4FUH7]M%<@CK1BRJ4&A4K)$D7<ZJP7O)"/PK-*7:12.Y0<N_\
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MSP.O'>8Y4<QLCD>(%"@!9&' X5; =L?$8W#LX!X>VN>E5Q:I&X.XZJW<CQ5
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M[7PU%%("GB>(G<3ZJ\? C[N_SD8#GMX[0?L'.YSZ?+Z/+S\OJ_!Y_P"'./\
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M /ARN_0WH=V4T3TF[V:4V/40XK8&\X6U6-<C(ENKA:(5<M6HI=1"XF%!I&1
M%8D&WD,.J(/Q\1FL^\.^EG&5XV+KOKGIO=];="[K6VYIM?HI=6^QF:I9A:(5
M]O';G[(I8EDF*P*S@1JW<>%4$G@1^ETNQJ:?=5+$*I8N1V4KKXL3!B]9XDY9
M&94!=@.6XXX)(X]OHUGH1V:&>#';>FDNHA4;Y+G'IT*N)M]<6*7&7O@#>TK7
M94$% V\_+<&5+]"YF%>V3B)Y8D+2WGU:Z\Z<F],E'K!+4QT$%=5DM&I9$H<:
M.S2[16,8G/\ Q,B)Y)QP>_GM!.4CTFP7I*;5&%1>>4,L?BQE2/7(YB?$#>&/
MJ:D_NN>1QP3[>V3I?K2WZ;ZG]>M4W^#'&737NIZ;4[./B3XA2-#,A@\:).CL
MD(+KT.8VT^VM"9$9UQEW&/6VK*<XSSE?6&RJ[CJKJ#:47:2G?VURU5D>-HF>
M"65FC8QOPZ$J>>UPK#WU&;1J:\M76TJ\ZA9H:\:2*K!@K@>Z 8<@\'RY!(/O
M'*"D>G&_IGB[3NVT43!&:7DZ<DTR-<HU@K;QR!8G]=*KC3S%6F/R)[ONI92<
MMKE#7X3GHPX^V[&RI"MZ3K#1#T1Q])/)))NEVZW&IFO86N]<;3U@AK2]D8#0
M<L0DJR<'M4A^,@WU-YNJ#M%55J&J81-WQEUD-8QAA$W)/#D<<J1R.2"/;U_;
MOZ5>)3?H>U==;8ZN=5NVUEN4XNQ3NW\U>N=9[%J@TD.8&#9;30,A0SBG*ZEA
MLL+$%!AF(/,+E,2I-O#XCQ7-[TG6/HWH2:G8ZGJ;JOI&M3CA:[T?'Z_LM9:D
MBD:21&\:/80#UDL8IIH9H6EA".JU)R[B#N:GJ&;UF&QK=;LY)FD\/:-ZO!9C
M5E"H04D@8=@'<BNDG:QX[G4 9WC>'SUGLG4/J7JS0UPL<2T6BILV&>>("W)3
MH2,3M5F+VB4( KFM1Y3@D0X7S CR7XT1R>XP^15#A^]^ZL\6Z]ZEK]7=5;3>
MU*KU*UIX(Z\<JJL[15:T-5)K 1F033"'Q&5681JRQ=\A0R-N6CU\FKUE:E+*
M)9(@[.RDE%:1VD*(2 2J=W:"0"Q!;@<\#K=\1WJ-W;V#WDT#VLZH4.D6Q_3.
MN@X^&Y=;4 %"_FN!:[X07%G!Y]AKY2="P,L<-[VL27&0IY?L\/\ J9<1GHWH
MYZKZ+H=$=0=+=5W[M(;G93.XIU;$TIJ25*,0>.:.M8BC?Q*[KPZ%@!W=O#*<
MU_?ZS<3;FELM77BG-6NJ@S21(HE$DS<%6EC9@%<<$$>^#\&0/OOJ1XP/B#1Z
M+JCL^,Z]Z>U&"N<*XEBU-GQ)LUN9#@$0V)[8Z%:;H3,$H8@T8:$BL30 B3*E
M^HJ0:PVQ(CS>BZJ]$?H^;8;;I>3J#=;>Q2>G'#;1T5D9XY>PR2UJ4,,3RP0&
M:7LGG")]3B8\J^#=UG56\->MLDJ5:J2B9WB:-@C*"@)5999'?L9^Q5(C)/+E
M?W0L3WFZ1]IA/:/J?VVZ7UBI[)+]>M<AM4NZ[NMC&@771 #YK@PY[LXJ6K<(
MC")5^Y%!9+W<Q")CYD>'/B19S;KS<77^B>M>F)>E^JNDNLK-S70=0;"?:#8T
M:TDX6:SZJ\D8CABL/&\<].*6+N@DBD1GCD9"!WR&YT^R78ZS9ZI([#4:Z5C!
M,ZIRL9D"L2SQJ59)6#!2&! (!Y\L1UVZ>]Z_NF0ONOV1K>MH8RS:Q,0+#&UW
M9X<D112$BHNU2OT:".(DY!\T^.@P!KYD\RE\8^7)3\PI;\&.V^N[U%U=T./1
MG/T5TW/LY)JVQB:LVQK,LU]!<6Y8O22(B5X5D>6988&9)!'&@=4=B,\T-5NC
MU"FWV$=95DKN)!7=>R%C%X<<(0LSN5"IW2>8))X;A1FL=;O#W[0ZWZO^)MJ^
MU4X)"MW9IRR9U)!8N-9FQS22(ZYQXF2!"*1=B L+=,P,9^*N1LHPXO*\8PTO
M.,OJ7K_IG9=3>C/95;<TE/IKP&V\AJ68VKF.2DS!(WC#6.!!(?J(;V#@DD9:
MU^BV-?7=0UY8566_RM5?&C82+VR@$E6[4/#@>[X\^3QQFI[A\,_M'>O"+Z\=
M7A5=KR=[:9V::O1JENVT"B,6'$[%MQ.(0>T9F9K:B2!M[$%FT324.)EIB;%7
M+1.;:CO9.H])/3-'TM=0]32SV#HMSK8:,-U:LY:*6.MJCWRU>P61%XE":$E(
MW<,T;A#&2RV[/3^QFZ7H:]8U6[4L/,\)EC(96DL>2RAO#[@LJM^Z \B.0?+.
M[CJ87['&M)5B5VIHM1UWN%IXI",5FDDV"P*.*A37(]?DHEQK#:&/?)8E$9Z>
MTT9E-HE^URC#"%)CM<7ZJBZ>AW=I>E[MO8:=A')#9NQ&&<S2+W6$[#!6;PTE
M+"-C"I*< ER"[;=JVOM2B^B444%I>Y6CA;N3L4\1MR))!W%>.X!C[KG@ <#*
M&[8ZA[TM/B^]?.W82N#).C]?:AEU&RV%RQ@XY.&=?K6ZA:([5<?G-FYC/O5U
MKZ<R(L-QG")#R_:>F,_E&\:OJW2U/1'U%TG+/*-YL-O';JUA7F:-X5L:60NU
M@*(%X6G8)5I%;W  !+*##6=7=DZII;1(U-."JT3RF1 5<Q6D $9;Q&/=*OF%
M[>#[?(G*^[!Z>=].I/<G=G:7HG7-9[DJ'8^1.+W[5]^,QJ],#64L378"<W#D
MZS5"+/C-6245*A2,"PHDL13I(,0 O88C%WYW7]6]"]6]':3I?KN;::>YTVL<
M-#::^$SI-6BB-:.,!*]R2,FJL4,\<E?M=X89XY_-X4PI]7NM7MKFRTJ5[<5\
ML\]>=@C)*[^(S<M)$& D+.C!^0'=&4^3'.]9O#M[(AZYWC["]C)]7*=L.W&H
M-HT$32JP0A?+=1BVZORT10LDUEY8M#\TO#K(N(W$(3Q@ "$BX?.EI,R:Y#L]
M1^D'IZ6UT-T]T[%;AZ2Z2W&JOS7K4;&U;:G/&6G6$ S=B0R6I)"\4<MBQ*_;
M!$B1B3UK]#L$CW5Z\8GV>TJ68(X8ROAQ^+&P"LX(7EW6,>3=J(OFY)/;<;PH
M^N&UNJO3ZN:AW.%@ +T/NM[-RQPTT+/QDP#ICWP:[@D'DRH3BW8_EE;:'E.-
M9QZ7,)5]'-3]*746LZIZOM;;3S23T)*E*".22&6NQ:"$)(/"F5)  _/!*CN'
MF,E>F:%G6ZJ.K;01S"65V4.D@ <@CW2$J?Z3Q]KC)B[W=6<=QNM%]TA&L/RE
M83"!YFG65>9.8@FU@)K1 7DHW$5B0Z')(1)"E\,H?>9&DY4F/&D26&6EPO1/
M4[=']2Z_>&MZY7@,L-VL.SOEJ6$\.41%_<B:,]L\/)4&6)$9E1F.9FYUOT5U
MT],2>%(X#PR>?:LR<E.\ $E&!:-N 2%<L 2 #TEOZI\=!?7B5THEZOT86US(
MH\C3CFY)EPK,D^YK9\6Y6EQ<SI%X;DN-9K2\AVRDG62K0D;Y/+94=0F>GLZ[
M+T'CJ%>M$V6]AV*WUW(TR5+"UEV2R"T)!&E$J#ZS]6:-=GZMXPX!\#ZF=0-;
MK'U#Z#FM3>N8#5]:,L9D\#L*=I+3^?*<1@F#O \_W0#9,VV?!PN4WP\M*=>=
M=WH*_OW15R,;7'V&8[)'U:SVRU/RY=JK<*<]'<F!X;65B&JT:EP?*1(K,%9>
M&-09FR!</J?3!77TA;KJ#9:^=>G][3BU4E=.R2U5J50BU+,D2N$E=OJYLPQR
M$HMIQ"\W@HLF5:Z4E.BJ4:\R&[3E>R)&)6.227GQ(PQ!*@#L\-B &>,%NSO)
M7=M7T'QB-\[^TI9.QA&K=7]0:AD,3KP(U+=H3[N[\QY@V;,&F006WW6)+0?6
M,8'NNDG04&O")QU\+'<)2VF58.SN^B'0Z#=5^G*]KJ?<;<>'2FV])A]! 4D1
M)8K$]6E(IK^(TH$7CO8L)!X["-"RWJ\'55Z_3?8/'KJE4EI5J3 "WP5Y5XXY
MI>XR $!F"K$A?L 8^ZJW6?#\[\:9[#]I':9H_KENF#V)MMD(U;M-N$N%(V#5
M$"UE;%+DV"$(E37[G&.M0;'E1<:' 3&9AX.-?8($1,=,=_:;/7O0FYZ>Z6]=
MW74>FEZ=J5DM=+:>*6*OM9*D<"K6>546DT#/6 ADFL1]E>=U:.*8EDC$T6[J
MW=B(Z5"ZM]Y.S8VF0R5O%9N9D#.TRR+XG<P6-F+IR&([0V'$^&5W-8\+.W]2
MI6N:\UMEWM7!VF&AHV%3G!!6EJJHD=)G?&<%O<XDN*2@/M9'RULRWF5L/--J
MQEWV61-Z2NCSZ4:G5B;"PVI'2LFKE?Z'W!-%>]<DD6,PF+O=&BD5O$0%%*N&
M8>Y#>5Z?V_TN2:PU4%D[,65 L0%&A\( L&\3A>&7CM/+'D'MXY*V.[B^'#OZ
MTV;J+V8TE3-5;-VQHC3=!U5L;1.W$@B-*NX^LA9\;*4.&9#5:*+C/V"P#Y2)
MY$;Z$)#&@1)) :A"]:Z/](NCJ5>KNFMW;VNLU6\W%_::W?:@S1W:369HV\Q#
MS:B[EKUY4,<<O),T-B(1R$"0V^@O2RZS8TXJUFQ3JP5[%*SV-%,(U8']V1&_
M >1"&9".5=&+#C)QZ!]:NUH3>MYWOV,T[UDZ]51\0Z)UOI;3VLM-_,==(R8H
M\?+,?TE5 %,L<,2^-8(IF#EW<@\:)F9:G1X01"C#YD+UWU'TQ+I*&AZ=W'5'
M4-I9O%V>[W.SVYK68U:21(?H;;L)7>593$8Y10C6&*% ))II&D3,T>OV:W)[
MU^IKZ$10)7IU:U7Q$8J%+^/$K2*O:"&4S-WLQX54'NK ^*7U<VEV]ZD6?4>G
MS44=<L6.M6R.&(D?A(F[Q:Y)>D.U D14KW:(B4\]&,C'9Z,COCP,2F<_!CJ6
M0B0/HRZGUG275M3;[:"26GZM:J--$@EFI-955%N.,\,_:%:&18SXA@GE*JY
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M_J?TF]/K^QO;Z5ALL.D9)!-K+:20O#16G2I1TVLE&BDEDJPRPM+ 94CD/?\
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M8SK_ %=U7H]MZ.>BNG:-B63:Z5T-^!JTT:Q!:MB(]LTB+#+[N10/#D;R/('
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M8%E'NV,C^[D[G+%2WL3M''ER;1\@\L8XQCC&.,8XQCC&.,8XQD$5C^\EN/\
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M8XQCC&=#_>GQLZMUFVD<TEJ;6C&U;E4)+4"\6(O8GP%4KQK"4O2ZW :A#9Y
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M&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC,>4*C@@^86+S8@P4-B29Y(F0E,0H
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M.$^F6G"'8[^4MX;<4PN1E7M'E(3#;"(1LLB@A)1W]OM[&'DZ\_![H=H^V/8
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MEKSP687,<]::.Q#( K%)87#QMVNK(W:P![65E;CA@5)!]*S(RNIX9&#*??#
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M')8C+L)3%&Z^(J%%7E=+T;UW%T(PBW0S(<D/?=67$*#*(S,3G)H^3"BS'R1
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MP8Q].?HY0D*.3[/YA_U(QG1EV4[$V$SWHH!_KC0;SV2:ZV4'8KNSZEKL?67
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M EC2FPO+'^Y5O.?+Z?\ ](.O?P?7_P"U//O+Z-Z[_P".S^+]A_M<XYZA:/\
MR1_A%<?_ /7-YUAJB]!-E:[-2\5@=%$7JHE))!S8NO66X# ^P#Y;TQQ[%JQE
MI$5ME3ZW,9QE"6\JQ]7,'9[:A/K=A"GK,K34;<2QC7;!C(TE>1 @'JOF7+!0
M/?YXR_6IV([->1A&JI-$Y;UBOY!75B?*7GD <CCSYS^B/5;95[N#@66FV(%;
M*V3:6Z,L-:+CSP,DTTZY'<=@%A<F7 FMH?:=96Y'D.H2ZVXVI6%H5C'Y[3P6
M*D\E6U7GJV("%E@LPO!-&2 RB2*54D0E2& 9!RI##R(SM221R1K)&Z21N"5>
M-U=2 2"0R$J>""#P3P01[1E4]TZ?,[!BK(B![AJ.],.!"PR),@PRC*8-N*%1
MI,;\5>C#):6GWY+4^')DL.K94RY#RM].<)222PV(9XE\0>K5HY(^[L)7P5\U
M/('D6/(Y7GR/)( '.>ING)=W7L>' UJ.:6Q5GBBEABLQ&#92VJ\]?UEDKR@.
M76>*61"R%?"^J $<:-TT:UL.BRBK3XZ)&FBPX45-E0I9/+16X#SI4@14,=D#
M8^7IZ&VH$*))?RS%0I4E?MW,XY>$@EE:3M[7:"7O'/D.(F "^WW@.?/W1//M
M)RUT?TM9Z?KQB</###)%6J5YI8I;!%G9)=LSV#79ZT??.>((87?LB',C%SR;
MG\Q<Z=CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQGBM&%I
MRC/U9QY?5C/_ ,,XSC_SQRA /M_]#\(^R/>QD8ZQTKJK3$6R0M64.N4:+;K)
M/MMC8KX]J"@H>(J\Y$Q_"//TMMIQAB#!9RT.%Q4IB#(D2*G#.,Z]LMCLS VQ
MNV+K5J\=6N;#ES%7CY[8UY][S)=VYDD<EY'=CSER6:69B\KM(YXY9CR3P .2
M3YD\  D\D@ <\ <2AS"RWE3^W]+VW9M<#[!HP;7S^T];6D/L*F5FRKAQA=D-
M@436(P>23(28D0;'DM$9&);OO8N5)B^UA0SP-Z3[^C;.C]AIJ6PN5^H'MPZG
M;:Z;5V[-1F+U8II(I6L&&-'DF*- A15615D[)'@L*G8-2ZKT=O<C1R4Q1:33
M;RIN?"N0N[224DF,'JLJS1)!.LTBMWRI(K1&5 8V?N-<.DG:#>W<HPK<<2J@
M:#UPA#X007%E2&"5KMEQ0)AIN3#L=@@^^*:K-H;?^$EI"H\0C6I49C(:25E2
MI@>1ZXZ4UW1TM75)L9+VX[K$M^(P,L$--W;Z&2PSD1@R35P#9BXG[)P_#+&$
M+VZ5C>[7;T]E7L0U>GXH+$%NC+ ))[=EEB\.6*57#0/7E# L_?$U<]GA&:7Q
M*W9_Y8S]>//FA9N.8*SUBOW2NG*E:A$ _6K*+G!#P0I&;ECBHDE'7$GP)L9U
M*FWXTJ,ZXR\VK'DI"L_5GRSB[#--6FBL5Y9()X)$EAFB8I)%)&P9)$8>:LK
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M(]]7C"5JQA*?PSW4>[/4.T?9&G#1[X88? A;O7ZBI7O+>''RS\\D]OP9E7+
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M^?S_ /.6/ZGWF_WRI;.E[)*A2MCKN_-N4O"JY+S.K\$;5;#@9"&!I3D ?+7
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M=A,I1*B#<J^(1FTI>990G&%<8R/A5MZ9WW8I !#JVF#=LIV+)H>>=(5W6N'
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MW?M%([%2JV!K4HD1?%0FV)&:T)3((SDP5LL2W%2&V\MJ8R%K)T/MSD$!FE[
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MDS>GLZ P[XII]HH&DE,@;?5W[T^B&M'8I&A3L8L5;O/>  R]A[@5P+L6Q$E
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MI"^3Z/XTI_ZF/ITT/U^?\&E_RQ]WG\/'[9['_1?8_P!WC]@WTA?)]'\:4_\
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M/8C RF2Y&P#E$[%?E^0JMF5+*5X[RL&)LTVKH5X\G,\$G+<\>Y*Q,"1R02"
M?9E[8OB(4A[9_<XC8Z7:[#J_>T_LK=]'19#0AJX:EVANW7=TUBR9DMI-K&I
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M\EB5^R1GF:1V7+V&SKVH)XH4E!EDUCCQ$B0 T:4M1R5BXC7O+(ZK&BJH+*%
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M_?GN/_NWW[_/FJ><+_\ :#_D11__ &DH_P"';;-SZ%_CF7[@G_/5L^M[>?\
M;O7C\OP3]GNRO_G]7/E'2?P?J'[PR_XEJ\Z7?_?M=]W1_F+.6 Y Y)8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,9!W8[KYKWM+IRXZ-VDT6<I5WCCV2BP,](PU$?$%QYX40%SG(\QAB9
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MI$U'U^__ %L'^VQ][N]'OMQV._/>@_PMX_;!=;?$NG?P*_\ I/'TB:CZ_?\
MZV#_ &V/O=WH]]N.QWY[T#^%O'[8+K;XET[^!7_TGCZ1-1]?O_UL'^WQ][N]
M'OMQV._/:@?PMX_;!=;?$NG?P*_^D\?2)J/K]_\ K8/]MC[W=Z/?;CL=^>U
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M72.P$CLTW9]1L#A:T_),")"*-?$'[8JM%KFT R-?PR09(R:B",6:$S(C->_
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M]C_KY_V8S)7/KWVA,0;@Y"H]_DP;0"W$/TW5XN]AU;G]?=AVV359.K]DV:?
MOBH1(?2H,22,7)JI"\GZVZ'(L5ZLG8%OG2EL99K26A=I43;0+8%AD'I,HU8^
MWZMDDIE](EQY4#;MU0;'H%#-9E'YPJ##@4MB4Z%&AAD?Y11/)#I+<"23GLR6
M,OSQC'&,<8QQC'&,K_O/^W>O'Y?@G[/=E<GM)_!^H?O#+_B6KR-O_OVN^[H_
MS%G+ <@<DL<8QQC'&,<8RAO;?K;L3M+:JS1VS8BD:GK-"OQ-ZT$0J+;.G;/O
M8@AKL2Z""1+;5R(,U0:06MQ83:WG76(9BU#'1C+\\:\[!8RMTK3G=2YP;L1L
MU4, ]^W2D.,TK<P7?/R_KW34]/6ES7)*MMU*OF9Q(Q@KO6.7V4)'1Z60 Y@7
M(':3-F@VZAP@"&,U_9773L998(MW7VJ-J:YH"6]AQ(VHVNPX,_<1E[-U76$"
MI[3=,$ME)J]/&"RM>O,>/)JESNEF"D3.=E1:7+L]J/"Q;&?M8>MW:UVV[@PV
M*V,:$646^Y/LR-OU-NPVF4SLW5MC'#J'.<LP( >!2ZP M<8IKO;NIJ'$$C'2
M.M:UMZ-6;>1,I8RP4[2>VK!TXUG2+G0LGMBT;<NL]@/T4;;?=24RGT?L<,N7
MPYHQ8]E6<0-LKNIXS[>:]_2B:J@ RO-=K%D^#C0K[#&>SU+U#O6AWV$2V**L
MP1D5J<K4]KV4[LY%W&;^W)(N8DD-VY5P+5B-OUH7%!0;*WC-@&4XZQ$MXRI-
M5]8:I#WV6,J08ZI=JY1!TC J5NA6H32Y==VG>\[?"%G^Q,A_L-KZ]'\T>!/O
MD1^KPK7K^OSV\B;4O70^;$BQ]6F5C*M!%%77S^?S_IQF:;ZP]O\ !C6KZY.S
M?A$(<)9JC"=L5+!'2A./OJ[W E*M,MRRR8C4&3K$U3@4>!21FZEM!:U(U3+D
MD*S[.Q$V,G3I93MH.WI6PB-9NM4J/P[L&!N)RW;&<M#&X+03WXF5K4Z#JSMB
M,3P$/7M- 64 A\\(JDF%$L$(  AFJ_$:)MLIY<>]Q_9QD):0U7V#MPP!;:S7
M-@U&$U<XJKV>L^W%$<[@4&[RZSNL<Z'!R+60GA!M#TI2=D5R5%/C:M-G"[&Q
M2*^+L8'+$E;*Y%.K-'=J-AZ*U%:Z<#V55ZW+USIJ;MNKG]K03MH[)3V"1,P6
ML@$>?O\ %&U_W45/#K(@[Y8M>/6<?&_HZ*,)K5>$R9K&2.>ZI]OG*\T]7_FA
MFQRM0?*ZI9#:X9VS17X^N_$2A56J%[!%+0L3_D\[O/0PN$OWTS!%RX\67&L]
MDQ3YEL6Q_;\_F<WG:75C?HXC.&Z^A7D[IYO85>LLO7@W9S) [87)6CV*R7.,
M.7_9-8A2V1^RHRS1H4;N(GWPV0SL,5%+V$6QB6QD];!U+N-W5'5T+9*[=-Z(
MU[6&Q.[:($VY!KELNUI7K=H$'M9&[$26KPUW36[4W,EDU$)5=<GSRL:]#0KI
MNOP!>6,S?2706R-*Q-FD-OOMFMA75W3;ANY(L4FP*N!&I]>M4U"VF'GY3V)2
MG7=BAKGYSR(X83+H]!-V,W%E1&VV4\_@_P#.7IXRN.,8XQCC&.,8XQCC&.,8
MXQCC&.,9HVSS9&LZUV'9!#J&"U?HUM-BWW&FWT,D1( A/A.K8>2MIY#<F.TM
M33J%-N83E"TJ3G.,L91_1&\MJCP^E"^UH^[33^][31*&.1M(;UXJX080L&JM
MA;0GVZE)TJT5+EA&?D? ;(NZR0TY#!D7,CH]XBD67&,AY?>_:A@R&N=3J*S%
M7ED'22-2PY(ETZ=$!NM_838Y&O";6X#]JLP7LFLPL\0YF(SAY]#013\>#.E/
MY93Y_/S^#_/[ L;L;M,:.=8MZ;OTS!C^Z4NRYKNJ[2Y,@D1^QV!)>HA#I^'%
MG#LQ!0[YMGVZC1L3?B.5NUIT]A3;,R/&997-?F=[)U<C;V@7/4\(9;^OVK^P
MVPK8,![$4:KQ:9HBNZFMC .O6(A2*_/?B7$%MX"I)DA6A[X$E!(07 A5OV$Q
MQC,+<N]6QZUF]%!W7T"8J=.%]I[*P5D[G<%%RU6ZAW"+5-ESU T:N),CRIUT
MA#S1A'QB8U/F)F,'RE>@,QRLQCY_/Y_!GKWWQ$T4FU[ "L:F590]5B;+;KY8
M3:SZ56"P:P6);*@R9=_6>-8B9,UV:0CY'@=G7.UUJ8-1"N=5KLR1-CB6/G\_
M[,GX;V.M7]%G8&W'-4HSL'KY9#U2-:]I]R=M(^U&Q]%IFP@[=6M,ZI5DE*8,
M!+X"CNMNTM!>.5;(P!@<X^V/228^?S^?ED04?O.<V+*^&5+5%<GE:J'FV?;+
M)/:LFDL4^O,7E5.C-"6=C:XIA]VWO18\^R3JELX!J!X+!CQ(Q$BAPV&D3&/G
M_ED?:>[';HA:_N&^=G,;KL=(J9"ZR3N"87KS7]2-4D!N=ZFG+-4)U.;G[CG3
M-=T"&5N$@;:X F*<8K9Z(Z0:E21#RV,M%([.JD:=%;7KE'27S>MM1M6:H%3+
M.D4+N31W9[VMZ;>BMC2!(9K=2L[#/SM&>C!K$0Q5Y([$"$5,$(XS+&06]WXL
M46;<F)>DA[<33@S!'>$IK:C3[P#,;=5STR48UO#S1&L[&]D]3)=L&+)OT-R>
M-?2"FQP]H2@4\QFF4#NMN65.$B+!0*W9+U;BH"L JX-OB0-"ARK/O?LCKP>9
MFV!W5\RU1<"16HHK!I*81QN>/C12(H3%,R2$.8RGG\/](\_[/+_S]CRS.U7O
M3=+T3U,*F:LCT&;LJ91C==1 V1 LL,H%/E]EU$H'M\J?K*.Y7F8]FHF)+$FO
M,%)\VOD(!+,X,19(UM0^7]G]IXRN<3?$"O$06'F,=?X9]5SLE[':T+TFZ[.V
M!4=AU?6 D:_=+R"ETOKJ:O**ZNQFAE2IY=[76:W:Y&"-F:L4"FM@CUC8S,!^
MY5[VCL+1;-#H2J=JRT;V :ONA:X%V(^PY9 YU*L?85=5DZXDUISY=AC'2M3B
MS#[=Q2?0<KQ88JNH!3D%9+'\_P!GY_;SLBXQCC&.,8XQD$5C^\EN/\D&@/\
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MQ AR/:-$A>:/8B-0BP8R'AD.O&'Q$*.Q"EY96QFDE.I74>;9Q5D)537CHC7
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M,9FCQ$UM0FRF=K.D+)93[V+F&$$240FQEF.MG5*XZ0WMLR_.-ZY%4.VL7]$
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MGDA'B5^F((0QBD3N5$4*?(^?D,R*\1_5-TMR->:MH&VM@WB83?%AQD&NA@D
M@Y&<6A^=*G'K##F Q$=M"I<R<8%1'($9*E38T=25I3FV/1GN]?0.TVVPTNNH
M)&DLTDEN:>1 X'9&L=:M*)YF+!42%V$K<"-V#+W>:'_M4=#]0]0?2IT?TYUO
MU/U#-:EJ4Z=;44]?!8,+E9+,UC:;.K+KZ42 S3SWZM=ZT0+6(8F5E7U.V?8_
M.(.:+I?84-G8P NI=Y!!7,YLP\="B.NR(H^2Y'5$F/CIF4J/0@<N67@-,+=D
ML,P(I1QG08/#\5D+(SCR0, 58\^?N6'F2O) ([E/P$'-F])G7K+ VDZ3WD2;
MVG9+;JG3?G905XH69XJ\A0PRO!*1Z]#3EEM0HC&1%@CL,OL]5.W[]ZB3*GM:
M<'%E0 ]B4Q=9TR$&'FHZY<4<S#(IE+CQ&S[TB4U[#$-3:";?M<MQ&7XR\R;Y
MIRRG_AH)IG[2S10123,%4%G?M0,P554L_DP4#GN'/8N7Z+/2-=ZG\?3[I(SL
M*-86$V2A8H[< EB@"V(_<I';$DT?#)VQV%9B$C>-C)V'I5A>,*3GSQGZ<9QY
M9QG&<>>,XSCSQG&<9^C/, $'S'F/A_R^'[>=JS$G+ $K0]\M8"XT&+C)1F03
M+SHPX?']HXAEK#\R8ZS':RZ\XAIOUN8];BT(3C*E)3FY%%-/(L->*6>9PQ2&
M&-Y9'[1R>V.-68\#S/ ]@)]@.>6=$4N[*BCVL[!5'/LY+$#S/E]O@>TC/FJ[
MF>)5V,V!O,OHWK%@_1X%-NQ6I,2:Q#;)WK8%AKI"8-F3,J<B24CZQ[>(](A"
MXT?#D@>THF>FYCO*'#OJ#H?T7=,Z_0P=0=4^K["784(+K);<QZ_6UK44<T:
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M8XZD?0B@&<VTN+[S+,2)L8>P2F1U D?-XB5@."WP<CSY;WNWR'(/*\CR/F>
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M+'O9:8]:I,?#$1MCTMQF<N*2PE:F\MT+(1[_ )^T'S^'WQ\_L^\,BOK+U/\
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M/@Q&$-L1([;;&:'V+1EW0NX6L)]67=<VUO"?9/O^>7 TM&,9:C1)S[F///\
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MD>Z!Y/P>_P ? ">!]K*$>YX/'L_L!]OER?9Y_;SL_P!"6%Q[KCK4E#!6)LB
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M&X[2P!YSQ)3BV,<FOGY\&\C4YNT\-X5E3#)P?>/8YX/PY\\_@S;?J5Z[%;-
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DC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g111280g19z56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g19z56.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 ET# 1$
M A$! Q$!_\0 'P !  $$ P$! 0            <%!@@) P0* @L!_\0 91
M  8"  $%"@<*"@<#!PT! @,$!08'  $($1465Y4)$A,4%U:7U=;745-5=Y&6
MTQDA,38W=92TMK<*&"(U.$>'QM+4(T%8=GBUT24T=!HD,C-"4H8F)RA%1F%Q
M<X&$LK/$Q?_$ !T! 0 " @,! 0             $!0$' @,&" G_Q !D$0
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M9NL1L1=2ID7)2U%)6F&S%<86XXMPD8[AIL2Y.(C)W(F\F1)MWT].T"10$[;
M*::==#JNSI5$7TI36#8]D3F,7:[F-3>IL5SLMUNB03-LK%F.)7PN.0*.P,<.
MVW.Q;3)WYT3R21=2JQ7U5^"Z95EJU5ID66P:*HXRJ#)HK).K33VZ:U1F(;M2
M>2IN;)G2)^>95HW8S#2HT?GFE/*"^@LS61Q9+C+EXJ%D\W-6:4G(5(7,<>1&
M09&TVPVQD<56(XM1+<DF15MPMJ++CCDO;*8BHQ-G$"75]8HD5*/?C+TTLD15
M5<0JE$<NM#6MX0%,2IDAU6RVWDM6RZR)FC&R2O=A(3T[(BKHU2PH339+2':S
M*(G* =3J:UUIC%9=?EHJBDQ9%%74J)/4I,8JG$I"ZG$IT-66B;7K2I]R0Y&I
M><MJ4B&UZF?FL9*82S-:4-'&)3K<U,>:Q8W,U=E%&=?>2:',L1DA.M#BLW"H
MG?*5;6;7&V@]JCM=N\B:VQ# W2*$6*G9&Y9(-AB\9?; KIO+6+RR%LD@C>]R
M",LCZJ?(UXHB0)11YNV5@MGDNA+14G9+R79%19CNNKG-2E4Y3[B&/YU)8@5!
MPT(-3<:<XRQ)>80Q)QUN*SASS55R#4Y*HR6T&EN.MU"4L*:*22$FX62;6_'2
M1F1&XPE;C:%FMNQ)+)I[/&[-2K$O%IF(7IE?UCSP\\(1CXXQ_3*4V:E"7A/I
M=#*V\M%'BD[*TJFB2)75I<6-O2HB6)Q1*F?Q%"-"-(3QP)A'3Z&]#R+S"&<(
M<+B8;?-XW<V7A767(KAKD&IYU+T9;3S;[BUJ?;6A[*+)9+/E6WLXFH=QT+-=
M/I6.I&(2<HFF1$N)Q6R)"#0X2DJ0DB)"B-&*5K%B+GK14"H&?S4D_.#C^K->
M=9>NJ_!I_66,]P_C+]"A3\[!@9Z\/%@5=#.$WB/16.DE[^:[WWPJ+6.*5W;C
M)4<V6A9X-Q8%.3Z0YNT LLYTC;()V;D3VD1QHG1#B_QTT][0"$G1N?@\(:?5
M)N%F#JZ<N)'2U0<*$/RZA2'ZM"1EIV"QMQU-M3Z:EJ2_DG%L*7)5C-QY!)87
MZI;5[3I$9FE5$I!/+-4VF&AJ/+1$>5BLU(C62E,2#4VC&22R2V7JEHNM.@E9
M7QCB2K^^3:5#:<1J$M@N#C/E<7G[7/'!+(WJ!4V"F.%*KB'O<HD"Q(N97MZ:
M(WMQ=[A.2M3ZXRV+.KJVN;64?(FU3Y65@Y/H)5K:N75SD4C R)*@.P4+C,SZ
MP=:PJJ:F<UCH4V\PR]))MJD$IUAN)*::<;=-,=U-HU46)QPSE,Q,G,K#C3Z7
MS)Q3$0H=,C8^46:30M:&\9<LR2LW6U+2I-UI/J1BIZ$-X>V4F1$48^+2*[X<
M9ZSN(GBLZXYS?Y#;E6AMUD<;')L64WE(5[%!99,X[:A;G#6.(UZM8UZJ)P\6
MF=C=W?E*JU>3A \<=5<80JH81P'F\C4JCDH\>DU0Z2\W3CIT6B1VWYT6%(I:
MFIC\NH(?0F7,++/LM9;B03I[9.)@N*S>G/I4:XT;&6N7%SM"I!2')SBD,.O-
MRL9E#;!H,V6C-"%*OE=7/#@.?*W=:BJ9NGA]03Q36%8 A?#\-Q12MLM>MT;>
M.01MDO??#Q:)P:O?;"/K1TD+A!WZ8IXVZOC["Y2ZM<*.DT%%1PCS!#*'*LY
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M&L ')KX-?1K !R:^#7T:P <FO@U]&L ')KX-?1K !R:^#7T:P ^=;+%L00[
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MU*0<&JP)*8$*"RF74*?FB6GHRI!R6_GN7AOAC@;A;LA,URIRZ;A5@;L=['V
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M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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MED9&6X9&3=R,M\M(D*KU!6E2%U.GK2LK*2IYI25$>@R41F9&1EW#(R#?='.
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M[N?X,Q_0(L7_ (GYU^[FI<^)O1'?\\4[_MJ%]HU4;=V/O:B9\YN_5(0]$^:
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M@ P B^ ?C7=_SH-/[EJARUJ/L2A?-3WVY61#B^OU'Y8C[/@B4,JA,# !@ P
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M<IF$[>351;:U;5N)NI 4R>/K3R(S&XI'R&]A1@,[V\'E,]XM\91X& P 8 ,
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M@'*OC$:=$JQ"YQYC<43@G<T:]&O:4"Q*N2/1I![PE6)U"<PI2G=CTJ8YS(.
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M.OW<U+GQ-Z([_GBG?]M0OM&JC;NQ][43/G-WZI"'HGS0 ]V& # !@ P 8 ,
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M:KD_18"0RBN-&E")Z<;V,9@Q$C";X4.BPE#!LLSPNA%V;<BE;32CVMDXNV<
MC3MD5S4<6I6/&S'01$2B,K'>Y'<K6.(IN9GS)9TSC9I)/&S4[6RT6Y8N<;IG
M8[WT6M;3HDKF"U^LF+^C0_V\RLSBDZLE<YIZ@)>2F\+9Y(?60Y@M?K)B_HT/
M]O,9Q2=62N<T]0#)3>%L\D/K(<P6OUDQ?T:'^WF,XI.K)7.:>H!DIO"V>2'U
MD.8+7ZR8OZ-#_;S&<4G5DKG-/4 R4WA;/)#ZR',%K]9,7]&A_MYC.*3JR5SF
MGJ 9*;PMGDA]9#F"U^LF+^C0_P!O,9Q2=62N<T]0#)3>%L\D/K(<P6OUDQ?T
M:'^WF,XI.K)7.:>H!DIO"V>2'UD.8+7ZR8OZ-#_;S&<4G5DKG-/4 R4WA;/)
M#ZR(U;&*TMW#-P!L2,Z/#6M6B,.W7)^P&$BE%PZ(*"3TXULL9(P*!C-\*/PV
MCRP:++\!L1MD[(I6U$$]K9.+ME52(MLBN1E%HV,9GF.DC(TD16*UC.YXUBB(
M:F9_(+.F;YI$TYH=K9:;8K9QOW,SOIT%8K:9*Y@M?K)B_HT/]O,K<XI.K)7.
M:>H"7DIO"V>2'UD.8+7ZR8OZ-#_;S&<4G5DKG-/4 R4WA;/)#ZR',%K]9,7]
M&A_MYC.*3JR5SFGJ 9*;PMGDA]9#F"U^LF+^C0_V\QG%)U9*YS3U ,E-X6SR
M0^LAS!:_63%_1H?[>8SBDZLE<YIZ@&2F\+9Y(?60Y@M?K)B_HT/]O,9Q2=62
MN<T]0#)3>%L\D/K(<P6OUDQ?T:'^WF,XI.K)7.:>H!DIO"V>2'UD.8+7ZR8O
MZ-#_ &\QG%)U9*YS3U ,E-X6SR0^LB-(XQ6ENS+,""Q(T$X+9 -G&[KD\0#0
MB1R#P00%=-P[*V7K0]"WLPSPFQ:WR [WD%9R9%*VLIAG3I)I-R?BEMDDC39Q
MB]SS$\:^BV@K6[HBM-3,ZE?SMJ^)&N>:'8_4N6L6<:+:;Z3O?N6$E\P6OUDQ
M?T:'^WF5F<4G5DKG-/4!*R4WA;/)#ZR',%K]9,7]&A_MYC.*3JR5SFGJ 9*;
MPMGDA]9#F"U^LF+^C0_V\QG%)U9*YS3U ,E-X6SR0^LAS!:_63%_1H?[>8SB
MDZLE<YIZ@&2F\+9Y(?60Y@M?K)B_HT/]O,9Q2=62N<T]0#)3>%L\D/K(<P6O
MUDQ?T:'^WF,XI.K)7.:>H!DIO"V>2'UD.8+7ZR8OZ-#_ &\QG%)U9*YS3U ,
ME-X6SR0^LAS!:_63%_1H?[>8SBDZLE<YIZ@&2F\+9Y(?61&D$8K2%*;HT58D
M:+&"RVH*@8JY/,T>=NG:G&$TL'3@'@ :3B()V5L1N]F$C.\)K1VBBK2?(I11
M*)>G23(Z6Z:2*I)+%3MU5R,C/,3QCQB4J]DZ%$FWJ<8XD9N9EI]I3)&4M!&>
M:&=SS&$=[9SHT&16T[E^[8I+Y@M?K)B_HT/]O,J\XI.K)7.:>H"7DIO"V>2'
MUD.8+7ZR8OZ-#_;S&<4G5DKG-/4 R4WA;/)#ZR',%K]9,7]&A_MYC.*3JR5S
MFGJ 9*;PMGDA]9#F"U^LF+^C0_V\QG%)U9*YS3U ,E-X6SR0^LAS!:_63%_1
MH?[>8SBDZLE<YIZ@&2F\+9Y(?60Y@M?K)B_HT/\ ;S&<4G5DKG-/4 R4WA;/
M)#ZR',%K]9,7]&A_MYC.*3JR5SFGJ 9*;PMGDA]9#F"U^LF+^C0_V\QG%)U9
M*YS3U ,E-X6SR0^LAS!:_63%_1H?[>8SBDZLE<YIZ@&2F\+9Y(?60Y@M?K)B
M_HT/]O,9Q2=62N<T]0#)3>%L\D/K(<P6OUDQ?T:'^WF,XI.K)7.:>H!DIO"V
M>2'UD.8+7ZR8OZ-#_;S&<4G5DKG-/4 R4WA;/)#ZR-:G=#VBP$_D@YUFS"X]
M_P"4#P'BL(-;? ][T)\+W_?2Q=X;PG?%][R>"\'X,7_I^$_D;+V.WJ<K;C)0
M7V[;7XV/.)W&]G6M:(WBVTWW;W+<MI\MA*W*+,L>0TOV3:T8TV]8O_[ZKWT;
MUK>$?G7/_P#/KU^=G']<.S[U9]::_!H_5(:;3N%\1?H%)SL&0P 8 >[G^#,?
MT"+%_P")^=?NYJ7/B;T1W_/%._[:A?:-5&W=C[VHF?.;OU2$/0^-6E+5$(AJ
M4X%BDE0H3)!G%A5*$Z,:8M6>0GV+1II*4:Q(!0:6 0"!JDP31!V>5H6@![L=
M,Y\94XW4I0\-9!C$A*<WLLYP2%#9FT\M6:0X.H!G!$WH3BD"XPI6KT2086B5
MC 8(*8[8 #LC<$!:8A:8N1EHU0T)296-22%,H,<SR$K:60>(>BC1N"I4F3(0
M%C$)6>H()(T88<6$0!R$JDJ@Q420I(/.0G 3+2B3BS#$:@Q,0L G5%@$(2<X
M:14E5 *-T P2920?H.RCBQ" "94E6DZ4(U*=61LPXK1Z8XL\G9J<XQ,H+T84
M(8-F$*"C2#@:%WQ1Q1A0]!& 0= %.,D4?)(7J37UG*3-3B2T.B@QS1 (;790
M)$%.V+S1'Z+1N)XG)N"2B4"+4FB7HM *%M41HP K& ' F5)5A8S4BE.J*+4*
MDHS$QQ9Y8%2%2:C6IAC*$((5"-80>E5$[WHQ.I)-(-" TL8= '/@ P C"HOQ
M4=OG/N[]\\^RTK'LMGYKH?V+3Q$A>LK^5S_KTD2?E6)88 =4Q>A)6)6\Y8D*
M7KBE1Z)"8H) L6$(=I]+3DJ80]'*"D>U:72HPH P)]J4^C1 V<7WP!;9=@0(
MX<H+*F\1-,A!@2IH67)688X@:, S %2@(5NQ,!@BRQC"!UTD$( !BUK80[WH
M YF*<0J4Z*W&9A%I%I0-<61MBD#2[Z.,:P-YCF K;>K4>$&W%N[4-<$'?"2
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M5)4NR-*5)"?:H\"5-H\XLK:A48$8RTQ&C!!V<>,!9@P$E]\8()8Q!#O01;T
M<^ # #5_W2+^IG^T3^XN;0V-O[:_T[]_'D\*/ZC_ )G]W'YNK_\ SZ]?G9Q_
M7#L_01GUIK\&C]4AI).X7Q%^@4G.P9# !@![N?X,Q_0(L7_B?G7[N:ESXF]$
M=_SQ3O\ MJ%]HU4;=V/O:B9\YN_5(0SCCW#/Q"N":MC9E,+'"\L[A!D<UD)5
MUR$N6K&242M[E5^M[-*&N0A=F2(NZ&+49&FI@C2U@/2[BL@7,Z=,N=5;\YZ
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ME?RN?]>DB3\JQ+# !@ P 8 , & # !@ P 8 8T<3-40Z\&FN:LL!(L71"5V
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M\/RN7TXUJ]T/KF+,_D@\1!(->,>4#POC<TF;C_ZGH3WG@^<7]7X'_P!:/O\
MP/@_"?R?"=_W@.]V7L=U*6]MQE#CGB[7VQ84)O=SZ]\G'1?<*U[VTVM<[^5P
MFBLHS+%RVG.;WDR%;F;[F,Z=MWN6OW=PA^=JZ)52Z3.*)$F/6+5CZL2I$B4D
MQ0J5*5#@840G3)R0C-///-& LDDH C##!!  (A"UK?WFA:&XZ%K4E"$,I4M:
MU$E*4I01J4I1F1)21$9F9F1$17,QIQ!&K%2DC-1V(B(C,S,[$1$1:3,ST$1:
M3,55M@D@5S=JK]V+1PE_<W]%'3QV$M)@S5'UJQ>%N$HE3I(]H$D:;&]0(8G9
MQ=QIDK802H/6#*+(,V'J<G,(A.SVC7-8;87(24!!S77T(0;F+%:CY1<EQQ-L
MDVT2E.*-*4$9J*_8EI9NI941-+4LFSRQDTE"C5BW<4YBDVE)_P!)2K$DB,SM
M89$WUP4VYPZQ95+IO(*=?FYLF,;@;^CK6X(-8[Y%I++XP_S",HI4RQ5U<'".
M!>F",/BMO-=B4H5(FY4G*T(],I+)\_0\,:5A!*3$AQZNPXY$DS6%U&DS:<Q)
MCQ)+$22N*]*:;;D&R_)92X3*EXI+2H[)4DU3YE)DP6C=>7%6E+K;*TL2F7UM
MN.MN.MDXAI:E-DI#2S2:R*]C(KV.W#7_  3WQ9-,2&^8XV14N 1Z,RV6#&[3
M2/-;^\-,*0RYW>],4=4+.=%ZSF2N+1>VU(,E.:[MM83HUN\9.9@$*LS\,J'3
MJQ'H<AR4<Z1)BQ2)J&^ZPR[,7$:9-^0E&2;1EJC3&7%XRB:<J4(G,4GL9.&:
M3,?B+F(2V3*&W7?5NH2M:64NJ7B(,\8SQ&)*TD9$:DQGC3?$*_L$_@S'] BQ
M?^)^=?NYJ7/E#T1W_/%._P"VH7VC51LO8^]J)GSF[]4A#<7$N+.L)<Z@ 4AF
MT?A+D.0EQ&X97&A,513H<6<],[SN.S!0L$%(F&N[_HRXRQ#&&RPD!1KU7"V7
M,@=..] #W=OX^,5J6\3].PP%\F.<CVM!PVU(FNFUQ,1 7K3)#U!MM$#3)]H3
MC=+),B.I2=E.,;#X-R0F)6XM06 3D1K'\?Q] S8]'A.WZ/*+0;>,FK'"1JV
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MQ=I:+ C:F6%3=17[M,XBH9HY8I%<O7,4RZ(OR=2XMYRUH4[TL"QO!K-('-F
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MX)8+36C)4<R-+L:O5J.X1&3_ /1>I=.=3=CU$V4G+Y!IG?MGR(/T<# !@ P
M8 1@U?EGG?S85/\ M7=&6;OM- ^<ZM]5HHAH]L)'R.'^WG"3\K!,# !@ P 8
M , & # "+XU^5*T?S77GZG(LM)7M72OPE0_:,"(U[+E_X(WZKHE#*L2PP 8
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MV^<^[OWSS[+2L>RV?FNA_8M/$2%ZROY7/^O21)^58EA@ P 8 , & # !@ P
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M6CP_&+^UQLV+"9Q1C/8L9;'B 6&DNQ]LZ?:J2[.'UUJ>*5_(>'&!163J:WO
M@4J=HP*=WPD)GLM,VW1Z.P_9LP"J+:X7*AGABV[OW*UK'NW\G<^(<U*\5UY6
M$Y4U*9FHHZ'U18/"#!N+J6& CTZ,D45CL@9(XKD$;*?#YL)H,$T+'E6N)?SV
M#9?-2,*8YI&J$)7@#*QF6\9D+DLOBNN.+2R1BKR$5A:M<-53L%O\]L+_ #H+
M['8;8<A116LI'*4*&(NX5C2\FII].74N+)G1<AKNJYDO"7IZ/C36^ (B/NZ=
M[Z>[?XB_&*/6G&#<-KN5-%0R)5&[H9Y:MHUS(P@?9\C7CC-$V%(HQ:5SQ(*V
M+%EF5\;'T,1,BVG,!@CK!L2)0I2ZGL[@7-A ,MW=*W@+N[E]/^WAMND6R; P
M& # #5]W7/\ HD+O]]6+_E[WF[_0]_\ 4NF_(JA^Q(?-?HN/^@N&O^B_;M-'
MDXS]$1^)88 , & # !@ P 8 , & &W#N77&/9E967&N'TUGD%BUK83WI&W1Y
MJ*,<'F!/"T0CE<D8BQC" N- #HYQF+:::0B2I"E<D2F)UB=P)>/G;9YV-:'7
M:'.PP3)AT6N4:+E'YDA1,QJO&:(DMP9:B*ZIQF:6::^E*W7'%-P7$K:6RJ-]
MH^A&V<,*\%,*Z7L:K@U+"?!;"6>3$6FPTJDSL')KYJ6_5:>E2B2BE)+'E5R*
MM;;#+*'JHRIM]N2W.]3&?! _7<, & # !@!&#5^6>=_-A4_[5W1EF[[30/G.
MK?5:*(:/;"1\CA_MYPD_*P3 P 8 , & # !@ P B^-?E2M'\UUY^IR++25[5
MTK\)4/VC B->RY?^"-^JZ)0RK$L, & # !@ P 8 , (O@'XUW?\ .@T_N6J'
M+6H^Q*%\U/?;E9$.+Z_4?EB/L^"-9%8]T*OV3QJK9HNH5PF\;M)%4RH!L3K.
MSJGW'7^S)6P,B6NX_(;Y6Q> 7(X+&9X=G]LL.#3%#!D*.(+%+]XFBE,6/550
MG&5CW2W3[M]'XKV_\[FZ)X+[I52AJEJ1)X5:Z]<\5^[39*S,J2M9'*@NK+3S
MY=ZVN5$&CMFNLW(FID,C;T0V+#([J /;\CYL9IRO+/3JS08IZ=S0=N[OVO>U
MK7,=F)=TEHB9S*O8,T-4J/?)[N-!."@D5*24F(CFMG3BHXAIW##K>D:V4 =Y
ME7T@*=#:L16&7 6D!+Q9PH2B X#0!BQ_%\>B^@C,OQ7+_:XR-U;,E#Q+%4<K
MAJ))%E=-/-GM,YZ0!5.#NY,LOB48<&/HV6@+TU(T ),6?SBI<E)KD=O0"$:0
ME,,U4&!C9'>Z$QE3TB+EU.6E'MP^S)!!9DZ-RBN7Y@AS2LXJ[7X3:@E#Z<&>
MH'U87:4_J:0)!ML2CTH40I4B<5,J&@B06:6OH9MX>Y?\US^@C_@] YU/="*[
M4U!8$Y!%Y17$Y9:8U<=?5U<&HJ@=I^P2"M)+8E?.:$=?S&=MY#?(RHJ^MJUK
M7N[9+&56R.9;JQ( #;%*\!E;P]S1OCHL_=%*[3FN!,NA5B)V>-O3PAG=EM;)
M$R*\@2<V^>(6BH@6])5EBJ9^['NLDX>)0D/5Q&'R(HHM<POKNCC")Z.;V0!E
M8KW+\^\1[WA%]PCCLJ^>4E95YM,/L0#'6&F@QUC)>ZV?Y.^$2!I9'9A,C2Z'
M61)8$M4. 7PEO.:U\W;'AD=D2]#(6]IV!(8L!;3:Y?[%;=W=X6.'NE-+:7SE
MJ4Q&>-SE ANK:ZIG.14*@+'*XQ:,.IB:0M0N478!NBS_ !6R)D3'_#3U7$F&
M; 8)([U:]3QE0HE[D"WT[VF^Y?>_CNV%H2?NGU<HHG$[(C=<60MJ[:EG5VK/
MW1OB.FFMF]75DYMEVC"EK:9VOE+W/&N+Q A7L<7CTD@*@3RWHTDT5KU.B"06
M/Z=POC.WQ;N^9";"N..NTRZ9L,JK^UH/,J[1OBN;0M_0P!>\L F7R$J0)!N4
M0L.41-S4.[-Q%UL_-AC')'-$% >]HG18V/[,H91@L?<T_%^/R'NB9^'2W'"]
MJ;AUJND(<ZY72H+Z(Z'/#JR/3@TZ9I,\Q\H1SG'5[DT*0N!+46YD>+*QC)(6
M%D*0$JBCB@ ,K&9;PPK[I%_4S_:)_<7-H;&W]M?Z=^_CR6%']1_S/[N/S=7_
M /GUZ_.SC^N'9^@C/K37X-'ZI#22=POB+] XV9Y>(X[-C_'G9R8GUE7I71F>
MF9<J:W9I<T)P%*)Q;')":0L0+T:@LM0E5I3BE"<XL!I)@# A%H\RU(:<8?:;
M?8>0MIYEY"76G6UI-*VW&UDI"T+29I6A1&E23,C(R,<TJ4A25H4I"T*)2%I,
MTJ2I)W)25$9&E1&1&1D9&1Z2%_3>[[ILUL3,ED6]:%@LR)>!T1M$WG\KEC8D
M<RDZE(6XID#\[+TI"\M*L5I@+"B@* )U2DD)FBSS0B@PJ+1Z:XIZG4FFP'EH
M-I;L*!%BN+;-25FVIQAIM2D&I"%&@S-)J2D[721EW/2Y<A)(?DR'D$K&)+SS
MCB241&1*)*U*(E$1F5R*]C,MPS';-OZ]SHR*%'77;9L-$R:C0HD;8\Q,C(HX
M%%IMU'Q,(GG;5MDTW:T@TU;2>(:1:TET1X#6B\X%0J(F3GA4:E%,RV<YV5/B
M%)S@UY0W\N3.5RQN??,KCX^/ZK&QM(Y'-FFWD3ERC9Q,GDCD.Y/)VQ<3$Q\7
M$Q?4XML6VBUA[7OX,Q_0(L7_ (GYU^[FI<^._1'?\\4[_MJ%]HU4;3V/O:B9
M\YN_5(0F=-P_6-Y+#8LQ\+DX2<3"./+D_$Q?B:;,-?+>(MO)M*$/UHQ-BF[9
M+"5EJ+^)2&-<O25<9-ES T4*U.Z=L<7RL'5(ECQV@![T_CT7T%O7_$=B*^FV
M[W+VN5T*J?LR*/$\OGA2X:WZLX[5[M1DHIWAH4$1&J$5FSM*@NZN^)5V1P9K
M?@1J&L\JJBV("2B$[CCQDOLFCV>0J&H"1&R2Z0/X\H> SN9WN>[O6T_B\-B/
M?T"TW7A)F,!F%5,U@4Y(.)RIH79-/N<^(.9(A.2+#<6W@\XE(?.;&7PN:O:1
MM5FN-]SF./[@6H)+-1/CVF=V]+HALVI1@OX;:+=W1ZKR$7XB$ZNM&\2SUP#W
ME3KF4Z,SD^4CQ#ZI>%QRP9,U7C#GF0R2RI%0=3O=E1N::8%A,$@3E7=9.6FR
M3N#2XK6):A6R-^C1PUJT%RQB/18K7T7+1NZ#W_B%;451=@NZ!ML^94#V37Q5
M@JI=,)D\LQJ?2NIA\)QE:-]11:7I;&<&]? ]WV-CL_=?K:^:'U-8+=+YDI"B
M:-,#].@Q?1;P?GONG^+1H\&GN#9I@8# !@ P 8 1A47XJ.WSGW=^^>?9:5CV
M6S\UT/[%IXB0O65_*Y_UZ2)/RK$L, (Z<ZDK9ZU*>=8<S+A3680N?R@Q028,
MYWF=<#AYT#D1YWA-&E.414P&'+6 U,,@+:O84:]. "W9YYP/X^G=$/[X*.%L
M>G0!M/L)Y#FROL:*1J7*2*6^-QB3K4+E(8O 6]0]&(:UC#PYMC6YKXY7R>,L
MJAS:VMQ&AVM;D1Y 9(S+</NW_'_'Z3WS%YQ_ALI*-IU"5%!4KB2KCT[B*H,K
M=Y%.!J(I9P(678$9.-FCP_G&1^6 KR&:>&81FVY3MA3"\6"(Y8)2"_\ &Y^@
M7=#JEK:ORXF5"X<S1TN"UTS5+$ MQ(R],%;1\*$++#F_OS![+9FX+:@TF)%L
M8P^*E=\8+DWRAC='R_U'6\G(G9#[$FQ?JS$[*FG!^]JDZY\!&B D1LT3DD4$
M.#>LCFP 5Q]>U*4*YD<P!=FM0E= Z6: .*(4[6<#/CRN*1%N:U\68Y;'61T$
M:N<'A,US^3MDUGFE#NYJEKFYN,XF+.VRN8O;HK6O4HD:0#T^."]Q$8I& 27@
M P 8 :\NZ8UY,[7X>4=?UZPJ9-,9%.6XIE8TAR-.H7C01Z3.RP)9R]2D2 V0
MWH%:H6SE!>M@($$&Q&;  6W-A2LTS![#B/6*S+1!IL.#+.5+<2ZM#)/&U&:-
M264..'COO-MEBH58UD9V21F6B/1)X,UW#'8@PFP;P:ISM6K=353$0*>RXPT[
M(5'JD.8\2%R7664Y.-'>=/'=21I;,DW4:4GYX?N<'&UU R7MJ&^TN?:7W:]B
M[WWP>2U/J(_*OTKNSY_=O5>7T+M4/N<'&UU R7MJ&^TN/NU[%WOO@\EJ?40]
M*[L^?W;U7E]"[5#[G!QM=0,E[:AOM+C[M>Q=[[X/):GU$/2N[/G]V]5Y?0NU
M0^YP<;74#)>VH;[2X^[7L7>^^#R6I]1#TKNSY_=O5>7T+M4/N<'&UU R7MJ&
M^TN/NU[%WOO@\EJ?40]*[L^?W;U7E]"[5#[G!QM=0,E[:AOM+C[M>Q=[[X/)
M:GU$/2N[/G]V]5Y?0NU0^YP<;74#)>VH;[2X^[7L7>^^#R6I]1#TKNSY_=O5
M>7T+M44X?<]N,DMW3,0Z*D8798W+G9,BV\1'OS6YM4MZ-<J"/4BV3H"=2ZMY
M0@","8+:D&P $$)@@=A;,NQD;*WRPMA&RAQME2\VJ-B<=2XMM-LRO=267#N1
M&18IW,C,K\#]#!L\DLFSV.:KCJ0I9)S^AW-"#2E2O;2UB-:2W;Z='=%1^YP<
M;74#)>VH;[2YU_=KV+O??!Y+4^HCGZ5W9\_NWJO+Z%VJ.0GN;G&V<:43J@Y"
M7LTP!>C#GZ%E% V,6@Z&:8*2]Z66'E[X8Q?R0!UL6_O:SBK9LV+DI4K^5T-6
M*DU8J8E34H[$9V2DH-U*.UB(M)G8AR1Z%K9\6M""V.:FDUJ2C&74:$A"<8R+
M&6HZK9*2O=2CT)(C,]!#T7\#' S#^$:&^/+_ !&2W+)T)(9I,@E=^2WDCV6?
MN)101Q83TD?1G@ )6J$ E9(EQ('!> A.0UM;5\7[*VRK4MD6IY)G*P<&H+JC
MIE,-5E/*+&051J!),T.3'4&9-MD:FH;2C99-:U/OR/T]]#YZ'VB;"]#SB1F]
M5PYJT=!5ZN)1C-QD'BN'1J.;B4N,TUAQ*3>>-+;]3D-IDR4MMMQ(D3/C-1CZ
M,# !@ P 8 1@U?EGG?S85/\ M7=&6;OM- ^<ZM]5HHAH]L)'R.'^WG"3\K!,
M# !@ P 8 , & # "+XU^5*T?S77GZG(LM)7M72OPE0_:,"(U[+E_X(WZKHE#
M*L2PP 8 , & # !@ P B^ ?C7=_SH-/[EJARUJ/L2A?-3WVY61#B^OU'Y8C[
M/@BI(:MKULBD)@R")-"6(UN;&#H*P%$CT@C!L, 47%C&LO9FQ%"8P$%!0[&,
M?@]%A[[OLJA,$.*N"[A?6*S5:BH& ?AO&Q#1 7R$EF\:<("IJMQ= ,)+R6R%
MO;E7"@$*<GXMO \N,<;F)L6KST\=80-H9N>[_P">[?\ 2*ZR\*E 1YYC\B:Z
M[2%OT<5%+T[NK?)2Z.#VYI)$\S!K>)PJ='Q8;8[VPRV1/TIC+W8 I,ZQ>2/+
MF^QY8V.BU0J,!<_X_C1X1,ID6CQLI2S8QH1CEB%@<(LD?M@WX^1'G1Q;79Q:
M"S.^[W2-6Y,[8L.!WN]B.1$"T+6@[UL,"$W;A-X?G=R4/9U<M1#RI>WN3&+D
MZMV 2=)'R5NE@&/+@T"<!,;RH:;&>WFR(RF>FQP016PWAWF\;2-<G=7%T4AF
MY_Q\5OT:!_:CX5Z8IJH3Z5C47TX1!VA35 I<.1KE[VZ3./M4.2P0EO?5Z]2<
M<!J!&DW-;?'6O;=&H^A//01MH:$ ])M ,[_29_2+C2\.U'HBW,E/6,4"0].C
M<].Z<QO\.G<G-IL";VHWJUJ<\PTE0)-8=D3N6!+- (D;K*'49A8RC]% #%[_
M ,?B_P!@C'#S34.AC[7K!!6\B'R92A4OS.O7/+YISVTI&MN94BA>^N3DY\UQ
M]K8V9HCC,6M TQUF:F]G9$2!L2$)0!DS,]/_ (_0* ]<*7#_ "!XD+^YUVDV
M]25QT\JW) ^RIG5M3X9)F.:+W^'&,[Z@W ) ^2^,QZ42=^@NHZ\2N0,K:[R5
M:ZKTA)X P*&7P5<+!?,Q>Z6B1Z!@0JVUM8UG.JZ,!1JR98CV6NBJQR/C;N-&
MTSN9QUH4.S4N4L44D[U$F4U!&5ZAI&&;GO\ ET>'^/S#G.X-^&E20SD+*M;7
M#;,Y.;L6L<GR5N3H[KG<Z&*%@Y<\+WY0ZSDD)];UR<@1S-:_(FDRO8&-J3HA
M0V-[; 7/?/\ C_\ 3^D3G#85%Z^8"(M#6@EBCZ5<].*5J3&JC4J13('IPD+K
MI(%6>H&E2G.SHN4)T! RT#<2:!"VIDB!.F2DAC^/H&N?ND7]3/\ :)_<7-H;
M&W]M?Z=^_CR>%']1_P S^[CR>(?X/9W0N:(D<Q96^F]L\L2IY*T[568 A3MM
M?2@.B#:@CF,?@3]I517ABN_%X,SO@=\+DY=_3SNSQ@!#<<B//U4GHJUQG<6F
MK4G*,*-IS%5E2QDXR3L=BN6FPUXS@97G6FG4,QS0XVAQ!G*;(S2M)*3<K:#L
M97+N#M?^3C]T>^3J4]*(/4.</3 ;'G?ZOS6OI1V?R(P@[Q&Y4WY _P#)Q^Z/
M?)U*>E$'J''I@-CSO]7YK7TH?R(P@[Q&Y4WY _\ )Q^Z/?)U*>E$'J''I@-C
MSO\ 5^:U]*'\B,(.\1N5-^0>E+N/_"KQ"]S^X9973%QUH?)9.^W')+"2+ZUE
ML =V$ME>(G!V),F4*9/*X@X <RU<:7F'DEMAJ4*<U(,M888,THCYWV6<)L'\
M.\(XE7I%3;CQF*1'@+148E19?-YJ7-?4I*8T.6V;9HDH(C-PE8Q*(T$1$9^[
MP6I]0HD!^++AN...S%R$G'>BK02%,1VB(S<D,JQL9I1F1),K&6DS,R+:QT]E
MO4G9/;-.^]7-7YA%UU3.*K/9(]+G+W )?CP>NAT]EO4G9/;-.^]7&81==4SB
MJSV2&<O< E^/!ZZ'3V6]2=D]LT[[U<9A%UU3.*K/9(9R]P"7X\'KH=/9;U)V
M3VS3OO5QF$775,XJL]DAG+W )?CP>NAT]EO4G9/;-.^]7&81==4SBJSV2&<O
M< E^/!ZZ'3V6]2=D]LT[[U<9A%UU3.*K/9(9R]P"7X\'KH=/9;U)V3VS3OO5
MQF$775,XJL]DAG+W )?CP>NAT]EO4G9/;-.^]7&81==4SBJSV2&<O< E^/!Z
MZ'3V6]2=D]LT[[U<9A%UU3.*K/9(9R]P"7X\'KH=/9;U)V3VS3OO5QF$775,
MXJL]DAG+W )?CP>NBSH*^3J,,BYM7TQ8!IZF96+(2QI'RHC"M(I=8,GE;:4,
M1UGD#TI);GI*2M!H BBUA9Y9!R@D):@V;/8@RGVW&ZS3B2F%38YDMFL$>4B4
MZ+$=,B32E%B&ZPLVSN1F@TFI*5&:2Z([DAIM2%0)1F;\ITL5R"98KTEYY!:9
MA'C$AQ)**UB41D1J(B4=X]/9;U)V3VS3OO5R%F$775,XJL]DCOSE[@$OQX/7
M0Z>RWJ3LGMFG?>KC,(NNJ9Q59[)#.7N 2_'@]=#I[+>I.R>V:=]ZN,PBZZIG
M%5GLD,Y>X!+\>#UT.GLMZD[)[9IWWJXS"+KJF<56>R0SE[@$OQX/70Z>RWJ3
MLGMFG?>KC,(NNJ9Q59[)#.7N 2_'@]=#I[+>I.R>V:=]ZN,PBZZIG%5GLD,Y
M>X!+\>#UT.GLMZD[)[9IWWJXS"+KJF<56>R0SE[@$OQX/70Z>RWJ3LGMFG?>
MKC,(NNJ9Q59[)#.7N 2_'@]=#I[+>I.R>V:=]ZN,PBZZIG%5GLD,Y>X!+\>#
MUT.GLMZD[)[9IWWJXS"+KJF<56>R0SE[@$OQX/70Z>RWJ3LGMFG?>KC,(NNJ
M9Q59[)#.7N 2_'@]=%FR5\G3R^UXYI:8L ">)RMQ?7(![Y403CDBN"3*,%EH
M@EV>: Q0%?(41HP'&)R])"U1@31' *(.FQ6(++%1:76:<:I<1N.T:6:P:26B
M?"E&:S.E$9)R<99$:24>.:2,B(S44=YR0X[%6F!*(F'EN+(W(-S2J,^R1)M,
M,C/&=29W,BQ24=[D1'>73V6]2=D]LT[[U<A9A%UU3.*K/9(D9R]P"7X\'KH=
M/9;U)V3VS3OO5QF$775,XJL]DAG+W )?CP>NAT]EO4G9/;-.^]7&81==4SBJ
MSV2&<O< E^/!ZZ'3V6]2=D]LT[[U<9A%UU3.*K/9(9R]P"7X\'KH=/9;U)V3
MVS3OO5QF$775,XJL]DAG+W )?CP>NAT]EO4G9/;-.^]7&81==4SBJSV2&<O<
M E^/!ZZ'3V6]2=D]LT[[U<9A%UU3.*K/9(9R]P"7X\'KHLU4^3HZP625@IBP
M--S;#93'CR1/E1:6"6O;W#W)(847JS]DB3%D1]:%0,:@!H#3$P2R30#,&3-2
MQ!33GXAUJGY5V;$D)/(UC$)MAB8VLC5M5C$LU2$&DB29&1*,U$9$1QU.2#E-
MOYA*Q$1WFC+*0<;&<<86DR+/+6LTJYWO>UB.YF5Y=/9;U)V3VS3OO5R%F$77
M5,XJL]DB1G+W )?CP>NAT]EO4G9/;-.^]7&81==4SBJSV2&<O< E^/!ZZ'3V
M6]2=D]LT[[U<9A%UU3.*K/9(9R]P"7X\'KH=/9;U)V3VS3OO5QF$775,XJL]
MDAG+W )?CP>NAT]EO4G9/;-.^]7&81==4SBJSV2&<O< E^/!ZZ'3V6]2=D]L
MT[[U<9A%UU3.*K/9(9R]P"7X\'KH=/9;U)V3VS3OO5QF$775,XJL]DAG+W )
M?CP>NAT]EO4G9/;-.^]7&81==4SBJSV2&<O< E^/!ZZ+-1/DZ36#)96.F+ V
MW/,-A$>2D@?*BVL MC3W8+DO,/+W9X20IC2)6W!2C+4&FF&DK FDD +)&HF+
M8@JI\6*5:IV59F3I"S-FL8AMR6*<VV25;58QK)41PUD:2(B-!DI1FHDQTN2"
ME.OG E8BX[#1%E(.,2FG)*U&99Y;%,GDXID9F9DJY$1$9WET]EO4G9/;-.^]
M7(>81==4SBJSV2)&<O< E^/!ZZ'3V6]2=D]LT[[U<9A%UU3.*K/9(9R]P"7X
M\'KH=/9;U)V3VS3OO5QF$775,XJL]DAG+W )?CP>NAT]EO4G9/;-.^]7&81=
M=4SBJSV2&<O< E^/!ZZ'3V6]2=D]LT[[U<9A%UU3.*K/9(9R]P"7X\'KH=/9
M;U)V3VS3OO5QF$775,XJL]DAG+W )?CP>NAT]EO4G9/;-.^]7&81==4SBJSV
M2&<O< E^/!ZZ'3V6]2=D]LT[[U<9A%UU3.*K/9(9R]P"7X\'KHLUH>YTWS.9
MR(ZF+ $BD2**IT113Y40E10V-.ZE*]J@"L\!0 F"7$[3[*..V,(3-F:*WH.A
M37F(+D*%'36:<3D9<M3AFS6,0R?4TI&(94HS,R)"L:Z4V.UKWT="')"7WW3@
M2L5U+))(G(.,63)9*QBSPB*YJ*UC/NWL+RZ>RWJ3LGMFG?>KD+,(NNJ9Q59[
M)'?G+W )?CP>NAT]EO4G9/;-.^]7&81==4SBJSV2&<O< E^/!ZZ'3V6]2=D]
MLT[[U<9A%UU3.*K/9(9R]P"7X\'KH=/9;U)V3VS3OO5QF$775,XJL]DAG+W
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M&,FY73C7*Y7+2*CG4)(8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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M,TD5Z%&J3ZDK=<R58J\E+L<DK0I$JEE!94TO*)QC2^6,HRL1(+'0I1V(8IV
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M$WB1LT.?1JX?-XPL8I$]*U#;%5DL?!O1+XR*PQD1:PPGOS"%R9*U,?*8/1:
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M@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
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MWS9P/]EFK-95KVYJWSG/^M.CU4#V#"^21OV*!)F5@EA@ P 8 , & # !@ P
M8 , & # !@!&%1?BH[?.?=W[YY]EI6/9;/S70_L6GB)"]97\KG_7I(D_*L2P
MP 8 , & # !@ P 8 , & &)/&#9#Q44+A%B,")L<'>-SX9J-&\%JC6TX3A I
MTT':4EHE2)4+0$[@:87X)45O1P"]BV(&A %Z_ VF,UB=-ILA;K;,JGDE:V30
M3J2;J$!XL0UH<05U-D1W0?J3.UCL9:XV5,*9V!>!\W">FL1),VEO1EL,3DO+
MBK.4Z4)>52P]'=,DMR5J3B/(]6E)F9IND]?7W32Y_,FL.SY7[69L;[EU$X=5
M>,B=3'R;Z:W#O4."7):QVT'W32Y_,FL.SY7[68^Y=1.'57C(G4P]-;AWJ'!+
MDM8[:#[II<_F36'9\K]K,?<NHG#JKQD3J8>FMP[U#@ER6L=M!]TTN?S)K#L^
M5^UF/N743AU5XR)U,/36X=ZAP2Y+6.VALNX<>(Z)\0D3TXMVR6F7M)1)<LB9
MA^AJ&U0/7>!7H-CY#%K&M,T+:-9H/?$CY4:S0%)?^DU?A+@U,P<F9)V[T-XU
M'#F$FR74EIR;EM"'T%;'1>QEZM%T'H^JMB_90HVR51BDQC1#K4-#::S1E.8S
ML5U7J2D1S593]/?41FP^170=V'R2ZGU61N>:&SPP C!?^6>*?-A8/[5UGEHW
M[2R_G2G?5*H(:O;!GY'*_;Q!)^58F!@ P 8 , & # !@!&#5^6>=_-A4_P"U
M=T99N^TT#YSJWU6BB&CVPD?(X?[><)/RL$P, & # !@ P 8 , (OC7Y4K1_-
M=>?J<BRTE>U=*_"5#]HP(C7LN7_@C?JNB4,JQ+# !@ P 8 , & # "+X!^-=
MW_.@T_N6J'+6H^Q*%\U/?;E9$.+Z_4?EB/L^")0RJ$P, & # !@ P 8 , &
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M4K1_-=>?J<BRTE>U=*_"5#]HP(C7LN7_ ((WZKHE#*L2PP 8 , & # !@ P
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MI7'5SMD2LV?UC,\2G]1#H!*^N^T.R:6]T.-L8FHJ5QU<[9#-G]8S/$I_40Z
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MI_40Z 2OKOM#LFEO=#C;&)J*E<=7.V0S9_6,SQ*?U$1JV024[N";E:NBRPF
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MBI7'5SMD,V?UC,\2G]1#H!*^N^T.R:6]T.-L8FHJ5QU<[9#-G]8S/$I_40Z
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M;4,5K(*SMW$ 5/+0@L35,_"E%VLZ*3VKD1,<;VNNV/A\VB<'N2PZ<+;(KG3
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M"K7MS5OG.?\ 6G1Z&![!A?)(W[% DS*P2PP 8 , & # !@ P 8 , & # !@
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% /6/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g111280g22b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g22b02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Q 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '"2^<@0X0DE-! 0      &$< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M($%C=&EV95\Y.#8Y-#8Q-%\Q,5]-
M:4Y+("T@4RTQ7T%M96YD;65N=" R7T1R869T #A"24T$)0      $$_Y*DB_
M#0Z*\7Y9EW S.]LX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <*RT0         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              ,.   $C0         !
M      $             !(T   ,.                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     $:0    !    H
M &L   '@  #(H   $8@ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( &L H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M+:PS>T%U7@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" $9 :,# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M      8'!0@!! D# @K_Q !3$  !! $# @,% P0.!P8$!P " 0,$!08 !Q$2
M(0@3,105(D%1%B,R"4)A<1<8)#,W5G6!D96QL]/P4E5R@I?!UB4T-6*ALC9#
M9/%$4W2#DI31_\0 '0$!  $% 0$!              0! @,%!@<("?_$ $X1
M  (! P," P0%"04' @4#!0$" P $$042(3%!!A-1(C)A<12!D:'P!Q4C,T)2
ML<'1)#1BDN%#4W*"LL+Q%F,(-41S@T5DHE1UDZ.S_]H # ,!  (1 Q$ /P#^
M_C2E-*4TI32E-*4TI32E-*4TI32E-*47LBK]-*5PBHOHNE*YTI32E-*4TI32
ME-*4TI32E-*5J%XT7<X#:Z Q@-=D%A;39NX$1\L9C74FV@LGX?\ >AVLF1UH
MS&2P^63LX_!@O/"ZTMI-@,1V_>;U>8*H?Q]A_'/%:%7]9XOZ:\QS;"O<S>PN
M,$JO#I!P#=N]A97=8IEN,7/B!PF7&L]R&*%^"]/S# <=CWN.[KUTB7 F9%0T
M4?*["?6UV9/MU:JU;?[$%?G>.>%J5>XGO&QFT??FSPGQ >^,LW1C3YCT' -Y
M;/-+6XGU-I45-E@MWN.U0W&)Y761(6-R:B9B591^[*](-!$4]/O^P_SQ5M>(
MJ%1,;L4;&[L#=N=LA'V=L6<)C[81=W;-&=UXV0DEJ5N.TH2+I,K<Q/[/AMM+
MOE\D9C>5)4/);..*:G6M5]Q-VO&!;O;I;=PL4S>HQ =KLDJ**GN<>RV7NHS3
M,>':LR:BS&1E>';?3L3L=R)NZ4E<5O)-5NT=.<YRVH:?%5R"F]YSU*LW:S<[
MQ&8[OIA&W]E"S*7MK>9]O&EC!D[?9-.GLQ+3?+Q&28%Y<Y/=8LS4LXI$H:W
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M["/3",?2)U7UCB DDSZ$Y$8/!R06Q^Z<5S\OB2YG!_-FES.A/LW>HL;*WQG
M=(0LEY*G0C,,6<^\.*C\G[<W"JMSF$B R2JJP<3B,T[8\\\)[RDK.M#XY3X@
M>C<\<H KZ34MK6+W(!(?WIV+G_( L8_RGO\ *M?))K%WS=ZP]NAZP:5"MH!\
M/I$OTBY;C@E70>BBL>.#XV3@R)\$KJ6/K+OI4J[D$O?XE.S>DHB]^> $1YX[
M=DU)$CJ,(1&/W8E6-?L0*#]?/ J(-*T\L'F@^F2#_:W\DM[*?CNN)),<\X4
M?"I%%KX4(4"'%CQ 3T",PTP")SSP@M "(BKW[)Z]]6')Y)8_-C_6I\:1PKMA
MBBB4=!'&J =>@4 =S7<TJXG)S^/Q^.E-*I32E?@VQ-%0T0A5.%$D0A5/HJ*B
MHNF/Z?'[:NW<;2 1Z$9'V=*C\W$,8L%4IE#5O.*O5YWL3#<A"^J2&@;?%?\
MS"XB]NRIJ]9)%& [X]"Q(^PDC[J@S:=I]P29K&T=C^WY"+)GCD2*!(#QU# _
M7BOBUCTZM42QW*\GI?+[M1O>;EM6@OT]WW*3FD#Z@T379$05'A.,;I#)GS8(
M7SU8)LD)^+Q[2?F<FD5I+;8-EJ>I6>/=C^D-=VHP!C-O>BX7:>ZILX&!@5G(
M^9[ATZ\6%939;#%%3S:LSH;A!1/QE$EN2JR02=_A;EP^I53@4]%B2:=;."8Y
M)(&[+)B5#\-RA7&>O1L#K4^+6-=M<^?;VFK1+U>V8V-V!^\893+;N?4":($G
MC'(J8TVZ&*6K[<"3)?H+=SA!J<B8]U2W#5>E!BN/&4.<I*J('L,J0I>O"<\:
M@36%S$-VSS8^OF0GS%Q_B &Y>G[2BMQ9^(],NG6!Y7L;IC@6NH)]%F8DX C9
MB89B3P/)ED)JPT5%1%3NB^B_7].H5;VN=*4TI32E-*4TI32E-*5$L@SK%L8,
M6+>W8:GN\)&JHXNSK>41?@&-5P@?G.]:_")(PC?*]S1.516OO-5L+ A;FX19
M6QLMTS+<R$^[LMX@\S!NQ";>>2!DB&GF^;7(HF.8>-/'/TM,VDK#<4%3\3-#
M5E*G$OS%)DN OIU"BJJ"R/X_C^'X-:YM2U2Y']ATT6J'&)]5<Q,0>NVSM_,F
M)'/$LL.#P0"3CH'CV56O)9%GUWP?"E!Q9F-C,,?J R&AF6[B?)3*Q;(D3T!4
M35.<=L_'[^W7ZN.M6-8WUQS>:Q=$'K%IZ)8Q 8R5W@273<\9\]21CW>QC;G"
MVG1D/T,6TEBG>9>N2+V42]E4B=MWIBJ2JG*JB(G5W1$7C5>>?C5$T32E8.]G
M'<2 8\V[:2[D/<Y:Y>7J>34KB5]?7CT0($*"")P@PXD>**)]$1AL$1%^:)VU
M0@$8/V]_M_&>^:V4<4,(Q#!#",8Q%&D8QZ>P!QGG_0D5W%55]?\ /?G_ )Z
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M4TI32E-*4TI32E-*5P1" J1D(B**I$2H(BB)RJJJ\(B(B*JJJ\(B<KIUZ4)
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M/##N.G(/3H?AL[6X'B4O/<$I86\YC72@Q$C31\AM4 VL2&"R16H_18VNQD(
MJT@ &P!ML!;;;$0;; 4   4X$  401 41$$11!%$1$1$UCKHA@ *  H
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M):W5['LDG>*WV(\F&BB9?-4 J6W 8&:]1\,>$_+VSZM:AII65;:UN I$0=D
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MI2OA)D,Q([\J0X#3$9EQ]]UPD$&F6A4W'#)>P@ "1$2]D1%5=5 +$*H)8D
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MW=U=6EY#+)Y%_I\FIV4=M:7D)9%N/:@N49IMRQ/#(T$\,Q1/,E60)!9FSFP
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MBESPK<B?)8KF7D7A40F')0O#S\/4"(J=]3=-ACGU"SCF_5-,/,7/O*H+E?\
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MJ"J*W+R&3&3VMXE[H25,9X8S:<"H2GY"\KT)Q$'Z:<G]B D#K@RE5#'MD(,
M=.23GC%:EC]+OCSF#3F*)CI)>.I\UCR<_1XV$8& 1([D'BI1J74VFE*:4II2
MFE*:4K S998Y<5V7-<^3'5NIR .%5':*9(!2E*@\$KM7*4);9(J\,+* DZ7-
M89H5GB>'HP!DA/I*H.%R<\2 %"..<$<BHDDYTZ\M]57 1-MK?C&0UC+(,R8'
M[5K(1,I'['F@Y!Q5[<H2(0JB@:(0$BHHD*]T(23E"14X5%1514[HNN=^ZN[R
M#R#D'D$8((/0@C@CXCCTII2FE*:4II2H-N9CKV5;?Y911@5R7-J'BA-(2"3T
MV&83H;(JO9%>E1F6T7Y=7=>.=2;.9;>Z@G8$K%(&8#J5(*MCXX.1ZD"M+XDT
MY]5T#5K",9EGM',(X]J:(B>),\XWR1HI.._RK1K;?(([L9F))06)$=49=!.1
M(2%5$D,5[@HDG!BO!"2+RB=];K4K<D^<K;TE 93D\@G<,$?#C@9Z _#R[P?J
ML+VXLY%6&:'$;C&#O!(8,IZ$%3D=SG(&.?MGNPE3GDV=<P;M:J18>6=C']E9
MF ^K+ MDY$(Y+)-R'$17$1YPV2=/JY83J0^M\/?E!O=#LX-/EL4O4M@ZVKB5
MH60,P8+,!%(KHK' V*CJJC);J-#XQ_)#I?BV_NM4@U9M+EOC&;^(VT=TLC)%
ML:2WW31/'(Z@E_,>1&D8L-@8H9EM]B>/[58I"QZ+.?3'J0+)YXY3D1QZ?/G2
MCFR)TB2TW'< G9#SR^0#3<9H$1IEM&VV#/7W]U?>+-7N=2N(5^EW3P@+$) L
M4448CCA16:0%5C11O9F=CEF)=F%=#H>F:1X#\/6>@VDS'3-+CN"\LSQ--=7$
M\SW$UQ/(B18>261SY:(D4:8C12%4M]-B$++]X\BRB(V[[BQNBEQ&'T$D8]X7
M,N,$9CJ+JZC]AC3GB1"Y'ELE1.L>K/XG@32O#]E8,W]JO;Q;B5&8,RPVT<B[
ML +A3,X5<J3[+ 'V:UGY/7;7?'.JZO$A_-^DZ;-;Q.HVQ_2KZ:()&<EMSBVA
MFE;#9 ="5&0*WBUYQ7O=-*4TI32E-*4TI32E-*4TI3]?=/FGUT/0]JJ.#W^K
M\#^-13!I"XOD=I@KG U<QI_)L255X1N*_*7W[3"O CTUMA(;E1&A13&'8=*J
MHLIP^KI6LTMC87MQI).+>57O]-R,;8WD_M=J#P"()G$D:C)\J;KA.+CTKHJ:
M4K\D2 )&2\"**JKV3A$]555X1$3YJJZ?*J$@<GI6N-)*^T%KD.8&JDW<SRAT
MRJJKT8_3F["KR;3E>@9[HR;,P'L2RQ4N51..FCB\B&*#@-&NZ3 ZRR#<^3CG
M:&"@^B_57GMM-].N;_522RWLS0VA(]VPM"T,&,^ZL[^9<D+P3*"<X%2C5U2Z
MZOML/VQ:_P!JC^WC&2:L+SVO:TAJYY*2O9NOSO9U>16D?Z/*5U%;ZNM.-*NV
MG /8G'U\_P!*YB38D^.U+@R8\R*\/6S)BO-2([P(JCUM/,F;;@=2*G4!*G**
MG/*+I0J1V^S/V?.NSRGU3_[^G].E4P?0_97'*=^_HG/;Z:4"DGH1\2/L^WI7
MQ8DL21,X[S3P Z\P9M.-N"#\=TV'V2(")!>8?;<9>;7@VG0)LT$Q5-,@].:J
M4(^/RS_2OMRGU3^G2J8/H?L-.47T5/Z=*8(Z@_91!1/1/3]*ZI@>GX^'H/@.
M*%B>"?N%8$L7Q];L,C*KC>^FP( G<'YB=;:-&YT=?D^>32(TLA6_/5M.CS.C
MMK$+>$2F81J)3U;G)[9(S@GISC(XYK>#Q)KIT=M &HW!TAG5VLQMV>R_F+'O
M"^;Y(DS((=_E>82^S=S6?Y3Z_P"?\HNLU:/!]#]GX]13E/JFE4P?0TY3ZII5
M<'T/V4Y3ZZ53!]*<HGJO&E,$]!FGKI3H?B*^1L,N<>8TV?'IUBA<?_R1=4V@
M]N^?K_'7UK(LTJ>Z[+Z[3C/SQU^NOT+8!V !%/H*(B?T)_;_ #:  =!C\?CZ
MN*HSNWO,6[<\GKGKUZU^]5JRL#D]RE#1V-IT^8[&C'[*SZ^T375%F%'04^(E
M?E.--\#W1"5?EK%-)Y<;-W X^+$@*/K)^%8+J<6MK/<$ M&F8U.?:E;V8DP,
MD[I"J]#UJ-X[5E3T\."Z7F2D I$]Y512D6,LRDSGS+\Y7)+KJHJ\J@=(^@HF
MJ01^7&H(]K!+'N68DDGUY[XZ8'3BHMI ;>WCC8Y?!>5B<EYI"7E8G SF1FP3
MSC [5FM9JDTTI32E-*4TI32E?&3'9EQWXL@$=CR67&'FU]#:=!6S%?UB2ISZ
MI\N^G(Y7@@@CY@YJR1$E1XY%#)(K(ZGHRL"K _,$BI!MS9/2<?6IF.$Y88Q+
M>H9)FJJX]'BH!U<LD55)4E5CD4NM553=%WE>15$TE_%Y=PS 828"51C !;(=
M0!P,.&Z=B.V*VWAVY>;3_HTK%I]-E>QE))+.D(4VTQSS^EMGB)8DY8-SQ@3[
M4*M[32E-*4TI3TTI6F.[?ASO#R.=N#M,\PW:6+A2[_$)<D8<*PFJOWEE2R'3
M"+#FR553F1)!,1I+RK)"2RXKC;V[T_4851;6_5W@!(CF3VI(00.&4Y\V/('L
MC# <*:\C\4^ ;_\ .$_B#PE(D=Y.?-O])ED$-O=R_M3VDC%8K>>3DR)(4BD?
MVPZ'=NJ9G)-T:7F!<;89RQ. ?+1V%1VD]@RX4?NY#$"1"=1%X)%;=>!?A7DQ
M)%7HH]/TJXVO%J^G[#[6V:40,.A8%'(<'LW!(.2/6N-.N>++'=!>^%/$*S@;
M=]O87-U&QQ@;)889(6P>A5F!&#R#648VUW>W:>9BR\??P;'G'&UF661B4>3Y
M(JA*C-2XK4Z2\G3\#;C$9CK_ 'U\4[+M[76-!\-JTL5Z=5O=K".WM"1;ABN,
MRSD;2N#SY9+$$X .",$GA?QKXW=+>?2SX>TIG4SW>J I<^6I#8ALB5G>3V3M
M$J11 @;W  !WBP/!:';G'(N-8\R0QV55Z9,?Z#FVD\T%)$^:\(CUO.J H(HB
M RR#;#2(VV(IYYJNJWFLWLM]>N&DD.$1>(X8AG9#$N2%1 < #J<L>6->\^'/
M#VF^%M+ATG2XBL466FGDPUQ=W#X\VYN'P-TLF .F$0+&N%50)CK75O*:4II2
MFE*:4II2FE*:4II2FE*@^=MOPX$#+(+9'8X78-7@"VGWC]2G,?(8/9%4@E5#
MLDNA$7J?885$Y%-,X/SX_P#'I]GKT.*U.KHZ0PZE$"9M*F6[&/>>WQY=["#Z
M2VK/QW9$]*NB)*8G18\R,X+T:6PU)CN@J$#K#X"ZTX"IZB;9B0K\T5%_3I71
MQR)+&DL;!XY$5T8'(9& 96!]"""*[&E7U7^YUN]58=:##-0LK;V:AJU%>"]N
MNI 0 ,%3NA1VG7I?*)R@QR5/34RPB$UU$&&40^:_IMC]K!_XB OS-:/Q'=26
MNDW0A.+FZ\NQMCT/G7KB!6'QC5WEX!("9Q4*KH+%; A5\8>F/"BQXC(\(G#4
M=H6@YXX3GI%%5?555>^MX222QZL23\S6@BC2"&*WC $=O&D,8[[(U"+GU.%&
M37=TJ^O.?Q";2[XV'B.?W<V@JW1FRMEL/V/*^6QK8S,*BSO)=WV\PN&(LJ:T
M;LO;:^G[2[COB<?S9]/2V=74%*G2W8HQ)4D\W>@YV!,G.,-O#'J -I*,?@">
M_.P@DC$ C?H7=\<G++Y14'L X$B9((4L"> :H3%MM_&)ME4;78'M5C67XK3;
M?P*2BI8<J]H+;!2I9M]GS-F=U"#)JQF(%:Q98R]9)<T^XF03&(L.=C!XRU'M
M%>QA94"J@*A?9 W#;MP1R,CH-OO;CDY4J.N8O Y=I&5BY9LX8,#[P (7//(X
M8+GW@2<BVWL-\45W0"F&VF_V*6M3MWNA;01W&SG 9#UKO1'P_;*/AD20E0[9
MM%A\K+/MO,B5UQ.EXXY:,V1L0ZS"'ZJME7[9B#M9A[+GDJ<N0H4$#(QP1MSZ
MXP,&K 80PW",@R1C*!AB++[NN/:P%!;EL'(.[)J$Y?-\1L3*8&(T#GB)B5^2
MXWOC<;/X_-RW#W,]BW]!B.P-?C-UN3:2;V3%EX54;H7^73&8-G;W;B0;5X+&
MLE8:<.JBVDR[\#S!N60H"0&R%0#?R,J'+$9SD<>@%X\HKD^5D-'YF%;80QER
M$&!AB@4YP!P,'.34EE[<>)S :O*+##1W%LG\TS'Q#V^38[29900JRJ8R+Q)X
M9<8;>XC"F^:]6.3MN;?<C)'XM)*K<IO8,B93)D&.Y.N+65)7;*@.T-[1E+ '
M &74J1R,>R6S@@C'!!JTO$Y7=@!%BP0A)XB(8''!PX0>T&7KU&0:FB9UXH<;
MRO;_ &]RW*\TA[F6^844?;R@EY)B[+$C#)6[.];]C.W-Q7[7Y7D^05,K;NNV
MV$;*-:YO:T,6DFM6^20Y'VJE7UF^8$ LP8GV "G(W29+ L2P*A>1NQ@[CNSF
M[;$RNP52H!,CE6X;9'@(V H._?E1C.> 1C&ZW@_J]_ZVJRM-]+;+;!]Z)A/N
MZ/E]13P)4;*6JB<FX4FLG5^X^X3UC43[0ZSR :3&L;BRHLQS$:.-3S/)C2(
MXR&+$<$;L=<'=CVW)&<''L $\#' BW)C/ZL+CGW23QD;<CRT (YS@MGN?7<S
M4BH=>='CA;R=[-MGH]5<65)3/;>[^C*FC^SD5"WE?M&SX8<<YO8BQK<D*];;
M<R)S'EFN2(Z,!>#$BNRR'B)<[MT>#@%9 ??QN]C9[G.<]/\ 3!G6FT)(2 2'
MB( *;MN)-^/,!7'NYSCG [\50/B2\3M;:8510<:S"$^QM]55V1TN?[8W]S95
MM\[X8K/<1C)K>;B-3/MLKD!NG$J\4N+2$_B#4VYD6^!TVWEID,-;T:>;*"%
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M<>-1; !^9$2(GUUAEN;>&%[F::**")#))/*ZQQ1QJ"6=Y'(1$49)9F"@9).
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M(((Y!!&01T-.O! ([@C(/P(/!'P-:D^'%"VQS3=?PQOJX-/MY*K-Q=GO.(E
M=F=SIMT]7XI#5PS<<8VTS:FR[#8+(D00,0#"(Y*!NHVG4>(R-2LM+\2+M,VH
MK)IVKXQDZSID<"RW3X50&U*RFM+MVP-]W]-; "@F#:?H9)[/&%B(E@[ P3%B
M$4<\0N&3.?=*<>NY^V!*.)!#5>5K+K(J[OZ]+-W.=;1/T"S(:1/T(GTUYYJ
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M91:6-Q-;Q6VZ2.)G@D:)IG4@ ERA<%@=JLJJ< EJI;C6>%VD/(,5FOU%K#?
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MBDF&+B\:2_N>H/G7C&;:0>ACC:.+'& @':K"TK<4TI6OMG#7&L^M('2H5N8
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M:U;M8]E=2Y=7F*,.2(5](JY\]YIFTLI6,7< (=;,O!I:XG)=U3V..P83+U5
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MR.=MU"9(&&0,NK'W<B"4]I'N:Z+8Q>4:DM"2@:*CK#HJH/QG@5$)M^,\!L/
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M;3H);:YBSSLFB93@\JVY#DK5CZDUSU5=C?\ "KNA_(FW']SE>L$?Z^?Y0_\
M2U29/[O!\W_[:M'6>HU-*4TI32E-*4TI56W,-S#K!^[A@9XS8OH]?0FQ4BJ)
MKI<'>10!.?8WD_\ %6!3[L^)H<_>BD-Q]'<R+S$YS(HZHQ/OJ!@8)SN'<G<?
M=K4W$;V$C7<:DV4[YNHU&3;R'K=(HR3&_2X4#*D"09!85)VG&WFVWF7 =9=
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MQ2#<F/\ #GE#\4(^.<"M-J.A66H/Y_Z2TO5&$OK1A%<8[++PT=Q'_P"W.D@
MR%VY)JNIE7GN,JJ3*]G,:P$54L:!L8=VV IRJRZ%][R9)KRG>KEJ1(BDD1%+
MI3:Q7EI* -QMWZ;93NB^8E !'_.H_P"+O7/366M6!_30+K%LHXN+%1!>!0#^
MML7?9*WJ;:8L>HB&<#X5V44EFZL5B8C5@"]+U9.;.OM&33U%VOF"S)%47E%5
M&R#E%X)4[ZE%& #8W(>CJ=R'T(9<KS\^X]:CP7UI<N8DF5)P2&M9PT%RA'56
M@F5)1CUVD'&02*D"=T1?KJVI1X)'I32E-*4TI32E-*4TI32E-*5TYMA!K65D
M6$R-"8'GEZ4^U':3COQUND \K\DYY750"QP 23T !)^X?CZQ5LLD4"&2>6*&
M,=7ED6-1\,N0,CTZ^F:P46]L[XO+PZ@GWPDO2-J^*U&.@O*(I>]9@(4M Y12
M&OC2R-.?+7T5+)'B@_7RK&1C,8]N;KTV+[O&?>(Y].M1XKF:]PNE6%Q?9X-T
MX-IIX/0GZ5,,R@=?[/%-D=#4L@[6RK,ADYU<K;!\)_9RG1ZMQ\"1?P2G$-+*
MW1.!)%E/1XY%U(4)07IUKI=3/(MH_+!_VLF'EZ <?L1YZ>R&.!G=FMK;^&I+
MC:^M7?TI<Y_-]H'M[ '@[9#N-S=@$ _I9$C)R/)VG%6U!@PZV*U"KXK$*(P*
M Q&BLML,- GH+;30B )^A!3OWUK&9G8L[,S$Y+,223\2>374PPQ6\:PP11PQ
M( J1Q(J1H!T"HH"J/@ *[>K:R4TI32E-*5T["N@VL-^!91(\Z%)!0?BRV6WV
M'07\UQIT2 D^:<HO"\*G"HBZ5CEABGC:*>-)8G&'CD171P>S*P((^KK562-O
M;G'U)[ ;H8T1.27%,B*3847=450K9Z$Y;4W/)*+8'.AH2H(PP%$TX/4<CH?Q
M\..U:%M'N;/VM'NA'$#_ /+KTR3VF./9@E!-Q:=R #-$"<^4!6+7-QJ7!C9K
M2V.(2.I&UFRQ]NQQ\U5$3V;(8@E$%"54X">W =%2$%!3YT/KV^8XQZ]_Y<5C
M_.RP,(]3M9],?./.E!EL7)S@)>Q@QCM^N$+995*[C4TC28TQEN3$D,2H[J<M
MOQG0?9-/J#K9$!)^D275 0>GX_K]5;1'CD0212)(C>Z\;!U(]0P]DCCL:^^J
MU=32E-*4TI32E-*4TI32E-*5C;2YJ*.,LNXLX-9&1%X=G26HXFJ<?"WYA"KA
MJJHB VA$2JB"BJJ)JF><?CIFL,]S;VJ>9<SQ6Z=FF=4!XSQN.6/H "2>@/-1
MAG),@R/AK"<:DR&37A,CR49%'0MBJ=GHT=QE;BV3_P L:+'97E%]K%%54K6N
M6_N[T;=*L'=3D"^OQ):68'/M(A7Z5<\C "1QQG_>CK6>KMLF),AFRS>S=S"P
M:-'F(DAE(F-5KHKU"L"A;,V'C!>!25:.6$@N@30FB[(P , <?'J?G_I_(5)A
MT-)'6?59VU.=2&2-U\JQ@8?[FS4E&(X'F7#32' (*'BK1$! 1$!01%$$1%$0
M404X1$1.$1$1$1$1$[(B>B:5O@ !@# '  Z >E?K2E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4X3UX[_72E8"]Q;'LF91B^J(-FV*<-K)8 W6
M5Y5>J/(1$?CFBJJH;#K9HJ\HO/?66*>:!MT4CQG_  L0#\U]TY[Y!SWJ%>Z;
M8:BFR]M(+E1[IEC5G0^L<G$D9'JC*1U!%5_*VF:B\GC&49!2+W0(<M]O(*MM
M%XX08MJARP1%3LC5DSPB\)VU/35),CSH8I?\0'E/_F3V>>^8SGY\UHW\+K'D
MZ=J=_9'G$4KC4+8#L!%=9E4#_!<)]58AS%]S*U24&L4R5D4X1694_')[G_F5
MF0S;PN?FHI,:'GLG"=TDIJ%HWO":$]\A95^T%&^1VG/?%0I-,\10]!I>H(.A
M22XT^=AZE)$NX<GX2*,\<#)K&.SLMA+TV6WN2MJGXG*MVFNV4^:JBP[,9"CQ
M]8R&J^@<:SK/:M[MU%\ XDC;Z]R;?L8CITJ*S:G#_>-!U,'UM7L[Q/F/*N!(
M1_\ B!SVQ76/*V&$YFTF60>W*^U8G?(@]_138@OMHO\ O>J_/MSD&UO<E@?X
M":/IZ\L#T^')Z5C-_"GZVTU6$]_,TN]P/F4@=?O'/3/?X+G>/"O!NV8+\A/'
MLA%?54X[U?//\W'9=7>6W9HS\1+&0/L<Y/UC^N,ZOIRG!:[4^C:??@_+FU'-
M?L<TJ75Z8T:_EG\PC8OD3QKWXY04K$[+\E543ZJFJ%2.LD"CH2T\0Y^(+C'W
M]1UJX:G9MQ&FH2G&=L>F:@S'Y#Z+T^)('?IS78"^M)"HD'",VF*7826C2O:Y
MX7\3MM+KQ%.?7UX_7JPR0CWKFV7O^M#_ '("?K&?EFL@N;A^(='UJ4YZFR$"
M_'+74EN/LSU^JL@S W)L.4B8A6U JB*$C(<BC]D7YE#I(]JYRB?FJ^WROYR<
MKQA:\LTZS/*1VBB.#\FD9,?/!SZ"LZVFOSY$6E06@/22_P!0C^^*RANFS\/,
M'SYK)1]M\NGJGO[,VJ]@T^\AXI4MQG!_V+>V>L'^I>R*006%1$3IX55XC-J<
M:Y\FV)/[\\A;/&,E(]HX/(]H^A'>IL?A_5)O[[K"P(>L6EVBQ,#\+JZ:X?ZU
MAC/7!%2JJVNPRL>&6Y6%<V \*EED,AV[F"7^DT4\GF8Q<]_W*RRB?+LB<1);
M^ZER#)Y:G]B$")?D=F&8?\3&MC;>&](MG64VQN[A<$7%_(][-D=U-P72,_&)
M(ZL 1$!011$$41$1$1$1$[(B(B(B(B=D1.R)VU#K> 8  P !C &!]0[#X5^M
M*K32E-*4TI32E-*4TI32E?-UEI]MQEYL'6G14'&W!$P,"3@@,211(23L0DBH
MJ=E32K656!5E#!@000"""""""""""1@@CDU6\[:?$W7SF4PV.)3S53*5BDXJ
M@7#7A>7Z\0=J9'*IP7GP#4A545>..*Y[<5II/#]@7,MKY^FS$Y,FG3-; G_'
M  UL^>^Z$Y'!K%N8SN76+Q6Y%CV2QQ7LSD58]3ST!.?@2RI"?BN$2+PKAU )
MU=U'CGFW:#W(R<G'/?/&?Y8YK#]#UVW_ %%]97R?N7L#VLP [>?:&2,L>A8V
MP' R#R:Z;E[F->O%QMQ=J*+TK(QVSIL@:+U^,62E5=AT+PJ\>Q*:)VZ2+A%'
M/89X^7?MSSV]/Z8S>ZC%GZ3HEW@<;[*XM;Q3TRP4O;S8YZ>5D'/7C/Q/<3'X
MJ?\ :D;)*0_11ML5R&.*+V[*\%<['^O='B1./7U73VNX'?.#GTY^6>/LQGK5
M#K=E'_>$OK0\\7&G7R#H#[P@9/F=Y [XH.YF EZY35-+])#QQ23CUY&2VT2<
M?/E$U7IQ@Y],'\?5WJ@U[1CS^<;9?^-RA'S#A2/EBOK^R1@*)S]L,>_4EI%5
M?YQ1SJ3U^FJX/H<CM@Y^RKOSYH^,_G.R[_\ U$9/'P#9^[GM7Q/<[ @[#DU>
M^O\ HQ$D335?H@0V'R5?T(BKJF".H(^KUS_2K3K^CCI?P/Z"/?*3\A&KD].P
MK]#N!5210JFHS"\Y15'W9B5UT'Q\AD3XT"+_ #J^@HG=51-4.X=@3]F/O^K^
M)JHUFUD7-M;ZG=\X'DZ;=A2?3?-'%'GIU< =SVKL-V.?6J(E1@)UK;B<A-RZ
M\KJX&^4[*Y7TRWLXB1?5I?)7CU<%>$5C(YX/\>>G7C(^-7"YU>8@6VCM"&!Q
M+J-W# JC_%#:_3)23TVY7C.6';MMX3G-JO.09JU51RX0X&&5;4-Q$Y^+FZN3
MLI2\CVY8A1"^:$BZJ !R.ORXQQVY^SG^-9%TW5KC^^:JMLA!S%I=N(FY_P#W
M5T9Y/3W(H^^,&I'3[:X?324GM5:6-LBH2W-X^]=VRFB\]0S;(I#C"\]T&,C
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*I32E-*4TI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g111280g22c03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g22c03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2=Z4&AO=&]S:&]P(#,N,  X0DE-! 0
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M @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M  #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M    $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M    !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G
M1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M      26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M   %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";"
M @9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"
M!5;G1&(U)L=                %)S;'15;G1&(U!X;$!N            "G
M9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M  3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M      4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V
M)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,96
M9T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296
M-T5&]P;&]N9P      .$))30/M       0 /     !  ( \     $  CA"24
MT$)@      #@             _@   .$))300-       $    >#A"24T$&0
M      !    !XX0DE- _,       D           $ .$))32<0       *
M$          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0
M"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M   3A"24T#^       <   _____________________________P/H     /
M____________________________\#Z     #_______________________
M______ ^@     _____________________________P/H   X0DE-! @
M   !     !   "0    D      .$))300>       $     #A"24T$&@
M #-0    8              D0   *Q          $
M       0             "L0   D0                      0
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M0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M       0$ .$))3004       $    !#A"24T$#      <W0    $   "@
M  AP   >   /T@   <P0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &
M2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,#
MP1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A
M04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,#
MP,# P,_\  $0@ AP"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M        ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0
MH+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!
M52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>
M/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1
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M3?_"E
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0IEWX4BSQ5O*AT9M>+R2/NEF%@Z+0)K:[MJM52N=9JMPU;6GA1K+L36<Y+P
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MU$E6%4(*MXT.T=3+L&]:?5>J6K=C@=Q]!]JM==1]9SEHK_6Z)%U'HW8^C;I
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MW1.RYBBV&>+"E8*/S2)9_#+402TZP4413QWOY-^Z_3&H::G]U)ZR[OD.VFD
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MHU<<;"Z9=5;SC7T=JG%LZ_:EG\ZWAHYV(A:5F3I$*4JO0L8^Z^0!"QZG,LQ
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MC7&NC=14&4U+1I"F:ODE>V?0:T77P7X:J&*]\1[1$* M@)W/OWO5;6?^JO\
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MCFTAQLSL[BW)<-[I.Z-@41AY[;>HY8.+#],EW/7AXUMKN&<J]G)I,6XL.P1
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M'/I(3E"58<=,B"GV<)1GT8><6KW7V2;MU*Z:PG^Z-@ W#6ZL8D6\Z7'VVZD
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M1.$3A$X1.$3A$X1.$3A$X1=55Y/OM*^_?\5>T?ZX7A%O,_)Q?L8^F7[OOO\
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M=T1R>B8[!;QGIK[7<Y2N8MM)MX?)[%CY(*]MY,I%!8F.LU JYRT;)3N(R^^
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M"9B$F<79G9V7L\[+R3A$X1=55Y/OM*^_?\5>T?ZX7A%O,_)Q?L8^F7[OOO\
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MI=B4A)-!<:./\&^41>/;WM),]7:G1I2J==]V]E[ILF_1VNJI0M*P(9KH<I)
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M6I\1>?>,+X7/:_P?Y/\ L5E?Z39XI/O_ +H_ #9'Y5PG#_!_DZ?I-GBD^_\
MNC\ -D?E7"</\'^3I^DV>*3[_P"Z/P V1^5<)P_P?Y.GZ39XI/O_ +H_ #9'
MY5PG#_!_DZ?I-GBD^_\ NC\ -D?E7"</\'^3I^DV>*3[_P"Z/P V1^5<)P_P
M?Y.GZ39XI/O_ +H_ #9'Y5PG#_!_DZ?I-GBD^_\ NC\ -D?E7"</\'^3I^DV
M>*3[_P"Z/P V1^5<)P_P?Y.GZ39XI/O_ +H_ #9'Y5PG#_!_DZ?I-GBD^_\
MNC\ -D?E7"</\'^3I^DV>*3[_P"Z/P V1^5<)P_P?Y.GZ39XI/O_ +H_ #9'
MY5PG#_!_DZ?I-GBD^_\ NC\ -D?E7"</\'^3I^DV>*3[_P"Z/P V1^5<)P_P
M?Y.GZ39XI/O_ +H_ #9'Y5PG#_!_DZ?I-GBD^_\ NC\ -D?E7"</\'^3I^DV
M>*3[_P"Z/P V1^5<)P_P?Y.GZ39XI/O_ +H_ #9'Y5PG#_!_DZ?I-GBD^_\
MNC\ -D?E7"</\'^3I^DV>*3[_P"Z/P V1^5<)P_P?Y.GZ39XI/O_ +H_ #9'
MY5PG#_!_DZ?I-GBD^_\ NC\ -D?E7"</\'^3I^DV>*3[_P"Z/P V1^5<)P_P
M?Y.GZ39XI/O_ +H_ #9'Y5PG#_!_DZ?I-GBD^_\ NC\ -D?E7"</\'^3I^DV
M>*3[_P"Z/P V1^5<)P_P?Y.GZ39XI/O_ +H_ #9'Y5PG#_!_DZ?I-GBD^_\
MNC\ -D?E7"</\'^3I^DV>*3[_P"Z/P V1^5<)P_P?Y.GZ39XI/O_ +H_ #9'
MY5PG#_!_DZ?I-GBD^_\ NC\ -D?E7"</\'^3I^DV>*3[_P"Z/P V1^5<)P_P
M?Y.M,KL35;OW=[6]M^S77/7NP[KJ#:/8_8=AJ%@^@MH">+CI',7(#X+!<BUO
D@E8&,'4\(1[+[*EX2XA.?3UXY_0[_+_%V7+ [_H_T\M_@O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g111280g22d04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g22d04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1R:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ''Z^<I0X0DE-! 0      &$< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M($%C=&EV95\Y.#8Y-#8Q-%\Q,5]-
M:4Y+("T@4RTQ7T%M96YD;65N=" R7T1R869T #A"24T$)0      $$_Y*DB_
M#0Z*\7Y9EW S.]LX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :V            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              &(   "J0         !
M      $              JD   &(                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     $?T    !    H
M %P   '@  "L@   $>$ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( %P H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MVC)V>HSU-@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" "L 2L# 1$  A$! Q$!_\0 '@ !  $$ P$!
M      D%!@<( 0,$ @K_Q !2$   !@$" @0)!@D* P@#   ! @,$!08'  @)
M$1(3&2$4%1@Q05A9F-86.5&7M]<B,S5A<W9YLK87,G%X@9&2L=CP(T*A"B0H
M-L'&T?$W4E/_Q  = 0$  @(# 0$              04&!P($" ,)_\0 .1$
M @(" 0,!! @#" ,!      $" P0%$082(3$'$T'P%")187&!D;$5,J$(%B,S
M0L'1X1<E4F+_V@ , P$  A$#$0 _ )L-LFUO,N^JW[V<EW/B.\0;$@4+?MN;
MPI4:'A#,E2JN/X&BX[M;5M66,;"SV-[4[:J-&;\69@1DTVQD&S?H-4E0656
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MN1T [(2X^UGXLOO#8V^Y'0#LA+C[6?BR^\-C;[D= .R$N/M9^++[PV-ON1T
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MHQD10!7I D*P-%UA2!02'!,3]$#] W1Y]$>0%9T T T T T T T T T T T
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MZM6Z!5X6HP2TR]R3N?;.Y52*@63!D>0<MV3)!=X*'A"J+1LDHH8B*92@2R:
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M*KN4?Q:ZRJ::BJI3G.0IC"4 +DT T T T!&_C/YU7=G_ %,]G/VH;J= 20:
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MMA+82YM5;C+'LG[F&/4X5^Z?;%RE.:CS*4GM-K'#9XT T T T T T T T T
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MKLG-=@',:DW0CG$+%KQZ#,A$FB+)5B@HT2:IIB*:;=- R9$4TQ$A$P*4HB4
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M]'@IR=DDY7.,5 D9* !SY<^\>8\PY=_=S'T>?_/6Q#S5\_@<Z : : : : :
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MMF?Z@V?[3KSJ%Z?G+]V#R<(/\@<0G]JCO5_C&&U(*KQ&FEDKU[Q'E:+<3K"
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M?%F@'EP[+?6ZVQ?7WBKXLT \N'9;ZW6V+Z^\5?%F@'EP[+?6ZVQ?7WBKXLT
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MA+0#LP^'%ZANT#W<\2?"6@'9A\.+U#=H'NYXD^$M .S#X<7J&[0/=SQ)\):
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M;QW9H2E/JH#^99,6EA3567)& 7A+<36AP1[$,EA3.*416#O47]T.SQ82I./
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MTUJ-FW3-F9P=1<S5LL^.B@9=0ZPI$**IA/TAU(,J: : : : : : : : : :
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GZ!UU%ES),V39!NF99554Q$P%10YQ$P@7!H!H!H!H!H!H!H!H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g111280g22f06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g22f06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[10V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %!J^448X0DE-! 0      &$< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M($%C=&EV95\Y.#8Y-#8Q-%\Q,5]-
M:4Y+("T@4RTQ7T%M96YD;65N=" R7T1R869T #A"24T$)0      $$_Y*DB_
M#0Z*\7Y9EW S.]LX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ;$            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              $O   % P         !
M      $             !0,   $O                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     "9D    !    H
M "8   '@  !'0   "7T &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( "8 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M       #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*
M"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R05
M4L%B,S1R@M%#!R624P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            _^% (VAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N
M,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R
M,2TP-RTR-%0P.#HP-BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^4%-C<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\
M+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P
M,C$M,#<M,C14,#DZ,S8Z,3@K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @
M(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q+3 W+3(T5# Y.C,V.C$X*S U
M.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O
M(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q
M,"XQ+C$V("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E
M;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @
M(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M($%C=&EV95\Y.#8Y-#8Q-%\Q
M,5]-:4Y+("T@4RTQ7T%M96YD;65N=" R7T1R869T(#<N,C,N,C$Q/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,C,P-S(X/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,C$Q0S S-4(S,T5#14(Q
M,4$X.3A%-CDX.$5$,C8T1#4\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,48Q0S S-4(S,T5#14(Q,4$X
M.3A%-CDX.$5$,C8T1#4\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HQ1C%#,#,U0C,S14-%
M0C$Q03@Y.$4V.3@X140R-C1$-3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,48Q0S S-4(S,T5#14(Q,4$X.3A%-CDX.$5$,C8T
M1#4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#<M,C14,#DZ,S8Z,#<K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HR
M,#%#,#,U0C,S14-%0C$Q03@Y.$4V.3@X140R-C1$-3PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-RTR
M-%0P.3HS-CHQ."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,C$Q0S S-4(S,T5#14(Q,4$X.3A%-CDX.$5$,C8T
M1#4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#<M,C14,#DZ,S8Z,3@K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,C Q0S S
M-4(S,T5#14(Q,4$X.3A%-CDX.$5$,C8T1#4\+W-T4F5F.FEN<W1A;F-E240^
M"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,48Q0S S
M-4(S,T5#14(Q,4$X.3A%-CDX.$5$,C8T1#4\+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#HQ1C%#,#,U0C,S14-%0C$Q03@Y.$4V.3@X140R-C1$-3PO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @
M(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D
M93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!#
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "! B$# 1$  A$! Q$!_\0 '@ !
M  $$ P$!              @%!@<) 00* P+_Q !$$  !!0 ! P,# @0#!08"
M"P $ 0(#!08'  @1$A,A%!4Q"5$6(D&1,G&!(T)AL? 7&"12H=$E<B8H,S9#
M8J*RP>'B_\0 ' $!  (" P$               8'! 4! P@"_\0 21$  @$#
M P,!!@,$" ,%!P4  0(#  01!1(A!A,Q00<4(E%A<3*!\!4C0I$6,U)BH;'!
MT20EX28T0T3Q"!=35'6"HC=C<G.4_]H # ,!  (1 Q$ /P#W\=*4Z4ITI6M'
MOH[Z[?M?T.1Q6*R=+I-5>T[M+9E:66P2IKJ13RJ\,> 2L*!**/.( /<Z9YL,
M 4(\3O8,<2K1K3]GOL\M^K[:]U"_O;BUL[>86D*6BQ":6X$:RR.SS)(J1QI)
M&NT1EG9S\2!/C@/6'6,W3T]K:6=M#<7$T?O$KW#2=N*$NT:*$C9&9W97)8N
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M!Y!!'(/@_:NBVR&]STLL5D<]\;8XO:C155SD3PYWI^5<J_'H2/TKX1.OHQ2
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M&_;1[.*>R]8-]6QGNA&+D!8++$DS"V1R02P1R_$L5Q#L9U0HY'X22RY\ _7
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M997MCCC8U%5SWO>K6,:U$55<Y41$3RJHG7(#,0JJ68\!5!+$^@ '))] *X)
M!)( 'DDX ^Y-8%[@-!)9<&<PU^#Y  RVW-XSVPN0T=9<ALLJ32SYVPCI+0%\
M!#IHRP[%P\X\D*++'(QLD:>MJ)UONGK?9KVC/?Z=+<V*ZI8M>6\T#F*6V%S&
M9XY%9<,C1A@P/PL"03C-:S5)@VF7XMKI8IS9W/8ECE0.DO:?MLC!OA8/C##E
M3R,D8J(7#!7*':=P])Q;SUW;<-[GE!TES<U^\YFY0M0[L&.V $BK!2*G2SS7
M=]4U%I 27%Z[@%Q\)#PQW@,8QS9?K$>E]7ZP-5Z?Z0UZRTM1%!)8Z'I,3V\I
M@E=I66:U46UO/-$RQMB&3MLH9A(<AM':376AV;6>IZ[I<MV2\B3ZE?LDJ"1%
M"J4F/<DCC8;U^,!MS ;1S45NRS3,SUSR#E3=/C6Z+E3>\:!GZO*D6.)-Y&?'
MR?KUU-GQZVI%D>\&VK+;[E[$>C%M:K.W,1 !$GH0EL[]H%B]Q::-?1V-][MH
M^CZFZ6UU'%>PZ:QTFS-G%J@F< R12Q",%[=XIKB%DD !V&"=&ZA$MYKEDU];
M-+J&M6NUH998);J$WLB3M8F/_P )E+$[)(S'"^X $$FG[[]3#BPK6\@\3Y'B
MKDJVDIK33X>70:KG[=T Q98!!M 3814XI.GEF#4R&62$<LP:8D7T)-]/)*^.
M+C1_95K#VNG:O=ZSI4 ECM+X6UKTYI]PRHZI<+&9REKM?:0N]$95<$J6 &>_
M6>O=-M);JRATS49RIF@[LVL742[ES'N[1EE#C=SL9@6& <$XJG\&<TR</\?V
MN?FS4F@%M#6VD%JWEO?X&(&>7.T]$X>2CSL%A6V2*M(PV.:-:\J9")!972>R
MPAVXZEZ4.OZM'>1WRVC11B%X6T73M29UCN)IMRW%SLFB.)MA4]Q5*AUQN*U$
MNG^LDT+2A9S6$ESF:21)(]4N;()W@HVO%&>W($92=RA"P)##@&K;X\[K*OMR
MX_/JURA6Y'(LX+&$P/F'>\<S1/%S6>S\@K\[0BV(DSG.H5.^X/>PB1IJ#3HY
M!8YY<C7.AYNI]3CN5OH]/*0"!HY-$T[4PP]XN)PZW-PT;KQ<",Q?$JE-RXWE
M1QT]UK%HUB]HUE->E[J6=6BU2[LB@D6-.VT$0(+!HR>YP6!"_P (SM*[2^9
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M/U(^WVR36JZ-UW3- U>34;VTN)D%O+%;"#M/)!([)\961XD;=%W(RP8,-QP
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MDY*#867H80206V,>G N;."O#D;4NMD,?4(KL_)GVDM6HDK9HU6614]9,DZK
M[)]U2:V$Z22"7R%5QM)WD;=@Y(4;<Y)!P21P150W756M0]1Q6LJ72VTENEPN
MK0W5R(XY/<O?!.;< Z>VG]S_ (,VQ7XCR9BY:,[/LO9$7&;H;8N%!BK.GK;
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M3CZGDY\CT^_0\JR2+M.50GXB/)W Y'!P 2 ..<DXQQ6W+]*<]Y';[V^L7SZ
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MB.<B.1!-Y:)_,YJ>$5$B3RY$\(J>43\=>Y+<]SI?3SZR:-;'@'_Q-/0XV_\
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M-99Y;1^S).ADC#&(([129BAUFKZ7<R7+3Z=JD5O,;#W>*X]R69H9F8NS;99
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M*%!V*+N*W$G/!*+/"L<9.TL&C+*#N ZMQ(\?)4 L5:3- X[+.>;%()],(O\
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MV]ZGM851%L+N&^5],G%N"\=O<W$$0FN;;X0VP=R)"Q07S@>UB3+;(J]*3/#
M$6 U@7-5E79MI:H$:EB+6MAM'_0T-;)8-B+,AKW3OF2-HK'LCC@DAZY9;F8(
MDCKVXR"-N0S8R 3QC//)'GQCFMQHWL_M],U.>]6*T@2>=)YW@GO+B:X$4HGC
MMU2Y_<V-LTX6:6.#>6P(E946,QS3Z59=.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI
M3I2G2E.E*=*4Z4ITI3I2G2E.E*=*50])1!:>AN,Y9,?)77M784Y[8W-9(H=D
M),&3[;G->ULGM3.5CU8[T/1'>E?'7;!,]M/!<Q8$MO-%-&2,@/$ZNN?F,J,C
MU'!XK%O;2&_L[JQN 6M[RVGM9U& 3%/&T3@$@X;:QVG! /./%08VW8MF7#94
MCCF2$.ZSM0-23D:0Z98+"$,6,6.U?%6U[AV7Q36(TX] VK-#&/!$T>.%K4F-
MGUC.;F\EU)#(EU*TRBWC3,;.X9HE,DF[L*!A$+$J23G/-59JWLLLS:Z;'H;I
M%-8P1VTC7TTF+A(U 6X/8A91=LPS+)VP'0!%V '-9_[E5),!1HM\57VB4EK'
MI#(7?7K+HC:D06N,IOJ&#QP5E/80SF1!D0>LILJI*]DLLDK-%?ZQ)?7$LK1J
M%)VQ *%80JS[0YR^7*/@MD^%Q^$5W+[+K,P6(]Z>"=;2X%_(A,W<OY;>..":
MW+",+!:S!W2-XP9%.&*EB1C')=G]Z+)=8FR>0%3W1%N1=:[Z8-RVZER>W/*.
M (>D0,YXCEC%B8_VP51))(R%B>V3JEU.XDDCG>XFDEA"]IFD??'CPJMG< OR
M&1\@!6IT[V=WB-<Z;<22I!<-.]SJA2,M<[F*EXX8[G%N\D9/:56VP'!VMMPV
M9+CLBXY4DH[#W6IX^/*CSP\DE-9/*%>%11',G%)')D;-9)>S%#F7$EH4:X@P
M"&9B1K,8A/?==0:A?6EM9W9CFCMI9Y49EQ(6G*DY(.W;'M(B 0%0[#U.)!=^
MRW1&GENM+N]0T>XF%@C-;3&2(PV22HT4D;L#/[V722Y:XDE+2PHZ!"TF_I77
M9[/?CS#V&]/^E%D+(JZB =6T\]@P(P>FM;2&2=SXR0); M\L0"-0B.962SRH
MR-K->ER$QA,\Y). 1SR >>/OZ\U\7?LY:]B>*?6)Q&ADD@M40^Z27"Q3):W$
M\;2$K)"T\I;L%"ZMAG8!57,6BX#SMWPA9<.MA!;$9FUKA[&81)(1-#".Z0/0
M(,CT?[L-RY;-6ME]Q7O>WW%1R^<O3=6GTW5+74D+GW>96>-&"F2 L.[!N((Q
M)'E#D8YSY J8KH%K'T^F@QK&(H[00H_;(47(7<;K9NR':XS.0&_$Q&2"<P2W
MO9_RS@ JBMXPU.MTN3/JX6Z?%5IHE53)I(J'/TMG=30/L82+<6^^T)/!7EPD
M,J5@]*2R+-_+8&F=6Z1?7,]QK$%K:W22GW2[E1II?=GFN)4B5Q$1$\ D 9T9
M>YG\..!#]4Z9UFTMX;?2[BYN;22("ZM(G6"(3I#;PM(5:7,RS=K*JT;"(+R=
MQW&;/;WPJ?Q?@R:C07]E>V&B]!A(<\LT F:%+K18YLW4Q,.+CAC%-6P((.$?
M XTPN0GVXT9$B0GJ+64U;4?>(+>*&.$E$=0&>X*.P%Q,QC0N70(%5E.U %Y\
MU,>G]+ETO3%M9[B29Y<2,C$A;8O& T$0#-M".7+%"H9V+8'%1?M_T\'G1656
MG,>HM:K2MN@="7H8'&7\=-:AO#^@#L8S_78Q^RYPLT5H](I!GJU_N1(HSI5;
M^T-H41CI%NDUJ89+18'1;?OQ.)!(\9A C(=0ZF-20V>0=K+&INA&:821:M<8
MD:4322J[W C==@5)>Z3(=A*$RG&,'!QMK$NX_2].B:,G&>PJ7#US*F"O"UCC
MQGL2"E&#MSIBZX6QCD,/M&%G0QH$V((4IP<,GA%<[=Z7[4XTW?M6RG+/W6>6
MS[399IGDB0)(\3!(XRB']XVYT#D XKX?H3L2,]E<1,H$:QK<!@X^ "9F=5<9
MDDW/\*KM4B,9&<[$N N <CP/@%QU(.X@BXG9<Z\XN9#5N="34U]98RM=)!#X
MK$B C' #="UD C4:YKI))G.KCJ'J"]ZAU(WURVU8@8;*- $[%LLTLL0PI/[[
M,A:63<2S\YP% FNFZ;!IMKV(UR9"))V8[NY*8T1SD@?!A $7&%7@"H^D_IK]
ML+3 %I<]HL_2Q%FEVV>KM9>25]VXQK?3%(38%F6]1&+(QDD'\/V-4YJHOA4?
MZ9&R1/:=U6(I5EN;:YE9(TBN9;.W$L 3@E5C2.&8LI.[WB.;)^8RIU9Z4T<,
MACBEB169FB2>38V[' +,SQ@$ CM,GY'!&:N#^U?BKM[U/(FFXTK3:A>1HL:-
M8U4I49%75"XFDDI:Z"H:Z%#6J=[Y-E;D6!AY1]F1(2^=J*C.M!KG56K]16VF
MVVJ2QS#3#>M%,$VS2O?3":0S$-VSV]JQ0K%'$J1 +@\UL[#2;+3)+B2TC,?O
M(@5DW95%@0HH3(W?$69W+,Q+L3QQ4D^HY6RITI3I2N%1%\>4\^/E.E*>EOGS
MX3RG_P#?_NO2F / Q7"L:JJJM157\_\ 'X\?\OCI2OTB(B>$^$3I2G2E.E*=
M*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I
M2J9;4U3>A2UUU6A6@$RHLHAXT14#W-7RUZQS,>WUL7Y8]$]3%^6JB]<$ C!
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M080.^R_$]\+R:#?BC-E4P24(*\*(LZ(LPKFE7SW:Z?F:/9YS&Y<S>UF9DL.
M+:D@Q7&]OKA^0[E>>J9G)55J]=1U!R\?U>2Q-;4W+Y9S\\)8UUU=3FS6];6F
M5\"E6'B^4N[;:V64SJVFTH5TYW'3>1M#8<%K2.X?U%P)R@5R!@,M+H\_#3ZG
M/429_*B@;,V#2"!S&@&DZ"YBTX%?$I5K"=P/>7+1_7ET.NBWT&:#8'Q]%P;<
MQ9N[H&]OQ>JM^4RM7-3RQU>M$YEBGS W'Z7D?J8 !0-RII6D!NFJ5LYXL%UP
MG'V3CWFB(U6NEIA3;Z[*HZ[-S$6-@BG3#_9*N <2NBK?J&UL$"1J1[(C'FRS
MF/GF>I60.E*=*52[I)5J;-($D=,ZN.2%L/J6995&D]M(D9_.LBN^&>C^;U*B
M)\JG2E:@JNN[JZG']JA>G6RT[(^WO*AV--38#D:HO**\(Y@[/&6$')Q9VOT*
MVNP#S#=B4XHFLS9@T55M+"<)U>RV%%?H4JE9;E;N)YOU_'&2AY#W-=:CW/!&
M^V!8'#JY]G&%IL*[N/K-Q251)M+%3;SCP!^4S]50:NU9J,R1:.&LUO+Z<F$0
M=3]?Y_K\Q4D]%S[W)X;@/+<O:OCJO<F2 XYL]A7BG.@V/)JZ."')Z>DCP)^9
MKY,%;5&DO@-6%"'H+@BS@H9J:(,=MHV%BE8!U7*'?#Q[934U91?6V<N@M2;K
M418+<V-#MMW5\=]OD U($#FN,N2Y <A>7=OR HL@#L0,2E42T?;5Q>:N6'/U
M^OT:?:JL[0\_IH<9C;*?E:AIHNX[+7=525O&6JOPMIG3^]/DHS:&ZCD*.FGD
MR&=R>"K,<570&VM%3D8ZQBEE'NZ>]!^V*5>O<-R=W'\>;[D(SC&EU#J;^.Z!
MT$=+QUI=4=K:P'A[,&LKL\6S([+.RSS:22QKUJR5PHFA,'?5,Y)R=L'(MF_7
M^7\_R_TI70.Y)[C=9K!J6P!Y$) CY2J;'6YJ+BFZRP'&X.2[J^+JK"@YW9CU
MHT.]J=QQ(1K-'K2H[S25K *>:TF*H*>62NG4K!3N9>[KD"KB,OAN8ZJHJ[;,
M7PXHG$&JIK&R)V7#7<O7V6"U%.'QG1.CIZ[:5/%U=9U@%GNA\==Z,$HSE"PL
MHZXRD4K+2\S=WH]?95])7:T;30U&OK9\@5PG;E9WCZDIA,O!QEMZ;7&5,*;B
MZU[2Y";K,OO+I\4MC;A)7T,^'MGS/U^OUZ4J?W MER,70;2KY,-L+BWRG)^S
MR])I+/.C9@S49*O($GSUY*!7A@5)"RC&O"^YTX8U=8*"I$43)'3-12LY=*4Z
M4ITI3I2N%\^%\?GQ_P /[?/Q\_CYZ4K6Q .+!S/LY.2,SS_;\RNY^"DXOM\8
M#R6F0$X>F'I&T"P:*#Z?B*OX]KZ-;Q.3J*X/BM;2[BM?-<?I[#(OG?K]?>E8
M.QW+/=WE^/,_1UX6]'U=#QM05-7DK_A+7:6M=G(.V"'5D\KWNM92D75QMJKF
MULF2+P8]O)<VB"-H(\:==6<%LY2NU+W#][#JCC?[9F[N.68W8PFW=]QSL)Q-
MS=UVSRH5#1/7,\"%6,>7GSEO8L'O+3%\&&7+AK*VB-&"RAQ%HI4B.WG4\O:S
MG[16?(1V^D8)Q?HPK3.7/&=UB\3A]3'RN3")F,SI)ZFNI=^J9@*O*%O(#KPX
MBO=]Y9:NK+X0"O4J/V=[E.[FIQ9]UI*ZVMKPC<T7&E2RWXT.RE.=I^7<Y;46
M!L:>'09# :9X6)Y7%R@VVSD]#;MS6<UI[B-]N6UC; -2NSKN2.ZP[3;C*6MM
MR>M'D>8>(CP]-AN*;NO@;D*#N.X\I+P0J-_'E>?/#;X2PL[^X'SMKRIG=7FJ
M>WO9;')YY3LD6I7WXMY@[Y>0)JJCU,9V#)O]9@@]/9@\7Z VPXTFM,]R_:;C
M,!KL.*,CDRZFK,S&+JJ^WCM>2651QPI9FPT0&KI('J5+7M0U?/&A"+_[;B;(
MXRTXQX5WXSS\&S#QT.GW=7JG[G""CQ#0.G9DRZ*H?*+9RE:&KEN'16Y'HG"B
MC4J8?2E.E*=*4Z4ITI6(^?XKJ?@CFN#-Q6LVBFXEY&AH(:)A<MW+=RX^X951
MT\=>BGR6CSW#MKXPD4MY:Q-&19E8G2E:\]J_NJR6KR-X="/O9P>,.&Y*X7-X
MG=93-"68O(CB+@77$6>UU0274(,<,EW;DE5$-=4^\3:A($CI(U*L/+\F=Q?,
M^RQH&=Y0Y$>_%VE+H+35/X-3(ET=AJ>V?EF^N<W:9>XSXE3:YV39PYVLSUM<
M5QXSI"0P*FSM;I!K\A2I9<J<P<ZYWCSMUTE#7PA:GFBFI.-[_,$9]&DX[ECD
MO+U-IFMH6!8I]R'HN.[>KTHVHSQ,;_6+9PR6'MK4RO52HU5G*W>'7;^FPXV2
ML*[%$:*[%C@L,9OGNUM-?<U<QUNNNIK8#C#4B5%AG<97YN\SD)W(/'P,'NU-
MC*/?TFJJAA%/U\_7Z?H>M=/B3D7FFENNV\GF$WEG/9KBRA@L-AER.*=I+1!X
M&C[._KY-]K]^+0%E7>E.WYU]5GY6SM"['^(0AZ\?.BWE).58J5)?NG,YNK>0
M*+?<,66J';B.V/N)V"5%3D)M72;O5T^DX,ML;@;,&8,F*&TU,0EX-6MK&0["
M0&.ZCSQ Z)9*JE1K_P"WOGC*:*KR5C8Z;&1F<ST>9H<FWBNSNP-KFN1^YWE?
M.:&QT6QL*TZ;#'#XP#/EXV*:WI&609<=C3!W@UO7_9WZ_P!Z5G'MVTO/^%X5
MT-7R-:Z&[GQW:5P]R+F;[7XS[#85&XM,;R#'JL,>2\0?[X5D9\9ER[2&\>7J
M!B;V9V@)D;8!,:I6*JKN;[C:S+V>C^GY+Y!RA?'^E(RVL;VWZZMT%CRV?P_3
MZC/Y.'%4^12U7-56T:>!5Z0FJ;2'F64F5M-%9&TJFE/T/O\ KZ4JD\K77=IH
M,]HM#/<\EUKY)>60Z$3&<9&!7>(H<@'B#13JQU93E6N@L=O'/?"CJ<&<\H4+
MZ+*BLLF%SSJ5,3@7DKES<<M<KXS6K$_)\.&'4:Z-M0* N]LM[:LV^"?$R.*!
M]87@.*)L]5:D1L JV.BT\LY L#J^.%JE3&Z4ITI3I2G2E.E*Q7SB=65G$'(Y
MUS#R$35C9*X><)Q./=$\E&CJ*]L@.(BSC'WO\1FH[Z6MEJ_:+'GF:1&2(L2E
M0J5J--J]V128/7T;.69I0S^4-1CNWPOC/N:*QT6GO;[B):'B.;D4NUP=]GYJ
MRNIS"!-AL<\9QR-8;'D2VHT_AW,EUD2E9AP8?<,EGR0G&T6SK^57<>=Q*<CF
M\H ;UV4/Y1FYFC?P9)C"=),'D3GP\>-UL>8)R),V<KLS+C1M/&@4-4+&I4L>
M0M'SAD^#L*9;G_;MJ5HL;4\FZSCK%G;4W)9HXN1EUH*/&2!Z<FV/B<VNJK.5
ME7<!53;*STC*]]=6>U&I4&N'N5>['/Y/$TD@_)+[L:6E@ILQIN"M86+M<;?M
MU]OL^2]?HCZX>RR>FREIZHZSCN?2T9B#4=!1OJK&?>4I8RE4R3N0[Z/X(SD@
M&>O7VC+;>Q'ZNXXKVS0+^\J<GQ9;8G,A5U/V_E:>3-WEOH]T&;+9\:<=633\
M\5DH=RVPH9KR^4J7O!G+/.5KS;S7G>3ZZ_FQ.?AU=GF"!L%=U-!4CTFNDKZJ
MD'MK?$Y,VSN;#/2L)!^U7/)M9KQ*Z?5 W>4C)AS$JE6CR#'R=0<*]M%V5><B
M9#2V_-#-]R?<XS#WO(U[D!.0<MRQJ;JM/R8%1?RST6?NM)69:%UI1GU5$HM2
M1."B #Q,4J+W)'.W>SI*HW,!T/*6:,M>)[$+0LS_ !)HJ\X&W,[8[[D&+2Y4
MT/C^^>);E\DPU&4C?/R+2VE-IR[# UG'UE;UD6K12LN66Q[A^19HLX/M>5Z>
MVDY<R,4 K.WZQJ:C*X2AYPX^"RG(#=J=34P%N?M>-R+'5:3,V(U[41S'7$-C
M4Y /$VE+:OU^OU_.E3\[?[W>:+BG.V')D1+-M$;JJBXG,HWYLJSCS^POZ&JN
MYJ1T4$8#[ZFK:^Z] L,0$J'_ %%?&P&8=J*5F;I2G2E<>$_9/[)TI4,=YW;T
M&)[JL#V]3/R25^@KZH/461^D#"TU3L=X)K3N-*NHSTL[)[4"Q;@K6OT!,4$L
ME=9;#CQK7-BM9E12K*)[\*>V)XDAQ?$W)=B5R9:9NQK\[:5N6K]-H^-]CQ_R
MYJ*#8XY/XV;0-:ZYXMG LA-;<T!E?5RN/E!2,ZGF*4JF7O?SVED7M3H[*K+N
M[?&X,_=T6AEHLF1HLU'HN'DYA-H*>IL;Z'=5MS>\<"BN.L@**/(O/F"S5IJ8
M;23Z)JE7B7W^\,U6E/QN@S^^S^HJ*@D^ZSAH>..T=791\?F<H@YJ7,4.TN-&
M=;6^(%'M0#*>ILLU&;:56=LK^OTI3JB%2NB1WY\:0YNJY!;6WCL;89[0V3QA
MY\.>>PRIWW'^&AGDUU=R"3QE7T49.Y'GLK*QU4-<#$CG'VU<57DU\RE3+Q.K
MJ]YD<ULZ>$B&JU%+6WM?":T5"XA+,6(R",CZ(DT)9F1RM;(X,TL1[D5PQ1$*
MLE>I5T]*4Z4ITI3I2L/\F\U8_BF0^+3CW$RUW%7)O,!'VL,<I%RG$TN0AT\,
M?OF"^JWE?M:?[2&[TP%HPU9BQ?8C292HFY_N4[><'8<AUW%?&M?@#,_RKG\K
MR(ZOQ^-J)[\P[376>+.DI\QHX-& 6X@"P)HS-W44B6(!X][4 VM0>I2J56+7
MO!X9V==4PW_"W)&DO:N&HY8H,+=8_"V>B%S-=DF[ZHY=K8CMA-0@C5=21_X)
MGWD?=!WDC*H?.LLI8HWJ5F7<]SN/Q%)A+]V/Y U 6\XZTO+ [,M4T91-!@<?
M7Y&TTE[H(K715#8UK0=I3R)6U,EO:GRH2)6A&%,@A(4JQB^]KCV!ET0)Q[RO
M;@TC^5SY;"LH\K*.?C>#KZ#,\J<@UD1&Q&.*S&6O#*^N8,X2+5Z(@Z%,MF;M
ML!SA%*ZIO?3Q>((:?_!7*1-=-:ZFCQ=@)19R0?DNVQO+>:X4T(6*1VLCG]P3
M<:Z@A@?J(<S#85Q)1U?(2VKLXQ%*MZK[^^*1;RHQFQ'MJG97&JMZ(JG]&7 *
MRL4O+^OXAR@MU7F;8BQO;$W2Y"QJK6? 1:X*OD!*T%HVDSDPQ72E?G']_>!.
MK>(8]WC-/BM)RS5UAP54^SPMFRL)O;#2!40BBP[%FHNA[%<Y(Y]SG\S:4]2^
MPKH=";2D2SP#*5DGCON^X^Y$,R=/#D>0LMHMRF&/R&:UE3GA;F]RG(6>VFJS
MFX%BJ=-<B0YI:#CW7G62FEBW56^H<";316)8(A2E2R\(GX3QTI3I2G2E?E_E
M&KX_/Q_7Q_5/Z]*5KBIN^&RR=KL)>>:G.X6MI:6QN1<FVOUN<VXA"<@9O!9J
MNKK?;PUG'G*%-HR]92N(W^0TE1ELL:8"/?I  ?%;0*558OU#N*E).NI1YTQ[
MZ3%"4$/W3(!WMCR'?[3FS,W^:GO;/8A<91UM-7\/FW0FA;M?L5F(Z>2MN;!2
MZJ A2JQIN^W(OXQV/)?&/&O(_(]-E<0_3SW85?0UN6!T#\$/R*-C-)9&Z!EM
M46,6;-KRK*U@I#\V.28)3CWA=Z8'63J5=HG>)QW5%7-5MH+>DN@].M+65_VL
M5C[*%W)5CQP;"$]EX=!8F80L."UY!+$G97U=$>'<!(3 1[$:E5_A;NZX?YYH
M]K?8\XBOKL+14^JO"KTS,_20930@6MI3:&>PSN@T5?5C$!T5K*?4W959I\_]
M&]NAH:IT@Z3*58G9]W8R=PF/WMYLQ<SD=!B;=LIV7#(+&O*?)%4-=:B6^BH+
M4@B\KQELET-92WQ@]:)N*FE@V-+4@5-P' BE6BWOK[7MKG@^3K'+WMT!@;[*
ME4MPN:RFSLLT=R=3Z.OX]NZQV8T&EGH++>FUIF" K97UVPK-!>5-1K*7/AW4
M!;WZ_E2LBG]['&U(1:P:/%<G9V(&XT61JC+&CSLX^LWV7/HZFSP&;;4ZJR+G
MT3[30UU=7SV8U7G;$I#6"7LC:XYXZE?%W>[QW!>%9PS <K!7&?.# Y$%FI,K
M(WC&8[7U>)A?K"1=B0.="^TO:,N*3%2ZWZFDM(;81)Q1;%0N,C]??'^=*H5/
M^H3P?I[*6FQ]5M=C=DWE719:HS4>)L#M@^WO;'."'5S';>!F<#;;5WHGAY"D
MQ=I" :#<.KOM,DQL'-*ZX'?#37.FAC%Q6DJ\0ZNQUS!>V0M<3;7 ^CXFYLY,
MM:2&E!T"$4M[0.XB)JY)CF&UIA<5D-#(D$]9;/4J]N(.[/.<X\@T^7Q-=+#4
MNI.6W:6>QLLW:FUNEXZ*X&EKPJVUP^FUN/MZNUHN:8;&<VNO3WCDBQ5\Z"'#
MV(D:E2_Z4ITI1?PO^7_7]4_YI_GTI6MDOO.VH?.QW&J5>4.JQ>;S.+V9V/)<
MF@Z1V0IJ6IO=9R)%R03 1Q<;_!M/8%:&WR\3XK62JKI!89&V,XK)5*OJT[SZ
MVSEX[K<KQ'R->%[S0Y>-<I95>7$T6BXRW_%O,VYR.YRT9&RBSZA7!/%!@QE=
MK;FAN:RO0]MO2!'S5L!"E<X7N/[8./\ CW^(.,./R\OC;?4&UZU>$XYK:::R
MOA>W)O<=,2[.U#A"IR5XU"AJ8TD%4YFA&@H5@B!A8<Q2JQQOW!X7GOE?C=*7
MBQ; ./CC?;W-<DVQ?'-_/D[.NU57@KBEI;',:C4CHZZ"-]9MMF+4X.8682M+
MF;/'9C *56'=WN;F;0R5'$?-%\/MM6_*<<&5>>R2 \C2P ;FT-M\V98[8 <.
MJ!K./=!93MU4F;MI:Q]58AU905F-.JE=1G>7Q=H@ZF#*XWD+D$O19RIO8LY0
M4&?>?&%8Y"3;:"JM8M#I*6N#N<3G)J2384A9C2QS=5G:>KBN+0Z8,52J7)WW
M<0LIKG4Q9CDDK%UXMX^EV V=IWU&TM<_CJS>FY[*"/T<=_/<29*S;:@K;4M/
M6%J!:5\5DMF#*%TI6/;;NY[52N2+:[U?%A3.6N+\]I)EL[',\9WW(-%9XS-K
MI]3B0I:?676DJ+//UMK:Q37!;:[!/+@T(]=L"&QDR3*5=LO?SV[6Q&,R]JRP
MD_[2J^K0BO+*X]M0Z^HV&UNN,Z-]BRNVUF/L*S0Z.EMPU?QRF\&#J()+B^6L
MIWM*<I5PXOO.XIO:#)D08OD/)0:RIX[LN.\]<YZ@'M-9E-Y:VU)2W6:JJ/26
MR?:J$2A.N]&(4H%E0YN,8^2M<A0L$JE8PN/U#L;8@++@,7?VDE>=K0M02;98
M2S&R8=-PGN>8*B\GCR6[N [B V#&E!6&>%NPM-4_1VPUE7U]K'6AV"E7P'W6
M\*<=C:62LXUUU)76NKV1 ]MF<?FPJSE7D:HWU!Q_R,F?@&OX+0[2";6^&%L;
M+6 4B7\0-D?3V5T)6RSHI4N,/K8]MG ]"VDNLY+.3;@&4.A;5MN:BSH;FPH+
M:OL%I+2ZJ))A;.L+A2>LMK$$B-C"!2YH96/52KMZ4ITI3I2G2E?ER>4_U3_U
M7Q\]*5%;*=RD17#?'/(^AREK::;DS6V>)R^&PT0)=E=:(.WU\4(5?/I+:CJ!
M(V9_'VM[8G7EW6@"CA%(A'K4:"52K0;WX\->7'347(8N5 &KW:+;$Y^JCS^3
MM[/-:;2P9R]'2_?I/O<,.0T-4>RIH+4"NN HQ3;"& X HE2KHL>Z49_$G.W(
M5;QCO*V^X/QQFJLL+LF9JEL[5JX;^/:5HUA4:/05# ;"FE&D+F^O4ZN>I84]
M>MH), BE667W^\*U]WK,T55Z^2_QP5O]PJ*]N*M;4S0YN>F!TN1!IZW:%W$%
MU3V-RVO:7< 56:NB:^U_AO07,(B32J5]K#OGQ-03:#6G$7-@+Z(;:EW4DE+@
MI8*N#C*#.E\G/GE%Y#(;*S"":FGELWB?4LN99" <B[1V 9(L:E99Y%[D,/QO
MR7Q[Q5<56A,TG),+)J @-,V%5O\ >M(:> :.?1:.B+O3W&D1R&5>1"T=G2UK
MFW5Z'5T\L)\BE8+PO?MB[S!9O9Z[CS?9J$RGRL^O,#&SMWG<1I-S7EVN-RA]
MB/HF61]CJ (ZV>N,JJ8RM!^_T$&E+SYA[Q!E*K-AWZ\34+<R_79/D'&MTV.,
MW0\&ACP#+<//0Y[4ZNO)ES%;OK+4V*W&?R91XKL[270U=-94]7H2:6X)G %4
MKX:WO]XBP##1M[E.0<5I*JZO*JVQVDCX_KKX 7-9#";>[NX9W[]V=N@A:+DG
M(.%J\Y?7&JN#;*0"DSMB0":R!2IO F"V @QP4C9A#!X"Q9FHJ-F&)B9-!*U'
M(CO3)&]KFHY$5$7Y1%^.E*[?2E.E*X5/**G[_MTI6);K@_C&^K]G7VF989#O
M]C0<@:F9UC;L//V&57)+F;P>RAL(K"J)H'87)NJ(ZDH$8%],/)!"Q\A+IE*Q
M5PWV=\1\1TG'X\85KJ-9Q_69L*OVM]H=4;8+-F\OKLH']MK[/0V86=HVU^_V
MLH^0J$AS0)>B,,&KT+B#)@4JJKV>=OBUT]*S%'PT)>33%G9X?;[T;.V5.S!R
M\81$6E /IXZ>RT(^ E7+#ZPX*?3P5<(<<5NR4 &4=2KGO>V[B'2:*WT]MGK.
M6RT 2AWHPNQVE90W,G\)38.*VL\Q6:$/.F:,7'3KG@M//6/T 5?"$P6RA?7@
MO'4JB#]IW" @\L8^?T<1\Y5@>1I&<C<CMV9-E:V63M3K0C:)J_XIGLY2<+DX
M4/EMG%1UM-!3Q2LJ9B0IE/U_E_L/Y"LSXK&9KCO*46)QU7'39C-U\-935D4Q
M)*"AP(OI:\HV<DTN:1[GS$%F$3EE3R23DS2S2/D<I5T=*4Z4ITI3I2L.\M<"
M\7\WP!C<CTEE;1!5&DSS?M6KUV2E*SNOBKHM/G;2?(WE'/;T%Y]GJ9;&EM)"
MZT@FKKR7#?4"0R,4JU">T[@DVVLKL_('6-C9G-/=+9[';6,-;(FB(UTHN>#,
MT<PF:JRM*5+<F5%#!759AJ0O)$E8,,R%2L:<U]F>%W]/7CY6XCXTL!\^'B"[
MUK=+9&38X/(V>'JZ0(ZMW&2MZ^0&HMR(F,=<F4>@D6*':Y[600APC/U_M2JY
MRGP'PX=5X&VY(TM@!QYP?Q3L\185[M5>9@2RRVE'P 1L^MM,Q=41)]-'68+[
M=94!T)E'>,MYT-#5XH[%4KLS<1=L_))!G'KJ>9QF7_CRTLJ0&YWV.-6HYEW>
MO=OJH\@2QHR;[#<@[+%::2QRT\]CD;@>B!)@K'TL-%,JE=;&]H?">52\LKH<
MO3V1&]VFS&-LM'I8:O+R:GFD7F\>ES&<9H9L_EX*[2TV+AL74 %4_5_PG5S7
M\!?OD#2*57LKP;V\;!,[RID:PF<?1D1[D"VIM=N*:NUWWW7V_+=>7I:2"\ #
MU 0^PU5UJZ2GU-:>%1%7!K:P $:>4=5*ZH/9;VZUQ@)H>.NX%KK*CN!@F\C<
ME+4+9YD^T/SAI5*[7.J3I:!;FP!ID-#(CK*66*A#9#3"! CJ5<5+V]Y:DY6Q
M/) \8$8O%O$[^(N,:*"L)0O.4)\]0MK-8Z(VWL"K^1H.?JZRA]X,*:E$)TBS
MEVLFAGD&4J0W2E.E*=*5PJ>4\=*5&>#M X"A4Y%R5P3$4 565PQ^_P"1+$/'
MA&:"IUD\?'(9^J)%XUD32T%#=#$X*+.D@G4E1(%- VM#9"_7Z^U*J"]JW"BC
M^VE!H&6#?M4D>GCY#Y$CVL!E+=[/0@V@^W9J6ZP>X6SY#VOUMO#<1V-E7:(^
MDL22:5T=?&I72/[0N +,>4(W&'SUQ.>=FRZIVWWJ5)XS\:7QZZXL:MFG:#8;
M)<4:3G%WAH\^T6N>UJWRRPP2Q*5<4?;UPF/;9&X(R%>=>8>RWU_E[*\M+:[L
M0;'D@5 ]^?+/<V9DUFNA@<S[G]S4R%LR0D1MA(8R5%*^^0X)XBP5!H\I2U!$
ME!KJ4/*7=3I=;I]>+/EQ:XJGKLD%'KKVZ6HS E=:%@U^=J' U(\)TK!PVNF]
M2J5T.->W;ACB:[TM[BJ<^"^U%'39S5V%[N=ILSKFBI87"9NNMW;'27RD"TH3
MIJZB29OJKJV8JO!?$&01#(I5IS=IW;='FW9^TR1&BS,8K)QJ/3;;>[.NAK*C
M-7F:JZ^JJKW2W#(J;-T>ENH<S358[ ,X;8NM*$0&Y:*;$I5L8;M!X(0#26=O
M%>[F/=G:74 IJ]-NV29VGWDU18,6HIKC1OGSFGBAHZ5L^V%#IMS.=61F&V$%
MJPE[E*R35=L/!@(ES&'EIBW:: >+1VAVKU=S<Z-PFJBVD)MY?6=\;;6UFW2#
M#%NM#3ISWCBBU+R%JA1P8E*[%)VQ<+YZU#MZO,6$9%3>AZ*@%)U^TL:?+V %
MA:VHT63H+'0E4>6J4L;JP+FHJ"OKJ4E[QF$ 20U]?&*I5%L>S_MZMAI ;'"2
MDU\M$S.35SM7LF5\U9'0<@9:-)08M P20Z+/\H[FKBM70K:1#W?^S,:^NJG@
MJ5=V"[?.+>-M"3K,M36[-,;_ !"IM]>[#8ZVU.=J@N/JZ]D,-U5]<SDRG!<6
M8,;W)7N<-#GQXP_IF$&M)4K-72E.E*=*5B.UX)XKNAR!;/*Q$QD\F!<PN>MC
M;Q$P\C *$D&C$,A/C*"DD' BKS:X2:&IL:J>PJ3P":VTLA2U*Q[%V><!C@!@
M"YO3!_:[&AL:6R!Y.Y/"T&>3+9_697-5&<T@VQBOJ#,T.?W.NK*G*5%B'FPH
M+^Q6&K:^;UM4K&G(G#/9[Q9:9-=5E]!6&7PUE4X_*Y&3FG1!3+2\6IQ;:V=;
M@^/I[< 2V!XM+'S)>M^R06T=='7O6V0X44F-2LG9WC;@+B2MCYIKX+G/LJJ'
M2VUEK=!H^13KDVKVCJ"UOR]J'I;,V[O;*7[!0OB9JP3KK/MKX@J]E8UDPW2E
M=?CGAKM\)L*[E#CRND-*I]5JB<U9SZC<6%1F-$*;R%C=0#FLY>7CZK/U:6NJ
MW81E!35M?1DEEM,'$?(!3%"*5COCW@#@,P3:<7&FDZ;=Y;D?8<F<DZ''IN^+
M6@[WFR R\T-=6WN6NA/HZXW+6U?6D8@;97LP67;FY-&R:>>L.(4JYLQV;\'T
MQNX?8UI%X)JK6]L!:!^AT@&8Q]+>46?S$M7G,H'H&YZE)CI\N)5+IZFKJ[R>
ML4BK<8@<I44ZE5:[XJ[=+;?:40QEB3L=='"9>4--M.165P9._K;( ?9#YO/7
MK,[C;S0AX*RAAY!K0*2V4NJ*<R\CL3WN.4JIU?:OP!2&5MS64%B&<%9-/,L8
MN0][[NJLX-<;LH)M]*NK<G(<P.RMK"Z!9M_O[:ZRL3&",@B+F@>I7ZU7#/;C
MF:+!FZK,4D%/PWDSN-L3+8%W)[\QE>10:WCHVD]+3"C3H+X&4"@^JLVG$Q,G
MFDB+'=.9.]2J9#V7=O$=:16/R6@*A,CK8"2+#DODZQLI0ZK':/CX*M=:G; B
MR;4QXG6W^8EJ6%,KBJ@U@Q0LWT83AU*N-.U;@U+6PN'8\F4FPL2+=!9]7L2*
M:KMC]71;BWL\]03W\E)F3M!K,U2WND*S]?6S:(X-7W+S6E&M)4K.E74 4P\H
MM=!]/!,?:VDD:/DD1QUW:&75I/YE>]Z*59'EDJQ'>W%[OM0,CA9'&U2JETI3
MI2G2E.E*X<GE/'GQTI490^T7A"K 6O$ W@M<-;.T54*G,O,2B92\6P-M)+K%
M02;Q\.'LEGLK.%YF493RNK+*SIWN=4V)H4ZE82J*SLCU65NLIEBZFIK2Q,,:
M$5< [*OK[1TS2>+>.];1,W HU-R-4&VFJ2G9;@)I,YK+B[@DT)-H3;13D*5>
M7&O W'O"F,WN)Y'V<>U@YWO*W&W[3EUD()\!''XF)KL@,E]M-[I@8R\U1FSR
M3%ZSZ89298:B.DK!:VO&4JYZ?@GMP,TFQI0QK:PN*5*F'64=ER#R3858%AJ(
MJ6Z&M_M5OIIJ)FEU"9VKLK?25T"W]X6TXFYL23+BW<<I60;C@+ARV6X^[YJ&
M9VE%Y)K[59;N[@4\?F#[)#R# WVK2'VW:+[#31^1O:DKW#-2I4)2)_>4KN[/
MAKBW?Z.@T^L GL;7-$T2 11:O1UE041FM!!J\S%?YVKN@J'3OH-()%=4D6CK
M+1:ZP;+,(V/WB&RJ5A=O;1VI4VFSO'O\/RQW!^=N+NIQTVXY$+J[&EQ!@%1)
M;V%1-HIZ(\W$OY/J*S*FW,4MOFPK2E$RKQ **L95*54.2>V3M]FI=;I+F!N6
M>WCXFG/NR]1HR<Q75.3P5[C0-!>XHZ^?C-(1DLA9VH3R]!3'SR5JRC'$/8C7
M,4JVN-NR_C8/-V<VRO;[?W6MT-GKIMA2ZSE#'ER5>EQ>%Q9^:&MTY*T.XLLC
M>9_ 9B>YI=1N-$#9GB03J..(!4 UJE39AAC'B9#"QL<43&1Q1L:C61QQM1C&
M-1$1$:QJ(UJ)\(B(B?\ %2OKTI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI
M3I2G2E0P[S.WS>]PV9RF<QI>(C#KY=>V\&VD0JM;)H,J704US5SGXCD 5L]$
M28042(-34UX=#*UE-M<O+'/*:I4<K3]/S4VV%TX)I/&9N_U]+RA6Z70V$5H>
MW1-U>(PE5DZN]M2:)]G94]'K\9%=N86-,VMD=%<U84EM(1$JE5L?LIY#3D&'
M4SA\/QM,U6>OX-7";H)=MQ8%0=TW*W/Y59QPUV2'")CTV7W=5Q]:*^PRT<40
MITA$5M41Q5)BE4>J['.1*P2B>51<$W,.49AJZVQ!I>C3(<]EY;-\K9T_E#EL
MB;&G2 [X\OD>MUL0WV7<.6\RS&'Z@R0BHM<^I5V=NG;;K^/>7\74W+BUP/#G
M#O&LYL< %@%D[[N2@XY;Q'8Z_&'V+HC;VGK^( (Z0ULX,8X5I90R/(FNH+"(
M)2MEO2E.E*=*4Z4ITI3I2G2E.E*=*5KRY@[3>0=QW"3<O59^,OZ26+)E!U.Q
MLIZ^>F9DJ+05AN#@C PE]:DXS?DVO_TE<)L::OB%N-']VQFR101G*5&PWL;Y
M;IIN/>,%JN.N4A4P7<4$5RQM)]3&_.6N_J>!:7,: ULU7IBG[+C5*6^H.( X
M[*.2?CG&5 <VESN@%+LYE*O9.PSEBTW6MN-3>\:6U!IBK,6YG\^Q9;:E*[B>
M'N60G:JMKN.:HD@P?&<?Z',FQ:39[]Q%S?ROK#Z3/'DU0BE5TGL8WP&_R=]D
MB^,J2CSEMMF@R(TB2;/XR[Y3Y=VE7D*+.&XRS@K8V9SD<.C%L,5I^.I*(D4V
M*XBY!SP='2"*5;4GZ?W)A5$W,F7/&KYFY^T$L^14,T:[?8!77#=1Q@G%&A:V
M@A6/C7,VH;M11EI=6#IGTF;B;D:FR2QMGOU^OUZ\&E; .#.(TX<"Y$H@8*&N
MS.@Y1TNRQU!FX'!569SU[7T36TL%8T0,*L<EL%;6$H=9$H#9#W3QO6:>=$?K
M_:E9RZ4ITI3I2G2E.E*=*4Z4ITI4<.:.!8^8M[P]?6=K:U^<X\7D"6WASFSV
MF$TAA&II:NMJOMMYA[.DL_IAY@IWV0DUL,-/$^%5@*>QK8U*CAR-VG\P:^ZV
ME-5W>"&P%I?<BZ?/V-I>ZTK72F[[BRBPD-3= .HB@81**RJ3#I+9E];&70IX
M\KQ*\P(A+!2J=QMVT[+*]P62@GE,?B*.'9<G<ER05Y\./TN[7DWEBVX/@I[(
MUHD=I=5-!RUHS]O .'*E=98#CA\Y*1MK'%*54^2NT7D8K8<Q[CB].*0[OETW
MDVK/=>276??'G>1^&^,L%'=6EAG\U9EW%YF=7A[J\%HIFL"L1-0<0W0U=C.6
MV52J+9=BM^\0PZH)X^&U%Q-R_-L3966L,?(U7K^6^,N0\IAMI8"U/W"PR).>
MPEIB=)$1&='3UNFL'4U5;0E'BDJ51Y>QO?%Z(R[IA.&N(ET-'](01Q>[1QG\
M?E0_]X8<(#)2&4(,MR*V/F;/7!)J&XNOCN\8D=1DZNM?4P52E=&#L T%ZEF[
M44?"]%33X/89JHXURZ7%IA*79'<8UF%I>3Q&6.6J&MU%S9BNM[Z=M(P^GCJ<
M\2):W]\.19JI7-EV1<TW'+-GNS='QJP4VQ*4FS&FF'O;ZFFO^,[ZN$N&A\=!
MW9,],F <*]VBWNQ$L#"AK&G$R @R4W2GZ_7\JVM)Y\)Y_/A//^?]>E*YZ4IT
MI3I2G2E.E*=*4Z4KX$QRRCS10R-BEDBD9'*Z-LS8WO8K6/=$]4;*C'*CEC<J
M->B*U51%^5*U9C=E7+D^?NL\>G% = *-Q^57\?0:[D/4<8[778;EW \BMT\.
M4VE!;"<!UAU)D;[,+B..8]10+_&<TIGU@^;JHRGZ_7Z_SX5:@?8?S)'JK757
MH7 VP@,TF7O[3&W!)5?EMV3E]SL=0TO0PTW$@KAY#PM:Z 6/2P\EV]<:$_[I
MJ=,(<K!E*^-U^GCRP105P#=KC-,P0,$.?+7)I=?FI7OPIN6@,B)ML'OGPIQW
M*4ZLPS(J6*WES$Y;1]!D[98"(U*S'W']NG(/)%]P9CJ7.Y/9#T7 G,^!N=WR
M 1=?;\;I;\?AZEHM_4RCUVA/*WH*U=Y?YN DBM,*E!L/1K:8O_Q[E*MW6]B-
M\73V+*2NXET&BU-UW/3Z6WV,=L+(-9\X\B1:;!\OA&5F?.-M.2N*,T&RCJ@)
M5I?IVW%H'F]GGA(WSV:E=)_9)RH#M':VJFXG(N<[)KK<'=&V&C!W/+]S;=RO
M#W<%G0^4Y@\J3#3!4=;QM8<=P6=>?KYP@; 2PKJH>MC3-B*5^9>R/D^[KMQ!
MM ^$=;9\F4G+P4EE=DZBV_[&K#D'DWGCD".3C5I69CGN([^OY<I<SK)RB,CZ
M(\G$7.#J07"THZE;(^/Z4O.83&9X^MI*8ZBRU#3EU.:EDGSM:36U8H<P5'-+
M6TTDM2-)"Z("22IK7N%;$K@15586*5=_2E.E*=*4Z4ITI3I2G2E.E*=*4Z4I
MTI3I2G2E.E*=*4Z4ITI3I2G2E.E*^+/\2?Z_\EZ4K[=*4Z4ITI3I2G2E.E*=
M*4Z4ITI3I2OP[_''_F[_ /:O2E?OI2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4IT
MI3I2G2E?-O\ C=_K_P TZ4KZ=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*
F4Z4ITI3I2G2E?A?\;?\ +_WZ4K]]*4Z4ITI3I2G2E.E*=*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g111280g36z36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g36z36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1MJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &TZ^:9 X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   ('_P X
M0DE-!"4      ! Q+*[R5]Q_=*V\,9$F4UT^.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             Z@   =D          $                          0
M           '9    Z@                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   Z@     4F=H=&QO;F<   =D    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   .H
M     %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      0O@    $   "@    3P   >
M )0@   0H@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 3P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MU'J6/]8'58^9D45BBHBNJU[&R39N=LK<UNY8U'5^H$/^T=3S6Z-],MOM/?\
M2& _W;6?0:NUZ_\ 4L]9ZD<\9IQYK97Z?I!_T"\[MWJ5_OK._P#&T=_Y9_\
M@ _]+*_CS8!CB)$ @"_3_P"@L)C/B)#@6=2R*_I=9ZB"8+??;!:1_.>][-R9
M_5K9!9UCJ&TN:'$VV>UONW[?=^E=I[?YO_B_]%U#/J+GL$-ZP8   .."! #!
MM_3>WVM4Q]2>I"8ZQSR3C-DQ_P!=1]_#^\/L_P#7:N&7;^7^,\I^UKVEI/5N
MHEI)W?I; 8AS6E@W[7?I?3=]/_25?\(G'4\DL#_VOU'8TQ9:'VN;)G;KN;LW
M?N+IV_4+,:26]5#7.GWC&:'>YS[#M=ZOM]]MB3OJ'E&\WCJ;6O(;(&,"WV M
M:=K[G_ON2]_#^\/L_P#7:N&7;^7^,\N>KV![8ZOU![2X;V^M8TAL.+VM.YVY
MV[TV[_\ P)*_JV55+&]1ZCZFW46W6L(=+.&;O]'ZOT_\+_P:ZEWU%SWMVNZP
M3JTS]G;,M(>SW>M^:]J=GU'SZV!E?5FL8)VM;BL@3SL_2I>_A[C[)?\ JM7#
M+^7_ *,\L.K/).[K&>V3 #;;7!HD>Z7N:^SV_2]BC7U/.L]$#JN?O?M%M;;;
M7$>W=8^N';G-W_R'KK!]2>HAS7#J^K(V_JS8&WZ/^%_U_P Q"_\ &_R2QM9Z
MJ',8'!K'8S2(=.^1ZONW;DO?P_O#[#_ZK5PR[?R_QGF:^K7.:-_5^H @$N#;
M+23_ .".KK]O\O\ XQ,>K91C;U;.W;H>P76[&MGZ?JO=ZG_@?_J3J_\ F1U'
M_P N-(B/LS8_S?5_U_XM+_F1U&"W]KR"9/ZLW7_P5+W\/<?8?_5:N&7\O_1G
ME!U>\6 ?M?J%C"TZBVP.W0W9L;O_ 'MZD>JY7J$5Y_4GU,<TVO\ 6MWAGO\
M5;LW;&^I%7H>I_UQ=0/J-GASWCJ_NL#0X_9F'1I+F;?TOLT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MX0HE,W1W@;89)C0UI['11$9'4E-55G-UA8>TQ__$ !T! 0 " P$! 0$
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M34;$6)R-NNTKR5Z5\Q:&8W:"?DD^V*SR)6K22N.CZ\N-LQ1D9\ISC 9)H!E
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M*S%'!5*M.<,C2NL\F.&**O)N:=Y\=+;(8YXF>$P.1F(FVD[Q"(BQ,^CR2-(
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M9^M)8AJY"SQ->XCP&0@<I#QUHFA>C/)NC%V+6.2&W"+2!)5EDBW&QNS;39,
MFJ2<LI(8Z,5*W"6@M/$+ES!%V)^UG$HR?:0RB)LPN+.IY=W?(1(!_9[-*&+2
M@ANZ.VE<W?&B2>S, LE!8/%I6W2%21R(D3U;0RA,G<2/,AB&A(5LL$3>K$='
M#-L@MH83@6: ^%VS<&+O0X7A/)86R#[IV\/NV:?Z6L,M>-GA.B-R"24GBE9I
MGC:-Q,B;+:RPR-?\%>Q 5K(PVP?R0=HHHYM!-P,FWM*41B+;A\G<[L[,SZR]
MD;?JVYYQ#+GB\<*0^R)4/9E.P<;;"A[2$N[-8/\ 74K-Z_7;%W#C1C/V^FLA
M-Q]Z+%Z Y*J0U9NR;1_HJUZ7AO$97#4KV&M6(;>-JRE%P]9*:0[HXN2/6*CD
M!*$1WX\G>M!/'+,\]88G,(C!Q?1NV8;,T5H(SCGD%BMAM!HGL"_E2P;2UVS,
MW,,#86"1WT=VT=1+M=:D=O'LC=-O1)L59QFQ+"D4K!-3K=LT,MQI=[NX;)$V
MK)X0:(/-$\ZX62;OG:6NWCC1??'V\V^%,79PG#>%Q-PHBM8_'P59R@,CA>2,
M=">,S",B#7L<HP=_.++QD+ 6[MJS&Q#'/-)((FS,3,9:MN9G=F?TLQ.W7]9^
MU7CFSNLUZUQ30CL%(;>K6Q*-A2=6(2&MH)%[%!6/6 <X8/Q)FZ8FYW WD2FH
M#61$X_\ $O,?#$Q;86[71:ND5D<T;XSB?!9',S</5L/D\=G+KY0J^2OVL=8Q
MV3F@B@MF,D%"\%NE.]>*PT>D$\4I2@+D#B0[7/HVX:HW#M0358G@YD$,<XS0
MB9G&SL<\!1RBTA!JV\"%A)]I-Y5T5]W1I8",N>K8>*E'6VL)3-ZZF=6R".UO
M7E\G!FT!AKV"%&UCQ&QR@X24)S\>[^M1$]&2[%R ENSEFS3? 7CI/-+?X+SD
M\N%RER>MQ)DZE+(T\I6L9*_@()6R%R.]&>.MXV(Y8X\>8-5BKVH9!L56$R(+
M  MF')4P&W7C"6G7EEAEKD$,-LP:*(HG:>*Q( D4K.\CF![@E=V;4"?3F-N^
M%:_M"*2$IM;$D#M>R/2RQ(\4D(6 (29[776<%/0DDU(BXEO&(P#-%=Y,Q<Q.
M*"&KD0+'><*ZDF_PQ%^_\OP+DVQ\%>(<37F\7>-:$\5:>^]:/(\36*$]5HI;
M;6;4\,;5Y1MVYB&:61FG&LSRO''Y_.D'/DD+PF1BNXN8#D"'F<FA%-')N")X
MX@-VD'E1AY+#J+F3BQ%XI'N-1<0AJ8*PR]HR2'-Y=9<@F7764U75UM5G9Z$M
M,D28):'RR7'A<CH Q[=VS9R=U%V1U7+\?F4"WBQ!WN.1\YS@W/7+I6,?#BZ]
MPJF-@H\15<MD\3D\452&.*<;=6I7DKYZ!B Y:H6C@9QD:M* 1@,C^Z>2JQQ,
M$[V#!I9CEI25ZUBO.TINXM%+(0RTRVNPR$#2.SCS0-R)@6FW5BT*UK&PIB1M
M1M,M8--:@MJLG_U ;#2$F';6+$G\;9O&"1LL&9+:#5'NKA7#A_IE9-'T]M=O
M5VSKV?%6,R>3QU./$O3>_2S&(R<?AYR15I&Q]R.Q($A0PS&/,$'9MD;NSOJV
MCLRK*,\$,LCV&E>&6O8@+DL+R#SHR 2T,A9]KNSNVYNSMTU=;M=?+#&%[5ZE
MT1UEC\]MR#U+([6DUMR&91T5"G,HB=^)1: W,H^C[&3R\;#:YC%9BQS10J9D
M[KQ*O"AE_HQ;Z,4\<1Q!CI(<5Q;GN*+&/Q%[+U\55Q%:G:ENA5M8%[5_#,%B
M2M3DN9&UDY)#Y,-8&Y010QN9/(3VE.82L8VI0CFL1USLG8*6$8M\=Q@BM;P
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M">TR;=S)&<79M#'4M!=]K49>]W1*SNU+N[0+,ZVB:YFJB&K,JT9('?1A$0A
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M E:Q7:Q)7N&<<$<FVZ,,D5IAC*>/=#,1O(!\QB%]6<"8MS<*N^S?5F#HAQ0
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M5IP,F$"Y$NA$[:LS/MZZ]=';H^CZ/T4V@W2B[)FQO<1M!K!&6Y2B%<K;4WO
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M>VK5NY4<;:IY]!Q%@9,D6&CS&-/*B1@^/&[7*VTD8N<D7(:3?SHP9SDA9N:
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MU/M/]+;KUPBABGFE*9WB??FMU&*PQ6*HQ6[M:4IJ37YK1!'.4A6G&S8*.M,
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M1PC=^IMMU,[=J12T[X[4-;TB!BOK;ZUR6M8KU_;J27>R$3<MJ5A70*K9'#E
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MM_9_X0][>(?JV/\ 6:JO$S)^Z*?TDW]]?[NB?+W=Q?O+ZZ?Q18OV_P#V8?\
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MQ?TOX]G_ (0][>(?JV/]9IXF9/W13^DE_A^_S)\O=W%^\OKI_%%B_I?Q[/\
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M^$/>WB'ZMC_6:>)F3]T4_I)O1I[G[NGR]W<7[R^NG\46+_L_P8?^'^?CV?\
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M''L_\(>]O$/U;'^LU'B;D^OZ>E])-T__ &_WZI\O=W%^\OKI_%%B_IAQ[/\
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M9/W13?\ [2;^'7Z/?H]^K!_ISUBB-)RJ2B)5)AQ61R$\3 )/$P29&2%ER.[
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MIW@O5*&5Q8;KKU$%X]V(@$TF?7D,'M$L1F#XC'*X+V_&HE9@]2OV@P"3GU>
M"SL:ZBI.5MPDD2;1XDFNDY^+ID4LD_?)LN*F,KK ! CM?1BOZ"D/[1;$M$?6
MD.;2N_7&YD8!-DW@HLHBWB5;N $U,M0C4Y*RKF61R/ XXY=/MW2!%;O4;LH0
M['Q^S7!D'&A)JKK,6KM^_A1N0'8?*45(7#IR+DL==2N*PR1(,G@R9-FBC0D"
MTQARQ6=L7Q$:[:.MR+4" =S+M>1-D$J^J8]-E(Q0$F[!R@]<%V2!$PJ(&6[;
MD-7B3(D+K(VN:./D8(FL >/T! H:T5W8/UO(.:*$2+YD>[%Y!9;=MB!H5%IG
M6N:XZ+%:GKTC-7D?--"_9Z9NXTPR2=MX$^:-71#<V_4DSA0H70&8B452$Z/$
MCAC((BDUT=^;/H4H]#SN"T#L;@X>$DY_#P-Y2$[.3FLH=I:%7U>QH55SUV+!
M 1[A!RV)VQ]0MCSM)^@S;("D&1TB^7IW_8BN(GW24"GRD#+09!K8@?L@=J-]
M'M#;A5-*K0,#5N=S='J?"='.PQ2GM$2.@S1OLV^NKE.*X+[XQL_P[]^_1%K7
M&_I1RY>+$YLZJN+.0AJE+2N&"#8S,IB6D$?VKV#O;"$Q:Y=R59 XY&W,OCC%
MQ[<M#STQ8"SK=0#MH0]9H37C7L^/X^G9JG^2MPOW=M:O5)6$M.CXFTF[F!4Y
M.JGCD'M!^>92!S=UI)T_&89-SIJ!QW2,& TM?"%Y 9##Y*&^#NGS@9AVN.21
M(2BDB7<"QHG:0:B[9JZ("K+?633<>6>P:=&)%"'T N<3:BX>7!WYN'1LYJ=!
MGZFD0$O&28=LW4TV9%F1M=%UNU;$48M+O=+(0G+<C:WC#(9%.Q4]I Q8LXD,
MV:5E$QL+@$1F3"2SDM"*ZFQ>/.)>0E/U=$).1:8!FJP</2,C2V]!BY(KOFW:
M!_$NFSWM0WAX$^395T(FV87'; $2:./G[]R/:.!02Q@#5Z(-CM7#M7 \ZT8Z
MIO$]$MW#)BKNLW;D6N\J[I=E*^?W"UF= U)HWZ^(U?*K2>Q^ZY013=P>VG6&
MH-I TGU1BU2\P!98218^D>UC@1;06,U%O'&YM3X21?)U](R[WM\Y$0\!C)*#
M +[<=>'.-)-,EK8<2!E*$H$3L!")#ZW?0[6OP\V5W9D4U9_K(M(NQ)2S##7V
MZ(5R10V#=T+YBM)UJ3L5.@5IS8<][#-6<BG=OF(\-<"Z[LXL!&QP-$XS5I&>
MRB0;/-WP(4C%X8["#(C&Q)N1FFTAD#:-;.[(N::^DNDJ45I6:,:K@\1CMH5!
M';,4+W!91^!Q0M)BDA, #-30JQ]*X*0%"5@M0N2GOK'.01H^9'(]C5FVU<D'
M UJS=KI\G;YNG?YN[YS;MG=L .=M"DNTIIY%HEV@B53UD0G5MHP*.0\&>J.!
M2_3XZ\V@^Q$PVV'E6QQ(3$V\VF16;2DS'V+3ZH1YO+%"*/QON9=]Q3+K*G#P
ML$CPPAV,O&H;<8LI;)%0,Q:5W4)&9,C,4?FJO'R;0,N#>J2H.U)#(X^6E0@(
M$(*; B#HZQ(I+2';*[+!KBN!-(5$.LPQ%>L],7'9.]JW2^'RTLM:# ^K'(1&
M9)]07S.63E\QB!H@1E,N^IL?R[<"D7.Z&'SMR-=^_P#DBVO["W;/ZO6HR/US
M7P"832\K+5K@<.F<O=0\-&E4JVG5@N3)@J#CTR<.4!:$+62>,AS!PH[3W5U8
MN=E?1SN3OW[NM41/?^RP8L+.K?I2'Q:LG4D[%UP7(Q"S"LLEK>>]9X;:DPFA
M$<!(0*."W,).ZT[,!$:5<GFQ_P!SD8\)#FS=ULFF196:=X;DIZ*OCURT;" K
M^1T+,KVJX=#K0,29!QB"J0]215W/WA"OX_L#D;(=.0;] T ;R "0W1+LT=D=
MV;58@16E?G;F3U%*;<BD;JS>;NJVK*B[ 2>(D)#NCJA<%I3FO3)21C8M$9;(
MFD3KH5#E)D=?QT)(S#L;EZ@B';ZM<O<DZ]V_FJ$=?21O]HS6[<2)HHI-;"DE
MGL$9,-M^1R&F1\7JUK$EB)YX6BM;&[%&2(T]G$>#-*^/0(.<#NE'Y TZ0&-V
M"Q8BVB!]J%3_ $WF7:=&"KC2L,K2U9B0@)(B[1;K'ZH:2?4F*92!<*S=.XX:
M(QE54!)<Q]LL_ /V!;8.@LKLP3=_F1:V2KNSV>A^+3P8ZZU)HK4E# NTLG20
MO*2K9Q4IG67YS$V>W[(=-7-J-?J-(LJ:Y]&&[>U2PF:4]PCG<BGDJ[KSL5I:
M%F1ZIHX6Z[4E9H.KK$DA*>$!EI/G[I6(MI7)(;"$(@0CCT)"G4T')JLS,T%$
MY%H,-J#]6GI#M")% ISV@NZ8&JDF,>B0:&=>U^XV]4JRX989;>Q9$'KLY/8C
M)'<HA&D2:!$8-+)!%2J#)@WEY$PCHP"NB(W=,FMJ)=>_HT_Q_<B@87Z2 _;4
M3,:C(<'C8>TZ:NN45@<ALJEYF?UT[B=:R2;Q5Y:K)[7T=BL><R(&)7?#WL0F
MDH1"25-A'U5'VSU(JD1=G5$E21ZD*;.&7SDF8,U57A4J2>K;N'A D1B(AX^?
M.UU,[*+N7;I95PNMOMG=153??;.=MLYX16KPB<(G")PB<(G")PB<(G")PB<(
MHE/_ .\2:_Z)2/\ W.]X4/U9_D=4CTH_Q-.I/^K)0O\ 57%.%*V;X1>NN^F^
M/-IMKOKX[8\VNV-L>.N<Z[8\<9SCQUVQG7;'[\9QG&?MQPB]N$3A$X1.$3A%
M\\JI:J:([*)ZK*:J;II9WUPHIHEG3"N^FF<^;?5/*B>%-M<9QIE33&V<>;7Q
MAW9G9G=F=V=V9W;5V;1G=F[79G=F?3LU;TLIT?1WT?1M-7\S:]FK_'H^GR+Z
M<E0G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBI"[:&B]ZMH
M+I()#.(H3K>:8GL0D5?GTXY(!4BQ&I%$MUDWZH\EIL@J$E)AJJCZ&,[97UW\
M^/)X;$7I3W7Z%4N0FL@"E)M+II8KD(O-9[8\L(S&7GF\9:.F,:%*D'N4FK )
M'V[\C@2'$L1[!LJ2(./0W<.UE=B*$J]0:O2KNJ*_ %IY$%J/?DB563V+R1)C
M/XHZ-H%F1S5(JX&/1)1@<&FR PL(-@R0A\UW;[K,<O&+%VW(K;J^HX54<#8U
MY%6;QP$;N3Q(@\D3]>0'I(=EA@C(I9(I.8(94<F3<F/%B94N[<>&BKAXHD@@
MW9IH-D2*GJSZ=595LEA1\08L4\/JID?&TU"Y=,7)V&U /DS/<65:0@;NU;O=
M\8!J+1T6YE).3/0,=7<! ;H</760W)W^58,9T3H>.UJM6$/;2J&BT[FTOP&=
MCQ_5.31>RFFZ*(4F">$6!$=\-CH-JSB@,$6%%1+6+LVHM5JXRAHO@BMRF:%B
M5'[V YC1J:2 G:,N1GDV,3>0[2,J8EVL="QAT8]UNU:^SP]&1\7IL+9Z(!1V
M&R;0$-$C$4&")%#83U$J* (%VX#2383-5(_I5[[PWJYS]2B4OG$W<ZHYPR2]
M,M\;L&093?\ AMC1IEDW]#.6V5%2*.N>D-.KNQZVA&?M&3.&T)"W01K*$] I
MIIUIF0R;5*8+,U1:VRL@"$1N[!T_:+,D2 <F3:+M,*N$G2!%\;/Z053:Q:U'
MIJ3VJ"#78N *6?#8C--0<7EDDBH4/'XY)WB.!3HP@2%C8]'TMAS(RVBY50*Q
M5.Q\KM[GW!%:RO72K'%Y.NP[H*L[L=[66U3NUW+GU0CB,*$LD5W"H/9+V>QY
MTGY1#DSG'N50*:8C;'M-?)PBIIAT-IYE&B$(<2>WS,"UKJ<53#(,;L5^_C59
M0BP1&P \*A+39IHY450![8# '\P=RU]'!6FH\*NS:;*HJ$5C6'U3J*TGAA],
M&1]VN9K*+U9NHQ/O!*PT-"IGK8,3.!7HW#8@*EP"7HM#0TZU>:*(.6+3^P9U
MTWU4(H4ZZ25B2'GESDQMH]8IZ4P*8[723F;?:T1!JKL$TX#@ 0:!6D8$"HZ@
M>D:*0-M%<!R6)+(%S+(B[*.'&2+T&=(ZZ #,I1BP;MC<IWL.76>YL0=867,S
M(2FP(Z!C<WV+J&1!2.F14C:QP8]6$EHZ]9B"26'$;3"I(M&[8BL+;J_5&O7?
M^2^V9&F569 8CZB"!IPK(%F^Y?!]Z^7./=':ZQ0F:V7)$':B6V%G+MSZ:2*>
MVB:9%[SCK+6=@[73O(-3^<WT!@$<GGLBVC;S#JV6*+QKX-XM%?ASC&Y=W[]7
M;W.'6OI8QHEY,^8BC&O3^M$9X_F+&16<,"%[,TN8U50R</656F+4U<HD%)D_
M I-\%=EGAELV/DH^@>0AY4^AJ7)1UV\W745(HHRZ*UB%+MCT4GUTPXLQ>V=J
M/?1R=MFSD9$[?D[":S>O!CAV!?.!T2=2UCF0"U6:J,K!$GKY43)VFB^$TR+@
M*_1_4QI"A5<AI1<$9A#6NOV12"-@;!60&SJLTS,@,M(G+4G@U]E31CM*3@UO
M(@&P"8J!WV[!Y(G>FB6^A%G)%T>J8U*R<T%2&S(2==3J*6<%WB$I9-6$-L&)
M5[BJ&TIBXHP#-#D'A6NM48J=8E6Q<*^8MV[A,8V(HIO=2+Z!.D541W(%T)DM
MK(G(]=IN_6TH<SE4E(WL[EL31A<X3+$"8YW@C'IL$T=)G@RZ&4TMR+S0$L&9
MX:-&COWT18E7H/2Z4=CL6 2"UX<&%5'&J(DS>(3QP$WLVJ(CJ0T!12P5DF&^
M[W+-(R<:Z'X_F-R?# X5&ZF=![G#5.-._P#=\GR(MCY-4L.E1>I##]L[:KTG
M*5Y=!&PQQJS8-2:\$E5<^@];814PZ'(QJ8%TD&FFR'I.M6;C"F=6^4E)15DO
MU*IMZ'CT>*#"Q<%';)N6TD1)(GA=D3/WR+L\+8; PGJV2V> 'PVW9BV9#=-T
M-V>BS#^VELL\^L[_ #HH6.Z+4SJ'-@9:7LZS19&J#=' F]BSIZ=W@=62'X?D
MM&86Y;-ACEBY>9# ?7E918Q-%]  9%Q(ED&6J6Q$9]'ZX24F!4K8=YR2:307
M6PQ]8INRG.9L*S4<B*2BOWL>(BQHQB)<!"9=UEPU3&*"#J6Z^9 ,*."1EP2(
MOFWZ,58PW:GQ,QML/:B$TE4]<7:-F+1"S"AV;QZ.Q25HE5M@*D.=@C$=B$4&
MJ1WZG:!6FT<$$AS)F7;?$-R*Y4J!@*-$G>N_GDKB!26%2Z#'7A*1D3,O*,)V
MS+-946?2@QN_?NY"65.$WZI)SZNJ;USXH-TVJ2+5,BPTLZR5E--[04-:G\[6
M[1 [KI+O:EM4,9KH9B;8:ZC/%HIED<\)^?\ 4*;97UW\67@UU]MGU2*$G.E-
M0GI :)."=ALXG+93%YU/:H&S!=G6$_FL/T!:!9-*8_HTV?J.]LQ>-JFQP@P(
M 2E<(Q6DX<OO[C*Y%Z;=*:GS-QTN3/68@'#6P_O$-6"4T5_9<+M(RX(.Y!*&
ML948*.-OCSLN9>/@CDJXCS9\:+OPXD8](.7&Y%Q8WT>J6,M=0C:26P0A(F*3
MJ%P2NRU@/GD)K./V()=@)"TAPO5JBZ5]$&^=B([F6OY3K%AJV[./Z#D,XTP1
M;3Q&,#(5%(Q#0F'& T2CP6,",.UL.'6!@$:V%,,.5\:)X6<8:M$O66PGIA13
MS;^37S>&"*0\(G")PB<(G")PB<(NO#M9](".ZPV>*J[%-3.QRSZ+1.;N'0,N
M*$Z;1F0265QPFH!:OT'"\C-!R4;#1AF$:Y;+'K)M:FH"U7;.9Y\5#D78?PB<
M(G"*)3_^\2:_Z)2/_<[WA078_P C_<J1Z4?XFG4G_5DH7^JN*<*5=E@QAW-H
M'-8:PD!*)O99$Y%&F<H#YSJ6CCHX(=C$#HS;55#;#\2JZT?M,ZK([>N@GY5D
ML^&^I%I=]'GTVE_2^LYE")A:V]G.Y5-5Y.TU:LR+ ''VV&2##TQ[<H_?N<OS
M&4-2)I77T$<N/0;Z:.=FV[]V1=@'")PB<(G")PBTAMFN^S!_LE6UEP9U$4:X
MKI'X?\#(R=^Q?'V<BQJG-UG3% $Z:Z+N&66S,2FL[7T1<!V)'.R*BN^B7&93
M'\1V.(,=D:1U!Q] >6\$EB0#G"P[-=<Q&$Q8GCVC VKLQ1"1$.YW:SKS40HS
MPR\WGS.SL0QB0ALZQLQ/(+_K=2\E^CN+=KNV[N/'PQX_O\/MYV??TJL7GA$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A%^>_Z464AX_P!M*\<[7Q9,%<L:DCK*:16'PXA)R,:K
M>4NKX2.V-73E/L!5@H+(TQT>.$I$<>0&PWC _ *=8 VLADIH%64V(OT(<(G"
M)PBB4_\ [Q)K_HE(_P#<[WA0_8_R.J1Z4?XFG4G_ %9*%_JKBG"E; 2:2!(=
M'#\MDQ% 1'(N&)R$^5=9VPV&!@S)<B3?K^GKOOZ+1DW674QIIOOG1/.--=MO
M#&2*BNM/;"E.VT5.R^E)$].#(T=VCQQN5"D0!0>_RW3>-=UAY-%%;9F09J:N
M&+I/SI*XU60WRD[:NFZ)%LAPB<(G")PB<(J^.6A#(Y/H76A8LDVEL^9GGT;'
M[>7/NDH\@DY>ZJ[>;Q0W60V7W8^IKC1WEB^33W]5#&F]?-DZ<%^IC996&U>"
M>2N#_P"V-<6,]7\VHN[AKHQ[#9GU'1\H02'%+,(ZQQ.#&_H<W=FT].FGE:=C
M.SOT5@XSC/VXSXX_RXY8+$G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G"+585VV@I?MM)^G:$4L)*?16NV-D/96X -]*_<B7NHK?1JR,:DMR*B^
MNIEJAAZH(2$*$VY(/H0R28Y;JD6+[5SF?#BG7^GZYE:]>&>P5LNX,5L=D/%$
MS40B<9KV9V1(]XLU/,B8+66'FD0TCH9Z7&$V@S!)X4T'N73)MC4BUY[%HW[U
M?K"PY)$+[F-H!'$BZX?4Z*S56+N[7%2 WV!A$3F@<;,FX8(Q=0F?Q@MJ"T;R
M(8\= R[E\JQ,,V"N&R1%FYM](&_J4),QEPU7%8';$;M: U6*C[BZ1^]4%7%D
MPIY8 &4%[B-0B.*Q:.C8X%DNTDW>0!X_:$@Z \.R.K%V7"=^_?JO2!?2#O+=
M0C\1J&K8I/;H+SJQH:^!#KH8JTRS'U=&X5*Y'.!=UB(*<>2&*/!MD05@#RSK
M5$TO(S#T,7$A<A7[O$:]_O103'=V? .T>:M/0(^RLBW*=Z_9JSKA*I2!!L(]
M.WDO[%:V[(#-@,AQEDVCXR+PP$2W*,AYDK(63..M@$4R5*N&3:4[]^_\KC1[
MJS-"1RDD;HIJ+I&&=D=>LD@LQ&T4GTF2EA"7BH,"E;*N=H,S0=P=Q)Y%&Q!E
MZI-FQT2Z(O5&@ R/%*OEW?YT6!1[S2 Q'HG.R%./(W1-V$YO#*;M,98S%]-W
MIT1'IF8C!65U\M"]64(#SEK"C*L2*-)5.';-UN%Q)(^.U(;IMR=^_9JH )[\
M3X%5NTB!T<3L:+U!UAH"^K=FTLN(,)EV\7LZ"O9&\^&,1]9I#9K/AS*/&RA)
M'5""1\SN@JHV7 K/& C<BV8ZRVU;=E6GV["3L='T876=WCH=6CL8=P](M@+B
MJ*VEB8E\,TAP'/E=-I*UERY5Z;,/D#,I+1!-+<3$Q9PX14+)OI%C42 G99(Z
M8C$7B;R^9QUUJZ33&] \8!S";U[-)U'9*>F)!Y!U4*W@+(- BQ?XXKM)S+DS
MY8N.C+]18>5($6 =?2BA589'306$UON7>6-/ZSDTAD=]L@/7L1((( B<F;)
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MY3Z %JA&@NL6%@*]#(Q'=JY6!9:+&3^Y8BX(7HC6T-![B*YGMM5TZ:PNDH6
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M[9HM,R,4@_?-?>,DE4H]'R_W/W\W]SFZZ_%_BS?WK9+J5VULBZYZ\@MJ@85
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MN9KS?+=F9^6;,(OJ^@CM[77;!SB%2+5/N "O"759]3:+$Y='Y"88ZFS&A\2
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M+)3#HYUVFIMT7(1R3B&9)_"#!J'Q&Q)W#J^D!ZMT1+2#GST"C<@&Q0L9CC
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MV'N2]@"JP<'E(0QE3Q<D1?\ Q!$+C5H7(/3;!%J8<K/]B*5QCKA4L/:4LR
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M)#+%YM**2J6*FY*ZRINZCQ$G+YZ];D7[=VBT1@:!5(=LJ/:IINW]_P [=/\
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MH4]G 4:)N::-!<&OX*88,MV1@U7(Z/(,UE&[]ELJP=-ME6OF[_S19XCW=O\
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M42W(LV8Z<4090TSL%EP@TC-I%8;29QBSK(B\_8RJ8 P\;EKUG.0,I'RA!G*
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M[MJ^NK]'U9U:4)9)Z=>:5V*20-Q.S,S/J[Z/H/1NFG9IU\S=BFQG_P"IRO\
M_37W_P#JJ\T8_P"LC_YX_P#U,MT/UQ_YP_>R_*P'3";D--3[@HU&9U5RJL%9
M-"!#"GDSZ&J;5\1&-MM=E?+JKLH[3SHGYMM-5-L8US]UD>7EZPC&4FK-I*1
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MS6,30FBFBYD,=$"QPN+DW) B82RKNR9MG+K0BH4KW%N/?:5LXOU=7<R"G:O
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MU9"JE96U#5*-D+<S7=V#K;@&T+L:WX]7YD=M*DZR;ZLIR,?/F\?/ GD6V:L
M\H:S&.'S"K%(<K/?OJH5G/\ Z3.,B;6(04I&:_;A8O;@.BYEJC=0Y:V4)V_)
MB8R>.Q"H58>V>RFM(G,"WP<C)'4CCTA>"1AJ3LH?L/'>@X(KY[%6[;U>WQU6
MBL%&1\A")X7M92PVQ.0?!WQ-A#ZY)2#1JUQ]3)&KI@2W3<R)G[0D*W,F!H\
M]69#7KDFV(HB;[SIAZFJ*T<UGNOK:G3ZU.V'P7$MPGD&G64 KV<[0;)#ZM[_
M !'8SB>8&XD>&3+##X7EYD&\]Y[9M#OI\SO\R*NI+WPO.))V'N:ZJ F^U9TH
M"[+R9-.^FRNS>E#>TFTP@GY:R\%K8:[1([E6'(Y4B6VK!?T[$WWW8:D)[_Y^
MA._?KZ//\JL&5=VSX5>QIP%IO0YUYINQ@E8679*\^2%39L;?*1=O(342K/ZJ
MOFL@B\(=2\2@>=D9Q'2SOVQI4&'(Z#4??D5P]=KUG]Z/K%*$JH'0:N8G/K&K
MJ*RG:?Z2 [,C596-):_.OU8HC%1FD?#.58_L[8KKG7[S9SEVSV99;(MB;TG?
M_!4TEW:ER$.D=[%J%>:=713"W"0ZS@=@#B\XW%50VDVZ<AD58.X^&1"1^?$(
ML]"P]0=-9";3(D0&TB!A6)%R[&D6$FW>2RJ>"RI2Z.NC6,RUM4>MSP&-Q.V6
M\Q92T QG,(@TJB9@\Z@T93C,]BCZQ(FY=,FH^1QLFB3SD=)M]&KA30BA%N]O
MNRHQ5S7@ZI(3 +?B=W]16!QBG;FTGB9^LK_L5Z!&L&LG7J'#M@5,%(J7@TPQ
MK$_4C(HBO+(R5/.FS(:Y(INKWAM!Q)#H()UW$D$7O8.7]7JI>O+A3'*SNU(6
MY.$SI$TSUKYYM#Z\&P*+R>4/I#HM(3FI0$O&6$6([/6)94GR]_WOWZ+XBNSM
M@3GL'05;EPSBK9/';LN>K[P@0J1(RZ+GE@O7%Q:4,)A90H# /#4:?LSD=D(Q
M5V"CQ1J03<L"(U/=GG9<B[)^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$42G_P#>
M)-?]$I'_ +G>\*"['^1_N5(]*/\ $TZD_P"K)0O]5<4X4K9OA$X1.$74]W,(
M=_/Y5G6<OUQK/X_25:%53<[;;V96T44M4C(V9(/)HTD$DLO$$GB<5@VQ!^#4
M<CLI)R)ZL5U3V2"M'?.WX>'A7\Q9N/,7.3E+@M%3?P*[8:B$)1RPS/)7KG&+
MSVF )&$B+DCLUU,A>[Q[8SP*XUN5QL2BXQ.T4TC0L'E1GN",A9Y)MHOJ3>0V
MU]-^K=A]RBZQ.5+/&5V,Q+NJ?JN2(6"TD*NZ07:,"$-BY7XOLW72SLP0;L=E
M7B6%LI.$4MT%-5D5-TU.3H27H[M0L:4@W^> 5'AZR\Z1^6'+9^KFY&S"[:%J
M[/T=55=YAGB>NY-/O88G%O*WEY+;=6[7UZ/IT[>BTZ^C.DW5&QJ&>6CU2K )
M4(.42DJ*G,)$[*ZNA<HC"ZC1E@VW]79KJ0>QQV(,(.$$==EA95BBJJKEMKA+
MH>,JV>I99J.>O29":"",ZUD^HR03-NUC=VWL(RB<;B3NS%&6UMKL1;^7"[%9
M:&[,5@@!GCE+30@/RGVOVZ,>X79WZ$S]&UT78OSDU5)PB<(J[M:<+5Q SDR0
M')EE1'P[RL%7.[--?WQ5D.SYG&B+C9/T\.\JX\$=O-G3&G\W&WFQ88J@V3OP
M4GD>%I^9K(([G'EPR2]!<A9]7#;^LW;Y^Q]2]9>G5EL,#2/'M?8Y;==Q,/ZV
MCZ::Z]C]FBKJB[DWNI&2K$(PQ#9CR@M)/71YDIEQ@EJ_VWSME9BUREZ?L\>&
M,84PIZF<_P WRXQFRS^"'!/6&*V=CPH)B=W#E;7B(69NDAZZ\S7J[.WQZZK4
MQN1_./.W0C'RG!F\OF:[V=W_ -D=---/C\^G8VMML1J\%[A/.(LSL/,4V+A]
MF.0[DTB$PTT'B\.O;)-7&C35#"^KG"VJ>F-,J85SMCQSOG/38BU@&PD 6RQS
M6VAG>3G1PE,YO+*X,;D#R.6CBS=KLVUVZ,JN[%D?#I"@:WR-\>UHB-H]NP6+
M:S$PZ,^NK=//YUV*.4-'39PU4SMA-R@JAOG7PQMC1;39/?.N<XSC&V-=L^&<
MXSC&?#.<9_=SYNSNSL[='9V=OB=GU;L=OW.NK9]'9V\SL_S+J0[%]2*0H.N%
M[#8L)G+G#<R*$_!C,L:L&*NA3=9+9?=P)CR#S"C?T\;I::*ZZ;[?8IYM?'&>
M^Q'$&4REQJCR5Z[%&9\R. S)MC-T89)B#1W?RG<7\^FCOJNHQ^4MW;#0&4,3
M.!'S C)R9Q=M>A2[&9V=W)W%^C/V:ZJJ:$ZKP[L\".RH*2>U8VCIA./*!D=5
MIIH17V8H$]BF2!-Z*6:[;:/4VGL]$54L>V]?"OG5VTUL<KG+6#DBKR"%XIHW
MEYKZ5G$6)XF#8 2,3:@Y[G=G\IV]#K9NY.3'%'&<867D#F-)T@<6=W';H#$Q
M=FN[IKKIHNTR7Q72#=>VT,3>[D4XI&X9'4R&Z&K;=[H&( A^KK=OJHMJALOJ
MWPILEA53">=LZX4W\/-GYO:G>U9L62%@>Q/+,X,^K#S#(]NNC:Z:Z:Z-KVZ+
MDIY>=-+-MV\V0Y-NNNW>3EIKHVNFNFNC:KK$[VT_!4YA-KMK2:6X:[5:K"8_
M'A TVQ$QJ(CG(K0.1RAN_BS-#00A%W))+V;"1+O714QLKNI_9WRR7J)B=M-H
MZ.+MN=W?S:MY(OUTW.3:B_E==6T;3]N?D XXSKX;!<!<587A"E^2(VN9+*6[
M-"Q<R>8L177NUQD:#+2R/=ERT%1^?-0C@AITN6 /&$4<F@8.V;@AL_'=H[&M
MF+L;4J6+IP!.N"Y HO*I*$"1MG&V;%(4P .03X;(")Q$N8(+2E-1$PX,G]6O
MJL6S#;(0LS.+BSMYWW,#:D^O0?EU=FU\ES?_ -5F?]%7^$N"L[PY8_)'PKP=
MF+'"/&.8+B,^*J=>G'B<3>OY.?)SV#N37XK]>UC:N..G1JAC#:6A'2Q[S<NQ
M+,/>?U_OYAV4K7J]9J*J&#KF<' LU8(8SIJ,F@:GK);G6VJ.?M2;NE-T2X[3
MQVS@638[;;>?;;775D'83MYNCMUUZ/U;XV?XGZ_+VO\ SB_+'^3RQ^2_\H>>
MX3/F'0AG>[@K,A;GMX.Z12XZ5S_VY8HV.G9)F9O"ZMEF9V;5]Z.>%\Q3A$X1
M.$3A$X1.$3A$X1.$5(7/0\9NCZFE'A^7P6<UN9>GZ\LFORC,5,(B_*#E!!I!
MKL5&FP18*?%JY8'H](@9@(503;;N6.7+-FX;D6/I[KO&:B5GYS:436Q+"M5R
M-<6'9U@D1;^72)(&.7%QX2FF"#1^. H]'&;M]J#C\? #!;)8B1=9;JNWSE=0
MBA1'I]!G%#TY00>:6-% E%$H&9K^8@",8S.&)6NFSEM'G[MT9BA>.O%L8=**
MN]-HWJ@LKKIG1%+3&=-B+GQ[JR,:S2 3NP+9MFZ358N)P]AB5G.8 L-%/YX#
M#1LD_P!A\-@$.0>/!H8:29 UGFJVS!.4R3.WK[.V>6)OCZHIW'*%@<6M&R;4
M$(.DR-K#86UEL96T%K1!4O!61$2)E; 7L,]RQDKP$^;@C+Q)_EL2&!0::C/5
M<?A=0BBDAZB=?)!8E<6?FL(4&E-:RPU-1[@##8<-TD)XT!+!-G4L4TC^[TQN
M-7+;R,2M[QNZ92AD.,ZN-EVN-=B+-W-1"5O.PA-K9UEUF5$!Y'&W#B"OHNZ%
MR&-2O(O8P'DD2GL5FT.+9PJ'9+B3"H#0\#5PZU%E&S=^_0<D5:".CM,1^M[0
MJD$O,!D0M:D8+01INF::.GHN$U]&)1% CD(]?"G2J9Y<?+2:Q)^3P3;N'NC5
M5)BW23416(OE).DU>2,[*5=YM9PJN[#EL;GMG4P)- 4:YL&9Q=*/HM#9G+B,
MNID*T*XBL=WE0:*RZ/@Y0J*24,#7&SHE[XBP$\^CQZ]6*XN]T?;RO1:_)W7D
M_F6S$RT0^'D*\]YZ F,^H+7R) RK)J6[3)COEVH9VFLIV3<L\D$_;D6T-G5=
M'K6C@B,2%<DS'!9Q74^9[!EFS5?)BL9L!GL?;*;.6CQ+(U<Q'6*!)#1%-98=
MNX0;.6BVZ;E(BI6;=/H#+Y=([&8RRP(591BR0-JA)W%"0%,Q"I4#K$?4*B8!
MF:CAD$^ GH0QV'R,!*Q,C'DE7CAQJFW428Y9D6 6Z51W4A")0+N:\15DP_6Q
MD'5HJGXA))=)F5KDP9B;,GS>90B1Q6.(.7T;#? M(#&HCK%6C/ \!JR9*K(*
M$7/K?I/5-7!#$?CQJ>.V!BD'= *[&S0XB\;P5Q+K"F*:R3SX*BNN?:/K)-,D
MBC_9WA8>S%^];NWZ;U\^(H"EU7<D>T% 2YW$6XJLNIM2.H?!9@[ER!616F=>
M@ L;BJ4@BK$8Q;#6M9#\S9\U)$%%574ADR3T&U8M]GVNI%L;<-$B[:)P65-9
MG-:SL*M'1]:%6# 5X]@X+9RP<B*E(1V-E\>E<5-!#S1HPW>,#$?>^B^%BR3!
M5H]8I+<(J,==#( BR<L(K:EY0A*3P%M6ML.@4P#/BMS1IN3DAC=Q.BTHBT@(
M,Y.Y>S&5ZJRR$+Q$ZB//.Q3%VT'-A;8>13C^1S4B,<F42&;R,+'9E:U,VVL+
M&/QZ3<&9HEG4H^# @.%Q3C9M&=65,Q-N29O-GS]PFL6PV)L\N&V69%4=Q=-B
MTEN"O9[6TTF4*6)=AY%>%E2\(9C2,@BA#;K4O2H+ZF#CL9,AR(UXN BK4V#/
MBSR#QH2/;N,^S630:D4S7Z$T82!H@I&K-90FYBMUQV5$S,@1P;FY2_9-"IC/
MIS(28T:/70F6)% @#^./(]\"%1S5'#0:'39M1J# BYA+ID$E$.L"*V%=E[V*
M^G@B% ])9)I-%D"T185W*6TTB*L5"1V& X,B9:R9DT*%I&8B9@])-VR+8X1>
MLDDFNA%]QG3:.B),X,#[?NUE&S4[#VK-:[&R:.AXI.K0%:BU7DQ..@T2'RX?
MI*2H=B?F$1BTGC\$D1C5QN\C/L'SX>Y)W[]_[U;=IT> M:2U3+2$@E,;.5'*
M"4B!.8TX#Z)%V4@!NHU*8K(FIL*:;NX])0+UP-(^QT'&6R>_KB3 UWKJXP1:
MV"/H\ZV8!4XT5M*[)3' ]'65UR@H(](8EN/KVH[-#B 90!'-1T)'+O"(D<#%
MMA$BDZ\@-Y;L6+4J[)M639%,C]?W?N?57-,>J]=S?]J/Q8E*D?VM=>A?6N2>
MQ(#4O:P,3M-MVQ 1ZPAQ[>3;YGICUGSKWH_;" _R"M/17]R10H]TEKPZ;D>V
MTWLX;74[E\:L"QZ7&&8^E74^FL6P ]F<,[.(PYF8U(JK%H\XE .,2X" D[@6
MFH7&./=$M7K3_'OW[>O:BV$JRKX_44:(Q:-."CH<2F]BSYPJ7<-W+O4S9L[D
M-A'T$E&K1DEJ/;FI*_0%H[([+H#DVJ+ER[7T4=*D6M>>A]5.OB$>.2VSI%3Z
MRUG/ E#DY"*1K*+/[>&241-' C D -F;MKEC,91K&@Q^7&0D/<&5WL;'#GC4
M8NP(ODYZ*0>0"I$QL6U+GM$D8@(RJPTEFAV)[FX;7@R61Z:;@(_\!A8,6Z>F
MSL4CBTFE4E&'Y6?3##DGQC;#;3/"*;VEU(@EIR"=RYY*9Y%I7.-:*7T/Q8@!
M1=14OUWFD@GE=G8VW,QTT/\ ?Z'9&^R91.M#8PBT2:M]&#;.BJBQ%\RG4*OB
M$2?1QI)9X$-9O20]CHU/Q!,*C,81:LE?%'1 O'5'$?<@%1BC0X;!+@CP$T,(
MQXP1%E$'J;C"FA%XA'4&OX9+(C8*LFGLLL&.6'.+3,3.4% JY6<S2?5YI5Q1
M])VPN/BA+8<+AS8>+C8**CHV("HC&6B+133#C5P3O]_Q_O\ /]VUW")PB<(G
M")PB<(G")PB<(G")PB<(O7??1+3=13?5--/7;=13?;&FFFFF,[;[[[;9QKKK
MKKC.VVVV<8UQC.<YQC'"*N3LECDNJV5R")GPDG OHE*?8FX\58FA#S+<:1;.
M/:DAJ[EFX]!RBJW6]%;?TETE$M_*IIMK@H?L?S='Z^A59TH_Q-.I/^K)0O\
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M:ZYS@BM/]_[N$6@W0#K!..M]2CQUC2HH1E+_ !)/=0Q<-46H6$ID)]*I @V
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M!X:X[?""6*.N,83:# XB=,A8I@WTQJDU'C6;5BT1UU0;-TD===,$7G]C,/\
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M>^FEDQ<]N6*8;LU">:"Q+"4F/(]F@[289XC.5ZUD6/26'G2BWDF)NQ;1\S"
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MMK6L]L"UFL0/T_#(319J !I2WM1B<0<3/:51^.S N3;SEC)QHZO@C,')FX8
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M)\!$0VGY)@P<F<;'@F<@)Q+&DTB3^PI=6AQ^(<LI7HE&R#.0115XVS)/+KL
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MS:>-/*1</0@U@*<JN<*;*L&;=MOG*26FN"+!02I:RK#W^:]@<5ARA5)BW)N
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M(_0#<:V82UBR1*S.J9K(#1T\00KV%0(<3 N0YS38?K8>E@S$R99L7$A.>,?
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M.Y3 !&'<RLDM*32HAFSM&/A[9-@-)$F+%TN@S:P>0-PS/$+)JG!EOF2$@%-
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M(MT$F!%.>0F-$I(6"$P9]"*S^:F&P75MM\.G,>(N22I'N&V>'!D;M<FN-71
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MTC3<@)TYA+.*5)."CD=+M'MU"JZC!? V0%%RHQYF#5X5-RE1K'QFB4V25=*
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M3$"RP1M%,N5OBKB)R- J1;>]<"TM*T94^MA-Y0A8HVM*X86'M+@Q4,8<3G>
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D3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g111280g45c49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g45c49.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &7Z^928X0DE-! 0      &$< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M($%C=&EV95\Y.#8Y-#8Q-%\Q,5]-
M:4Y+("T@4RTQ7T%M96YD;65N=" R7T1R869T #A"24T$)0      $$_Y*DB_
M#0Z*\7Y9EW S.]LX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8Z            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              "_   "50         !
M      $              E4   "_                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #OX    !    H
M #,   '@  !?H   #N( &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #, H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M_P"ZN([TO^O)*?2_J'D9&3]5<*_*N?D7.-VZVP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" !U 6T# 1$  A$! Q$!_\0 'P   @(#  ,! 0
M  H("0$'"P0%!@(#_\0 5A    8! P$% @<,!0D##0   0(#! 4&!P ($1()
M"A,4(14Q(CE!46%WMA87(S4W.'%U>+2U\':AL;?!&"0R,X&1T>'Q&1I")28G
M*#9#5E=B<I2SUO_$ !X! 0 !! ,! 0             # @8'" $%"00*_\0
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MUXQ?>1:.8M/$G1VLHS01_+#3DF'-6,?O)^F7XS <7C'K&WW*"TDD9*6",D)
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M2$*4I2@   %#CT] 5POK];?I\SY4SIW7'\S?/'[23_\ NTQ]I5:/9'G\33-
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M?\X24YZA)9:(W\,$8SOC&>XG]&GV4E,+^SMPF,?'*-*QTKY4E([=,B2F1D$
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M*W=HTI1I2F;>PLVC55U6;#NNN40VE;$I8'U/Q>60;)KI5]I%-TONBLC$BH"
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M*"6ZO!KS;=N%RIA9VLL[1I%G<-8=\X*!5Y"MR*"$Q67RP%^#X[J!D(Y9P)0
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M\Y\<[#P[_+88KJLX=Q=5L)XJQWB*DLDX^IXWJ$#3H)JF0A>&$%'(,$UE>@I
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M;/K+4D-@$[-L/^@W,H2,]#)N$AP]/663U)-22[OE^5#<;]7]/^T$EKO.$/\
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MBT5L7L#UI)O=]T*\,V1>2Z.+ZVM%-' B5!U(IR\N=DW6, E$J2SH$DU! Q1
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MZ?=([S*1#'2"2A)1L8S:7KLZU(<YF,Q"R"2[!ZW4'X1TBN$3*-ET53JEK?\
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M2IM]U_8S4)^9.>@-3(;+"DA4AQR0ZRII14.1E#:&%.N/N$(2C;!40#L3P[X
M*USPY=XGS]:V726E[3K27IC4\^\LK+-F@1[+;KHS=&0T\9%UF3I5R8M<.SQ(
M_I#TA270Z&@ODDYA2W9-NM&:3^6L8IXDMZSU^DO3$[2PN/E6;=<4V3LTS&MF
MK10SY$/&\ B8F0 2E,?JY*'>6Y^9(BI=G0_0)!4L*C]NF1R@*(2>T2E*3S)
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M"]I^;IG4-LLQ/(J^PX$V3)5<K9&<YA-<8*51&REUP$'%6%$.!P$0]W/H(#R
M_H'^?HY 0'5U@YK6OX^'>,U#;.VZR4HV0H?!N%<9.\ZYVDH4UOE:2RLD?4XB
MF4@BP,B66WVB10=-(L'LDNS;1$7X!GTD515PF"2*)#+6]<[VY'EM6NVPE7.Y
MN-&0N.EY$=J+&!".WDON)6EL+6I*&D%/,Z.=2?5036<.'O!^'J'3,[B#KW5K
M'#OAW%GBR0]02+7)O4V_:@4VJ0JTV*T1'67YACQ6WGILSM$QHA2AI94XM0;]
M?@7=O*Y R=+X)S-B6>P+G"-A#6J,JDO+LK)7KK4DERMG<]2+<P2;,9Q..750
M2E6B:!73(ZH@8#^ Z\#BV7YR5-<M=QM[UJN2&C(;9=<0\Q*CI*4K=B2&\)>#
M:EI#J.5*T9!(Q7T<1>"T33.E(/$70>M+=Q'X>S+B+-+O,&#(M5ST_>EMJ>:M
MVH;+*<=D6]4IM#BX3ZEJ:D! QCM&BY-9=7P4U%.GJZ"&/QSQR)2F-Q[OEZ>.
M?IU<). 3X#-8(2.924].924@^!4H)!_6H\;5L\I[E,.066T:VI4TIN4M,66#
M5D2RIV_W,V64KHK"](U9$4!V:,%R!2MB>$"OA"*@D\0W66:YIO$!J>EE3 <6
M\CLU*"R"P\XR3D >T6^8#&P(K)?%[APOA1KJXZ*<NR;TJWPK/,]/1%,,."[V
MF'= WV"GY)26!+['F[4\_)S8&<#P*-N(2NNYG-NW<E658+8;K5 L2MI/*E<(
MSI;PP,]*U2BRLDCL!CRD\,RAWKD')A X)H@' QQKL)%YN5H[$I-N8AOE_F!2
MZ):5*">7 *2CD.=R#G;&#GZ=1<,%V'A5H#B>J\-R6]=7;4EK19Q#4VNW'3LE
M,=3RY?;K3($DJY@D,-%K!!4OJ-G9?METH]#F;+C[';[*ULCP9^S*)'3<;77D
MUX[YNV=>%+RP"P:^1:++/S^, ^*FV.B3X:A=?;-??CQG78L5<U] !;C(6AI3
MI)Q@+7ZJ<#<D]U6GHRS6&_ZCM]JU-JAC1MEE%_TO44FWR[FS [..ZZR%PH)$
MEWTAY#<=);V0IT+7ZB354G9T;@MTEZDLC0]NPU9K!39#<GE9G/Y(LV78N6<8
MJ!N@P6#'[2O.DG,A(QU8<$;,&HPSEM%G/)G59HID(KU6-I&[7R8Y.;E6UUR,
MJ]7%#LQVX-N*@\JDGT,1\<RT, )0%-K2@%9(3L<[A_:BX9\(=.Q=+S;)KNT6
MR_1>%.C'K9I6TZ*F06M9%QR2V=2NW1EQJ-&E7=M;LET3F7IJ4Q A]Q:E-A-T
MI?\ 5CZ\^@^[D?I]/>(_\]9$K1.HD;1,NU++T7FYW4L:1&-$J1N"R+CR;0B"
MQQ2VZP5H\:61NS[V=&1A1D9T729G7FBO'G*!17?N!$HEZ.QW!FX(N19B)B")
M=IL%P)*2'WHZDA<CU4(QVO,#@@J\5$UFCC1HF]Z)EZ 9O>K)NK%ZAX::7U/;
MW9OI7-9;7=4RS%T_',J9,)C6[LEAKL2PQAP]G';&<R$R1D*IXIHMJR->I=O!
M5&FPSV>GI5P;X+1@P3,JIX:8?#<.EC 1NS9H@=P[=K(-4$SK+)D-V<V9'M\2
M1-EN!J-%:6\\X=^5"!DD#J2>B4C=2B$@$D"L::8TU>M8ZAL^EM.P7+C>[[/C
MVVVPVL<STF2L(3S*/JMLMCF=?>60VPRAQUQ24(417-'[U]UUG@"Y6I6Q*UR^
M%'#8\W$OI'(L%#9/L%4-PX:6*+QXX8'=B+^-XD6,09PHZ>IG2*U74!9$Y[31
MJ._/LIGQ]+R%VY6%H[28RU<'8YP4OMPN11]9L\Z6U.!:A@ #.:V=D\ ^#-GN
M)T;?_M%V:%KYIY,"='BZ7N4_2-LO0*FGK7,U.W)2SB-+'HLF:EI#,=:5EYM)
M0M*9[X0S12MP.,JKE?'SIPYK%K9+.&Q'J(M9&.>L7CB,EX:59F,8S25AI9F\
MC)%N(F!)VU5*4YR"0YKFMERBW:$Q/AJ*F'T\P"T\KB%!10MMU!W0XVM*D+0=
MTJ20:UVU_H6_\-M77G1>IF&V;O97VVW5,.!^+*CR&6Y4&?"?3@/PY\-]B7&=
M '.R\C(2KF2/A]S&Y&O;;Z?#3,A7IR[6Z[6F,H>-,>5@B:EAO5VF@5-'0[(5
M?P3)J4B"B\E*K@9O'MB^(8JJBB**OSWF[M6B,VZMIZ0_)?1%AQ&!EZ3)<SR-
M([D[ K4I7JI0E2CTP>_X4\+KGQ3OEPM\:Y6_3]ET_9Y>H]5ZGNZEIMFGK! +
M8E3I 1Z[[Q+B6XL-HAV2Z>1)2E+BT15FMZVX'#:D'9]T&U);&>(9V<BH5[D.
MF9+ALC#0E9QRDQBW=WA6,>S791HO%R(/9)NJ9!HH8J7AK*J)I*=&[J.ZVX,O
MWNQF';W7&VURXTUN8J&IU:4-KEMA".5L*4$J6A2PD[^X9>M_ 7AIKM,^T<(N
M,R-5ZX@6^;<(VF+]I.?I8:C1;F7)$QC3T^3)D-2)@8;4['BO(#KR$K62A"'%
MILQ0>(.6Z#ENH19NY12706(<IDU45B%4343, B!B'(8IBB'H("'&KR!! (W!
M&0?$&M4W$+9<6TZDMN-K6VXA>RD+0HI6E0/0I4""/$5Y6N:IHTI1I2C2E&E*
M-*4:4J,N[C;;6-UN#+KARS]#49MEYRM3QDO'4K-NCDU%8">03 Q#F*T=F\)Z
MDF<AG4:N]9B?H<CQTU_LT>_6N5;G_5[9!+3H2%*9?2"670._D7@E.1S#*>^L
MJ<%^*=XX-\1+!KNSA3PM\@,7:WA?9HNUDE*2BY6YQ1!2"^R.9AQ:5!F4TP^$
M\S8I$#.F"\E;=,CSV+\IUYW 6.#=*)IJ*I*^S9J/$1,SFX)\<A4I*)D$!(NV
M=(B( !Q17*BY3513U2NUHG62:[!N#*FG6E$)4$J+3R,Y#C*\86E6<[;I]E0!
M2:_1;P[XB:4XI:6MVK]'7-FY6NX,H6I*%H]+M\G [>WW&.E17$FQG,MNL. $
MX#C96TM#BM/\@/'R\\@'^/\ 9KK,#?H?$=?S'3/ZU?&",]V-S\C^M9] ^CY
M_P"&F0/G@$_GCYUQN??WG^-;&Q/B3(><+U"8YQ?69&UVR><IMVD?'H'.1!(Q
MR@K(2+GI\&.C&9#>,]D'9TFS9(HF4/SP&ONMUMFW:6W!M[*Y$AW9(0"I*!S
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M\PS)R:SF@9VR%4(]510Y(N?KL%= ;%$P=*#=ZW=51P*1 #I SKS2PB("=4W
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HQ-?K2N:-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g111280g72l45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g72l45.jpg
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M/V2_@Z/G:R_YA3VZ;-^$3\CG?EJ?7=^F5]X_/[*=S_X>]/<3]DOX.CYVLO\
MF%/;ILWX1/R.=^6I]=WZ97WC\_LIW/\ X>]/<3]DOX.CYVLO^84]NFS?A$_(
MYWY:GUW?IE?>/S^RG<_^'O3W$_9+^#H^=K+_ )A3VZ;-^$3\CG?EJ?7=^F5]
MX_/[*=S_ .'O3W$_9+^#H^=K+_F%/;ILWX1/R.=^6I]=WZ97WC\_LIW/_A[T
M]Q/V2_@Z/G:R_P"84]NFS?A$_(YWY:GUW?IE?>/S^RG<_P#A[T]Q/V2_@Z/G
M:R_YA3VZ;-^$3\CG?EJ?7=^F5]X_/[*=S_X>]/<3]DOX.CYVLO\ F%/;ILWX
M1/R.=^6K:#6+'#W&MUZW5XK)T!:8.)L<&:I@@51D/. #R<84H4MI@L;) 13#
MN6"F62&<K]MYIMQ*D8^8RHST.3(B2$[DB*^[&?0%)6$/,.*:=3O(*D*W5I4-
MY*BE6,I)!!KTK3J'VFWFCO-O-H=;5@IWD.)"T'=4 H920<* (X$ Z5WG6BME
M.E*=*4Z4ITI3I2G2E.E*\*?.?UZ- \<.8O)?1,CZ5NBMFR6K-RWJGR6PI?83
M$3*W61BYLE!]FDH[&I)?X,V8+4\:2SF3/REYU>5%/9SE>?:1_9*V]@QX\.+M
M?M!'BQ6&HT:.S<Y*&F([#:6F66T!P!#;;:4H0D#"4I &@KY;.]A'V(;G-F7*
MX>QOL?,GW"5(G3IDBQPG9$J9+>6_)DON*:*G'GWG%NNK42I:UJ43DU5/_P#2
M4^.W_P#!TX\_M29_P3ZV^ZI[(GPUVE^=97I:J^X'["O_ )7;$_,$#T5<V/\
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MK4$(6LA()"$J41A)(Q"5$*(22$@%1 )"02$@J(X J4E()P,D#B17%ZRJ*Y1
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MB=+1^Q]L+K\O0SHD6OW4B_EG5KM)O BJ9LOMU<86+JY$E3XUV:>3/:@VL0V
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MN1'JA<Z+1='&93)O)W:Q<34A7_-3H^;&3EB2L+[.58% 5WRMJ+0M)QN$X]S
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MF@ GTZ<C/<,-%/%'=07[C3K*\#,.9+:)$7XO_$/):0EU"4*PM*L]345Y9_5
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MM*4E7;(\/]/MTU[:D$ CL/KGC]'56=ZYU-#Q 0A[D((Y85(2J41'"O$NH?\
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MC.<_9C.>K]LM5T$UDFVSP-U_4PY &L=T#4M])( [:K2YD0QUXE1CJWP?:_\
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M4-HRXO+A]R('PK",?:KPPO*\X_-V3G.<XQWSU@0"H9SH =/&?7';0<1T5O\
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MU\-?MS67QO(/<5^T?P!3%V>"HE]Y?9KPESV7BL RS58]CC_>]U3@]'K4L0J
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M%SUO(&XZ\B9(BYG1>&<O^[AVK8;B81K+;YS<>Q@TK):!,D$(8;RAQA(P$ (
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M_1[2_P"[<;UT+M_2MS_O";_$NU6A?L<3^S,?X2*D+KGU9ITI43[G_P!BU_\
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M?>:1[9[3;C;C@:^Q#:%H4IO"5)SFZA]ES')O-+WFPZG<<0K+2B0'!NDY;)!
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MX^00ZX\ZM7VK<6I6?MSU_,&[-MLW6YM-(2VTU<)K;:$C"4-HDN)0A(Z$I2
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M?0M4*(DIX>+,<"DE$RS6]G4EO*.#*#D3'7B7,/LDBN+PMMU"=OJ*IYQT>+/
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M6),ZV.2)B9J%N-3V&V"),!,-H\W0VVRVI@IWU%ML+>"AO.)W,*RE&\8Z3>@
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MU;DMEW)P590T7%[J331;)+KTEEHLJYL^(RW%OM,MJ=4XXVT&R\I&]RJFU;@
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MOH81*=<?4WOE$F2^PTMQU4=EDN*SA)NLJ4P([NX4Y1E0"]XI;WN31NEPM)"
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M2X[+F&%LH2M)*4@+6E4,1N]9INZ7ZZ6BF:\V$[L@Y<K8H&WP<FB#:E$S;4^
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M(D.+"TEF=-$]\*&Z-XE\=Z= E!*2#QK2].??2M*]P!;K+QW4D$+89Y!&#DX
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MF+D'8&.DHR&D)IL,A<4#+S0LL;#Q9<@EO(H\A*AP,X7'!O.H(-&AY1\=MQL
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MZ,:%_=6)Z_F%>OZ9NW]YS_XIVOTO"_8XG]F8_P )%2=US*LTZ4K!=@0;]DB
M8=CRQ\7-QV'W$X[^P*WA]PI[\W;NVPA>48SVPISP1W[JQU*3@YZL_54*&1CK
MQ]=9F*,P&,.(,VEH<5EH=AI/^JVRRA+;2$_]R4)2G'_A]O45-?OTI3I2G2E.
ME*^1CZG\$S8_5TYOP[F,807R\VXEY2E^*<CXNTDI_OGMG&.S:5?;G';';[>J
MTMWD(K[N<*0@[IUZ<XTX'&1VYX=(KL[/P!<[Q;X13E+KXWQD]\A"BM6,8.J$
MG@?/7H4XL 5&L:)K<5$QC(SY0.#)+"&^V"2R&L)*<SC"_MRM6581G/;*DI2W
MC&4=DXB-'0B,PAU"%N-C*B4X458Z2>WB"=>OA6RX7E^5/N$J.[(8;??*BVT\
MM"78ZB/T;B48"DI! 2!HA( &F,T$Y/4G7FI]D4VVB$NM6&RV =XU\R0:;$&$
MR8(.L=L?*TMI&=0G"L]T8;\VE84G"DK5U2>1R$B(\VL O;R7&ACAE/? =&!Y
M?L[]J<7=+!<;?/62S !DQ)KBB0A: HB*7#E2U.DY2DG3=)TXU'&V>4VMA6,0
MDA97XF.%-=Q\8V.Z<CV!LJ'&]EH=.5.C_$(QE2$K\5(5G/96$8ZZQ&2#PQGL
MXX]=?JX^%&B=< JXI/$ 'RC7H)'0<54#&U$WKC!R!F1TY)'CMF:J5[J\N(04
MV:JZM8>PISL\VVZG./).<]T=\-]L)QG&/H]D><3['^U*4J(2)T%('1AY3*7#
MXRE(&1U#6N'( [MP%$ _[.[Q&<%"E*!&>K)Z1TY/"M<K,E:1)SY7B0'OM?[#
M-C8RZUA;?V(PVI'=:LX5^4GOW4KOW[=_MZ^<'0[H&@ 3D$9 &@TZ]./2<GC7
M;R3WQ&I[XZ:9.O#JUX=56C3R>M5>B(LPP.U5;8$.5[/RFRA;4<>$MK&4)?'>
M2RIMU3+;*%I;PI#K:$KSGOWSF,GCT>+/E&.@^3K[#.>@CAZZCH[<=O7I,$KZ
MG>S96@?-]U&$S*DX%,*SAOVSF5X5E3W;#>'65IPK*/!M>,=_%7E^3C&6\-=1
MT_RTZ?'D"HT[?/\ RK6=)3!E@EC9"0><=6>2Z4\A3J\IPMQS+G9/DK/;ME6?
MM_/V[_;]O6((42#^KC./-J3QXZGZZE.<\,\,C@2G>&0.K3R 5Z$/3-XV0M:K
M NX#<E,VE\D4B*<#G+'72W0&U-EDQ^)FLGQDS%C20SF0WB "TD)\E$>#WBTS
MUSMQ^63(2YN)9<6EIM)P%@;N\5 '!.4C=SG&3Q&:^AHD6S9X1;).B(DMSXC4
MNZRDMI<D)2^.4B-1BHY9+;:UEY*5)+BB@K W15W^3 ^[[6N''UY;[G0JF8>T
M)-1H7(+>-@?-P0C/PX#Y<]<E>3?O-*[/!@@*4M]IE3..Z5*@3)3;S8?;!:5A
ML$#&N3J5 9U'CJD]9]FKC%N#EAE3695O"9:XTYH)7(C*SOI: 6H820 ',E6N
M" !6)Z^U#5Z/4IP26N>QB[W+#.E2<K'[-M8$@PX7XOX0,05/.MI6'\(MY9RV
MEE>*E8[Y<7C/7I[=$:EW"+'</)MO.QD*!5@X=7NK[[/$CACA7A);O(,ON(;*
MBEHN( R2"1D#_JQH#J!DZ\,B=M!UR:G)B9ID):-E77Y&G' '9Z^3RIL@DN,4
ML:0'B'RF6'&!6$L+8D,K4YCX[+OM+2VVG*^EM5:8=FO<^VPI)?:CH9<2I8'Z
M(K *FE+'ZRDC*==0K&:J6N2N;!CONH*5N%8*L;H5C482= >CB!YJB/D7I"J7
MO<$%2-K\C]650F3>>9AZG"%RD[86L(\G T*&%0RRV5[JQ\JP4YEOP:S["U]U
M8Z\Y70! Z,GKSP^@U:O4/%K5D6L6LQ')VPR4N/AK(D4]%1\<VI#3*/X+ T@V
MX00QA:$Y4EI]E7CC*,)RM7?"H)ST >*FUP[!JC)*)@^,G*VS(X#?G8DGXL@0
MMI",-(EHW#?_ $>_C*,9?PLA;3:,M*PI25=*BL#N^Q*Y,ZRDQF)B,:^4H&1&
MCROC&T8\BTD"I(:4._@I"%.)7E#PBDN-N]UM*1G'?"E;-=(.22]+:A7(2!IQ
MZ]7T!1QKQQ)3QABJI$Y)*=*??6^2Z0]E;KC[RUNO+7EQQ2EJSG*H.<G0><_=
M7G!TQOB'XZ<@[AL6<TMJS?(.4[%K?S%V_"XGJFE^P/EB,SB0584CY2C%8[,N
M*;4I09)XS#H11#$B'_26\V)[:+9^';F+S<[$O_=TGGUI>Y"7NQTH6IC?!!Y-
MT<0#@+2A2@M*5-K_ #M%G(M]QD2%PXTY),EKD):-]K+BE +W=1O)\6J2H I)
M"AT'&G=SFAK+L"Z1QA$;93]8S<!3W6 &I()5C+L=4E!P9D$I2A2J\>!$2($R
M$<V6#)1Y#T6>*2&:^VJQM)9!?8T"$XA+L9%S8D2PIPMK$=$>4TIQE:1O(D-N
M.MN,K04N-N)#K:DK0DC7;9O,79#Z24N*C.-LX3O)Y13C2@E:3H6U)0I*PK*5
M))2H$$U=O')_BBX90U0D/(5BKUB)U4]<J=8]>Q=X=MM#BIK:]FV9QMKT[)O2
M!4;$/R-ZC(2NVHUV*8LT8*)9[.=#V.HP()?B3LQM4$3^7>;E29+MU$.9'N#L
M(1)[K%JC6S:-]AM+:''@W!=>DQ4<JJ,XM<6,AZ/+?<1VNZ=J)C[B5--M-Q>6
M:<CI?+K*%RW)%N;6HDI1O/H0VZHH#B0''%)<:0DUHT'M73=2TKM*G;$:97+6
M!-N("$C:<*3:IMXNBJBJ7%L6R5#LU>>KS-NSDF=!E8*JV"DBK<NNM[J1<G6(
M^-])?K5>9=ZM<RWE0:C\T2M;DQ2(K(1.#LUU41I<:0F08FD=QI^4Q-6!"N,)
M,,*<<YL"7#9ARF9 &\YRI2E+(4ZO>8W&4!U0<;+8=U6E:&ELC]-'>+I"4SIN
M_E+H65&V&1JNOUH.9FZ)L."UR6WJ6&%(IL3<-P:$FZQ3B79AEZ,CI"FZTIVU
M8L!RNPCX-.+M1(]6NT]\OX<KG#LFR]^:7;TW9^0MEF=;W[BDW9Y29CL.SWYB
M3,2&5)==;F7*9:W'!(>2N8B*A4J$QR!$B]-ND!0D&(VVEQ;$AN,1%0"RAZ7!
M6VTHK&ZE349F4E/)H*62Z0T\LN MY.[RCXH-WQVSHK8A&MV]KN6%&I&]/UA)
MKYB>9F=PIV8W-/8:$2(YQTQC52*P](M%X<SBBKB$4GRG4UALOM68"8ID*%R-
MJ$<W8W>3N)1[3NX_<PLIRLJ&T/\ O0R0V48_VX/&;^AK9W3M0?+FX#&YUR@B
M"&WO%7=?G?.=\X&[W/\ ]F#6]O9_0[@9[^L-H6X>+=%I8] )G19UH/5$?5[5
M<8_4+8UFM4RWL/DI9))BF25F$L$>\R_![+UQ%E1.R:4Q&VE%9B3%6:C'T" ;
MDKD^S[43YBIZ6%L%=U=E18;EW*HT5DV_9N,TJ8W&6PX"E^V7%U#UNFJ=BF2Z
MCFLU$^06M4>9:V&1'+@6$Q4M./)B8<=6)%Q=4&E.!P8*)+"2B0R$N<FA7*LJ
M8;*H6TYMRG5#4 4#$R$-"['CKE=YB2@)K5%8OK&VG9J)H NHX]VP6)OX6!C:
M):8.QR<DW(EQ[<*U*_+%=:GY68E  >U>+1,F7=Q]UIYZW.0X3+4AFZR8*K2&
M79ZKLX(\<[[[DZ,]&;;+27"\IKDI!8:9:6NG"F,LQ$-H4A$E+SRU-+BMOB6I
MQ+"8@Y1P;K:6'$.*5OJ2$!6^V%K4H)M+/;_X[:PN>Q=0Q$<$/J>$MVJ96/C@
MZE5;RS,2\98MKW2V-33[3Q,#<3=1V[;D3!PS9$JNJ[!I^F1(9<@R#.,BE^78
ML&T5SAVZ[NN+5=7XEU:<<7+EP2RT[&M4*(64D(?AHNT2TO/O%+7.;?,O"G@A
M2V2M/47<+?%>DQ$I2(J'HJTI#+3X6M+DIY[?(RAU41V4A" 5<D^S#",A*PDX
M43R6X^9U[<]?RX_SEO5GK%=C7MY@T(2-'1L*%JFY!U[*C*,2P,$^4<%;*/J"
M1G)>&'MS4 U8]K0P@.Q6HE]JX-FMH#<(<]I1C0(TJ0Z+&Y/4XHV]Z79U"VNS
MD*6X$MKB3KNVPR\J(9!CVMY;EO+J55S<K?S=Z.O]*^ZTVDSDL!($A#4P&2EE
M0 *E)=8B*6M =#?*24!+X01SY7E?QH(NJA"=>@3>F'73IN9I;&M*C&2,],)Y
MH#;4$'1)X'8D1,JX_-&TL!>99D**9EY:K,MLQLK)J)P:V4VE3"WDSW&;R-QE
MF8JY2W6V&3L<NUK5R6\IM?\ OY2)C@Y(K=+34HDNM-!.2KK;B_@L!</*EK9Y
MLTE3BNZZ9*0%8"A_L.\TGOPE 4IH8"U9BR^[TTQ*<D^.^P$@U^R5+7DO5S=E
M'@:Z;CP+5&QNR92RKCY"MS"!A[;@"J%!PRVY&O0XC8C;5)%:EJW78>7/ZD"Q
MWEK9O:&WE<B/+N#4E%M;7<2XY$<<MS48.-R6E+5$WY2%O MR7EE9,U19DR'F
M6ZTB?"5<K?(PAUJ.I"I*Q'W0ZD/J<W5-KP'MULA/?-H 'Z$!;;:%JEVA<M]$
M1=;TE*V*(CF;;6+IK6S7A@#70>)YFYUS=;EZN>RH>7B4P,.PF=HWE7 VV7CC
M<BG8HZJG'P%<K5E"Y$_9*^NRKRU'=<5$DP[E&@E=Q7R!AR;*(,.VO-/%]XEB
M=B0O*4(WF^?<[<?DR8J[<>[04M0EN@<LV]&<? CC?#S<WEWI*%H"$#?9')C!
M4HA7(EI*&VW$_P"C\C>+)$=JX1B/ J^:U7X7$.D?7([Y]%L43H2P4>?&GK"Y
M"S7:*N6T9&-M94U4:[;[>>3%Q^P1YG7M['<0Z5LYM2ERYK+CDH29#Q>*KBI*
M)T=V^L3F%,,!YG+L.V-.14,2Y$.&A+KEO6S<(*A@+C:RF* $M<DVC< C J8<
M1!<96%KW'!N.R5)=*VD//+*4O[\=\'/-E.1_$,A&PL&00DK5+!>X&[NU&O:L
M"K-GMBW8'3;DS '2<XJUP'S<5.U:])?PP93K;4#IJ;E:I<;B+=I8,?!K9S:Y
M)@;CZVI4>"_!3*D71<F+$"7[P&7VVF.:OB1R$F"4E2)D26VTRU*APUPFEJR5
M<K2><;R$K:<?0\6FX@:<=);AE2%*<#K9:WVGP1EIYE2UK:>=#R@(9VSO30UC
MW[HJZMP$+:J12+ Q(7_$/KH2#1-UCY]OSD;7RJW*O1D1:G*Y7G,#IA#HJ(@4
M,NIH \Q,5&+BY-OL6FQ7Z-8+[",AZ+.G1U-P.6N*WN0D\Q##LA$EI+KL427Q
MO%]MUU\J!GJ99ENNMFG+G0')\%\-H=89<WI&Y'"-]KERM#9;7N)=+3>FX4(;
M PP%K:2E0ZK;&^M>&:JG*C5S8FV;2FP-50-QVJC5U?K^+K'0DWR1E[63$K.B
MF9B );@;SI.F$R[0,%/6(>EF#D+7$!,.26ZU6*XHNL>7*;=B6MARZ/P[6;H_
M(YDX\QLXS$2Z&W2U(29$&]3$M*6^Q'5-2I(#JU!O7+GQU17&FE(=E+3%;>E<
MU0WRZ4+N*W2C>0%-D-OPV5*W6W' P1DH'?9MK'DUH:''UU7=@TZ-G:?3JKJ)
M28U&MJF2\QLFO25G1:[>>0L1DVSI9#FXTD\.9-*&N$=" UZ086*#'(&IW/9J
M^O*N,BWRW6)DR5=_TAN4I(5;I#<8Q8C:0M2(N\MEU*%LH0N&Z^Y(;(6XX56(
MMS@($=N0T%M,LP\($=HXDMK<Y9U1*<N82M)(62'4H""#NIQD4MO3BW9)]J5G
M5Q3!M4F(";.E(C5))#>U'VM96RJF,,JD'AB5/"60ZKNR<Q9XVJYG(X NSKA2
M+4.H6<JM6+:B/'4TP'5(ELOL(:>NJ4FUI-SB2D*.X%IW5QT2@TS&<E<@XXB*
M'TQ5;[&Q<ZUN.!:RD%I;:U*3$)YT1&>:4!O$'.^MHJ6XEK?2@N%!=&ZK@P7)
MS1KY0R9D**B:[6Q]1!2]=9T]4C<[:UM5=1A0=YU,R<, R[6)6?V8[9)TBVG/
M-.S+]E3=9"<38J)4(XK8_LS?$H46%.NR9)NRVI!N\M'<JY2KLM^#=E(4X1*:
MCVU,=A$1 4&!&YDTQS:=,<3BW<X)(WPE#;8B)6V(;1,J,U$2V_$W@D%M2Y)<
M675?K\IRREE;+23V,WRATG9X[X^<D6S#U42*BKU#'ZJAC3]I,#<5]9ZIJM%%
MGUC?^RF-:[?JMTMS,^P^ TT!< ;;7W9"T5:(@TZV=F+U%<Y-AHH;Y\Z[!>;N
MKR&[6I6U-RNLJ:N/O@2NZ5HE0XA8(62Y$<B2 W%E//U*[G"=25+7D\@E+S:H
MJ5&2!:X\5I@.8_1&-+;>>#@P EU+K9+K26Z[G')KB/FPQ!S]2'> !HT95IK*
MM051;=@W!&W^@3$WR/5#+<Q'NAW6-A\RS^L35M1X352*JKH^(^YG9=T>UG:W
MD'4)EJ#BYKLIC_>\H&/:7($]EC9WE@"X%PW'>1%S0"XLRTR@KE(:,;.Z=I*T
M*+8PEA#2\PVSRDM,AA:[AN?JD/)1OF.H@ ,EO!#I!Q>-Y/4"O0%NB(FX"3^R
M+'4=BUT[9#&FZ[78RVGRU(T.BM &QJ@L$%1I=HUY:H7Y=FXL&2/?D6K=9(V.
M?GIGX>V[LS<)#\1YV(N/;H\NW246Y5XD2'8B&9U],E:'0O=2XB-<(C_(LNN-
MMI;5$CNN)89"M2;FPVAU"'TKDN-2&U2!#;;2ZM;,+DP4E.2E3C#K>^XE*E$A
MUQ*=]1&$;DO6C*IRHUBB.IT*[J?74U%6F]P,/%5BQL?.:_64O:%WK2QFS2("
M["ZA=LX&H HDV8=K=H!U8VVMX8&P'.KN6>!?)>RUT+DQX7:XLNQ8#[STF,KF
ML",BV09 64)?A*NZ8KEW6\AD28KET)"5+CH T3'X+5TBA+*#%C+2Z^A"&W/T
MLATRGF\;RFWA$Y5,5*%++;@C8)"7%&IGJ'*/1<'&!PL_;Q)PT.R: L6W)Y.C
MH8F*Y%0VN9ODN7>ZN+&'@L.0<I-4':NMM9"2\[%P*;$BK2A\[)1HS(K\GQYF
MR]\?=6]'AK80N-?X]I8[MO(=V>>N+.S28,I3C:U!]IB?:[E<E,L.O\W,EIMA
MMU2E);N-72$VD(6^'"ER Y+7S%!3<$1EW OM)2I.6UK8DQHX6M+8665*6M P
M5<.N<D.+P4+K)$F%'?.JOZV=J<":#K=F.K&O+!BB5"%=M-C#>B+):U6D^8A)
MT<F:I5EML*;(V O;(M2J=V=7$)RD[.;4+>N7)+<YK(N(E/H7<E.2;@QSZ6^(
MK"P['B\U;9?84EF;&BOH;CHM2Y<J$ \3=RM:41MX)Y5N,6FRF-NMQUEAI!<<
M!0X[RJEH6E2V7'4*4M4H-MO'<K"YGDCQZL=H#I\C6PHG2MRG-QHVB54]356'
MLP_SI8%3KZ\5AEXHN4')JUB$1; JF/9@XD 8R9@P1HP>9>'8NL[-[0QXJYC<
MA;MZAL6<VQ,N[2GHRN:*4;A"DJ"4-*$J.KFBY:HRW5J0R\M3I9"E:%W*WNN!
ME3:40WE3!*+41I#HY0#F[[>2I8+;HY4-!P)&5H 2%XK-(?EIQ@.J]9-M.JZL
M(O-Z L5XUH!KB.ETDFIY.?26Y+UTQY<17TQ$3HQ(&J0DS$B3(2 4431#*NFL
M6(NW TGMD]IVY4I$6Z2ECF+D>%<G+BMDI0=FNYH:DH2'9!==O9<NBRRTAMMQ
MU$Y$KG,=$1>Y%VMBFFE.Q6@>72X]&3'2O*NZ7.-]L]XWN(A;L5.^HJ4E!84U
MR;BG4U)Y2[1@-E*T@'$7%-_E->:A/IENMP]*:H<?,V$W=&W[^R['1"!@'BF!
MJY>*^$3*FQD<89)C'X='=2RV<7ZW9>UR+;W;6]#,!JXW=N9$B*FF>XS'19K1
M;R''BIQ*2J1!?6AI#CB$-*;PH$E".3=)3<GF24/<X7'BK9=>#/()6M4N4^"E
M&$D@-O(25%*25!6F ":J=>JKE4Z4KZD6D_XF=1_T8T+^ZL3U_,*]?TS=O[SG
M_P 4[7Z7A?L<3^S,?X2*D[KF59ITI3I2G2E.E*=*4Z4ITI7R1?4L,Q&^K]S>
M*><PSC_.SW0RR]V3GVW2[9+"LKSY92GP0X[AQ>,JQC*/+.?M^SJE<&R[#?2!
M@$9/B203YTCS'I KTVR3Z8U_MSCAW>^6A!SC"GFU--DXZ L@G7K[:V]\5MBB
MF:[A%R4IDUU]I#2(N.#==D UI3["1D!#-.DOI><1C*&6TK<RK*NWV8SG&Q<N
M,VTW(4Z=US0$YXZC'$ZZD=74,54C6*[S+B_;HL<.3X^2^TI:$)2!T[ZUMI Q
MP)6G0:GHK79ZFVZ\3S\-2 :_*QL^&4*Z&U*13L=,END+=PI; +Z4FI&5V']C
MW&TY>=>4XTCMW\N>DB7<67T)!CLL.I!Q@!Q6[C X9P.TZ:'0UZ.=">L.R\^V
M3GXXES[I#DMQ6I##RVT1T/!:MUM"B$C?2">6 U'>JQD:GM<ZZVEN6Y-4R#CY
M.7D&RT?*3!R7\"QB$/92XH[+F$I&\%8<2EIS*%+7W;2G*\YQUUDE6N=<XQT=
M![.&G9U\3@^"QDY/4 2>@ X \F>%;D+IJ747&SBSLB+M) FQ98IS6,K?:K4B
M6H<*$G3)6S"5@7XGP?<2AMQ;CQBG$*6^EE6&TH3GNKZ-9-T; [49U_WC;00>
MD;[6/)QZ,::=5<.5GNW;\:#D'QGKT6<=.//G[<6XE<P.'-*K+,#>^/=+D+?%
M&NO1)MKPJ2&E6#34+0PDUYI3 90;.6?RB!\M+[KSC.,XQW^=#/?$DGOE]IU6
M<=? :::=6F*[AU( T&ZD#.F.]'KU^,U?&_2O!OF[0YJJ0%%@-:;,CLJD8LB/
M<CT R6 6W77AFG&LMX?PH=OVFDX3AU&?#VTX;RI.9TX#3UZNG_6G:=1X_7L\
M6E:7MW^GC:J+J,W=6O+6-L>.K\T8)LJD1T.^):];1SKR\1,\8,DDKY7K9>,>
MR_+B,CM />"26TMJRM&)&0<<>KQ='ESGJ)P>VH-:[X5E)$L ,M24I(+'87E6
M.Z?%QY"585_NQVSGR_DSCOC\V>M1.ZE?#(0KIQKU>/J[:M0FTNRXS2CA+CS:
M#U$+6$X/9KGR5ZEN(14@%32  XR1>!C&(@<-67F$BNOY:=<>9'PIQ66VV1LL
M8]W*,(3GQ0A.<XSWQA_LZ,#&<G&,:DY.FO'KZ:[.UR7&]H+BRHDM-K:0T"HG
M"$M) 3QT"0 !T8SCB:_KD)MQX:EVK_2EQ!%-D0)IQE@I(Q*6@E^ZEHHG'CA&
M'"DH0GV\)RK*?+/FA.>^,_\ X3/#(>&,CADCM^KZ<5=V, 5.G)<TBFTW#EW3
MJIG$9Q2-T\05J2"=?ZHZLC57(<LMK;VOM?H&M6I(4R4>8B3)##BWS"(Y\C+A
M#++;/=MM;WNN#I>_*=<PI#2<H\T]>BL$=Z9=[8PV$K6Y,AC>(&B0XG()4= !
MQ.<#Z:\?,=Y%F4H %/(K"<ZG='ZI'42 ">(U..-;*MP<OIKBU4=PV!D!^,M\
MY=[?7=>#J?>'\4.S)[SLOD//BI;6&R7BLNMK3AQ>4*4K\I/GU]NT/-[3W9+J
M EHR6RV!PY+D4*0<<,$X4!UG37-<ZSE1M<7>)R.4T'!*M[4#JQ_IH:\\?TRW
M:9V C8$Q.R95F3(-R(LFLQY9+)C3N'VU8<6ZIWPRZG'EA*LX2G.48QA/V]>1
M"@<X_GYNJNCZZ>+US5RH+FUM_%OB[)"S\L>2'[+I \JZKX@$M*NSR@#!O8>6
M.1GQRA#B7O%>5H5CQ\59>,X\VGBT[,G.>%*VM4_E;L'8<0]*LP@LS+2"F"+A
M5R7,O.GC- CCNGI95E+;^'%)7[ZUH6\K.$I7G/AVZ9ZNSU\?9]53@=?KV_>,
M]F:H)RVIUE?@Y/8>LK)/ 0+KF$ETP&5)6W4VF5*6MA [?@IJ-][*R62F^['F
MXXTK+:T8QEIK]/\ .GBXC7CY<^/ZL>/'KBXO)=5QHX[J(]UTC.B]29?<4ZVI
M3CV:!7\NK4I2LJ4I:_)659SG.<Y[YSG.>_4U%>>[3% T-LGD'<*WR-W69H/7
M6$[%D\7L&G2=W?58XY\MZ"@\P\4E9*6Y)_+CBG_;4E[(F(QM8Q,B.6/_ $EO
M,^^VW9^')V=LJ+]<?]W-<Q<F-0DB,XE ??Y9TA)+:< )SD;_ "I"DMJ0K\ZQ
M(\&3<7V[A-,&/F2OEPTIX\HE2BA&XG)[XY.<:XW!@J!&,\=*#'[(EMKUK%>=
MMME1I'84UK^$#8+*F3;;7L14PT]!1@*_BY*5"KP=@D$@,M%K4&,:[@9WV.Z;
M6T4]RW-6J29 B1C>[>S/?6I"&41)'*LE+[JQN-M+D+CM[ZB@;ZD#>&]6JW,)
MD+EM\GRS@A2%QT $K4\V4*!;0DY4L-AQ6Z HX"C@XJZT+PKI=J@]9BSU7V=5
M[8Y&: H6Q&ZQ'LCB:OGMQM[CM!.V]RC3D7*&Q<)5ZC6*A.RT"XJH-&50]V5=
MLL!D5G,EXI[;2;%?N:F)-LE14NW^?;C)<*EW./9U6B*BTV93#K2'7Y,N3+8:
MD 2RB4V&A&?WE<GV469AUN,'&I+;I1!8?#*4@1G)?.W3*F!:%%"&FFVEK02U
MEI6\7$8[Z!^/6@M?;<TW-S<G7KV?<X'9%A]PRFR;;AD]5Z[H^[[% UQ!09,)
M)ACVVXSM0(& L!&),@,%!A,?6IYZ*<AI7N[07^X6F\L,-2(#<.1;8^$36R$1
MY4B]PK<Y<7WTOM+5$AL2TJ<CIY-*W-Q*Y,<.AYJC;X$>7#<<4V^IUN2X-YE6
MKC;<)Z0F,V@MJ2'7EM$)<.\4IR4MK*2A720^H-=4OF1JO55Q@K1;*!8;/HU<
M[39.:9J=OBVMLUVDV,NBVR6"A2LL3-&D+<NKV](,1!2,F_!R3##-+DS/;A=[
MMWN,W8ZZ76&_%B3X\:^!B8VPJ5$=-ID38R9T1E;R,LSD1!)B;[S[;27VU%4U
MM&7L$Q(S-XBQ74.NQW'86^RM8:>3SIMEPL.J2DX6PIWDW=U+:EE"@ RI7>?Q
MHK5M.NMDY414QK^ZWUBAZND+#4ZQK=:OGJS( <BM+5=3\ 0_$V5#&6*I8)\.
M3-+KMB2)!DR9F8Y;[+98TWVZ3(4;99UF?"@*G71N/+DW(?[$IMS9Z]2=V0E+
ML8J!E1XZVT(D1RI]#:>4"24*0HK+SUU0MAY\,1EK9:C?\<*3<(;?Z,E#N,-+
M<2I2FW,-E9W20"+A'<2M3T.I7F.-" NY]=K.UU1=E*%=C)%+]/I7JPL /'L1
MTJ0$Y+-3W'35\R?A#A PLE51(IATN/'(>DO'M[6W:?,A.(6N"W(DVL.QD+#K
M93+F>Q4I8;4XTE8:+&T5S91HE2VY2G5!+A0&NSW*B,-/(4A#Q;:EE#BDX5EI
MG:G<*MU1!6%P(RU8R II*1E()5U1W :@SFV9&G(D[U$ 2VVYR+3?X>-BV=7U
MR/;YH/\ &%&JDA/A%/C[%7 99V-$N.VE?M"R-?@'::1%'JNK>U&WL]BTHF%J
M"\XS:F73 >==-SDN'8T;3&Z[X<2E=N$C-N=2F*,J;D/B8EU A'6JQ1W):FMY
M] 7*<3RR$H3%;2+N;;S4#=41(+?^T()<QA3;9:*27JJQ"Z8US);CXJQM4<LF
M:9O>)"G"HV\YB)N3BG!-P;,U0>P^]"B00$@')_1TFR,B8%'=BDS:H!P^8S%8
MGI/U+]YN+=GVI<E",)EB=6RAV#RS+3H7:+;=6U)#RWW&UM=T.;*7O*#O(\N&
MV>5Y!OEHA1E3+6EHN%F<D+*7]Q:D[LR3%()0$)4%<WY3=P-W?W"I>[OJO#6N
M-/'VY3A<U!4N)830],\'8C9M))E)%S&;GN#8_#!S&UX)EV12:J/V-4=A[.I=
MMCQE$@UNPAO2N5QWS[K(4?XB3M+?X;"6'YKRC.O.V[ULFI:;&(5GMVV2>Y3Z
MDM[G*6Z7;[9-B.+W5R8ZTM8=YC)6YVFK;;WG"M#"!R$2RMR62I1_32Y%H/.D
M JSNR&9$EEU(REMQ)5WO+- 8!#ZRTS5^17%&IT+7=)VYH/;6ZXK5-NO]UAYQ
M<[.W.1VS5*YLJFFP[4V-C7+](@B(M6NXL4@R0DZ1< ;U-R9LO9%P%,Z#MRO,
MK9[:J7/N,ZTWZTV5VZQ($)Y@,,0V[3*DVV:AXLJ[HIG/I=%P=6E#;4Z&Y!8;
M0S&Y>9H$>&U<+8TQ&8E0)<T177WD++BWE2VFY+)2%IYN6$;O-DI*BIAX/+4I
M;A0S3C5E(A]_W+:%@D:3))'I% "MXVI]"QJ(JP7 C-WH&NL1=38DP;JJ/6"S
M<'KM/EI@[$ZZ# R3*  F#'9>(]?=)KU@AVN.W-;*IT]<15VOSI=CPT\RGW#E
M92FEPN4#BH:83""_' 6^V2M90&G>/%81/?E+4RH!AA+J8D!.ZX\>68C[K06'
MMW=#O+.'<62$* 2D**T7-J?!S4<#):NE9B?MMC<E+_4$R438:S81JY/0]@VI
M8*$_KN0-KM3D:%"W:"CH1V4L)49O6S-O3$/<*J! M?(@L_)>/E;;W9]NYM,Q
MXD8-0)?)NQY,=4EAZ/:X\]-P;1(EMSWH3[CP:CI=L<8AEZ'*6^0^IAOLLV.(
MVN,IQQYPJ?;WD.-K#3B%R7&>04IMM3"7D)05N%$UT%:'F@V @.*CG;G$RBC:
MGN^TZN)9X^6K5+UM84Q@C1H%,!!=USH9Z?-</EZL] 3Y<W/;"F3CV =HQ5NA
M)-V&%#UI.PTTU-"="T[63E7:%:I2XKC4F;<(_*K*')CBQ<;ZEA 0S*3(CI98
M@,MMJ7:W8C[0>4NY,/,EE5>9:6$Q9$II+J5-,QW E.4LI'-X)62I;10X5K?6
MI0$I#R%% $=:%A8_#57".G;(I^GCY"9V-2BMD5>AW K9,S% DZO(?MO)1_09
M6LJD$/%-2,S?F(=#NP8K*;,\5)(A9V!S4V16$V9O*Z[;3+;,O#;;-NFIMLJ?
M#3;675IN:4P]FTWY-SEK4Z6V8!>*8#N8R4MEYA\2E+5S8XQ;*Q)9AJ4J2R9+
M3#RI"TI,4EVXF"J,R @*4^$ OI_2**MQ;?)8'*5A&[N-6I=6T&Z7<"<V,8:/
M]"<=5ZI(QTM$.5^<V@YR%7)IMLI>]8ZRG[%'!1.BPIJ%)AM?5I@]J\L!9-=^
M0'SI.[9=I+M=)\*"Y'MR$*[MN2I;;C3HD,6L;/AHQ&H-SN;$=Q;M\6R\EZ?)
M*#!4L)'.$H;TSK;#BL//)<DJ4.9)::4E2.3<E=T"KE5/QHRW$!,)*T%##84'
ML%1W"I6>5/A#6;37M?F-C[<!*G:AJ:_R%C-'@Q:;<X^]UZP6"STG7#CT+@ER
MTU2-K,O--F,F6^2E(V)M (%#,F:]&B6NC+VVE19%P056E:&)=U@-QT*?5,AK
M@R(T>--N(#^X(TIV4TR4E$1IMUV*MR<AF0XJ+O9LC3K3"@):2XS%?4XH(#+R
M7VW%NLQ\MY+K26E+W@IU2DI<2EA2VP'<\E>&NKZC$;, 1#7 Z:B*VF[05LL;
MTSF*@:W8N#&[]Z#P$M#3%%H$@88#?J+F/!MLI6ZE(Y>AQW456/(!E8HZ@UMC
M=);UM67H:&7I',GHD8,AV1)C[<62QJD-/,SK@A*'($[E'(C4B6V$O*!E.!;3
MJ-ZK/%91(3N/*6ELO(=<*RAMMRRS9@0M"V&%$I?8PEU3;2LH&&TE*DJZ+;7"
MK1NG6+_-2]QV=:8C5M=O1$M%P\=*5<J^&T[;_'O5T;9JM:[UJ6$KD;6+:G=D
ME*) @!MKL5]JM19#%TM8EF96%8M.VE\O"K>PS#MD5ZZ2(*677G&I2(+<NT7^
MYNQI46#=GY#DJ)W%;:+DA=J5(,EU*H45<907A+LL&&'UK>DN(C-OE24)4VI]
M3,J!&0XVX]%0VEMWGBU;K8DAL-I(?=#F1!W*OCO7=0 UF-U_6KM+KJDIOJ V
M5L,O!1T%-8UOR)LFI8"<> $CU1]+6D5%4CY,94P6&Y(6>LC8RW(2+1$SV]E=
MH9%W7)=N$F$SSMJQ2+;;D%"'V>Z.ST:[/L)6M8<F J,MQM7(I6&XTE6K;92S
M1NMO;B):3';>7R:Y[<E\Y4A?-K@Y%;60$[K)QR25#>()<;&BE KRRA\0ZI:*
MMK>0+$W$:5;:,1L=^Y5F.KQ6O;*2Q ;7G1M$TQ1PS4BK;4Z3K1NHP)PQEM=+
MNTC+0CFOFAH!N3F*D_:Z7%E7)M"[.A,2<FW)AR7)";C'2J1:F%7R8$++8M+"
M;D9;Z%(B!,)MIX3RJ06V=K%H:=:C*4)A+K'.2\TEM4=P[DE8@L[P"N=KYOR2
M% NDO*4@QP$!2\P?X?Z4@08N2MDAN2.*M5;VM<8^GX)J05DH8>J.+M8Y+R=3
MO#DA6TYD+%+-RA%.CCQHFMMM1DQ!WXR"8=")H<K43M?>GUNMQ&[.XF+)M4-V
M9NRUQIR[KM/)V::EP0W)_1QV2TF8XVIV02ZR_ 0^H+3/:W&T0FTH4ZJ8DNM2
M7@T"T'&!%MC=R4T]O-#><5O%I*@AL!*T/E *2RO^I7@_2$U8V:@U[;);G8O9
M]AK5N*;KV*%11J7Q]U9OFIU;8<K\C"BREBOI.R6M7@2#4O10F;'\B3(,;+XE
MW*V%#.V\XR4,OBTI+#EL8DQ$&3S^<J;?[I8I<JWM<LM34> BVJN;C99G+,?E
MV5N-<B)*RK(QR2EHYV=],EQIXAOF[ 9@1IS34A6X IQ\R!&2H+92'-Q82H++
M:?VVOP@UWJ^-LUDD#]I)B:W1=A%(@R&V I>4OE(W?I338PKL[9:'4(4")D'M
MQCRLP/ "7B'A'(1T:#V+=12\2 ^-JVWN%S<C1FV[7RLF=;T%Y)4MIJ!-LEZO
M"UAB-/EO..MILZVF5/K@O/AX*?MT-:.35,JR1XR7'%&5N-L2#N'"5J?9FPHB
M05N1VD)2HS M80'D)W"$2'4JWQ)$MP1H- AMEFDT;=>R' -?WN.$J5?&,3?A
M;MK+D-QII<K.5Z3*UF%##XD*]L^;%E@(* VY5XD<228A-B6U!>)^"Y[6W4^>
M];$)G66W!RX07%2I"T\P7"N6S^TDQIB0TBY./*Y.1;&%LK??M,IU2VU/V^(4
M%A^RNQ1V&Y)Y";)(CO!+2 >7#T>?;F5+;4J,E WFY*PM*&Y3: %;C[H5OHY+
MO 33Q[$+&DWJ58;KJI;7)UDI]?MLX7,2+G)WF+1QMT6B(IM'VHIR%AJCIJL
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MD%M6'6L#*T9Q-'&3?8[2GSZLQ61QIZQQ;Y-NO5%I H,Q39)V%LI)A-LM4(P
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M[($%1_JCM81O2TTC]1MM&.&ZA*<:J/0!TK6?&M1XJ.=96M7ZRU'QJ)ZNL_\
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M-8;^,6)/T>OFJ2#C0@CQG.F?+KU]':=*S[9EMX&(I''N[Z\](NE;L!V?LW-
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ME4!YR^C-L3:,V3L+1-!U/4)@AMXF6K5-DW*[%RQBW5..*&ABF!84%_".^?<
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MS7I%QF<0V.*-A8HYK#:6G#79W@3@:^H^_C_/"MZM\NUQEHXR1B8?59\XKV7
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MWM0>^) R0#T5=*#UW8)ZST#;-[D[0B[$"G2E=K-9<:-CHN(D'E_+438@&!?
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%]*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g111280g89a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111280g89a09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &7Z^928X0DE-! 0      &$< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M($%C=&EV95\Y.#8Y-#8Q-%\Q,5]-
M:4Y+("T@4RTQ7T%M96YD;65N=" R7T1R869T #A"24T$)0      $$_Y*DB_
M#0Z*\7Y9EW S.]LX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :&            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              #    "5P         !
M      $              E<   #                       $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   #      %)G:'1L;VYG   "5P    9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    P     !29VAT;&]N9P   E<    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #OT    !    H
M #,   '@  !?H   #N$ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #, H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MWH_]>24^E_43(R,GZK8=^5<_(N>;MUMKB]YBZP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" !? 2<# 1$  A$! Q$!_\0 'P   00!!0$
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MCFC]%L<UB QM*QE3<TJB3C#UF8J,7+RI7+J9KCV671?/5UCJD&1*)"*"1N=
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M;=TV$[:%.TOV3J0\&C5H(P&+XC5^UF4!'@YN'\C&2V]#_:6GA'II9GSQ/L/
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M=&<F(J+7523>O6+ RKA)(15,(D[R-7J@%:KL9:4;3</8&P;@'&]%VUQ\&WQ
MC7(R6JLM!.6\DE;VDNR;O2W.0G6X<V&4LJ:J<F[FE3G,[%8@) DV30028QQN
MF,6F,6F,"NZPN*'F--[E\F10,2%RM$UW(L*OVB!%3NXU*"GT^X"E)XR=C@I1
M8Y"B82H.FQS\"IYZO>IFN:CRNW/UU%LH*]V-OP+",5YAV?J1)!YG\.I%/U)S
MWC^P]S*#E?H!QR@)%:_PV[M.+WX^QY(L-I]EK7\>R0C:S8U(U8] O#*%^%R+
MC5@9M[BTQDR71=VS4[.6?K1?,@P[:P5O"T'%3<7"OTRN(UY=YV140KKN2:J
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M*)%]G2!O=PQ=^X"AS^H4'Y '^O=QKBP 5N@!^JWX?L.?O4)-NK\_^D0?7O\
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M,O7:LO:GBU!G8:GCBWV*$=+,Z+$-G:3>5B8AVQ65:N$SH.$TUS&16(9-0"F
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MN&M(*#UTL]?YM[2220KT1Y>2Q/&Y)3R"], &()/7P;.X9+Q6+D>N?F=7>7=
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MIC%IC-IB 8?,1^7NX^0\_=J"._V?N_M^/]N,T!,H#S]WR\N/+W?+GR^7G\M
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:<A2@4. $1\^?/C[@#Y 'R#4YQ_LZ_GZY_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
